<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00201</drugbank-id>
  <drugbank-id>APRD00673</drugbank-id>
  <name>Caffeine</name>
  <description>Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans.[T716] Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.[T716]&#13;
&#13;
The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999.[L9863] According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely.[A187694] Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants.[T716]</description>
  <cas-number>58-08-2</cas-number>
  <unii>3G6A5W338E</unii>
  <average-mass>194.1906</average-mass>
  <monoisotopic-mass>194.080375584</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A298</ref-id>
        <pubmed-id>1356551</pubmed-id>
        <citation>Nehlig A, Daval JL, Debry G: Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev. 1992 May-Aug;17(2):139-70.</citation>
      </article>
      <article>
        <ref-id>A187232</ref-id>
        <pubmed-id>22113078</pubmed-id>
        <citation>Ding R, Shi J, Pabon K, Scotto KW: Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance. Mol Pharmacol. 2012 Mar;81(3):328-37. doi: 10.1124/mol.111.075556. Epub 2011 Nov 23.</citation>
      </article>
      <article>
        <ref-id>A187685</ref-id>
        <pubmed-id>24761278</pubmed-id>
        <citation>Kole J, Barnhill A: Caffeine Content Labeling: A Missed Opportunity for Promoting Personal and Public Health. J Caffeine Res. 2013 Sep;3(3):108-113. doi: 10.1089/jcr.2013.0017.</citation>
      </article>
      <article>
        <ref-id>A187691</ref-id>
        <pubmed-id>30574005</pubmed-id>
        <citation>Michael Z, Spyropoulos F, Ghanta S, Christou H: Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches. Clin Med Insights Pediatr. 2018 Dec 11;12:1179556518817322. doi: 10.1177/1179556518817322. eCollection 2018.</citation>
      </article>
      <article>
        <ref-id>A187694</ref-id>
        <pubmed-id>28589122</pubmed-id>
        <citation>Collins JJP, Tibboel D, de Kleer IM, Reiss IKM, Rottier RJ: The Future of Bronchopulmonary Dysplasia: Emerging Pathophysiological Concepts and Potential New Avenues of Treatment. Front Med (Lausanne). 2017 May 22;4:61. doi: 10.3389/fmed.2017.00061. eCollection 2017.</citation>
      </article>
      <article>
        <ref-id>A187709</ref-id>
        <pubmed-id>29067618</pubmed-id>
        <citation>Lipton RB, Diener HC, Robbins MS, Garas SY, Patel K: Caffeine in the management of patients with headache. J Headache Pain. 2017 Oct 24;18(1):107. doi: 10.1186/s10194-017-0806-2.</citation>
      </article>
      <article>
        <ref-id>A187718</ref-id>
        <pubmed-id>1544897</pubmed-id>
        <citation>Schneider E, Freundlieb S, Tapio S, Boos W: Molecular characterization of the MalT-dependent periplasmic alpha-amylase of Escherichia coli encoded by malS. J Biol Chem. 1992 Mar 15;267(8):5148-54.</citation>
      </article>
      <article>
        <ref-id>A187721</ref-id>
        <pubmed-id>26074744</pubmed-id>
        <citation>Cappelletti S, Piacentino D, Sani G, Aromatario M: Caffeine: cognitive and physical performance enhancer or psychoactive drug? Curr Neuropharmacol. 2015 Jan;13(1):71-88. doi: 10.2174/1570159X13666141210215655.</citation>
      </article>
      <article>
        <ref-id>A187724</ref-id>
        <pubmed-id>16402111</pubmed-id>
        <citation>Boswell-Smith V, Spina D, Page CP: Phosphodiesterase inhibitors. Br J Pharmacol. 2006 Jan;147 Suppl 1:S252-7. doi: 10.1038/sj.bjp.0706495.</citation>
      </article>
      <article>
        <ref-id>A187730</ref-id>
        <pubmed-id>27100333</pubmed-id>
        <citation>White JR Jr, Padowski JM, Zhong Y, Chen G, Luo S, Lazarus P, Layton ME, McPherson S: Pharmacokinetic analysis and comparison of caffeine administered rapidly or slowly in coffee chilled or hot versus chilled energy drink in healthy young adults. Clin Toxicol (Phila). 2016;54(4):308-12. doi: 10.3109/15563650.2016.1146740.</citation>
      </article>
      <article>
        <ref-id>A187736</ref-id>
        <pubmed-id>12204386</pubmed-id>
        <citation>Mandel HG: Update on caffeine consumption, disposition and action. Food Chem Toxicol. 2002 Sep;40(9):1231-4. doi: 10.1016/s0278-6915(02)00093-5.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T716</ref-id>
        <isbn/>
        <citation>Justin Evans; Amanda S. Battisti (2019). Caffeine. Stat Pearls Publishing.</citation>
      </textbook>
      <textbook>
        <ref-id>T719</ref-id>
        <isbn/>
        <citation>IARC Working Group on the Evaluation of Carcinogenic Risk to Humans (1991). Coffee, Tea, Mate, Methylxanthines and Methylglyoxal. International Agency for Research on Cancer.</citation>
      </textbook>
      <textbook>
        <ref-id>T722</ref-id>
        <isbn/>
        <citation>Institute of Medicine (US) Committee on Military Nutrition Research. (2001). Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations.. National Academic Press.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L9827</ref-id>
        <title>Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry</title>
        <url>https://www.fda.gov/media/112363/download</url>
      </link>
      <link>
        <ref-id>L9851</ref-id>
        <title>Caffeine citrate injection FDA label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20793s1lbl.pdf</url>
      </link>
      <link>
        <ref-id>L9854</ref-id>
        <title>DailyMed Search: Caffeine</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=caffeine&amp;audience=consumer</url>
      </link>
      <link>
        <ref-id>L9857</ref-id>
        <title>PDB reference</title>
        <url>https://www.rcsb.org/ligand/CFF</url>
      </link>
      <link>
        <ref-id>L9863</ref-id>
        <title>FDA approval</title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=020793</url>
      </link>
      <link>
        <ref-id>L9869</ref-id>
        <title>Alcohol and Drug Foundation, Australia</title>
        <url>https://adf.org.au/drug-facts/caffeine/</url>
      </link>
      <link>
        <ref-id>L9872</ref-id>
        <title>Migergot, DailyMed</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a31ad0c-7bdd-544b-f5df-a99d04cf541c</url>
      </link>
      <link>
        <ref-id>L9896</ref-id>
        <title>Caffeine pathway: Pharm GKB</title>
        <url>https://www.pharmgkb.org/pathway/PA165884757</url>
      </link>
      <link>
        <ref-id>L9899</ref-id>
        <title>Caffeine and sodium benzoate injection</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2c6b352-f837-4903-8e4c-fb0a2b20bb60</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Kaspar Bott, "Preparation of caffeine." U.S. Patent US4380631, issued December, 1976.</synthesis-reference>
  <indication>Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth.[T716,L9851] In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs.[L9899] Caffeine has a broad range of over the counter uses, and is found in energy supplements, athletic enhancement products, pain relief products, as well as cosmetic products.[T716,L9854,L9872]</indication>
  <pharmacodynamics>Caffeine stimulates the central nervous system (CNS), heightening alertness, and sometimes causing restlessness and agitation. It relaxes smooth muscle, stimulates the contraction of cardiac muscle, and enhances athletic performance.[A298,T716,L9857] Caffeine promotes gastric acid secretion and increases gastrointestinal motility. It is often combined in products with analgesics and ergot alkaloids, relieving the symptoms of migraine and other types of headaches. Finally, caffeine acts as a mild diuretic.[T716]</pharmacodynamics>
  <mechanism-of-action>The mechanism of action of caffeine is complex, as it impacts several body systems, which are listed below. The effects as they relate to various body systems are described as follows:&#13;
&#13;
**General and cellular actions**&#13;
&#13;
Caffeine exerts several actions on cells, but the clinical relevance is poorly understood. One probable mechanism is the inhibition of nucleotide phosphodiesterase enzymes, adenosine receptors, regulation of calcium handling in cells, and participates in adenosine receptor antagonism.[A187221,L9857] Phosphodiesterase enzymes regulate cell function via actions on second messengers cAMP and cGMP.[A187724] This causes lipolysis through activation of hormone-sensitive lipases, releasing fatty acids and glycerol.[T722]&#13;
&#13;
**Respiratory**&#13;
&#13;
The exact mechanism of action of caffeine in treating apnea related to prematurity is unknown, however, there are several proposed mechanisms, including respiratory center stimulation in the central nervous system, a reduced threshold to hypercapnia with increased response, and increased consumption of oxygen, among others.[L9851] The blocking of the adenosine receptors enhances respiratory drive via an increase in brain medullary response to carbon dioxide, stimulating ventilation and respiratory drive, while increasing contractility of the diaphragm.[T716]&#13;
&#13;
**Central nervous system**&#13;
&#13;
Caffeine demonstrates antagonism of all 4 adenosine receptor subtypes (A1, A2a, A2b, A3) in the central nervous system.[T716,L9851] Caffeine's effects on alertness and combatting drowsiness are specifically related to the antagonism of the A2a receptor.[T716]&#13;
&#13;
**Renal system**&#13;
&#13;
Caffeine has diuretic effects due to is stimulatory effects on renal blood flow, increase in glomerular filtration, and increase in sodium excretion.[T716]&#13;
&#13;
**Cardiovascular system**&#13;
&#13;
Adenosine receptor antagonism at the A1 receptor by caffeine stimulates inotropic effects in the heart. Blocking of adenosine receptors promotes catecholamine release, leading to stimulatory effects occurring in the heart and the rest of the body.  In the blood vessels, caffeine exerts direct antagonism of adenosine receptors, causing vasodilation. It stimulates the endothelial cells in the blood vessel wall to release nitric oxide, potentiating blood vessel relaxation. Catecholamine release, however, antagonizes this and exerts inotropic and chronotropic effects on the heart, ultimately leading to vasoconstriction. Finally, caffeine is shown to raise systolic blood pressure measurements by 5 to 10 mmHg when it is not taken regularly, versus no effect in those who consume it regularly.[T716] The vasoconstricting effects of caffeine are beneficial in migraines and other types of headache, which are normally caused by vasodilation in the brain.[A187709,L9872]</mechanism-of-action>
  <toxicity>The oral LD50 of caffeine in rats is 192 mg/kg.[MSDS] An acute fatal overdose of caffeine in humans is about 10–14 grams (equivalent to 150–200 mg/kg of body weight).[T722]&#13;
&#13;
**Caffeine overdose**&#13;
&#13;
In the case of caffeine overdose, seizures may occur, as caffeine is a central nervous system stimulant. It should be used with extreme caution in those with epilepsy or other seizure disorders.[L9851] Symptoms of overdose may include nausea, vomiting, diarrhea, and gastrointestinal upset. Intoxication with caffeine is included in the World Health Organization’s International Classification of Diseases (ICD-10).  Agitation, anxiety, restlessness, insomnia, tachycardia, tremors, tachycardia, psychomotor agitation, and, in some cases, death can occur, depending on the amount of caffeine consumed.  Overdose is more likely to occur in individuals who do not consume caffeine regularly but consume energy drinks.[A187721]&#13;
&#13;
**Overdose management**&#13;
&#13;
For a mild caffeine overdose, offer symptomatic treatment. In the case of a severe overdose, intubation for airway protection from changes in mental status or vomiting may be needed. Activated charcoal and hemodialysis can prevent further complications of an overdose and prevent absorption and metabolism. Benzodiazepine drugs can be administered to prevent or treat seizures.  IV fluids and vasopressors may be necessary to combat hypotension associated with caffeine overdose. In addition, magnesium and beta blocking drugs can be used to treat arrhythmias that may occur, with defibrillation and resuscitation if the arrhythmias are lethal. Follow local ACLS protocols.[T716]</toxicity>
  <metabolism>Caffeine metabolism occurs mainly in the liver via the cytochrome CYP1A2 enzyme.[A187730] The products of caffeine metabolism include paraxanthine, theobromine, and theophylline. The first step of caffeine metabolism is demethylation, yielding paraxanthine (a major metabolite), followed by theobromine, and theophylline, which are both minor metabolites. They are then excreted in urine as urates after additional metabolism.[A187730,T716,L9851] The enzymes xanthine oxidase and N-acetyltransferase 2 (NAT2) also participate in the metabolism of caffeine.[A187730]</metabolism>
  <absorption>Caffeine is rapidly absorbed after oral or parenteral administration, reaching peak plasma concentration within 30 minutes to 2 hours after administration.[A187730] After oral administration, onset of action takes place within 45 to 1 hour.[L9827] Food may delay caffeine absorption. The peak plasma level for caffeine ranges from 6-10mg/L.[L9851] The absolute bioavailability is unavailable in neonates[L9851], but reaches about 100% in adults.[T716]</absorption>
  <half-life>In an average-sized adult or child above the age of 9, the half-life of caffeine is approximately 5 hours. Various characteristics and conditions can alter caffeine half-life.  It can be reduced by up to 50% in smokers. Pregnant women show an increased half-life of 15 hours or higher, especially in the third trimester. The half-life in newborns is prolonged to about 8 hours at full-term and 100 hours in premature infants, likely due to reduced ability to metabolize it. Liver disease or drugs that inhibit CYP1A2 can increase caffeine half-life.[T716,T722]</half-life>
  <protein-binding>Plasma protein binding of caffeine has not been determined for neonates or infants. In vitro studies indicate a protein binding of about 10%-36%. Caffeine is reversibly bound to plasma proteins.[T722,L9851]&#13;
</protein-binding>
  <route-of-elimination>The major metabolites of caffeine can be found excreted in the urine.[T716] About 0.5% to 2% of a caffeine dose is found excreted in urine, as it because it is heavily absorbed in the renal tubules.[T722,A187730]</route-of-elimination>
  <volume-of-distribution>Caffeine has the ability to rapidly cross the blood-brain barrier. It is water and fat soluble and distributes throughout the body.[T716,T722,L9851] Caffeine concentrations in the cerebrospinal fluid of preterm newborns are similar to the concentrations found in the plasma. The mean volume of distribution of caffeine in infants is 0.8-0.9 L/kg and 0.6 L/kg in the adult population.[L9851]</volume-of-distribution>
  <clearance>The clearance of caffeine varies, but on average, is about 0.078 L/kg/h (1.3 mL/min/kg).[A187730,T722]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.</description>
    <direct-parent>Xanthines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Imidazopyrimidines</class>
    <subclass>Purines and purine derivatives</subclass>
    <alternative-parent>6-oxopurines</alternative-parent>
    <alternative-parent>Alkaloids and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>N-substituted imidazoles</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Pyrimidones</alternative-parent>
    <alternative-parent>Ureas</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>6-oxopurine</substituent>
    <substituent>Alkaloid or derivatives</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidazole</substituent>
    <substituent>Lactam</substituent>
    <substituent>N-substituted imidazole</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Purinone</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Pyrimidone</substituent>
    <substituent>Urea</substituent>
    <substituent>Vinylogous amide</substituent>
    <substituent>Xanthine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000866</drugbank-id>
      <name>Caffeine citrate</name>
      <unii>U26EO4675Q</unii>
      <cas-number>69-22-7</cas-number>
      <inchikey>RCQXSQPPHJPGOF-UHFFFAOYSA-N</inchikey>
      <average-mass>386.317</average-mass>
      <monoisotopic-mass>386.107378176</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">1-methyltheobromine</synonym>
    <synonym language="english" coder="">1,3,7-trimethyl-2,6-dioxopurine</synonym>
    <synonym language="english" coder="">1,3,7-trimethylpurine-2,6-dione</synonym>
    <synonym language="english" coder="">1,3,7-trimethylxanthine</synonym>
    <synonym language="german" coder="">3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion</synonym>
    <synonym language="english" coder="">7-methyltheophylline</synonym>
    <synonym language="english" coder="">Anhydrous caffeine</synonym>
    <synonym language="spanish" coder="">Cafeína</synonym>
    <synonym language="french" coder="">Caféine</synonym>
    <synonym language="latin" coder="">Caffeinum</synonym>
    <synonym language="german" coder="">Coffein</synonym>
    <synonym language="latin" coder="">Coffeinum</synonym>
    <synonym language="english" coder="">Guaranine</synonym>
    <synonym language="german" coder="">Koffein</synonym>
    <synonym language="spanish" coder="">Mateína</synonym>
    <synonym language="english" coder="">Methyltheobromine</synonym>
    <synonym language="spanish" coder="">Teína</synonym>
    <synonym language="german" coder="">Thein</synonym>
    <synonym language="english" coder="">Theine</synonym>
  </synonyms>
  <products>
    <product>
      <name>(extra Strength) Acetaminophen, Caffeine &amp; 8mg Codeine Phosphate Caplets</name>
      <labeller>Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02236871</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-22</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>217</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00666645</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1910-12-31</started-marketing-on>
      <ended-marketing-on>1998-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>217 Strong Tab</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00259802</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>1998-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>222 Tablets</name>
      <labeller>Mcneil Consumer Healthcare Division Of Johnson &amp; Johnson Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00108162</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>2015-08-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>282 Mep Tab</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00108316</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>282 Tab</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00108103</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1998-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>282 Tablets</name>
      <labeller>Pendopharm Division Of De Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02234510</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>292 Tab</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00219843</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>292 Tablets</name>
      <labeller>Pendopharm Division Of De Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238645</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>357 Super Magnum</name>
      <labeller>King Richard Promotions Dba Dbi</labeller>
      <ndc-id/>
      <ndc-product-code>70682-941</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength>200 1/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>4229 First Aid Kit</name>
      <labeller>Honeywell Safety Products USA, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0498-4229</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>4248 First Aid Kit</name>
      <labeller>Honeywell Safety Products USA, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0498-4248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>4346 First Aid Kit</name>
      <labeller>Honeywell Safety Products USA, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0498-4346</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>692 Tab</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00108146</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-02-13</started-marketing-on>
      <ended-marketing-on>1998-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>692 Tablet</name>
      <labeller>Lioh Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02234509</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-09-01</started-marketing-on>
      <ended-marketing-on>2006-08-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>7 Select Migraine Formula</name>
      <labeller>7-Eleven</labeller>
      <ndc-id/>
      <ndc-product-code>10202-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-09</started-marketing-on>
      <ended-marketing-on>2021-02-28</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>999 GANMAOLING Cold</name>
      <labeller>Kingsway</labeller>
      <ndc-id/>
      <ndc-product-code>63922-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>A &amp; C Tablets With Codeine 15mg</name>
      <labeller>D.C. Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00095508</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>A &amp; C Tablets With Codeine 30mg</name>
      <labeller>D.C. Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00095516</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>A.C. &amp; C 8mg Tab</name>
      <labeller>Vita Health Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00180041</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on>2019-09-23</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>A.C. &amp; C. 8 mg</name>
      <labeller>Laboratoires Confab Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245670</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>A.C. &amp; C. 8mg</name>
      <labeller>Westcan Pharmaceuticals Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230426</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>A.C.&amp; C Tablets</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01922246</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2019-06-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ac and C Tab 1/8gr</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00589470</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2013-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ac&amp;c Tablets</name>
      <labeller>Vita Health Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00688851</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2005-07-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ac&amp;c Tablets</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303299</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-11</started-marketing-on>
      <ended-marketing-on>2019-06-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acet 2</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00706515</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>2013-05-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acet 3</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00706523</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>2013-05-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen 250mg Aspirin 250mg Caffeine 65mg</name>
      <labeller>Walgreens Co.</labeller>
      <ndc-id/>
      <ndc-product-code>0363-1320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen 300mg, Caffeine &amp; Codeine</name>
      <labeller>Tanta Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277816</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen 325 C &amp; C</name>
      <labeller>Technilab Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229962</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen 325 Mg Caffeine and Codeine</name>
      <labeller>Tanta Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02271834</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen 325 Mg With 15 Mg Caffeine and 8 Mg Codeine Phosphate</name>
      <labeller>Vita Health Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00706221</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen 500 Mg Compound Tablets With Codeine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00617059</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on>2016-10-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen 500 Mg With 15 Mg Caffeine and 8 Mg Codeine Phosphate</name>
      <labeller>Vita Health Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00708712</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2014-07-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen 500mg and Caffeine 65mg</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02269988</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen 500mg Caffeine 60mg Pyrilamine maleate 15mg</name>
      <labeller>Walgreens Co.</labeller>
      <ndc-id/>
      <ndc-product-code>0363-2310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen 500mg Caffeine 65mg</name>
      <labeller>Strive Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>70692-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen 500mg, Caffeine and 8mg Codeine Phosphate</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02259001</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen Caffeine &amp; 8mg Cod Phos Tab</name>
      <labeller>Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00656119</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen Caffeine &amp; 8mg Cod. Phos. Tab</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01997688</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2012-12-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen Compound Tablets With Codeine 8mg</name>
      <labeller>D.C. Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00599131</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on>2005-07-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen Headache Ultra Relief</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02290901</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen Relief Regular Strength</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02290944</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen Ultra Relief Extra Strength</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02286807</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen W Codeine Tab</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00589489</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2013-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen With Codeine - Caplet</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02143933</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen-caffeine-codeine</name>
      <labeller>Laboratoires Confab Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254700</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Aspirin, Caffeine</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>69842-541</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen, Butalbital and Caffeine</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-022</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-02-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089536</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine &amp; 8mg Codeine Phosphate</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237420</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-12-17</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine &amp; 8mg Codeine Phosphate Tablets</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246085</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine &amp; Codeine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02028174</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2019-06-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine &amp; Codeine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025337</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2019-06-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine &amp; Codeine Tablets</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387255</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine and 8 Mg Of Codeine Phosphate Tablets</name>
      <labeller>Cellchem Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248817</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine and Codeine Phosphate Tablets</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02154234</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine and Dihydrocodeine Bitartrate</name>
      <labeller>Mikart, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0525-0032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine and Dihydrocodeine Bitartrate</name>
      <labeller>Boca Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64376-611</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-03</started-marketing-on>
      <ended-marketing-on>2013-05-23</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040701</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine and Dihydrocodeine Bitartrate</name>
      <labeller>Larken Laboratories Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68047-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204209</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine, and 8mg Of Codeine Phosphate Tablets</name>
      <labeller>Cellchem Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251914</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine, Dihydrocodeine Bitartrate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6851</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-05</started-marketing-on>
      <ended-marketing-on>2017-05-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine, Dihydrocodeine Bitartrate</name>
      <labeller>Mesource Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>45865-866</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-05</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine, Dihydrocodeine Bitartrate</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-8918</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-11</started-marketing-on>
      <ended-marketing-on>2018-03-05</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophen, Caffeine, Dihydrocodeine Bitartrate</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acetaminophene Codeine Et Cafeine Caplets</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01996541</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2019-06-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetaminophene Codeine Et Cafeine Fort</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01996568</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2019-06-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetylsalicylic Acid, Caffeine &amp; 8 Mg Codeine Phosphate Tablets</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246103</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acetylsalicylic Acid, Caffeine and 8mg Codeine Phosphate</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00095494</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ache and Pain Relief to Go</name>
      <labeller>Breakthrough Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51596-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-15</started-marketing-on>
      <ended-marketing-on>2013-08-01</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ache and Pain Relief to Go</name>
      <labeller>Breakthrough Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51596-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Added Strength Pain Reliever</name>
      <labeller>Better Living Brands</labeller>
      <ndc-id/>
      <ndc-product-code>21130-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2018-07-20</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adults Acetaminophen and Caffeine Pain Reliever Fever Reducer</name>
      <labeller>Genvion Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>62049-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advanced Pain Reliever</name>
      <labeller>Advanced First Aid, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67060-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advanced Pain Reliever</name>
      <labeller>Advanced First Aid, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67060-174</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alagesic LQ</name>
      <labeller>Poly Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50991-514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-15</started-marketing-on>
      <ended-marketing-on>2015-02-06</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alert</name>
      <labeller>Time Cap Labs, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>49483-343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alert</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alert Aid</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>46122-457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alert Aid Caffeine Capsules 175mg</name>
      <labeller>Sun Products Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01941089</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2004-03-11</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alert Aid Caffeine Tablets 175mg</name>
      <labeller>Sun Products Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01941100</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2004-03-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alert Alertness Aid</name>
      <labeller>L.N.K. International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alert Tab 100mg</name>
      <labeller>Nutribon (1986) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01943642</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alertness Aid</name>
      <labeller>We Care Distributor Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70005-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alertness Aid</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-680</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alertness Aid</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alertness Aid Maximum Strength</name>
      <labeller>Harmon Store Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63940-229</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alertness Aid Stay Awake</name>
      <labeller>Healthlife of Usa</labeller>
      <ndc-id/>
      <ndc-product-code>69517-132</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alka-seltzer Morning Relief</name>
      <labeller>Bayer Inc Consumer Care</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02244451</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-10</started-marketing-on>
      <ended-marketing-on>2006-07-28</ended-marketing-on>
      <dosage-form>Tablet, effervescent</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Allertness Aid</name>
      <labeller>Select Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>52904-470</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Allertness Aid</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-195</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-03</started-marketing-on>
      <ended-marketing-on>2018-10-23</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ana-dent</name>
      <labeller>Belmora LLC</labeller>
      <ndc-id/>
      <ndc-product-code>27854-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anacin</name>
      <labeller>Insight Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63736-206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-29</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Capsule, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anacin</name>
      <labeller>Insight Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63736-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anacin</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332450</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anacin AF</name>
      <labeller>Insight Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63736-203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-29</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anacin Caplets</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01933469</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1945-12-31</started-marketing-on>
      <ended-marketing-on>2011-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anacin Caplets</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02335573</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anacin ES</name>
      <labeller>Insight Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63736-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anacin Extra Strength</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332469</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on>2019-05-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anacin Extra Strength Caplets</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01933507</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>2011-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anacin Extra Strength Caplets</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02335581</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anacin Extra Strength Tablet</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01933493</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>2011-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anacin Tablet</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01933477</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2011-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anacin With Codeine Tab</name>
      <labeller>Whitehall Robins Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01933515</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1965-12-31</started-marketing-on>
      <ended-marketing-on>2000-07-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antidol Tablets</name>
      <labeller>Les Produits Gerbex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00766496</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>2007-12-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-acetaco #1</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02265052</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ara Menstrual Complete</name>
      <labeller>Ara Avanti Rx Analytics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02461153</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Arco Pain Tab</name>
      <labeller>Laboratoire Romilo</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00443689</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Arthriten Inflammatory Pain Formula</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Arthriten Joint Pain Relief</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-10-28</started-marketing-on>
      <ended-marketing-on>2010-05-17</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Arthriten Max</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-337</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Asa and Caffeine</name>
      <labeller>Therapharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250691</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Asa-caffeine-codeine</name>
      <labeller>Laboratoires Confab Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250683</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Asa, Caffeine &amp; 8mg Codeine Phosphate</name>
      <labeller>Canapharm Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238961</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-03-13</started-marketing-on>
      <ended-marketing-on>2006-08-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ascomp with Codeine</name>
      <labeller>Nexgen Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0722-6094</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075231</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ascomp with Codeine</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-074</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075231</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aspirin Rapid Relief</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02276267</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aspirin, Caffeine, and Dihydrocodeine Bitartrate</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-419</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA011483</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Atasol 15</name>
      <labeller>Church &amp; Dwight Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00293504</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Atasol 30</name>
      <labeller>Church &amp; Dwight Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00293512</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on>2019-04-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Atasol 8</name>
      <labeller>Church &amp; Dwight Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00293490</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Awake Maximum Strength</name>
      <labeller>TOPCO ASSOCIATES, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-844</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Awake Maximum Strength</name>
      <labeller>Better Living Brands, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>21130-944</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Awake Maximum Strength</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-3440</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Back and Body Extra Strength</name>
      <labeller>Greenbrier International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>33992-0413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Back and Body Extra Strength</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-143</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Back and Body Extra Strength</name>
      <labeller>L.N.K. International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Back and Body Extra Strength</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Back and Body Extra Strength</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-143</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Back and Body Extra Strength</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>BackAid Inflammatory Pain Formula</name>
      <labeller>Alva Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-622</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-22</started-marketing-on>
      <ended-marketing-on>2018-10-23</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Basic Care Migraine Relief</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-7374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bayer AM extra stength</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>0280-2600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-15</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bayer Back and Body Extra Strength</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>0280-2150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bayer Headache Relief</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0280-2635</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bayer Migraine Formula</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>0280-2030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-26</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bc</name>
      <labeller>Glaxo Smith Kline Consumer Heathcare Lp</labeller>
      <ndc-id/>
      <ndc-product-code>0135-0500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bc</name>
      <labeller>Medtech Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>BC Arthritis</name>
      <labeller>Glaxo Smith Kline Consumer Heathcare Lp</labeller>
      <ndc-id/>
      <ndc-product-code>0135-0501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>BC Arthritis</name>
      <labeller>Medtech Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>BC Cherry</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>BC Cherry</name>
      <labeller>Lil' Drug Store Products, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9815</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Berkley and Jensen Migraine Formula</name>
      <labeller>BJWC</labeller>
      <ndc-id/>
      <ndc-product-code>68391-536</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Berkley and Jensen Migraine Relief</name>
      <labeller>BJWC</labeller>
      <ndc-id/>
      <ndc-product-code>68391-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-10</started-marketing-on>
      <ended-marketing-on>2014-12-09</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bi Electro Extra Strength</name>
      <labeller>Genomma Labs USA, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>50066-285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>BioElectro Day</name>
      <labeller>A&amp;Z Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62211-285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-18</started-marketing-on>
      <ended-marketing-on>2015-04-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Blowfish</name>
      <labeller>Rally Labs Llc</labeller>
      <ndc-id/>
      <ndc-product-code>75920-0464</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, effervescent</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Buscapina</name>
      <labeller>Opmx Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69729-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital Acetaminophen and Caffeine</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-590</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital Acetaminophen and Caffeine</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49999-151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA088616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital Compound</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-3892</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-01-28</started-marketing-on>
      <ended-marketing-on>2016-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Goldline Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0182-2694</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-24</started-marketing-on>
      <ended-marketing-on>2010-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040336</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Keltman Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68387-520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040336</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Red Pharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-0718</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-913</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-257</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040336</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-843</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040496</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Mikart, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46672-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-23</started-marketing-on>
      <ended-marketing-on>2012-04-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040496</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-323</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-4856</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-2538</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Mallinckrodt</labeller>
      <ndc-id/>
      <ndc-product-code>0406-0970</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-28</started-marketing-on>
      <ended-marketing-on>2009-09-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA087804</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Mikart, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46672-633</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040387</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Kaiser Foundations Hospitals</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67544-394</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-1774</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-2545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-25</started-marketing-on>
      <ended-marketing-on>2013-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Mikart, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46672-059</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-05-23</started-marketing-on>
      <ended-marketing-on>2014-01-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089451</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5943</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-30</started-marketing-on>
      <ended-marketing-on>2014-01-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-022</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-2544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-13</started-marketing-on>
      <ended-marketing-on>2018-05-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Victory Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>68453-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-10-28</started-marketing-on>
      <ended-marketing-on>2013-11-22</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-862</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-25</started-marketing-on>
      <ended-marketing-on>2013-12-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Sunrise Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>11534-187</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-1313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Mikart, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46672-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-03-17</started-marketing-on>
      <ended-marketing-on>2015-07-17</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089007</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-276</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-11</started-marketing-on>
      <ended-marketing-on>2017-01-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-275</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-11</started-marketing-on>
      <ended-marketing-on>2017-01-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-11</started-marketing-on>
      <ended-marketing-on>2017-01-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-0832</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on>2011-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Marlex Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>10135-628</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-1787</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>West-Ward Pharmaceuticals Corp</labeller>
      <ndc-id/>
      <ndc-product-code>0143-1787</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9025</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2073</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-24</started-marketing-on>
      <ended-marketing-on>2016-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-369</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-139</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71610-042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-365</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66267-039</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Vintage Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0254-2357</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-08</started-marketing-on>
      <ended-marketing-on>2006-11-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Vintage Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0254-2355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-14</started-marketing-on>
      <ended-marketing-on>2007-11-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204733</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-396</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6538</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Mikart, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>46672-053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7988</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Golden State Medical Supply Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51407-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207118</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-879</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-179</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089007</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-2544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-955</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206615</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-253</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA211106</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4657</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-589</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine Plus</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-581</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen and Caffeine with Codeine Phosphate</name>
      <labeller>West-Ward Pharmaceuticals Corp</labeller>
      <ndc-id/>
      <ndc-product-code>0143-3000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-03-21</started-marketing-on>
      <ended-marketing-on>2015-11-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075618</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-10</started-marketing-on>
      <ended-marketing-on>2012-03-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040336</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on>2018-06-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-253</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-08-18</started-marketing-on>
      <ended-marketing-on>2018-06-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040336</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>42549-553</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>West Ward Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0143-0170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Rxchange Co</labeller>
      <ndc-id/>
      <ndc-product-code>33358-059</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-1695</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Mirror Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>52682-041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-08</started-marketing-on>
      <ended-marketing-on>2017-09-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040864</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Mirror Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>52682-026</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-08</started-marketing-on>
      <ended-marketing-on>2017-09-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040883</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0371</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA088616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>West-Ward Pharmaceuticals Corp</labeller>
      <ndc-id/>
      <ndc-product-code>0143-1115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-08-18</started-marketing-on>
      <ended-marketing-on>2014-03-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040336</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-3369</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA088616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6939</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA088616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7452</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-06-12</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089718</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-1695</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0365</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-6030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-536</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2640</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2564</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3249</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3369</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA088616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Nexgen Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0722-7029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Nexgen Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0722-7320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209587</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-662</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-933</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>medsource pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>45865-352</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6938</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200243</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-823</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-15</started-marketing-on>
      <ended-marketing-on>2012-11-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040513</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine</name>
      <labeller>Westminster Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69367-203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209587</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine and Codeine Phosphate</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68258-2012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076560</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine and Codeine Phosphate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0194</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076560</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine and Codeine Phosphate</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-073</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076560</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5162</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA020232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3152</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0653</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075929</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>Vintage Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0254-3109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-22</started-marketing-on>
      <ended-marketing-on>2007-01-22</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2641</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076560</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-2553</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075929</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>Nexgen Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0722-6670</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076560</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>Nexgen Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0722-7028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076560</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3220</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetominophen and Caffeine</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4099</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040883</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetominophen and Caffeine</name>
      <labeller>Rising Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64980-154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-08</started-marketing-on>
      <ended-marketing-on>2010-07-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040864</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Acetominophen and Caffeine</name>
      <labeller>Rising Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64980-155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-27</started-marketing-on>
      <ended-marketing-on>2010-07-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040883</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-354</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>Goldline Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0182-1631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-03</started-marketing-on>
      <ended-marketing-on>2011-07-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66336-619</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>West Ward Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0143-1785</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-370</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-2951</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-06-05</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0339</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-09</started-marketing-on>
      <ended-marketing-on>2013-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-2548</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-06-05</started-marketing-on>
      <ended-marketing-on>2012-07-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-23</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-06-05</started-marketing-on>
      <ended-marketing-on>2018-08-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin and Caffeine</name>
      <labeller>Vensun Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42543-098</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204195</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>Mutual Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>53489-622</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-139</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086231</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-922</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-6554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-8372</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-934</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-31</started-marketing-on>
      <ended-marketing-on>2018-09-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, aspirin, and caffeine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-10-11</started-marketing-on>
      <ended-marketing-on>2017-07-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086996</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, aspirin, and caffeine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-10-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086996</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1464</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-06</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0228-2023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2011-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1465</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-06</started-marketing-on>
      <ended-marketing-on>2016-06-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, aspirin, and caffeine</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-10-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086996</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, aspirin, and caffeine</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-1552</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-10-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA086996</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <labeller>Jerome Stevens Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50564-507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1037</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074359</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0337</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019429</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-26</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019429</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-2952</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075231</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-1312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074951</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1993</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074951</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3546</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019429</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine, and Codeine Phosphate</name>
      <labeller>Endo Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60951-675</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-19</started-marketing-on>
      <ended-marketing-on>2006-09-19</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine, and Codeine Phosphate</name>
      <labeller>Watson Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-0425</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-17</started-marketing-on>
      <ended-marketing-on>2007-02-17</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Butalbital, Aspirin, Caffeine, and Codeine Phosphate</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68308-312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203335</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>C T Acetylsalicylic Acid Codeine and Caf Tab</name>
      <labeller>Pharmavite Laboratories (1987) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01908596</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2006-07-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>C-2 Buffered With Codeine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238670</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-06-15</started-marketing-on>
      <ended-marketing-on>2016-10-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>C2 Buffered Tab</name>
      <labeller>Wampole Brands, A Division Of Pangeo Pharma (Canada) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00693901</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>C2 Buffered With Codeine Tab</name>
      <labeller>Wampole Brands, A Division Of Pangeo Pharma (Canada) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00693979</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1999-06-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>C2 Tab With Codeine</name>
      <labeller>Wampole Brands, A Division Of Pangeo Pharma (Canada) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00693952</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cafcit</name>
      <labeller>Bedford Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55390-357</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-04</started-marketing-on>
      <ended-marketing-on>2016-04-30</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020793</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cafcit</name>
      <labeller>Bedford Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55390-358</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-04</started-marketing-on>
      <ended-marketing-on>2016-05-29</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA020793</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cafcit</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0641-6164</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020793</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cafergot</name>
      <labeller>Kaiser Foundations Hospitals</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA084294</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cafergot</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1953-04-24</started-marketing-on>
      <ended-marketing-on>2008-08-12</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>NDA009000</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cafergot</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA084294</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cafergot Pb Sup</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176214</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-12-31</started-marketing-on>
      <ended-marketing-on>2003-01-15</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cafergot Pb Tab</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176222</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cafergot Sup</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782920</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>2006-11-13</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cafergot Tab</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176095</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>2014-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Caffeine</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>69842-509</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>69842-500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine</name>
      <labeller>AAA Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57344-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine</name>
      <labeller>Added Dimensions</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229824</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-20</started-marketing-on>
      <ended-marketing-on>2006-09-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Caffeine 200 mg</name>
      <labeller>ULTRAtab Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62959-941</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength>200 mg/200mg</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine and Sodium Benzoate</name>
      <labeller>AMERICAN REGENT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0517-2502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>125 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Sun Pharmaceutical Industries Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>62756-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA090077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Sun Pharmaceutical Industries Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>62756-290</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090357</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Exela Pharma Sciences, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>51754-0500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA077233</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Paddock Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0574-0152</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-21</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077304</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Paddock Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0574-0823</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-21</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA077233</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Exela Pharma Sciences, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>51754-0501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077304</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Exela Pharma Sciences, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>51754-0503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077304</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Exela Pharma Sciences, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>51754-0502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA077233</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-734</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-31</started-marketing-on>
      <ended-marketing-on>2014-10-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090357</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Auro Medics Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55150-187</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205013</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA077997</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47335-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA090077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47335-290</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-02</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090357</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Micro Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code>42571-244</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 mg/3mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA207400</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-406</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078002</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>AMERICAN REGENT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0517-0020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA077906</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Sagent Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>25021-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA090827</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Citrate</name>
      <labeller>Sagent Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>25021-602</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caffeine Maximum Strength</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-345</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Calmine Tab</name>
      <labeller>Les Laboratoires Vachon Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00775231</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2008-02-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Capacet</name>
      <labeller>Magna Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58407-534</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-02</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089007</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Care One headache relief added strength</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-13</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Care One migraine relief</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Careline Perfect Care BB</name>
      <labeller>Cosmopharm Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>69939-690</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-17</started-marketing-on>
      <ended-marketing-on>2019-09-01</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part352</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Careline Perfect Care BB</name>
      <labeller>Cosmopharm Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>69939-645</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-17</started-marketing-on>
      <ended-marketing-on>2019-09-01</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part352</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Careone Stay Awake</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-708</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Circle K Headache Relief</name>
      <labeller>Lil' Drug Store Products, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66715-5738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Circle K Headache Relief Extra Strength</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-6706</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Circle K NoSnooze</name>
      <labeller>Lil' Drug Store Products, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66715-5730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on>2022-09-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citramon</name>
      <labeller>Borisovskiy Zavod Medicinskikh Preparatov Jsc</labeller>
      <ndc-id/>
      <ndc-product-code>16638-118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cl Light</name>
      <labeller>Powerful X</labeller>
      <ndc-id/>
      <ndc-product-code>70042-0003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cold Remedy Gan Mao Ling</name>
      <labeller>International Nature Nutraceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51367-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Comfort-Time</name>
      <labeller>Time Cap Labs, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>49483-347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Complete Menstrual Relief</name>
      <labeller>Western Family Foods, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55312-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-16</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Complete Menstrual Relief</name>
      <labeller>Good Sense (Geiss, Destin &amp; Dunn, Inc.)</labeller>
      <ndc-id/>
      <ndc-product-code>50804-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-16</started-marketing-on>
      <ended-marketing-on>2021-12-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ConRx Alert</name>
      <labeller>Eagle Distributors,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68737-229</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ConRx pain Reliever</name>
      <labeller>Eagle Distributors,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68737-234</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Corytab</name>
      <labeller>Les Laboratoires Vachon Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00776386</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>2009-02-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cotabs</name>
      <labeller>Pharmavite Laboratories (1987) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00162965</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1961-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cove Migraine Relief</name>
      <labeller>Thirty Madison Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71713-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Darvon N Compound Pulvule 405</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00261459</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-11</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Destim - Tab 200mg</name>
      <labeller>D &amp; E Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02130521</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2009-06-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dg Health Headache Relief Added Strength</name>
      <labeller>Dolgencorp</labeller>
      <ndc-id/>
      <ndc-product-code>55910-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-10</started-marketing-on>
      <ended-marketing-on>2017-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DG Health migraine relief</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>dihydrocodeine bitartrate and aspirin and caffeine DC</name>
      <labeller>EUSA Pharma (USA), Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57902-419</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-25</started-marketing-on>
      <ended-marketing-on>2012-12-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA011483</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dihydrocodeine Bitartrate, Acetaminophen and Caffeine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5900</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040701</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diurette Water Pills</name>
      <labeller>Alva Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238753</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Diurex Ultimate</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diurex Ultra</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diurex Water Pills</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diurex Water Pills XPL</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-406</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diurex Water Pills XPL</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diurex WaterCaps</name>
      <labeller>Alva Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-613</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part357</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dolex Forte</name>
      <labeller>Pharmadel LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55758-019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dolgic Plus</name>
      <labeller>Shionogi</labeller>
      <ndc-id/>
      <ndc-product-code>59630-074</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-10</started-marketing-on>
      <ended-marketing-on>2015-01-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040496</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dolomine 37</name>
      <labeller>Frega Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00774626</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2008-02-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dristan Capsules</name>
      <labeller>Whitehall Robins Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01929399</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-04</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drowz Away Maximum strength</name>
      <labeller>Care One (American Sales Company)</labeller>
      <ndc-id/>
      <ndc-product-code>41520-252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-31</started-marketing-on>
      <ended-marketing-on>2020-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drowz Away Maximum strength</name>
      <labeller>Care One (American Sales Company)</labeller>
      <ndc-id/>
      <ndc-product-code>41520-051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-05</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dvorah</name>
      <labeller>Skylar Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70362-730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204209</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dvorah</name>
      <labeller>Phlight Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70569-152</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204209</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emercidin D Tab</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00763519</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2001-03-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Emertabs Tab</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00789305</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Equaline headache formula added strength</name>
      <labeller>Supervalu</labeller>
      <ndc-id/>
      <ndc-product-code>41163-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-08-30</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Equaline migraine formula</name>
      <labeller>SUPERVALU INC</labeller>
      <ndc-id/>
      <ndc-product-code>41163-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Equaline Stay Awake</name>
      <labeller>Supervalu</labeller>
      <ndc-id/>
      <ndc-product-code>41163-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-08-30</started-marketing-on>
      <ended-marketing-on>2014-07-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Equate Migraine Relief</name>
      <labeller>Walmart Stores</labeller>
      <ndc-id/>
      <ndc-product-code>49035-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-16</started-marketing-on>
      <ended-marketing-on>2015-03-18</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ercaf</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-01-01</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA084294</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ergodryl Cap</name>
      <labeller>Erfa Canada 2012 Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00156086</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on>2013-07-09</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ergotamine</name>
      <labeller>West Ward Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0143-2120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ergotamine Tartrate and Caffeine</name>
      <labeller>Mikart, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46672-198</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040590</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ergotamine Tartrate and Caffeine</name>
      <labeller>Kaiser Foundations Hospitals</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0067</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-25</started-marketing-on>
      <ended-marketing-on>2011-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040590</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ergotamine Tartrate and Caffeine</name>
      <labeller>Cintex Services, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>24470-917</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040590</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esgic</name>
      <labeller>Forest Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0535-0011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-06-01</started-marketing-on>
      <ended-marketing-on>2015-02-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esgic</name>
      <labeller>Forest Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0535-0012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-04-09</started-marketing-on>
      <ended-marketing-on>2016-08-28</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089007</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esgic</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68308-219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089007</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esgic</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68308-220</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089175</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esgic-Plus</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2778</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-10</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089451</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esgic-Plus</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-3441</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-10</started-marketing-on>
      <ended-marketing-on>2014-06-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089451</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esgic-Plus</name>
      <labeller>Forest Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0456-0679</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040085</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esgic-Plus</name>
      <labeller>Forest Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0456-0678</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-10</started-marketing-on>
      <ended-marketing-on>2014-06-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089451</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exaprin</name>
      <labeller>HART Health</labeller>
      <ndc-id/>
      <ndc-product-code>50332-0105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin</name>
      <labeller>Bristol Myers Squibb</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01990683</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>2004-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Excedrin Extra Strength</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0834</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9710</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-10</started-marketing-on>
      <ended-marketing-on>2016-06-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-27</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength</name>
      <labeller>Navajo Manufacturing Company Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67751-141</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength</name>
      <labeller>Lil Drug Store Products, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01990675</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>2019-02-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Excedrin Extra Strength and Excedrin Tension Headache</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength and Excedrin Tension Headache</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength Caplets</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength Geltabs</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength Pain Reliever</name>
      <labeller>Jones Contract Packaging Services</labeller>
      <ndc-id/>
      <ndc-product-code>67414-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength Pain Reliever</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength Pain Reliever</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Extra Strength Pain Reliever</name>
      <labeller>Mechanical Servants Llc</labeller>
      <ndc-id/>
      <ndc-product-code>29485-8027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Menstrual Complete</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-6341</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on>2017-07-31</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Migraine</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0835</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Migraine</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2037</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-15</started-marketing-on>
      <ended-marketing-on>2014-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Migraine</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-22</started-marketing-on>
      <ended-marketing-on>2018-03-07</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Migraine</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9749</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Migraine</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2039</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Migraine</name>
      <labeller>Jones Contract Packaging Services</labeller>
      <ndc-id/>
      <ndc-product-code>67414-239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EXCEDRIN MIGRAINE acetaminophen, aspirin (nsaid) and caffeine</name>
      <labeller>Mechanical Servants Llc</labeller>
      <ndc-id/>
      <ndc-product-code>29485-8028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Migraine Geltabs</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2035</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Mild Headache Caplets</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-24</started-marketing-on>
      <ended-marketing-on>2017-01-10</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin PM Triple Action Caplets and Excedrin Extra Strength Pain Reliever</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin PM Triple Action Caplets and Excedrin Tension Headache</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Tension Headache</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-10-31</started-marketing-on>
      <ended-marketing-on>2011-07-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EXCEDRIN Tension Headache</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-10-31</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Tension Headache</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8139</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excedrin Tension Headache</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02267586</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-05</started-marketing-on>
      <ended-marketing-on>2019-02-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Excedrin Tension Headache Pain Reliever</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-8119</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-27</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Excinol Migraine (Acetaminophen)</name>
      <labeller>America Medic &amp; Science, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49638-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, delayed release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exdol 15tab</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00372331</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on>1998-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exdol 30tab</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00372358</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on>1998-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exdol 8 Tab</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00372323</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on>1998-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exdol-15</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02232388</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-09-01</started-marketing-on>
      <ended-marketing-on>2016-07-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exdol-30</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02232389</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-09-01</started-marketing-on>
      <ended-marketing-on>2016-07-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exdol-8</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02232387</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-08-01</started-marketing-on>
      <ended-marketing-on>2016-07-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Extra Pain Relief</name>
      <labeller>Time Cap Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>49483-370</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Pain Relief</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Pain Relief</name>
      <labeller>Apace Packaging, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>15338-703</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Pain Relief Acetaminophen, Aspirin (NSAID) and Caffeine</name>
      <labeller>Medline Industries</labeller>
      <ndc-id/>
      <ndc-product-code>53329-988</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Pain Reliever</name>
      <labeller>Gericare Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57896-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Pain Reliever</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strenght Headache Relief</name>
      <labeller>Spirit Pharmaceutical LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68210-0017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Back and Body</name>
      <labeller>Dolgencorp</labeller>
      <ndc-id/>
      <ndc-product-code>55910-314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-12</started-marketing-on>
      <ended-marketing-on>2016-09-13</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Back and Body</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Contac Plus Cold Nasal Congestion</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288168</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Extra Strength Headach Relief</name>
      <labeller>Mechanical Servants Llc</labeller>
      <ndc-id/>
      <ndc-product-code>29485-0751</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-669</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2014-06-19</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Target Corporation.</labeller>
      <ndc-id/>
      <ndc-product-code>11673-788</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-09</started-marketing-on>
      <ended-marketing-on>2018-11-04</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Sam's West, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68196-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2015-10-09</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Family Dollar Services</labeller>
      <ndc-id/>
      <ndc-product-code>55319-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2019-07-08</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>49781-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2020-05-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Healthlife of Usa</labeller>
      <ndc-id/>
      <ndc-product-code>69517-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Rite Aid</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2011-08-04</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Mechanical Servants Llc</labeller>
      <ndc-id/>
      <ndc-product-code>29485-0752</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Spirit Pharmaceutical LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68210-0170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Headache Relief</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2020-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Menstrual Complete</name>
      <labeller>Vita Health Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306328</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-14</started-marketing-on>
      <ended-marketing-on>2014-07-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Extra Strength Midol</name>
      <labeller>Bayer Inc Consumer Care</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02217732</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-01</started-marketing-on>
      <ended-marketing-on>2007-08-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Extra Strength Midol Relief</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247967</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Extra Strength Pain Reliever</name>
      <labeller>Rite Aid</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0751</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-09</started-marketing-on>
      <ended-marketing-on>2018-11-11</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Pain Reliever</name>
      <labeller>Redicare Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71105-242</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Pain Reliever</name>
      <labeller>Spirit Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68210-1700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Extra Strength Pain Reliever</name>
      <labeller>Chain Drug Consortium, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68016-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Family Wellness Migraine Relief</name>
      <labeller>Family Dollar Services Inc</labeller>
      <ndc-id/>
      <ndc-product-code>55319-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fioricet</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-02-15</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA088616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fioricet</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-957</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-11-09</started-marketing-on>
      <ended-marketing-on>2013-07-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA088616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fioricet</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3416</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-11-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA088616</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fioricet</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-080</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fioricet</name>
      <labeller>McKesson Corporation dba RX Pak</labeller>
      <ndc-id/>
      <ndc-product-code>65084-454</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fioricet with Codeine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-24</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fioricet with Codeine</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-958</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-07-30</started-marketing-on>
      <ended-marketing-on>2013-07-26</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fioricet with Codeine</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-082</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076560</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fiorinal</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-05-04</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fiorinal</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0023-6146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fiorinal</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-955</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-05-04</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017534</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fiorinal</name>
      <labeller>Aralez Pharmaceuticals Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00226327</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fiorinal Tab</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00275328</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>2009-08-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fiorinal with Codeine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-10-26</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019429</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fiorinal with Codeine</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-6010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019429</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fiorinal with Codeine</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-956</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-10-26</started-marketing-on>
      <ended-marketing-on>2020-03-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019429</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fiorinal-C 1/2</name>
      <labeller>Aralez Pharmaceuticals Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176206</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fiorinal-C 1/4</name>
      <labeller>Aralez Pharmaceuticals Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176192</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>First Aid Shot Therapy Hangover Relief</name>
      <labeller>First Aid Beverages, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57815-041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>First Aid Shot Therapy Pain relief</name>
      <labeller>First Aid Beverages, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57815-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>First Aid Shot Therapy Pain Relief</name>
      <labeller>First Aid Beverages, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57815-081</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Formu Care pain reliever added strength</name>
      <labeller>Access Business Group</labeller>
      <ndc-id/>
      <ndc-product-code>10056-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-20</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ganmaoling 999</name>
      <labeller>Kingsway Trading</labeller>
      <ndc-id/>
      <ndc-product-code>63922-600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Granule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Geworin</name>
      <labeller>OASIS TRADING</labeller>
      <ndc-id/>
      <ndc-product-code>72689-0019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy headache relief</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>24385-544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-23</started-marketing-on>
      <ended-marketing-on>2009-02-23</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy Headache Relief</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>24385-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-06-16</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy Migraine Relief</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>24385-365</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy Stay Awake</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>24385-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Sense headache formula added strength</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-0430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-01-20</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Sense Migraine Formula</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-0374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Sense Stay Awake</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-0409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys</name>
      <labeller>Glaxo Smith Kline Consumer Heathcare Lp</labeller>
      <ndc-id/>
      <ndc-product-code>10158-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-08</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys</name>
      <labeller>Glaxo Smith Kline Consumer Heathcare Lp</labeller>
      <ndc-id/>
      <ndc-product-code>0135-0462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-23</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Cool Orange</name>
      <labeller>Lil' Drug Store Products, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66715-5301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-01</started-marketing-on>
      <ended-marketing-on>2021-05-11</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Cool Orange Headache</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-663</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Extra Strength</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-662</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Extra Strength</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-655</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Extra Strength</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-633</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Extra Strength</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-644</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Extra Strength</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-677</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GOODYS Extra Strength Headache Mixed Fruit Blast</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-664</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GOODYS Hangover</name>
      <labeller>Medtech Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-665</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Headache Relief Shot</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-639</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Headache Relief Shot</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-629</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys Migraine Relief</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-612</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Goodys PM Pain Reliever</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gravergol Capsules</name>
      <labeller>Can Med Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00116858</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1957-12-31</started-marketing-on>
      <ended-marketing-on>2011-12-07</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Green Guard Pain and Ache Relief</name>
      <labeller>Unifirst First Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47682-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Handy Solutions Headache Pain Relief</name>
      <labeller>Navajo Manufacturing Company Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67751-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Harris Teeter Migraine Relief</name>
      <labeller>Harris Teeter, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69256-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Formula Added Strength</name>
      <labeller>Meijer Distribution</labeller>
      <ndc-id/>
      <ndc-product-code>41250-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-03-06</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Formula Added Strength</name>
      <labeller>Kroger</labeller>
      <ndc-id/>
      <ndc-product-code>30142-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-01-30</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Formula Added Strength</name>
      <labeller>Hyvee</labeller>
      <ndc-id/>
      <ndc-product-code>42507-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-01-17</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Formula Added Strength</name>
      <labeller>Hannaford Brothers Company</labeller>
      <ndc-id/>
      <ndc-product-code>41268-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-07-13</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Formula Extra Strength</name>
      <labeller>ARMY AND AIR FORCE EXCHANGE SERVICE</labeller>
      <ndc-id/>
      <ndc-product-code>55301-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Formula Extra Strength</name>
      <labeller>ARMY AND AIR FORCE EXCHANGE SERVICE</labeller>
      <ndc-id/>
      <ndc-product-code>55301-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Pain Reliever</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>Nash Finch</labeller>
      <ndc-id/>
      <ndc-product-code>70253-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2019-01-26</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>We Care Distributor Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70005-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-433</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-30</started-marketing-on>
      <ended-marketing-on>2020-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>L.N.K. International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-258</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>SUPERVALU INC.</labeller>
      <ndc-id/>
      <ndc-product-code>41163-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0359</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>AAA Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57344-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>Goodsense</labeller>
      <ndc-id/>
      <ndc-product-code>50804-283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>SMART SENSE (Kmart)</labeller>
      <ndc-id/>
      <ndc-product-code>49738-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>Harris Teeter</labeller>
      <ndc-id/>
      <ndc-product-code>72036-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Added Strength</name>
      <labeller>Medicine Shoppe International</labeller>
      <ndc-id/>
      <ndc-product-code>49614-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-04-09</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Added Strength</name>
      <labeller>Western Family Foods</labeller>
      <ndc-id/>
      <ndc-product-code>55312-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-20</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Added Strength</name>
      <labeller>Publix Supermarkets, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>56062-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-08-24</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>SMART SENSE (Kmart)</labeller>
      <ndc-id/>
      <ndc-product-code>49738-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Walmart Stores</labeller>
      <ndc-id/>
      <ndc-product-code>49035-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2017-08-19</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Lnk International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-807</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-915</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2019-04-19</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Supervalu</labeller>
      <ndc-id/>
      <ndc-product-code>41163-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2020-12-28</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>FRED'S, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>55315-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2021-07-20</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache relief Extra Strength</name>
      <labeller>AmerisourceBergen (Good Neighbor Pharmacy) 46122</labeller>
      <ndc-id/>
      <ndc-product-code>46122-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-15</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Marc Glassman, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68998-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>MEIJER, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>41250-248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-28</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache relief Extra Strength</name>
      <labeller>Hy-Vee</labeller>
      <ndc-id/>
      <ndc-product-code>42507-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-15</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Publix Supermarkets, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>56062-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-19</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>P &amp; L Development, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>59726-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-01</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>TOP CARE (Topco Associates LLC)</labeller>
      <ndc-id/>
      <ndc-product-code>36800-147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-31</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Western Family Foods, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55312-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-31</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Allegiant Health</labeller>
      <ndc-id/>
      <ndc-product-code>69168-285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-30</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache relief Extra Strength</name>
      <labeller>Western Family Foods, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55312-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-19</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>L.N.K. International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Greenbrier International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>33992-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Dolgencorp, Inc. (Dollar General &amp; Rexall)</labeller>
      <ndc-id/>
      <ndc-product-code>55910-686</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-09</started-marketing-on>
      <ended-marketing-on>2022-03-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0586</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>WAL-MART STORES INC</labeller>
      <ndc-id/>
      <ndc-product-code>49035-433</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-547</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-31</started-marketing-on>
      <ended-marketing-on>2020-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Hy-Vee</labeller>
      <ndc-id/>
      <ndc-product-code>42507-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-28</started-marketing-on>
      <ended-marketing-on>2021-03-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Dolgencorp, Inc. (Dollar General &amp; Rexall)</labeller>
      <ndc-id/>
      <ndc-product-code>55910-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-08</started-marketing-on>
      <ended-marketing-on>2020-07-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>WAL-MART STORES INC</labeller>
      <ndc-id/>
      <ndc-product-code>49035-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on>2020-09-11</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>SMART SENSE (Kmart)</labeller>
      <ndc-id/>
      <ndc-product-code>49738-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-31</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Salado Sales, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57243-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Family Dollar (FAMILY WELLNESS)</labeller>
      <ndc-id/>
      <ndc-product-code>55319-586</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Valu Merchandisers Company</labeller>
      <ndc-id/>
      <ndc-product-code>63941-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>GREAT LAKES WHOLESALE, MARKETING, &amp; SALES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>64092-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Family Dollar (FAMILY WELLNESS)</labeller>
      <ndc-id/>
      <ndc-product-code>55319-625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0443</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0751</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>CHAIN DRUG MARKETING ASSOCIATION INC</labeller>
      <ndc-id/>
      <ndc-product-code>63868-485</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-883</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>TOP CARE (Topco Associates LLC)</labeller>
      <ndc-id/>
      <ndc-product-code>36800-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-686</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Publix Supermarkets, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>56062-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-30</started-marketing-on>
      <ended-marketing-on>2021-12-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Publix Supermarkets, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>56062-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0258</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-594</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>69842-586</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>69842-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>AmerisourceBergen (Good Neighbor Pharmacy) 46122</labeller>
      <ndc-id/>
      <ndc-product-code>46122-248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-31</started-marketing-on>
      <ended-marketing-on>2021-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>AmerisourceBergen (Good Neighbor Pharmacy) 46122</labeller>
      <ndc-id/>
      <ndc-product-code>46122-382</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Dolgencorp, Inc. (Dollar General &amp; Rexall)</labeller>
      <ndc-id/>
      <ndc-product-code>55910-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-31</started-marketing-on>
      <ended-marketing-on>2021-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>FRED'S, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>55315-934</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>WinCo Foods, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67091-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>P &amp; L Development, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>59726-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Dolgencorp, Inc. (Dollar General &amp; Rexall)</labeller>
      <ndc-id/>
      <ndc-product-code>55910-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>L.N.K. International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Dolgencorp, Inc. (Dollar General &amp; Rexall)</labeller>
      <ndc-id/>
      <ndc-product-code>55910-625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>EQUATE (Wal-Mart Stores, Inc.)</labeller>
      <ndc-id/>
      <ndc-product-code>49035-786</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>The Kroger Co.</labeller>
      <ndc-id/>
      <ndc-product-code>30142-625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Hy-Vee</labeller>
      <ndc-id/>
      <ndc-product-code>42507-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache relief Extra Strength</name>
      <labeller>Good Sense (Geiss, Destin &amp; Dunn, Inc.)</labeller>
      <ndc-id/>
      <ndc-product-code>50804-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-18</started-marketing-on>
      <ended-marketing-on>2021-12-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Good Sense (Geiss, Destin &amp; Dunn, Inc.)</labeller>
      <ndc-id/>
      <ndc-product-code>50804-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-30</started-marketing-on>
      <ended-marketing-on>2021-12-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Good Sense (Geiss, Destin &amp; Dunn, Inc.)</labeller>
      <ndc-id/>
      <ndc-product-code>50804-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Extra Strength</name>
      <labeller>Family Dollar (FAMILY WELLNESS)</labeller>
      <ndc-id/>
      <ndc-product-code>55319-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-31</started-marketing-on>
      <ended-marketing-on>2021-12-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief Mild</name>
      <labeller>Meijer</labeller>
      <ndc-id/>
      <ndc-product-code>41250-673</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-01</started-marketing-on>
      <ended-marketing-on>2019-03-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief to Go</name>
      <labeller>Breakthrough Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51596-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-15</started-marketing-on>
      <ended-marketing-on>2013-08-01</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief to Go</name>
      <labeller>Breakthrough Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51596-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief To Go</name>
      <labeller>Breakthrough Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51596-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Headache Relief To Go</name>
      <labeller>Breakthrough Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51596-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Health Mart Migraine Formula</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-29</started-marketing-on>
      <ended-marketing-on>2016-07-06</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Health Mart Migraine Relief</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0243</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Health Mart Stay Awake</name>
      <labeller>McKesson</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-21</started-marketing-on>
      <ended-marketing-on>2019-10-16</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Healthy Accents headache relief added strength</name>
      <labeller>Dza Brands,</labeller>
      <ndc-id/>
      <ndc-product-code>55316-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-11</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Healthy Accents migraine formula</name>
      <labeller>DZA Brands LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55316-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Healthy Accents Stay Awake</name>
      <labeller>DZA Brands LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55316-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-04</started-marketing-on>
      <ended-marketing-on>2020-06-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Herbopyrine Tab 325mg</name>
      <labeller>Herbes Universelles Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00738220</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2009-07-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Instantine - Tablets</name>
      <labeller>Bayer Inc Consumer Care</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02150468</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on>2007-08-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Instantine Tab</name>
      <labeller>Sterling Winthrop Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01928279</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isometheptene Mucate, Caffeine, Acetaminophen</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-01</started-marketing-on>
      <ended-marketing-on>2010-09-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isometheptene Mucate, Caffeine, and Acetaminophen</name>
      <labeller>Burel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35573-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-17</started-marketing-on>
      <ended-marketing-on>2017-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isometheptene Mucate, Caffeine, and Acetaminophen</name>
      <labeller>Womens Choice Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50967-620</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-12</started-marketing-on>
      <ended-marketing-on>2014-01-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isometheptene Mucate, Caffeine, and Acetaminophen</name>
      <labeller>Xspire Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>42195-145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-01</started-marketing-on>
      <ended-marketing-on>2018-01-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>JET ALERT Double Strength</name>
      <labeller>Bell Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>15579-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>JET ALERT Regular Strength</name>
      <labeller>Bell International Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>15579-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>jet-Alert Maximum Strength Alertness Aid</name>
      <labeller>Bell International Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>15579-824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-26</started-marketing-on>
      <ended-marketing-on>2016-01-07</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Alertness Aid</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-195</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-02-10</started-marketing-on>
      <ended-marketing-on>2012-03-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Headache Formula Added Strength</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-703</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-04-02</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader migraine formula</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader migraine formula</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-195</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-24</started-marketing-on>
      <ended-marketing-on>2017-01-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader migraine formula</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-280</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-16</started-marketing-on>
      <ended-marketing-on>2019-03-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Migraine Relief</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lil Drug Store Headache Relief Extra Strength</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-27</started-marketing-on>
      <ended-marketing-on>2021-09-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lil Drug Store Headache Relief Extra Strength</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-6822</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lil Drug Store Headache Relief Extra Strength</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-5822</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lil Drug Store NoSnooz Maximum Strength</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-6830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-23</started-marketing-on>
      <ended-marketing-on>2021-06-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lil Drug Store NoSnooze</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-08</started-marketing-on>
      <ended-marketing-on>2021-07-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lil Drug Store NoSnooze</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-08</started-marketing-on>
      <ended-marketing-on>2021-07-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Madelon</name>
      <labeller>Les Laboratoires Du Saint Laurent E.H. Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00800511</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Margesic</name>
      <labeller>Marnel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0682-0804</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-06-01</started-marketing-on>
      <ended-marketing-on>2018-10-15</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089007</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Maximum Strength Menstrual Complete</name>
      <labeller>Rite Aid</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-14</started-marketing-on>
      <ended-marketing-on>2018-11-11</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Medi First Pain Relief</name>
      <labeller>Unifirst First Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47682-811</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Medi First Plus Pain Zapper</name>
      <labeller>Unifirst First Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47682-911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MEDIQUE Back Pain Off</name>
      <labeller>Unifirst First Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47682-073</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Medique Pain Off</name>
      <labeller>Unifirst First Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47682-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Megral Tabs</name>
      <labeller>Glaxo Wellcome</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00068586</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2001-03-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Menstrual Complete</name>
      <labeller>Healthlife of Usa</labeller>
      <ndc-id/>
      <ndc-product-code>69517-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete</name>
      <labeller>WinCo Foods, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67091-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete</name>
      <labeller>WinCo Foods, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67091-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-31</started-marketing-on>
      <ended-marketing-on>2020-12-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete</name>
      <labeller>TOPCO ASSOCIATES, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete</name>
      <labeller>The Kroger Co.</labeller>
      <ndc-id/>
      <ndc-product-code>30142-181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete</name>
      <labeller>Tanta Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02397420</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Menstrual Complete Maximum Strength</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on>2020-10-16</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete Maximum Strength</name>
      <labeller>WAL-MART STORES INC</labeller>
      <ndc-id/>
      <ndc-product-code>49035-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete Maximum Strength</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete Maximum Strength</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete Maximum Strength</name>
      <labeller>L.N.K. International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-930</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete Maximum Strength</name>
      <labeller>CHAIN DRUG MARKETING ASSOCIATION INC</labeller>
      <ndc-id/>
      <ndc-product-code>63868-032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete Maximum Strength</name>
      <labeller>L.N.K. International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Complete Maximum Strength</name>
      <labeller>H E B</labeller>
      <ndc-id/>
      <ndc-product-code>37808-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Midol Complete</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02275201</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Menstrual Pain Relief</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-3900</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>Velocity Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>76168-064</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>Woonsocket Prescription Center, Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>59779-391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-14</started-marketing-on>
      <ended-marketing-on>2015-02-24</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-14</started-marketing-on>
      <ended-marketing-on>2018-09-16</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>We Care Distributor Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70005-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>Better Living Brands</labeller>
      <ndc-id/>
      <ndc-product-code>21130-391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-14</started-marketing-on>
      <ended-marketing-on>2015-02-24</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>L&amp;R Distributors, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>15127-938</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on>2021-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>TOP CARE (Topco Associates LLC)</labeller>
      <ndc-id/>
      <ndc-product-code>36800-187</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-930</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief</name>
      <labeller>Freds Inc</labeller>
      <ndc-id/>
      <ndc-product-code>55315-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-15</started-marketing-on>
      <ended-marketing-on>2021-12-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Extra Strength</name>
      <labeller>Better Living Brands, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>21130-990</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>Better Living Brands</labeller>
      <ndc-id/>
      <ndc-product-code>21130-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on>2017-12-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>MEIJER, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>41250-193</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-30</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>SUPERVALU INC.</labeller>
      <ndc-id/>
      <ndc-product-code>41163-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-736</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>ASSURED / DOLLAR TREE (Greenbrier International, Inc.)</labeller>
      <ndc-id/>
      <ndc-product-code>33992-0183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-31</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-20</started-marketing-on>
      <ended-marketing-on>2020-05-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-31</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>Chain Drug Consortium, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68016-300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-14</started-marketing-on>
      <ended-marketing-on>2019-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>Care One (American Sales Company)</labeller>
      <ndc-id/>
      <ndc-product-code>41520-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-20</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>GREAT LAKES WHOLESALE, MARKETING, &amp; SALES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>64092-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menstrual Relief Maximum Strength</name>
      <labeller>Family Dollar Services Inc</labeller>
      <ndc-id/>
      <ndc-product-code>55319-391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol</name>
      <labeller>Savings Distributors LLC</labeller>
      <ndc-id/>
      <ndc-product-code>73097-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol</name>
      <labeller>Navajo Manufacturing Company Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67751-145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Complete</name>
      <labeller>Your Safety Company</labeller>
      <ndc-id/>
      <ndc-product-code>70262-303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Complete</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>0280-8005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Complete</name>
      <labeller>Jc World Bell Wholesale Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50269-204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-14</started-marketing-on>
      <ended-marketing-on>2014-07-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Complete</name>
      <labeller>R J General Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>70264-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Complete</name>
      <labeller>Lil' Drug Store Products, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9745</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Complete</name>
      <labeller>Jc World Bell Wholesale Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50269-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Complete</name>
      <labeller>Jc World Bell Wholesale Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50269-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Complete Gelcaps</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0280-8015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Midol Extra Strength Gelcaps</name>
      <labeller>Bayer Inc Consumer Care</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02236973</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-06-02</started-marketing-on>
      <ended-marketing-on>2004-06-28</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Midol Extra Strength Menstrual</name>
      <labeller>Bayer Inc Consumer Care</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02236972</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-06-02</started-marketing-on>
      <ended-marketing-on>2007-08-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Midol Multi-symptom Caplets Extra Strength</name>
      <labeller>Sterling Winthrop Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02047705</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Midol Multi-symptom Caplets Extra Strength</name>
      <labeller>Bayer Inc Consumer Care</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02150484</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>1998-07-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Midol Multi-symptom Gelcap Extra Strength</name>
      <labeller>Bayer Inc Consumer Care</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02150492</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>1998-07-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Midol One</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02273438</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Midol Regular</name>
      <labeller>Bayer Inc Consumer Care</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237094</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-06</started-marketing-on>
      <ended-marketing-on>2007-08-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Migergot</name>
      <labeller>Horizon Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60809-166</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-01</started-marketing-on>
      <ended-marketing-on>2017-11-30</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>ANDA086557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migergot</name>
      <labeller>Horizon Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75987-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>ANDA086557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migergot</name>
      <labeller>Cosette Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0713-0166</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>ANDA086557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Formula</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-07</started-marketing-on>
      <ended-marketing-on>2017-03-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Formula</name>
      <labeller>Western Family Foods</labeller>
      <ndc-id/>
      <ndc-product-code>55312-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-10-04</started-marketing-on>
      <ended-marketing-on>2017-08-09</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Formula</name>
      <labeller>HYVEE INC</labeller>
      <ndc-id/>
      <ndc-product-code>42507-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-09</started-marketing-on>
      <ended-marketing-on>2019-02-25</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Formula</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Formula</name>
      <labeller>H E B</labeller>
      <ndc-id/>
      <ndc-product-code>37808-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Formula</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Relief</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-550</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-28</started-marketing-on>
      <ended-marketing-on>2017-05-05</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Relief</name>
      <labeller>Hannaford Brothers Company</labeller>
      <ndc-id/>
      <ndc-product-code>41268-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-10-31</started-marketing-on>
      <ended-marketing-on>2012-05-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Relief</name>
      <labeller>Publix Super Markets Inc</labeller>
      <ndc-id/>
      <ndc-product-code>56062-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Relief</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Relief</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-896</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Relief</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Relief</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migraine Relief</name>
      <labeller>Shopko Stores Operating Co., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>37012-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MigraTen</name>
      <labeller>Azur Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66663-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-01</started-marketing-on>
      <ended-marketing-on>2010-06-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Migrenol</name>
      <labeller>Four Ventures Enterprises, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69293-565</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nano Ppc</name>
      <labeller>YBK Investment, INC</labeller>
      <ndc-id/>
      <ndc-product-code>60709-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>5.0 mg/1000mL</strength>
      <route>Topical</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nano Ppc</name>
      <labeller>YBK Investment, INC</labeller>
      <ndc-id/>
      <ndc-product-code>60709-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neo Tigol Tab</name>
      <labeller>Hilary's Distibution Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00492426</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on>2000-06-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nervine</name>
      <labeller>J L Mathieu Cie Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00766178</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1967-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nervine Tab</name>
      <labeller>J L Mathieu Cie Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00763578</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1967-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>NoDoz Alertness Aid Maximum Strength</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-9799</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NoDoz MAXIMUM STRENGTH ALERTNESS AID</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0067-2070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-31</started-marketing-on>
      <ended-marketing-on>2019-07-11</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgesic</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-03-04</started-marketing-on>
      <ended-marketing-on>2006-12-31</ended-marketing-on>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA013416</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgesic</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0089-0231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-03-04</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA013416</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgesic Forte</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0089-0233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-03-04</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA013416</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgesic Forte</name>
      <labeller>Poly Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50991-999</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075141</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgesic Forte Tab</name>
      <labeller>3 M Pharmaceuticals, A Division Of 3 M Canada Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01966189</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on>2006-07-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Norgesic Tab</name>
      <labeller>3 M Pharmaceuticals, A Division Of 3 M Canada Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01966170</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on>2006-07-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>NoSnooze Circle K</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-5830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NoSnooze Circle K</name>
      <labeller>Lil' Drug Store Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66715-5930</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novo Ac and C 8mg Tab</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00426865</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-gesic C15</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00687200</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>2003-02-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-gesic C30</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00687219</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>2003-02-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-gesic-C8</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00615528</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-propoxyn Compound Cap</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00277118</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>2005-08-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-acetaco #1</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02336472</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Only For HEADACHE</name>
      <labeller>O4 Global Trading Usa, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>73006-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oradrine 2 Tab</name>
      <labeller>Nutribon (1986) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01940783</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2001-03-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Oradrine Tablets</name>
      <labeller>Pharmavite Laboratories (1987) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00763527</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2001-03-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Orbivan</name>
      <labeller>Atley Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>59702-661</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orbivan</name>
      <labeller>ECR Pharmaceuticals Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0095-7029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-21</started-marketing-on>
      <ended-marketing-on>2013-07-17</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orphenadrine Citrate, Aspirin and Caffeine</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074654</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orphenadrine Citrate, Aspirin and Caffeine</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0713</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>2013-11-30</ended-marketing-on>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074654</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orphenadrine Citrate, Aspirin and Caffeine</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0714</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>2014-11-30</ended-marketing-on>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074654</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orphenadrine Citrate, Aspirin and Caffeine</name>
      <labeller>Atland Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71993-999</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075141</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orphengesic Forte</name>
      <labeller>Galt Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>61825-999</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075141</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Aid</name>
      <labeller>Zee Medical</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00806773</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pain Aid ESF</name>
      <labeller>Zee Medical Inc</labeller>
      <ndc-id/>
      <ndc-product-code>35418-560</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Away Plus</name>
      <labeller>Medex Merchandising, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>68826-180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-15</started-marketing-on>
      <ended-marketing-on>2019-03-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Free</name>
      <labeller>Afassco Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51532-0242</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Free Plus</name>
      <labeller>Afassco Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51532-0560</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Relief Added Strength</name>
      <labeller>Better Living Brands, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>21130-959</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>pain relief back and body EXTRA STRENGTH</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-4130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Relief Extra Strength</name>
      <labeller>L&amp;R Distributors, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>15127-857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2021-08-03</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Relief Maximum Strength</name>
      <labeller>Select Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>52904-468</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever</name>
      <labeller>Advanced First Aid, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67060-113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Added Strength</name>
      <labeller>Target Corporation.</labeller>
      <ndc-id/>
      <ndc-product-code>11673-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on>2018-05-07</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Extra Strength</name>
      <labeller>Costco Wholesale</labeller>
      <ndc-id/>
      <ndc-product-code>63981-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Extra Strength</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Extra Strength</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-1590</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Plus</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-4672</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Plus</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-5135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Plus</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-5135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Plus</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-18</started-marketing-on>
      <ended-marketing-on>2017-04-28</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Plus</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-5135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Reliever Plus</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0852</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Stopper Extra</name>
      <labeller>North Safety Products</labeller>
      <ndc-id/>
      <ndc-product-code>0498-2420</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-07</started-marketing-on>
      <ended-marketing-on>2017-01-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Stoppers</name>
      <labeller>Honeywell Safety Products USA, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0498-2422</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Stoppers EX</name>
      <labeller>Honeywell Safety Products USA, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0498-2521</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Stoppers Extra</name>
      <labeller>Honeywell Safety Products USA, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0498-2520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-07</started-marketing-on>
      <ended-marketing-on>2017-01-04</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pain Stoppers Regular</name>
      <labeller>Honeywell Safety Products USA, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0498-2421</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-18</started-marketing-on>
      <ended-marketing-on>2017-01-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Painex Tab 0.25gr</name>
      <labeller>Icn Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00294942</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Painex Tab 0.5gr</name>
      <labeller>Icn Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00295124</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pamprin Max Menstrual Pain Relief</name>
      <labeller>Chattem, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>41167-3006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pamprin Max Menstrual Pain Relief</name>
      <labeller>Focus Consumer Healthcare, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71687-3006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PANADOL Extra</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0135-0620</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pancold S</name>
      <labeller>Kafus Co., Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>55277-1001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panlor</name>
      <labeller>Skylar Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70362-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-09</started-marketing-on>
      <ended-marketing-on>2019-02-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204209</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panlor SS</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5594</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-18</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040316</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Penzal Q</name>
      <labeller>OASIS TRADING</labeller>
      <ndc-id/>
      <ndc-product-code>72689-0034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pep-Back Peak Performance</name>
      <labeller>Alva Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pep-Back Ultra</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peyona</name>
      <labeller>Chiesi Farmaceutici Sp A</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001014</ema-product-code>
      <ema-ma-number>EU/1/09/528/001</ema-ma-number>
      <started-marketing-on>2009-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution; Solution</dosage-form>
      <strength>20 mg/ml</strength>
      <route>Intravenous; Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Peyona</name>
      <labeller>Chiesi Farmaceutici Sp A</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001014</ema-product-code>
      <ema-ma-number>EU/1/09/528/002</ema-ma-number>
      <started-marketing-on>2009-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution; Solution</dosage-form>
      <strength>20 mg/ml</strength>
      <route>Intravenous; Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Phenfree Caffeine 100mg Capsules</name>
      <labeller>Upper 49 Th Imports Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239784</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-07-01</started-marketing-on>
      <ended-marketing-on>2004-09-09</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Phrenilin</name>
      <labeller>Valeant Pharmaceuticals North America</labeller>
      <ndc-id/>
      <ndc-product-code>0187-0843</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-05</started-marketing-on>
      <ended-marketing-on>2007-09-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074911</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phrenilin Forte</name>
      <labeller>Wraser Llc</labeller>
      <ndc-id/>
      <ndc-product-code>66992-955</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206615</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Physicians Care Extra Strength Pain Reliever</name>
      <labeller>Acme United Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0924-0130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PMS-pharnal Capsules</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02232988</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-pharnal Tablets</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02232989</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-pharnal-C 1/4 Capsules</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02232985</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-pharnal-C1/2 Capsules</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02232986</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Powerbooster Mild</name>
      <labeller>Peterpanlab</labeller>
      <ndc-id/>
      <ndc-product-code>70843-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Powerbooster original</name>
      <labeller>Peterpanlab</labeller>
      <ndc-id/>
      <ndc-product-code>70843-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-19</started-marketing-on>
      <ended-marketing-on>2018-07-20</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Powerbooster Original</name>
      <labeller>Peterpanlab</labeller>
      <ndc-id/>
      <ndc-product-code>70843-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prodrin</name>
      <labeller>Gentex Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>15014-145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-01</started-marketing-on>
      <ended-marketing-on>2018-01-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pronal - C1/2 Capsules</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229734</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on>2013-01-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pronal C1/4 Capsules</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229735</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on>2013-01-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pronal Capsules</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229733</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-23</started-marketing-on>
      <ended-marketing-on>2012-07-23</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pronal Tablets</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229736</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on>2017-11-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Re-action E</name>
      <labeller>Goldeneye Permanent System GmbH Germany</labeller>
      <ndc-id/>
      <ndc-product-code>71056-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Regular Strength Aspirin</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0164</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on>2018-06-18</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ru-21 Hangover Relief</name>
      <labeller>RU-21</labeller>
      <ndc-id/>
      <ndc-product-code>73156-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rx Act headache formula added strength</name>
      <labeller>H.E.B.</labeller>
      <ndc-id/>
      <ndc-product-code>37808-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-03</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Saridon - A</name>
      <labeller>OASIS TRADING</labeller>
      <ndc-id/>
      <ndc-product-code>72689-0002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Scot-Tussin Original SF Multi-Symptom</name>
      <labeller>Scot Tussin Pharmacal Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0372-0002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-12-01</started-marketing-on>
      <ended-marketing-on>2011-01-14</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part341</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sed-max</name>
      <labeller>Command Brands, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69197-029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sedalmex</name>
      <labeller>Belmora LLC</labeller>
      <ndc-id/>
      <ndc-product-code>27854-301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sedalmex Pain Reliever</name>
      <labeller>Midway Importing</labeller>
      <ndc-id/>
      <ndc-product-code>76095-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-15</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ShopRite Migraine Formula</name>
      <labeller>Wakefern Food Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>41190-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Signature Care Migraine Relief</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-569</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sinugex 38</name>
      <labeller>Frega Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00777285</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>2008-02-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Smart Sense Migraine Formula</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-444</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense migraine relief</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense Stay Awake</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>SMITH BROS WILD CHERRY DAY TIME with Caffeine Soothing Drops</name>
      <labeller>Universal holdings I LLC dba Smith Brothers Company</labeller>
      <ndc-id/>
      <ndc-product-code>76461-500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-29</started-marketing-on>
      <ended-marketing-on>2015-02-12</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>SohMed Alertness Aid</name>
      <labeller>SOHM Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50405-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>SohMed Pain Reliever</name>
      <labeller>SOHM Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50405-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Spirit (chewable Squares)</name>
      <labeller>Warner Lambert Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239043</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Wafer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Stanback</name>
      <labeller>Glaxo Smith Kline Consumer Heathcare Lp</labeller>
      <ndc-id/>
      <ndc-product-code>0135-0499</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stanback</name>
      <labeller>Medtech Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63029-501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Alert Aid</name>
      <labeller>Rite Aid</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-21</started-marketing-on>
      <ended-marketing-on>2018-11-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Alert Alertness Aid</name>
      <labeller>L&amp;R Distributors, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>15127-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on>2021-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Kinray</labeller>
      <ndc-id/>
      <ndc-product-code>61715-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Nash Finch</labeller>
      <ndc-id/>
      <ndc-product-code>70253-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-11-21</started-marketing-on>
      <ended-marketing-on>2018-04-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Publix Supermarkets, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>56062-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>H.E.B.</labeller>
      <ndc-id/>
      <ndc-product-code>37808-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Freds Inc</labeller>
      <ndc-id/>
      <ndc-product-code>55315-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-28</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Freds Inc</labeller>
      <ndc-id/>
      <ndc-product-code>55315-250</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-01</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>National Distribution Network (Smart Choice)</labeller>
      <ndc-id/>
      <ndc-product-code>53441-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-30</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Western Family Foods, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55312-051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-28</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Western Family Foods, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55312-250</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Chain Drug Marketing Association</labeller>
      <ndc-id/>
      <ndc-product-code>63868-109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Allegiant Health</labeller>
      <ndc-id/>
      <ndc-product-code>69168-076</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Greenbrier International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>33992-2261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>SUPERVALU INC.</labeller>
      <ndc-id/>
      <ndc-product-code>41163-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>WAL-MART STORES INC</labeller>
      <ndc-id/>
      <ndc-product-code>49035-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-2260</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>CHAIN DRUG MARKETING ASSOCIATION INC</labeller>
      <ndc-id/>
      <ndc-product-code>63868-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-7955</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on>2021-11-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>WinCo Foods, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67091-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-30</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Meijer</labeller>
      <ndc-id/>
      <ndc-product-code>41250-320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Marc Glassman, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68998-076</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Strategic Sourcing Services, LLC (Sunmark)</labeller>
      <ndc-id/>
      <ndc-product-code>70677-0021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>SMART SENSE (Kmart)</labeller>
      <ndc-id/>
      <ndc-product-code>49738-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Harris Teeter</labeller>
      <ndc-id/>
      <ndc-product-code>72036-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Family Dollar Services Inc</labeller>
      <ndc-id/>
      <ndc-product-code>55319-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Salado Sales, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57243-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>FRED'S, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>55315-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>HYVEE INC</labeller>
      <ndc-id/>
      <ndc-product-code>42507-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-05-28</started-marketing-on>
      <ended-marketing-on>2020-06-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0691</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-14</started-marketing-on>
      <ended-marketing-on>2022-10-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>Strategic Sourcing Services, LLC (Health Mart)</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake</name>
      <labeller>ARMY AND AIR FORCE EXCHANGE SERVICE</labeller>
      <ndc-id/>
      <ndc-product-code>55301-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake Maximum strength</name>
      <labeller>Valu Merchandisers Company (Best Choice)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake Maximum Strength</name>
      <labeller>SUPERVALU INC.</labeller>
      <ndc-id/>
      <ndc-product-code>41163-434</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake Maximum Strength</name>
      <labeller>Better Living Brands, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>21130-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake Maximum Strength</name>
      <labeller>GREAT LAKES WHOLESALE, MARKETING, &amp; SALES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>64092-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Stay Awake Maximum Strength</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sugarloaf Spring Caffeine, Caffeinated Spring Water</name>
      <labeller>Sugarloaf Spring Rain International Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237490</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-10-15</started-marketing-on>
      <ended-marketing-on>2002-07-09</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sunmark Headache Relief</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>49348-722</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-13</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark migraine relief</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49348-506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark stay awake</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49348-771</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark Tension Headache</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>49348-855</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-25</started-marketing-on>
      <ended-marketing-on>2008-07-25</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Synalgos</name>
      <labeller>Caraco Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49708-419</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA011483</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tamicode Tablets</name>
      <labeller>Viva Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439220</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teen Midol Complete</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02273454</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-29</started-marketing-on>
      <ended-marketing-on>2018-03-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teen Pms Relief Complete Caplets</name>
      <labeller>Tanta Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02307103</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tension Headache</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0454</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-05</started-marketing-on>
      <ended-marketing-on>2013-02-24</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Aspirin Free</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Aspirin-Free</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Aspirin-Free</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-972</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-09</started-marketing-on>
      <ended-marketing-on>2020-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Target Corporation.</labeller>
      <ndc-id/>
      <ndc-product-code>11673-787</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-09</started-marketing-on>
      <ended-marketing-on>2018-11-04</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>A&amp;Z Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62211-029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-10</started-marketing-on>
      <ended-marketing-on>2015-04-16</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Healthlife of Usa</labeller>
      <ndc-id/>
      <ndc-product-code>69517-118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Spirit Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>68210-0190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Spirit Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>68210-0019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Allegiant Health</labeller>
      <ndc-id/>
      <ndc-product-code>69168-029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>CHAIN DRUG MARKETING ASSOCIATION INC</labeller>
      <ndc-id/>
      <ndc-product-code>63868-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Greenbrier International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>33992-0428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Chain Drug Consortium</labeller>
      <ndc-id/>
      <ndc-product-code>68016-694</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Harmon Store Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63940-428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief</name>
      <labeller>FRED'S, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>55315-428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tension Headache Relief Aspirin Free</name>
      <labeller>L.N.K. International, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50844-428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Teva-lenoltec No. 1</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00653233</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-lenoltec No. 2</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00653241</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-lenoltec No. 3</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00653276</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-tecnal</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00608211</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-tecnal</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00608238</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-tecnal C 1/2</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00608181</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-tecnal C 1/4</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00608203</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Texaclear Pain Reliever</name>
      <labeller>GM Pharmaceuticals, INC</labeller>
      <ndc-id/>
      <ndc-product-code>58809-389</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Thrulife Extra Strength Headache Relief</name>
      <labeller>Polygen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52605-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Headache Formula</name>
      <labeller>Topco Associates</labeller>
      <ndc-id/>
      <ndc-product-code>36800-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-01-13</started-marketing-on>
      <ended-marketing-on>2014-02-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Migraine Formula</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Migraine Relief</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-533</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare Pain Reliever Simple Relief</name>
      <labeller>Topco Associates</labeller>
      <ndc-id/>
      <ndc-product-code>36800-518</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare stay awake maximum strength</name>
      <labeller>Topco Associates</labeller>
      <ndc-id/>
      <ndc-product-code>36800-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-14</started-marketing-on>
      <ended-marketing-on>2015-10-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trezix</name>
      <labeller>Wraser Llc</labeller>
      <ndc-id/>
      <ndc-product-code>66992-340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040688</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trezix</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-5637</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trezix</name>
      <labeller>Wraser Llc</labeller>
      <ndc-id/>
      <ndc-product-code>66992-840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trezix</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-705</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triaminicin Colds &amp; Flu Caplets</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01906658</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2000-07-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trianal C½</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01971387</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trianal C¼</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242406</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trianal Capsules</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01971417</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trianal Tablet</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01971409</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triatec Fort/strong Ultra Efficace/ultra Relief</name>
      <labeller>Laboratoires Trianon Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02295814</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triatec-8</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00852163</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triatec-8 Fort</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01977881</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol Advanced Headache</name>
      <labeller>Mcneil Consumer Healthcare Division Of Johnson &amp; Johnson Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02253682</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol No 1 Tab</name>
      <labeller>Mcneil Pharmaceutical, Division Of Ortho Mcneil Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00425362</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol No.1 Caplets</name>
      <labeller>Mcneil Consumer Healthcare Division Of Johnson &amp; Johnson Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02181061</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on>2016-09-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol No.1 Forte Caplets</name>
      <labeller>Mcneil Consumer Healthcare Division Of Johnson &amp; Johnson Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02181088</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-28</started-marketing-on>
      <ended-marketing-on>2015-08-06</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol No1 Forte Tablets With Codeine</name>
      <labeller>Mcneil Pharmaceutical, Division Of Ortho Mcneil Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00630594</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol Ultra Relief</name>
      <labeller>Mcneil Consumer Healthcare Division Of Johnson &amp; Johnson Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254468</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol W Codeine No2 Tab</name>
      <labeller>Mcneil Pharmaceutical, Division Of Ortho Mcneil Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00425370</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol W Codeine No3 Tab</name>
      <labeller>Mcneil Pharmaceutical, Division Of Ortho Mcneil Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00425389</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol With Codeine No. 2 - Tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02163934</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylenol With Codeine No. 3 - Tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02163926</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tylo Migraine (Acetaminophen)</name>
      <labeller>America Medic &amp; Science, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49638-108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, delayed release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ultra Headache Relief</name>
      <labeller>Genvion Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02412152</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ultra Headache Relief</name>
      <labeller>Vita Health Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264870</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Up and Up Migraine Relief</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uricalm Intensive</name>
      <labeller>Alva Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-642</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-23</started-marketing-on>
      <ended-marketing-on>2018-10-23</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Valumeds Maximum Strength Stay Awake</name>
      <labeller>Spirit Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68210-0403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vanapain</name>
      <labeller>Gm Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58809-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vanatol LQ</name>
      <labeller>Gm Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58809-820</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040387</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vanatol S</name>
      <labeller>Gm Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58809-359</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040387</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vanquish</name>
      <labeller>MOBERG PHARMA NORTH AMERICA LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16864-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-26</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vanquish</name>
      <labeller>DSE Healthcare Solutions, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42364-0011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vanquish</name>
      <labeller>Strides Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>59556-810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vivarin</name>
      <labeller>Glaxo Smith Kline Consumer Heathcare Lp</labeller>
      <ndc-id/>
      <ndc-product-code>0135-0077</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-08</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vivarin</name>
      <labeller>Glaxo Smith Kline Consumer Heathcare Lp</labeller>
      <ndc-id/>
      <ndc-product-code>0135-0078</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-08</started-marketing-on>
      <ended-marketing-on>2014-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vivarin</name>
      <labeller>Mylan Consumer Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46017-018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vivarin</name>
      <labeller>Mylan Consumer Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46017-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vivarin</name>
      <labeller>Navajo Manufacturing Company Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67751-160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part340</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vtol LQ</name>
      <labeller>Monarch PCM, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70154-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040387</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Wampole-acetaminophen/codeine/caffeine</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02453703</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Wigraine Suppositories</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00489212</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-18</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Wigraine Tab</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00489220</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zebutal</name>
      <labeller>Shionogi</labeller>
      <ndc-id/>
      <ndc-product-code>59630-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-10-28</started-marketing-on>
      <ended-marketing-on>2013-11-22</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA040261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zebutal</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68308-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA089007</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Caffedrine</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Dexitac</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Durvitan</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Enerjets</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>No-Doz</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pep-Back</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Quick Pep</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Wake-Up</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Peyona</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Peyona</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>292 Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>282 Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine and Dihydrocodeine Bitartrate</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>MigraTen</name>
      <ingredients>Acetaminophen + Caffeine + Isometheptene</ingredients>
    </mixture>
    <mixture>
      <name>Orbivan</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine Plus</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Isometheptene Mucate, Caffeine, Acetaminophen</name>
      <ingredients>Acetaminophen + Caffeine + Isometheptene</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Orphenadrine Citrate, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Diurex WaterCaps</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Tension Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pep-Back Peak Performance</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Butalbital and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Trezix</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Scot-Tussin Original SF Multi-Symptom</name>
      <ingredients>Caffeine + Pheniramine + Phenylephrine + Salicylic acid</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Dihydrocodeine Bitartrate, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin ES</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vivarin</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vivarin</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fioricet with Codeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Fioricet</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetominophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Allertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake Maximum strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Panlor SS</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief to Go</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ache and Pain Relief to Go</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys PM Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Bayer Headache Relief</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>999 GANMAOLING Cold</name>
      <ingredients>Acetaminophen + Caffeine + Chlorpheniramine</ingredients>
    </mixture>
    <mixture>
      <name>BackAid Inflammatory Pain Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ganmaoling 999</name>
      <ingredients>Acetaminophen + Caffeine + Chlorpheniramine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ercaf</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal with Codeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Orbivan</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine and Dihydrocodeine Bitartrate</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Nano Ppc</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief to Go</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Esgic-Plus</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Aspirin, Caffeine, and Dihydrocodeine Bitartrate</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>ConRx pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>ConRx Alert</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Esgic-Plus</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Esgic-Plus</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>SohMed Alertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Esgic-Plus</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ergotamine</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Norgesic</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Thrulife Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Synalgos</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>SohMed Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>dihydrocodeine bitartrate and aspirin and caffeine DC</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Uricalm Intensive</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Bc</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>BC Arthritis</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Cold Remedy Gan Mao Ling</name>
      <ingredients>Acetaminophen + Caffeine + Chlorpheniramine</ingredients>
    </mixture>
    <mixture>
      <name>Nano Ppc</name>
      <ingredients>Caffeine + Vanillyl butyl ether</ingredients>
    </mixture>
    <mixture>
      <name>Stanback</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pancold S</name>
      <ingredients>Acetaminophen + Caffeine + Chlorpheniramine + DL-Methylephedrine + Guaifenesin</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Plus</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Berkley and Jensen Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ache and Pain Relief to Go</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Migraine</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief To Go</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief To Go</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Phrenilin</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Cafcit</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Cafcit</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Orphenadrine Citrate, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Orphenadrine Citrate, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>First Aid Shot Therapy Pain relief</name>
      <ingredients>Caffeine + Choline salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Plus</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Allertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Maximum Strength Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Alert Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Norgesic</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Norgesic Forte</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Dolgic Plus</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alagesic LQ</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vanapain</name>
      <ingredients>Caffeine + Choline salicylate</ingredients>
    </mixture>
    <mixture>
      <name>SMITH BROS WILD CHERRY DAY TIME with Caffeine Soothing Drops</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Added Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>First Aid Shot Therapy Hangover Relief</name>
      <ingredients>Caffeine + Choline salicylate</ingredients>
    </mixture>
    <mixture>
      <name>BioElectro Day</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Margesic</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>First Aid Shot Therapy Pain Relief</name>
      <ingredients>Caffeine + Choline salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetominophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetominophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Esgic</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fioricet</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fioricet with Codeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Regular Strength Aspirin</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Ergotamine Tartrate and Caffeine</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Pain Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Back and Body</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Zebutal</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fioricet</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Free</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Esgic</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>GOODYS Extra Strength Headache Mixed Fruit Blast</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Mild</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>jet-Alert Maximum Strength Alertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>357 Super Magnum</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Citramon</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Plus</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Bayer Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Bayer AM extra stength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine with Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Isometheptene Mucate, Caffeine, and Acetaminophen</name>
      <ingredients>Acetaminophen + Caffeine + Isometheptene</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Formula Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Leader migraine formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength Caplets</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital Compound</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migergot</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Equaline Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy headache relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Plus</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ergotamine Tartrate and Caffeine</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>EXCEDRIN Tension Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Health Mart Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Formu Care pain reliever added strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stanback</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pamprin Max Menstrual Pain Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Isometheptene Mucate, Caffeine, and Acetaminophen</name>
      <ingredients>Acetaminophen + Caffeine + Isometheptene</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Tension Headache Pain Reliever</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Stopper Extra</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, aspirin, and caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Menstrual Complete</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, aspirin, and caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Formula Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Good Sense headache formula added strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alertness Aid Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Complete Gelcaps</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Leader migraine formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Capacet</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Equaline headache formula added strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Headache Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Care One headache relief added strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Away Plus</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Tension Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Circle K Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>BC Cherry</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Mild Headache Caplets</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Cool Orange Headache</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Formula Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Formula Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Rx Act headache formula added strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Sedalmex Pain Reliever</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Headache Relief Shot</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Headache Relief Shot</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Leader Headache Formula Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin AF</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Leader Alertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine, Dihydrocodeine Bitartrate</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Trezix</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Berkley and Jensen Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Topcare stay awake maximum strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Healthy Accents headache relief added strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Equate Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Bayer Back and Body Extra Strength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine, Dihydrocodeine Bitartrate</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Migraine</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Migraine</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>JET ALERT Regular Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vanquish</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migergot</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Buscapina</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Dg Health Headache Relief Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Tension Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Isometheptene Mucate, Caffeine, and Acetaminophen</name>
      <ingredients>Acetaminophen + Caffeine + Isometheptene</ingredients>
    </mixture>
    <mixture>
      <name>Prodrin</name>
      <ingredients>Acetaminophen + Caffeine + Isometheptene</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin PM Triple Action Caplets and Excedrin Tension Headache</name>
      <ingredients>Acetaminophen + Acetaminophen + Acetylsalicylic acid + Caffeine + Diphenhydramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Pain Reliever Simple Relief</name>
      <ingredients>Caffeine + Choline salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine, Dihydrocodeine Bitartrate</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Pain Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Aspirin, Caffeine</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Powerbooster original</name>
      <ingredients>Caffeine + Hydrogenated soybean lecithin</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength Geltabs</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Migraine Geltabs</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Powerbooster Mild</name>
      <ingredients>Caffeine + Levomenthol + Witch hazel</ingredients>
    </mixture>
    <mixture>
      <name>Powerbooster Original</name>
      <ingredients>Caffeine + Witch hazel</ingredients>
    </mixture>
    <mixture>
      <name>NoDoz MAXIMUM STRENGTH ALERTNESS AID</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Lil Drug Store NoSnooze</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Lil Drug Store NoSnooze</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Arthriten Joint Pain Relief</name>
      <ingredients>Acetaminophen + Caffeine + Magnesium salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Cl Light</name>
      <ingredients>Caffeine + Garcinia gummi-gutta fruit</ingredients>
    </mixture>
    <mixture>
      <name>Panlor</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal with Codeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Stoppers EX</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Stoppers Extra</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Stoppers</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Pain Stoppers Regular</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Lil Drug Store Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headach Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Goodys Cool Orange</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Pain Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin PM Triple Action Caplets and Excedrin Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetaminophen + Acetylsalicylic acid + Acetylsalicylic acid + Caffeine + Diphenhydramine</ingredients>
    </mixture>
    <mixture>
      <name>Migrenol</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal with Codeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>JET ALERT Double Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Saridon - A</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength and Excedrin Tension Headache</name>
      <ingredients>Acetaminophen + Acetaminophen + Acetylsalicylic acid + Caffeine + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength and Excedrin Tension Headache</name>
      <ingredients>Acetaminophen + Acetaminophen + Acetylsalicylic acid + Caffeine + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine 200 mg</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Bi Electro Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Sed-max</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Geworin</name>
      <ingredients>Acetaminophen + Caffeine + Propyphenazone</ingredients>
    </mixture>
    <mixture>
      <name>Leader migraine formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Health Mart Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Comfort-Time</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Alert</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pep-Back Ultra</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Up and Up Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Cafcit</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, aspirin, and caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Complete Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylo Migraine (Acetaminophen)</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excinol Migraine (Acetaminophen)</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fioricet</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Back and Body Extra Strength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Harris Teeter Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Relief Added Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Careone Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Back and Body Extra Strength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Awake Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Formula Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Phrenilin Forte</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Trezix</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Penzal Q</name>
      <ingredients>Acetaminophen + Caffeine + Ethenzamide</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alert Alertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>4229 First Aid Kit</name>
      <ingredients>Acetaminophen + Acetaminophen + Acetylsalicylic acid + Ammonia + Bacitracin + Caffeine + Isopropyl alcohol + Neomycin + Polymyxin B + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Family Wellness Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Plus</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>MEDIQUE Back Pain Off</name>
      <ingredients>Acetaminophen + Caffeine + Magnesium salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>NoDoz Alertness Aid Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Norgesic Forte</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Back and Body Extra Strength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Green Guard Pain and Ache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Medi First Pain Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Medi First Plus Pain Zapper</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Alert Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Back and Body</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Arthriten Inflammatory Pain Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Arthriten Max</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Diurex Water Pills</name>
      <ingredients>Caffeine + Magnesium salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Diurex Ultra</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Diurex Water Pills XPL</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Diurex Ultimate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>pain relief back and body EXTRA STRENGTH</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alert</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Only For HEADACHE</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Fioricet with Codeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine, Dihydrocodeine Bitartrate</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>4248 First Aid Kit</name>
      <ingredients>Acetaminophen + Acetaminophen + Acetylsalicylic acid + Ammonia + Bacitracin + Benzalkonium + Benzethonium + Benzethonium + Benzocaine + Benzocaine + Caffeine + Calcium carbonate + Ethanol + Hydrocortisone acetate + Isopropyl alcohol + Levomenthol + Lidocaine + Neomycin + Phenylephrine + Polymyxin B + Salicylamide + Tetryzoline + Water</ingredients>
    </mixture>
    <mixture>
      <name>4346 First Aid Kit</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Bacitracin + Benzalkonium + Caffeine + Calcium carbonate + Lidocaine + Neomycin + Polymyxin B + Salicylamide + Water</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Alert Alertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Diurex Water Pills XPL</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>EXCEDRIN MIGRAINE acetaminophen, aspirin (nsaid) and caffeine</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Cove Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Fioricet</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Orphenadrine Citrate, Aspirin and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Orphengesic Forte</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Esgic</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Zebutal</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ru-21 Hangover Relief</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Drowz Away Maximum strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Midol</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Bc</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>BC Arthritis</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alertness Aid Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Back and Body Extra Strength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Formula Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Aspirin Free</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Plus</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Advanced Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Valumeds Maximum Strength Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Sedalmex</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Awake Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Migraine</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine and Dihydrocodeine Bitartrate</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migergot</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief Aspirin Free</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vanquish</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Careline Perfect Care BB</name>
      <ingredients>Allantoin + Caffeine + Octinoxate + Talc + Titanium dioxide</ingredients>
    </mixture>
    <mixture>
      <name>Careline Perfect Care BB</name>
      <ingredients>Allantoin + Caffeine + Octinoxate + Talc + Titanium dioxide</ingredients>
    </mixture>
    <mixture>
      <name>Dolex Forte</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark stay awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vivarin</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vivarin</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ana-dent</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>7 Select Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 500mg Caffeine 65mg</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Ascomp with Codeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pamprin Max Menstrual Pain Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Free Plus</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Aspirin-Free</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Back and Body Extra Strength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Circle K NoSnooze</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Aspirin-Free</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Aid ESF</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Reliever Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>PANADOL Extra</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Migraine</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Pain Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Extra Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Ascomp with Codeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Basic Care Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Advanced Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Aspirin, Caffeine and Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine Citrate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Back and Body Extra Strength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Dvorah</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Medique Pain Off</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Physicians Care Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Drowz Away Maximum strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Awake Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Re-action E</name>
      <ingredients>Aloe Vera Leaf + Bambusa arundinacea stem + Caffeine + Maltodextrin</ingredients>
    </mixture>
    <mixture>
      <name>Vanatol LQ</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Esgic</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vanatol S</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vtol LQ</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tension Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Dvorah</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, aspirin, and caffeine</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Texaclear Pain Reliever</name>
      <ingredients>Caffeine + Choline salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Trezix</name>
      <ingredients>Acetaminophen + Caffeine + Dihydrocodeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Vivarin</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Lil Drug Store Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Lil Drug Store Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Lil Drug Store NoSnooz Maximum Strength</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 250mg Aspirin 250mg Caffeine 65mg</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Migraine</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Good Sense Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 500mg Caffeine 60mg Pyrilamine maleate 15mg</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>DG Health migraine relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Topcare Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alertness Aid</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Handy Solutions Headache Pain Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>ShopRite Migraine Formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine and Sodium Benzoate</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense migraine relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Leader Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Care One migraine relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Equaline migraine formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Good Sense Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Healthy Accents Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Healthy Accents migraine formula</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>NoSnooze Circle K</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>NoSnooze Circle K</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Adults Acetaminophen and Caffeine Pain Reliever Fever Reducer</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Exaprin</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine + Salicylamide</ingredients>
    </mixture>
    <mixture>
      <name>BC Cherry</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Circle K Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Signature Care Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>GOODYS Hangover</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Pain Relief Acetaminophen, Aspirin (NSAID) and Caffeine</name>
      <ingredients>Acetaminophen + Caffeine + Salicylic acid</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark migraine relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Complete Menstrual Relief</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Headache Relief Extra Strength</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strenght Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Vanquish</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ergotamine Tartrate and Caffeine</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Health Mart Migraine Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Stay Awake</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Pain Reliever</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Blowfish</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Butalbital, Acetaminophen, and Caffeine</name>
      <ingredients>Acetaminophen + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Relief Maximum Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Headache Relief</name>
      <ingredients>Acetaminophen + Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol Ultra Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 500mg and Caffeine 65mg</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin Extra Strength</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Megral Tabs</name>
      <ingredients>Caffeine + Cyclizine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Oradrine Tablets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine + Diphenylpyraline + Phenylpropanolamine</ingredients>
    </mixture>
    <mixture>
      <name>Emercidin D Tab</name>
      <ingredients>Acetaminophen + Caffeine + Diphenylpyraline + Phenylpropanolamine</ingredients>
    </mixture>
    <mixture>
      <name>Emertabs Tab</name>
      <ingredients>Acetaminophen + Caffeine + Phenylpropanolamine</ingredients>
    </mixture>
    <mixture>
      <name>282 Mep Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine + Meprobamate</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot Sup</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Pain Aid</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>692 Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Dextropropoxyphene</ingredients>
    </mixture>
    <mixture>
      <name>Alert Aid Caffeine Capsules 175mg</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alert Aid Caffeine Tablets 175mg</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Triaminicin Colds &amp; Flu Caplets</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine + Pheniramine + Phenylpropanolamine</ingredients>
    </mixture>
    <mixture>
      <name>Instantine Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Norgesic Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Norgesic Forte Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Orphenadrine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin Tablet</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin Extra Strength Caplets</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin Caplets</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin Extra Strength Tablet</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>217 Strong Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Darvon N Compound Pulvule 405</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Dextropropoxyphene</ingredients>
    </mixture>
    <mixture>
      <name>Midol Multi-symptom Caplets Extra Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-propoxyn Compound Cap</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Dextropropoxyphene</ingredients>
    </mixture>
    <mixture>
      <name>Alert Tab 100mg</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Oradrine 2 Tab</name>
      <ingredients>Acetaminophen + Caffeine + Diphenylpyraline + Phenylpropanolamine</ingredients>
    </mixture>
    <mixture>
      <name>Destim - Tab 200mg</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Painex Tab 0.25gr</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Painex Tab 0.5gr</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Instantine - Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Multi-symptom Caplets Extra Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Multi-symptom Gelcap Extra Strength</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol W Codeine No2 Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol W Codeine No3 Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Midol</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot Tab</name>
      <ingredients>Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot Pb Tab</name>
      <ingredients>Belladonna + Caffeine + Ergotamine + Pentobarbital</ingredients>
    </mixture>
    <mixture>
      <name>Wigraine Tab</name>
      <ingredients>Belladonna + Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Herbopyrine Tab 325mg</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Nervine</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Dristan Capsules</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Chlorpheniramine + Phenylpropanolamine</ingredients>
    </mixture>
    <mixture>
      <name>Wigraine Suppositories</name>
      <ingredients>Belladonna + Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot Pb Sup</name>
      <ingredients>Belladonna + Caffeine + Ergotamine + Pentobarbital</ingredients>
    </mixture>
    <mixture>
      <name>Pronal - C1/2 Capsules</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Caffeine</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>692 Tablet</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Dextropropoxyphene</ingredients>
    </mixture>
    <mixture>
      <name>Midol Extra Strength Menstrual</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Extra Strength Gelcaps</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Midol Regular</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Sugarloaf Spring Caffeine, Caffeinated Spring Water</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Phenfree Caffeine 100mg Capsules</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Alka-seltzer Morning Relief</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>217</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ergodryl Cap</name>
      <ingredients>Caffeine + Diphenhydramine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>C2 Buffered Tab</name>
      <ingredients>Acetylsalicylic acid + Aluminum hydroxide + Caffeine + Magnesium hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>Neo Tigol Tab</name>
      <ingredients>Acetylsalicylic acid + Aluminum hydroxide + Caffeine + Magnesium hydroxide + Passiflora incarnata flower + Valerian</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Nervine Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Corytab</name>
      <ingredients>Acetaminophen + Caffeine + Diphenylpyraline</ingredients>
    </mixture>
    <mixture>
      <name>Sinugex 38</name>
      <ingredients>Acetaminophen + Caffeine + Diphenylpyraline</ingredients>
    </mixture>
    <mixture>
      <name>Antidol Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Dolomine 37</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Calmine Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Diurette Water Pills</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Asa and Caffeine</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol Advanced Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen Ultra Relief Extra Strength</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen Relief Regular Strength</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Triatec Fort/strong Ultra Efficace/ultra Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Teen Pms Relief Complete Caplets</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin Caplets</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin Extra Strength Caplets</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Ultra Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Tamicode Tablets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Gravergol Capsules</name>
      <ingredients>Caffeine + Dimenhydrinate + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Arco Pain Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Tension Headache</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Excedrin Extra Strength</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Contac Plus Cold Nasal Congestion</name>
      <ingredients>Acetaminophen + Caffeine + Phenylephrine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>A.C. &amp; C 8mg Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine &amp; Codeine</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine &amp; Codeine</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine and Codeine Phosphate Tablets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine, and 8mg Of Codeine Phosphate Tablets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 325 Mg With 15 Mg Caffeine and 8 Mg Codeine Phosphate</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>A &amp; C Tablets With Codeine 30mg</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>A &amp; C Tablets With Codeine 15mg</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 500 Mg With 15 Mg Caffeine and 8 Mg Codeine Phosphate</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen Caffeine &amp; 8mg Cod. Phos. Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acet 2</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acet 3</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Anacin With Codeine Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>C T Acetylsalicylic Acid Codeine and Caf Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Exdol 8 Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Exdol 15tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Exdol 30tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Cotabs</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Exdol-15</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Ac and C Tab 1/8gr</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen W Codeine Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen Compound Tablets With Codeine 8mg</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 500 Mg Compound Tablets With Codeine</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>(extra Strength) Acetaminophen, Caffeine &amp; 8mg Codeine Phosphate Caplets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>C-2 Buffered With Codeine</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Asa, Caffeine &amp; 8mg Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>C2 Buffered With Codeine Tab</name>
      <ingredients>Acetylsalicylic acid + Aluminum hydroxide + Caffeine + Codeine + Magnesium hydroxide</ingredients>
    </mixture>
    <mixture>
      <name>C2 Tab With Codeine</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen Caffeine &amp; 8mg Cod Phos Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Ac&amp;c Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>292 Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>282 Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>222 Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>A.C. &amp; C. 8 mg</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Asa-caffeine-codeine</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen-caffeine-codeine</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 500mg, Caffeine and 8mg Codeine Phosphate</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Apo-acetaco #1</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 325 Mg Caffeine and Codeine</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 300mg, Caffeine &amp; Codeine</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine &amp; Codeine Tablets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Ara Menstrual Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal-C 1/4</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal-C 1/2</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Novo Ac and C 8mg Tab</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Exdol-8</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-gesic C15</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Atasol 15</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Atasol 30</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Trianal Tablet</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophene Codeine Et Cafeine Caplets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophene Codeine Et Cafeine Fort</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Trianal Capsules</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Menstrual Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Ac&amp;c Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>A.C. &amp; C. 8mg</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-pharnal-C 1/4 Capsules</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-pharnal-C1/2 Capsules</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-pharnal Capsules</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-pharnal Tablets</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Spirit (chewable Squares)</name>
      <ingredients>Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Extra Strength Midol Relief</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Midol One</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
    <mixture>
      <name>Aspirin Rapid Relief</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetylsalicylic Acid, Caffeine and 8mg Codeine Phosphate</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>A.C.&amp; C Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine and 8 Mg Of Codeine Phosphate Tablets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen Headache Ultra Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen 325 C &amp; C</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine &amp; 8mg Codeine Phosphate Tablets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetylsalicylic Acid, Caffeine &amp; 8 Mg Codeine Phosphate Tablets</name>
      <ingredients>Acetylsalicylic acid + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen With Codeine - Caplet</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Teva-tecnal</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Teva-tecnal C 1/2</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Acetaminophen, Caffeine &amp; 8mg Codeine Phosphate</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Trianal C½</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Trianal C¼</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Ultra Headache Relief</name>
      <ingredients>Acetaminophen + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Wampole-acetaminophen/codeine/caffeine</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Pronal Tablets</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Triatec-8</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol With Codeine No. 3 - Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Teva-lenoltec No. 3</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Teva-tecnal C 1/4</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Teva-tecnal</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Teva-lenoltec No. 1</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Teva-lenoltec No. 2</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal Tab</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-gesic-C8</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-gesic C30</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Triatec-8 Fort</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol With Codeine No. 2 - Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol No.1 Caplets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Atasol 8</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol No 1 Tab</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol No.1 Forte Caplets</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Pronal Capsules</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Pronal C1/4 Capsules</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Exdol-30</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Tylenol No1 Forte Tablets With Codeine</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Nu-acetaco #1</name>
      <ingredients>Acetaminophen + Caffeine + Codeine</ingredients>
    </mixture>
    <mixture>
      <name>Fiorinal</name>
      <ingredients>Acetylsalicylic acid + Butalbital + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Madelon</name>
      <ingredients>Acetylsalicylic acid + Caffeine</ingredients>
    </mixture>
    <mixture>
      <name>Teen Midol Complete</name>
      <ingredients>Acetaminophen + Caffeine + Mepyramine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Actavis Group</name>
      <url>http://www.actavis.com</url>
    </packager>
    <packager>
      <name>Aidarex Pharmacuticals LLC</name>
      <url>http://www.aidarex.com</url>
    </packager>
    <packager>
      <name>Alphagen Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>American Regent</name>
      <url>http://www.americanregent.com</url>
    </packager>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>Amneal Pharmaceuticals</name>
      <url>http://www.amneal.com</url>
    </packager>
    <packager>
      <name>Apotheca Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>APP Pharmaceuticals</name>
      <url>http://www.apppharma.com</url>
    </packager>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Athlon Pharmaceuticals Inc.</name>
      <url>http://www.athlonpharm.com</url>
    </packager>
    <packager>
      <name>Atley Pharmaceuticals</name>
      <url>http://www.atley.com</url>
    </packager>
    <packager>
      <name>Bedford Labs</name>
      <url>http://www.bedfordlabs.com</url>
    </packager>
    <packager>
      <name>Ben Venue Laboratories Inc.</name>
      <url>http://www.benvenue.com</url>
    </packager>
    <packager>
      <name>Bioniche Pharma</name>
      <url>http://www.bionichepharmausa.com</url>
    </packager>
    <packager>
      <name>Blansett Pharmacal Co. Inc.</name>
      <url>http://www.blansett.com</url>
    </packager>
    <packager>
      <name>Blenheim Pharmacal</name>
      <url>http://www.bpipack.com</url>
    </packager>
    <packager>
      <name>Brighton Pharmaceuticals</name>
      <url>http://www.brightonpharma.com</url>
    </packager>
    <packager>
      <name>Bristol-Myers Squibb Co.</name>
      <url>http://www.bms.com</url>
    </packager>
    <packager>
      <name>Bryant Ranch Prepack</name>
      <url>http://bryantranchprepack.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Carlisle Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Comprehensive Consultant Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Concord Labs</name>
      <url/>
    </packager>
    <packager>
      <name>Corepharma LLC</name>
      <url>http://www.corepharma.com</url>
    </packager>
    <packager>
      <name>CVS Pharmacy</name>
      <url>http://www.cvs.com</url>
    </packager>
    <packager>
      <name>D.M. Graham Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Direct Dispensing Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>Everett Laboratories Inc.</name>
      <url>http://www.everettlabs.com</url>
    </packager>
    <packager>
      <name>Forest Pharmaceuticals</name>
      <url>http://www.forestpharm.com</url>
    </packager>
    <packager>
      <name>G &amp; W Labs</name>
      <url>http://www.gwlabs.com</url>
    </packager>
    <packager>
      <name>Gilbert Laboratories</name>
      <url/>
    </packager>
    <packager>
      <name>GlaxoSmithKline Inc.</name>
      <url>http://www.gsk.com</url>
    </packager>
    <packager>
      <name>Goldline Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Heartland Repack Services LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Hope Pharmaceuticals</name>
      <url>http://www.hopepharm.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Innoviant Pharmacy Inc.</name>
      <url>http://www.innoviantpharmacy.com</url>
    </packager>
    <packager>
      <name>J T Baker</name>
      <url>http://www.jtbaker.com</url>
    </packager>
    <packager>
      <name>Kaiser Foundation Hospital</name>
      <url/>
    </packager>
    <packager>
      <name>Keene Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Keltman Pharmaceuticals Inc.</name>
      <url>http://www.keltman.com</url>
    </packager>
    <packager>
      <name>Lannett Co. Inc.</name>
      <url>http://www.lannett.com</url>
    </packager>
    <packager>
      <name>Liberty Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Luitpold Pharmaceuticals Inc.</name>
      <url>http://www.luitpold.com</url>
    </packager>
    <packager>
      <name>Lunsco Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Mallinckrodt Inc.</name>
      <url>http://www.mallinckrodt.com</url>
    </packager>
    <packager>
      <name>Marlex Pharmaceuticals</name>
      <url>http://www.marlexpharm.com</url>
    </packager>
    <packager>
      <name>Marnel Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>MCR American Pharmaceuticals Inc.</name>
      <url>http://www.mcramerican.com</url>
    </packager>
    <packager>
      <name>Mikart Inc.</name>
      <url>http://www.mikart.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Nexgen Pharma Inc.</name>
      <url>http://www.nexgenpharma.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Paddock Labs</name>
      <url>http://www.paddocklabs.com</url>
    </packager>
    <packager>
      <name>Palmetto Pharmaceuticals Inc.</name>
      <url>http://www.palmettopharm.com</url>
    </packager>
    <packager>
      <name>Patient First Corp.</name>
      <url>http://www.patientfirst.com</url>
    </packager>
    <packager>
      <name>PCA LLC</name>
      <url/>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Perrigo Co.</name>
      <url>http://www.perrigo.com</url>
    </packager>
    <packager>
      <name>Pharmaceutical Utilization Management Program VA Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Poly Pharmaceuticals Inc.</name>
      <url>http://www.polypharmaceuticals.net</url>
    </packager>
    <packager>
      <name>Preferred Pharmaceuticals Inc.</name>
      <url>http://www.preferredpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Prepackage Specialists</name>
      <url/>
    </packager>
    <packager>
      <name>Prepak Systems Inc.</name>
      <url>http://www.prepaksys.com</url>
    </packager>
    <packager>
      <name>Prescript Pharmaceuticals</name>
      <url>http://www.prescript.net</url>
    </packager>
    <packager>
      <name>Prometic Pharma Inc.</name>
      <url>http://www.prometic.com</url>
    </packager>
    <packager>
      <name>Qualitest</name>
      <url>http://www.worldoftest.com</url>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Redpharm Drug</name>
      <url/>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Rising Pharmaceuticals</name>
      <url>http://www.risingpharma.com</url>
    </packager>
    <packager>
      <name>Rite Aid Corp.</name>
      <url>http://www.riteaid.com</url>
    </packager>
    <packager>
      <name>Sandhills Packaging Inc.</name>
      <url>http://www.sandhillspackaging.com</url>
    </packager>
    <packager>
      <name>Sciele Pharma Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Seatrace Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>Stat Rx Usa</name>
      <url>http://statrxusa.exporterus.com</url>
    </packager>
    <packager>
      <name>Talbert Medical Management Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>US Pharmaceutical Corp.</name>
      <url>http://www.uspco.com</url>
    </packager>
    <packager>
      <name>Va Cmop Dallas</name>
      <url/>
    </packager>
    <packager>
      <name>Victory Pharma</name>
      <url>http://www.victorypharma.com</url>
    </packager>
    <packager>
      <name>Vintage Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Watson Pharmaceuticals</name>
      <url>http://www.watson.com</url>
    </packager>
    <packager>
      <name>West-Ward Pharmaceuticals</name>
      <url>http://www.west-ward.com</url>
    </packager>
    <packager>
      <name>Xanodyne Pharmaceuticals Inc.</name>
      <url>http://www.xanodyne.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Mead johnson and co</manufacturer>
    <manufacturer generic="true" url="">App pharmaceuticals llc</manufacturer>
    <manufacturer generic="true" url="">Luitpold pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Paddock laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Sun pharmaceutical industries ltd</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Butalb-apap-caff 50-500-40 tablet</description>
      <cost currency="USD">1.2</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fioricet 50-325-40 mg tablet</description>
      <cost currency="USD">1.24</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Darvon 65 mg pulvule</description>
      <cost currency="USD">1.49</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Cafergot 1-100 mg tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Darvon-n 100 mg tablet</description>
      <cost currency="USD">1.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Esgic-plus 50-500-40 mg tablet</description>
      <cost currency="USD">1.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Esgic 50-325-40 mg tablet</description>
      <cost currency="USD">2.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Esgic tablet</description>
      <cost currency="USD">2.5</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Migergot suppository</description>
      <cost currency="USD">7.39</cost>
      <unit>suppository</unit>
    </price>
    <price>
      <description>Caffeine citrate 20 mg/ml vial</description>
      <cost currency="USD">12.8</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Caffeine cit 20 mg/ml oral sol</description>
      <cost currency="USD">15.21</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Cafcit 20 mg/ml oral soln</description>
      <cost currency="USD">16.4</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Cafcit 20 mg/ml vial</description>
      <cost currency="USD">16.4</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Migergot 12 2-100 mg Suppository Box</description>
      <cost currency="USD">105.43</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Caffeine 200 mg tablet</description>
      <cost currency="USD">0.01</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Caffeine powder</description>
      <cost currency="USD">0.07</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>CVS Pharmacy caffeine 200 mg tablet</description>
      <cost currency="USD">0.09</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ra stay awake 100 mg tablet</description>
      <cost currency="USD">0.09</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Stay awake 200 mg tablet</description>
      <cost currency="USD">0.1</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Caffeine citrated powder purif</description>
      <cost currency="USD">0.13</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>No doz 200 mg caplet</description>
      <cost currency="USD">0.16</cost>
      <unit>caplet</unit>
    </price>
    <price>
      <description>Vivarin 200 mg caplet</description>
      <cost currency="USD">0.17</cost>
      <unit>caplet</unit>
    </price>
    <price>
      <description>Vivarin 200 mg tablet</description>
      <cost currency="USD">0.17</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Propoxyphene hcl 65 mg capsule</description>
      <cost currency="USD">0.33</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Caffeine citrate powder</description>
      <cost currency="USD">0.36</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Butalb-apap-caff 50-325-40 tablet</description>
      <cost currency="USD">0.44</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alkaloids</category>
      <mesh-id>D000470</mesh-id>
    </category>
    <category>
      <category>Anorexigenic Agents &amp; Respiratory and CNS Stimulants</category>
      <mesh-id/>
    </category>
    <category>
      <category>BCRP/ABCG2 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Caffeine and Caffeine Containing Products</category>
      <mesh-id/>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Stimulants</category>
      <mesh-id>D000697</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Stimulation</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors</category>
      <mesh-id>D065609</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors (moderate)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2E1 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Diagnostic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Drugs for Obstructive Airway Diseases</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Phosphodiesterase Inhibitors</category>
      <mesh-id>D010726</mesh-id>
    </category>
    <category>
      <category>Psychoanaleptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psychostimulants, Agents Used for Adhd and Nootropics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Purinergic Agents</category>
      <mesh-id>D058905</mesh-id>
    </category>
    <category>
      <category>Purinergic Antagonists</category>
      <mesh-id>D058914</mesh-id>
    </category>
    <category>
      <category>Purines</category>
      <mesh-id>D011687</mesh-id>
    </category>
    <category>
      <category>Purinones</category>
      <mesh-id>D011688</mesh-id>
    </category>
    <category>
      <category>Respiratory and CNS Stimulants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tests for Gastric Secretion</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tricarboxylic Acids</category>
      <mesh-id>D014233</mesh-id>
    </category>
    <category>
      <category>Xanthine derivatives</category>
      <mesh-id>D013806</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, multilayer</form>
      <route>Oral</route>
      <strength>200 1/1</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>200 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, effervescent</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Syrup</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>200 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, multilayer</form>
      <route>Oral</route>
      <strength>200 mg/200mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>125 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>60 mg/3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>200 mg/1</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Granule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength>200 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>5.0 mg/1000mL</strength>
    </dosage>
    <dosage>
      <form>Tablet, multilayer</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution; solution</form>
      <route>Intravenous; Oral</route>
      <strength>20 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Lozenge</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Wafer</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, delayed release</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>200 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="R03DA20">
      <level code="R03DA">Xanthines</level>
      <level code="R03D">OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
      <level code="R03">DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
    <atc-code code="V04CG30">
      <level code="V04CG">Tests for gastric secretion</level>
      <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
      <level code="V04">DIAGNOSTIC AGENTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
    <atc-code code="N06BC01">
      <level code="N06BC">Xanthine derivatives</level>
      <level code="N06B">PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS</level>
      <level code="N06">PSYCHOANALEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>28:20.00</ahfs-code>
    <ahfs-code>28:20.32</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1c8l</pdb-entry>
    <pdb-entry>1gfz</pdb-entry>
    <pdb-entry>1l5q</pdb-entry>
    <pdb-entry>1l7x</pdb-entry>
    <pdb-entry>2a3b</pdb-entry>
    <pdb-entry>3dd1</pdb-entry>
    <pdb-entry>3dds</pdb-entry>
    <pdb-entry>3ddw</pdb-entry>
    <pdb-entry>3g6m</pdb-entry>
    <pdb-entry>3rfm</pdb-entry>
    <pdb-entry>4y4d</pdb-entry>
    <pdb-entry>5mzp</pdb-entry>
    <pdb-entry>5t9v</pdb-entry>
    <pdb-entry>5ta3</pdb-entry>
    <pdb-entry>5tal</pdb-entry>
    <pdb-entry>5tam</pdb-entry>
    <pdb-entry>5tan</pdb-entry>
    <pdb-entry>5tap</pdb-entry>
    <pdb-entry>5taq</pdb-entry>
    <pdb-entry>5tas</pdb-entry>
    <pdb-entry>5tat</pdb-entry>
    <pdb-entry>5tau</pdb-entry>
    <pdb-entry>5tav</pdb-entry>
    <pdb-entry>6icn</pdb-entry>
    <pdb-entry>6icp</pdb-entry>
    <pdb-entry>6jhn</pdb-entry>
    <pdb-entry>6ji0</pdb-entry>
    <pdb-entry>6jii</pdb-entry>
    <pdb-entry>6jiu</pdb-entry>
    <pdb-entry>6jiy</pdb-entry>
    <pdb-entry>6jrr</pdb-entry>
    <pdb-entry>6jrs</pdb-entry>
    <pdb-entry>6qtl</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00201.pdf?1265922810</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00201.pdf?1573157536</msds>
  <patents>
    <patent>
      <number>5972916</number>
      <country>United States</country>
      <approved>1999-10-26</approved>
      <expires>2017-07-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06213</drugbank-id>
      <name>Regadenoson</name>
      <description>Caffeine may decrease effectiveness of Regadenoson as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00640</drugbank-id>
      <name>Adenosine</name>
      <description>The therapeutic efficacy of Adenosine can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Allopurinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Disulfiram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04854</drugbank-id>
      <name>Febuxostat</name>
      <description>The serum concentration of the active metabolites of Caffeine can be increased when Caffeine is used in combination with Febuxostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The risk or severity of hypokalemia can be increased when Caffeine is combined with Formoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The risk or severity of adverse effects can be increased when Caffeine is combined with Indacaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The serum concentration of Lithium cation can be decreased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>The serum concentration of Lithium citrate can be decreased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>The serum concentration of Lithium carbonate can be decreased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>The serum concentration of Lithium hydroxide can be decreased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Mexiletine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>Caffeine may increase the hyperkalemic activities of Olodaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Pancuronium can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Pentoxifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>Caffeine may increase the hypotensive activities of Riociguat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>The metabolism of Caffeine can be decreased when combined with Thiabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The serum concentration of Zafirlukast can be decreased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The metabolism of Zolmitriptan can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The serum concentration of Agomelatine can be increased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The serum concentration of Pirfenidone can be increased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The serum concentration of Tizanidine can be increased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The metabolism of Caffeine can be increased when combined with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Amphetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The risk or severity of adverse effects can be increased when Phentermine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>The risk or severity of adverse effects can be increased when Midodrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Norepinephrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The risk or severity of adverse effects can be increased when Labetalol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>The risk or severity of adverse effects can be increased when Metaraminol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Epinephrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Methoxamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Orciprenaline is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00830</drugbank-id>
      <name>Phenmetrazine</name>
      <description>The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>The risk or severity of adverse effects can be increased when Dobutamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Benzphetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The risk or severity of adverse effects can be increased when Ritodrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of adverse effects can be increased when Terbutaline is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00935</drugbank-id>
      <name>Oxymetazoline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The risk or severity of adverse effects can be increased when Diethylpropion is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The risk or severity of adverse effects can be increased when Dopamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of adverse effects can be increased when Acebutolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The risk or severity of adverse effects can be increased when Fenoterol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Ephedrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The risk or severity of adverse effects can be increased when Mephentermine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The risk or severity of adverse effects can be increased when Procaterol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The risk or severity of adverse effects can be increased when Clenbuterol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The risk or severity of adverse effects can be increased when MMDA is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The risk or severity of adverse effects can be increased when Midomafetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Metamfetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of adverse effects can be increased when Celiprolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of adverse effects can be increased when Nylidrin is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>The risk or severity of adverse effects can be increased when Tetryzoline is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08841</drugbank-id>
      <name>Tyramine</name>
      <description>The risk or severity of adverse effects can be increased when Tyramine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>The risk or severity of adverse effects can be increased when Etilefrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>The risk or severity of adverse effects can be increased when Synephrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09352</drugbank-id>
      <name>Hydroxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Racepinephrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The risk or severity of adverse effects can be increased when Ritobegron is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The risk or severity of adverse effects can be increased when Bucindolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13064</drugbank-id>
      <name>Tramazoline</name>
      <description>The risk or severity of adverse effects can be increased when Tramazoline is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The risk or severity of adverse effects can be increased when Mephedrone is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13341</drugbank-id>
      <name>Fenozolone</name>
      <description>The risk or severity of adverse effects can be increased when Fenozolone is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>The risk or severity of adverse effects can be increased when Tretoquinol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The risk or severity of adverse effects can be increased when Gepefrine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The risk or severity of adverse effects can be increased when Epanolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>The risk or severity of adverse effects can be increased when Prenalterol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13852</drugbank-id>
      <name>Mefenorex</name>
      <description>The risk or severity of adverse effects can be increased when Mefenorex is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of adverse effects can be increased when Esmolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of adverse effects can be increased when Betaxolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The risk or severity of adverse effects can be increased when Atenolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The risk or severity of adverse effects can be increased when Timolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The risk or severity of adverse effects can be increased when Propranolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The risk or severity of adverse effects can be increased when Bisoprolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Alprenolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The risk or severity of adverse effects can be increased when Pindolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The risk or severity of adverse effects can be increased when Carvedilol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The risk or severity of adverse effects can be increased when Bevantolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The risk or severity of adverse effects can be increased when Practolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The risk or severity of adverse effects can be increased when Penbutolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Oxprenolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The risk or severity of adverse effects can be increased when Dexpropranolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The risk or severity of adverse effects can be increased when Nebivolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The risk or severity of adverse effects can be increased when Bufuralol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The risk or severity of adverse effects can be increased when Bopindolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The risk or severity of adverse effects can be increased when Bupranolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The risk or severity of adverse effects can be increased when Indenolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>The risk or severity of adverse effects can be increased when Befunolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The risk or severity of adverse effects can be increased when Arotinolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The risk or severity of adverse effects can be increased when Talinolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of adverse effects can be increased when Anisodamine is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The risk or severity of adverse effects can be increased when Landiolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The risk or severity of adverse effects can be increased when Esatenolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The risk or severity of adverse effects can be increased when Cloranolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The risk or severity of adverse effects can be increased when Mepindolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The risk or severity of adverse effects can be increased when Tertatolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The risk or severity of adverse effects can be increased when Metoprolol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of adverse effects can be increased when Sotalol is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The risk or severity of adverse effects can be increased when Caffeine is combined with Doxofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The metabolism of Caffeine can be decreased when combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00060</drugbank-id>
      <name>Interferon beta-1a</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon beta-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05396</drugbank-id>
      <name>Albinterferon Alfa-2B</name>
      <description>The metabolism of Caffeine can be decreased when combined with Albinterferon Alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The metabolism of Caffeine can be decreased when combined with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The metabolism of Caffeine can be decreased when combined with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14999</drugbank-id>
      <name>Human interferon beta</name>
      <description>The metabolism of Caffeine can be decreased when combined with Human interferon beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15119</drugbank-id>
      <name>Ropeginterferon alfa-2b</name>
      <description>The metabolism of Caffeine can be decreased when combined with Ropeginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15131</drugbank-id>
      <name>Interferon alfa-2c</name>
      <description>The metabolism of Caffeine can be decreased when combined with Interferon alfa-2c.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Methohexital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Thiamylal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Hexobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Barbexaclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The therapeutic efficacy of Lorazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>The therapeutic efficacy of Temazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00546</drugbank-id>
      <name>Adinazolam</name>
      <description>The therapeutic efficacy of Adinazolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The therapeutic efficacy of Clorazepic acid can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The therapeutic efficacy of Flurazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>The therapeutic efficacy of Halazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The therapeutic efficacy of Diazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>The therapeutic efficacy of Oxazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The therapeutic efficacy of Clonazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The therapeutic efficacy of Estazolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01489</drugbank-id>
      <name>Camazepam</name>
      <description>The therapeutic efficacy of Camazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The therapeutic efficacy of Delorazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01553</drugbank-id>
      <name>Cloxazolam</name>
      <description>The therapeutic efficacy of Cloxazolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The therapeutic efficacy of Bromazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01559</drugbank-id>
      <name>Clotiazepam</name>
      <description>The therapeutic efficacy of Clotiazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The therapeutic efficacy of Ketazolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>The therapeutic efficacy of Prazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The therapeutic efficacy of Quazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01594</drugbank-id>
      <name>Cinolazepam</name>
      <description>The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08811</drugbank-id>
      <name>Tofisopam</name>
      <description>The therapeutic efficacy of Tofisopam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>The therapeutic efficacy of Brotizolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The therapeutic efficacy of Etizolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12537</drugbank-id>
      <name>Benzodiazepine</name>
      <description>The therapeutic efficacy of Benzodiazepine can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13335</drugbank-id>
      <name>Pinazepam</name>
      <description>The therapeutic efficacy of Pinazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The therapeutic efficacy of Medazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13643</drugbank-id>
      <name>Loprazolam</name>
      <description>The therapeutic efficacy of Loprazolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13837</drugbank-id>
      <name>Doxefazepam</name>
      <description>The therapeutic efficacy of Doxefazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13872</drugbank-id>
      <name>Lormetazepam</name>
      <description>The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14028</drugbank-id>
      <name>Nordazepam</name>
      <description>The therapeutic efficacy of Nordazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14672</drugbank-id>
      <name>Oxazepam acetate</name>
      <description>The therapeutic efficacy of Oxazepam acetate can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14715</drugbank-id>
      <name>Cinazepam</name>
      <description>The therapeutic efficacy of Cinazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14719</drugbank-id>
      <name>Bentazepam</name>
      <description>The therapeutic efficacy of Bentazepam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15197</drugbank-id>
      <name>RSV-604</name>
      <description>The therapeutic efficacy of RSV-604 can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The therapeutic efficacy of Clobazam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The therapeutic efficacy of Alprazolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The therapeutic efficacy of Midazolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The therapeutic efficacy of Triazolam can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The metabolism of Rifampicin can be increased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The metabolism of Caffeine can be increased when combined with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The metabolism of Caffeine can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The metabolism of Caffeine can be decreased when combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The metabolism of Ziprasidone can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The metabolism of Anagrelide can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The metabolism of Carmustine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The metabolism of Disopyramide can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The metabolism of Lidocaine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The metabolism of Conjugated estrogens can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The metabolism of Ropivacaine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The metabolism of Olanzapine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The metabolism of Chlorzoxazone can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The metabolism of Mirtazapine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The metabolism of Tacrine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The metabolism of Triamterene can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The metabolism of Promazine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00442</drugbank-id>
      <name>Entecavir</name>
      <description>The metabolism of Entecavir can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The metabolism of Nabumetone can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The metabolism of Flutamide can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The metabolism of Haloperidol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The metabolism of Albendazole can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The metabolism of Cinnarizine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The metabolism of Diclofenac can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Imatinib can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The metabolism of Guanabenz can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The metabolism of Pemetrexed can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The metabolism of Riluzole can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The metabolism of Zileuton can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The metabolism of Etoposide can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The metabolism of Estradiol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The metabolism of Acyclovir can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The metabolism of Naproxen can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The metabolism of Trifluoperazine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The metabolism of Perphenazine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The metabolism of Dacarbazine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The metabolism of Ranitidine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Ethanol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The metabolism of Maprotiline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The metabolism of Alosetron can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Ramelteon can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The metabolism of Azathioprine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The metabolism of Frovatriptan can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The metabolism of Levobupivacaine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The metabolism of Selegiline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01056</drugbank-id>
      <name>Tocainide</name>
      <description>The metabolism of Tocainide can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The metabolism of Melatonin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01094</drugbank-id>
      <name>Hesperetin</name>
      <description>The metabolism of Hesperetin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The metabolism of Cilostazol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The metabolism of Domperidone can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The metabolism of Dexfenfluramine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The metabolism of Oxtriphylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The metabolism of Rasagiline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The metabolism of Theobromine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Aminophenazone can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Antipyrine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The metabolism of Fenethylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The metabolism of Thiothixene can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The metabolism of Etoricoxib can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The metabolism of Genistein can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The metabolism of 8-azaguanine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The metabolism of Xanthine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The metabolism of 9-Methylguanine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The metabolism of Peldesine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The metabolism of Resveratrol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The metabolism of Hypoxanthine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The metabolism of 9-Deazaguanine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The metabolism of Estrone sulfate can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Flunarizine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The metabolism of Lofexidine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The metabolism of Mianserin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The metabolism of Asenapine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06235</drugbank-id>
      <name>Vadimezan</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The metabolism of Propentofylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The metabolism of Axitinib can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The metabolism of Bendamustine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The metabolism of Capsaicin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The metabolism of Perampanel can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The metabolism of Pomalidomide can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The metabolism of Tasimelteon can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The metabolism of Zotepine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The metabolism of Propacetamol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>The metabolism of Ramosetron can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The metabolism of 6-O-benzylguanine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The metabolism of Binimetinib can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The metabolism of Voxilaprevir can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The metabolism of Lisofylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The metabolism of Lobucavir can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The metabolism of Cafedrine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The metabolism of Theodrenaline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The metabolism of Dihydralazine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The metabolism of Bamifylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The metabolism of Proxyphylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The metabolism of Acefylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The metabolism of Etamiphylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The metabolism of Pentifylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The metabolism of Bufylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Enasidenib can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The metabolism of Estradiol acetate can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The metabolism of Estradiol benzoate can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The metabolism of Estradiol cypionate can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The metabolism of Estradiol dienanthate can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The metabolism of Estradiol valerate can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The metabolism of Bromotheophylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The metabolism of 8-chlorotheophylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The metabolism of Caffeine can be decreased when combined with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The metabolism of Caffeine can be decreased when combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The metabolism of Dosulepin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04889</drugbank-id>
      <name>Bicifadine</name>
      <description>The metabolism of Bicifadine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The metabolism of GTS-21 can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Efavirenz can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The metabolism of Pazopanib can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Stiripentol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01321</drugbank-id>
      <name>Josamycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Josamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00954</drugbank-id>
      <name>Dirithromycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Dirithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09308</drugbank-id>
      <name>Solithromycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Solithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13287</drugbank-id>
      <name>Miocamycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Miocamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13338</drugbank-id>
      <name>Flurithromycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Flurithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13409</drugbank-id>
      <name>Rokitamycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Rokitamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13456</drugbank-id>
      <name>Midecamycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Midecamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01152</drugbank-id>
      <name>Candicidin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Candicidin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01873</drugbank-id>
      <name>Epothilone D</name>
      <description>The metabolism of Caffeine can be decreased when combined with Epothilone D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03010</drugbank-id>
      <name>Patupilone</name>
      <description>The metabolism of Caffeine can be decreased when combined with Patupilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04070</drugbank-id>
      <name>6-Deoxyerythronolide B</name>
      <description>The metabolism of Caffeine can be decreased when combined with 6-Deoxyerythronolide B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The metabolism of Caffeine can be decreased when combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05903</drugbank-id>
      <name>KOS-1584</name>
      <description>The metabolism of Caffeine can be decreased when combined with KOS-1584.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06233</drugbank-id>
      <name>Ridaforolimus</name>
      <description>The metabolism of Caffeine can be decreased when combined with Ridaforolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06318</drugbank-id>
      <name>AVE9633</name>
      <description>The metabolism of Caffeine can be decreased when combined with AVE9633.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06342</drugbank-id>
      <name>Coltuximab ravtansine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Coltuximab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06419</drugbank-id>
      <name>Cethromycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Cethromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06587</drugbank-id>
      <name>Mitemcinal</name>
      <description>The metabolism of Caffeine can be decreased when combined with Mitemcinal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09309</drugbank-id>
      <name>Kitasamycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Kitasamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11383</drugbank-id>
      <name>Carbomycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Carbomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11405</drugbank-id>
      <name>Eprinomectin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Eprinomectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11442</drugbank-id>
      <name>Oleandomycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Oleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11459</drugbank-id>
      <name>Selamectin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Selamectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11470</drugbank-id>
      <name>Tildipirosin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Tildipirosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11471</drugbank-id>
      <name>Tilmicosin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Tilmicosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11475</drugbank-id>
      <name>Tylosin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Tylosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11554</drugbank-id>
      <name>Tylvalosin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Tylvalosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11752</drugbank-id>
      <name>Bryostatin 1</name>
      <description>The metabolism of Caffeine can be decreased when combined with Bryostatin 1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12266</drugbank-id>
      <name>Epofolate</name>
      <description>The metabolism of Caffeine can be decreased when combined with Epofolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12391</drugbank-id>
      <name>Sagopilone</name>
      <description>The metabolism of Caffeine can be decreased when combined with Sagopilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12489</drugbank-id>
      <name>Mirvetuximab Soravtansine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Mirvetuximab Soravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13633</drugbank-id>
      <name>Mepartricin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Mepartricin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The metabolism of Caffeine can be decreased when combined with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The metabolism of Caffeine can be decreased when combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The metabolism of Caffeine can be decreased when combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07348</drugbank-id>
      <name>Brefeldin A</name>
      <description>The metabolism of Caffeine can be decreased when combined with Brefeldin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Enoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Technetium Tc-99m ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Pefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The metabolism of Caffeine can be decreased when combined with Nalidixic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Rosoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Gatifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Enrofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Orbifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Sarafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Difloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Prulifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Delafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Sitafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The metabolism of Caffeine can be decreased when combined with Oxolinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Rufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The metabolism of Caffeine can be decreased when combined with Pipemidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Pregabalin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>Topiramate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>Trimethadione may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>Metharbital may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>Paramethadione may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>Magnesium sulfate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>Ethotoin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>Acetazolamide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>Phensuximide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>Progabide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>Tiagabine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>Zaleplon may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>Gabapentin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>Vigabatrin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>Phenacemide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>7-Nitroindazole may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>Valpromide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Ezogabine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>Methsuximide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>Brivaracetam may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>Rufinamide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>Lacosamide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>Remacemide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>Clomethiazole may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>Deramciclane may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>Tramiprosate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>Gaboxadol may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>Sulthiame may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>Beclamide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>Cannabidiol may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>Paraldehyde may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>Eslicarbazepine acetate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>Doramectin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>Tiletamine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>Brexanolone may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>Etiracetam may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>Vinpocetine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>Carisbamate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>Pheneturide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>Neocitrullamon may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>Phenibut may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>Ethadione may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>Cannabidivarin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>Eslicarbazepine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>JNJ-26489112 may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>Lamotrigine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>Ethosuximide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>Oxcarbazepine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Zonisamide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>Felbamate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>Levetiracetam may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>Cenobamate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14025</drugbank-id>
      <name>Clinafloxacin</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Clinafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14029</drugbank-id>
      <name>Furafylline</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Furafylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The metabolism of Caffeine can be increased when combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06442</drugbank-id>
      <name>Avasimibe</name>
      <description>The metabolism of Caffeine can be decreased when combined with Avasimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The metabolism of Valproic acid can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The metabolism of Caffeine can be decreased when combined with Nitric Oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>The metabolism of Caffeine can be decreased when combined with Methoxsalen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>The metabolism of Caffeine can be decreased when combined with Obeticholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The metabolism of Caffeine can be decreased when combined with Safinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06803</drugbank-id>
      <name>Niclosamide</name>
      <description>The metabolism of Caffeine can be decreased when combined with Niclosamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11198</drugbank-id>
      <name>Peppermint oil</name>
      <description>The metabolism of Caffeine can be decreased when combined with Peppermint oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11994</drugbank-id>
      <name>Diacerein</name>
      <description>The metabolism of Caffeine can be decreased when combined with Diacerein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13975</drugbank-id>
      <name>Black cohosh</name>
      <description>The metabolism of Caffeine can be decreased when combined with Black cohosh.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Caffeine can be decreased when combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The metabolism of Caffeine can be decreased when combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The metabolism of Caffeine can be decreased when combined with Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The metabolism of Caffeine can be decreased when combined with Tegaserod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The metabolism of Caffeine can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The metabolism of Caffeine can be decreased when combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The metabolism of Caffeine can be decreased when combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The metabolism of Caffeine can be decreased when combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13174</drugbank-id>
      <name>Rhein</name>
      <description>The metabolism of Caffeine can be decreased when combined with Rhein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The metabolism of Caffeine can be decreased when combined with Medical Cannabis.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The metabolism of Caffeine can be decreased when combined with Nabiximols.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>The metabolism of Caffeine can be decreased when combined with Curcumin sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The metabolism of Tamoxifen can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The metabolism of Dapagliflozin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Caffeine can be decreased when combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Caffeine can be decreased when combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The metabolism of Caffeine can be decreased when combined with Clopidogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Caffeine can be decreased when combined with Triclabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The metabolism of Clozapine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Duloxetine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The metabolism of Chlorpromazine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The metabolism of Primaquine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Lorcaserin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The metabolism of Rucaparib can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Caffeine can be decreased when combined with Cinacalcet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Zolpidem can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The metabolism of Dasatinib can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The metabolism of Caffeine can be decreased when combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The metabolism of Flecainide can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The metabolism of Nifedipine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The metabolism of Nortriptyline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The metabolism of Pimozide can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Amitriptyline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Imipramine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The metabolism of Clonidine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The metabolism of Cyclobenzaprine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The metabolism of Desipramine can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Caffeine can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Caffeine can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Caffeine can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Caffeine can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Caffeine can be increased when combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Caffeine can be increased when combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Caffeine can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Caffeine can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Caffeine can be increased when combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Caffeine can be increased when combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Caffeine can be increased when combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Caffeine can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Caffeine can be increased when combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Caffeine can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The risk or severity of adverse effects can be increased when Caffeine is combined with Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>Carbimazole may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>Propylthiouracil may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>Methimazole may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>3,5-Diiodotyrosine may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>Potassium Iodide may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>Dibromotyrosine may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>Potassium perchlorate may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>Methylthiouracil may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>Benzylthiouracil may decrease the excretion rate of Caffeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>Thyrotropin alfa may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>Liothyronine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>Levothyroxine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>Liotrix may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>Tiratricol may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>Thyroid, porcine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ketoprofen may decrease the diuretic activities of Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The risk or severity of adverse effects can be increased when Caffeine is combined with Theophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Givosiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Viloxazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The metabolism of Caffeine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Nevirapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The serum concentration of Alpelisib can be increased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>The metabolism of Caffeine can be increased when combined with Menadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The metabolism of Caffeine can be increased when combined with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The metabolism of Caffeine can be increased when combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06732</drugbank-id>
      <name>beta-Naphthoflavone</name>
      <description>The metabolism of Caffeine can be increased when combined with beta-Naphthoflavone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin beef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The metabolism of Caffeine can be increased when combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00400</drugbank-id>
      <name>Griseofulvin</name>
      <description>The metabolism of Caffeine can be increased when combined with Griseofulvin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The metabolism of Caffeine can be increased when combined with Secobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The metabolism of Caffeine can be increased when combined with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The metabolism of Caffeine can be increased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00607</drugbank-id>
      <name>Nafcillin</name>
      <description>The metabolism of Caffeine can be increased when combined with Nafcillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>The metabolism of Caffeine can be increased when combined with Modafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The metabolism of Caffeine can be increased when combined with Rabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Caffeine can be increased when combined with Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The metabolism of Caffeine can be increased when combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The metabolism of Caffeine can be increased when combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The metabolism of Caffeine can be increased when combined with Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15328</drugbank-id>
      <name>Ubrogepant</name>
      <description>The serum concentration of Ubrogepant can be increased when it is combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Caffeine may decrease the excretion rate of Folic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>Caffeine may decrease the excretion rate of Pravastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>Caffeine may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>Caffeine may decrease the excretion rate of Gefitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>Caffeine may decrease the excretion rate of Cerivastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>Caffeine may decrease the excretion rate of Teniposide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>Caffeine may decrease the excretion rate of Prazosin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>Caffeine may decrease the excretion rate of Raloxifene which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Caffeine may decrease the excretion rate of Celecoxib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>Caffeine may decrease the excretion rate of Zidovudine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>Caffeine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>Caffeine may decrease the excretion rate of Vincristine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>Caffeine may decrease the excretion rate of Ivermectin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Caffeine may decrease the excretion rate of Testosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Caffeine may decrease the excretion rate of Clofarabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Caffeine may decrease the excretion rate of Sumatriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Caffeine may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>Caffeine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Caffeine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>Caffeine may decrease the excretion rate of Lamivudine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>Caffeine may decrease the excretion rate of Irinotecan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Caffeine may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>Caffeine may decrease the excretion rate of Donepezil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>Caffeine may decrease the excretion rate of Dactinomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>Caffeine may decrease the excretion rate of Ezetimibe which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>Caffeine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>Caffeine may decrease the excretion rate of Glyburide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>Caffeine may decrease the excretion rate of Topotecan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>Caffeine may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>Caffeine may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03496</drugbank-id>
      <name>Alvocidib</name>
      <description>Caffeine may decrease the excretion rate of Alvocidib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>Caffeine may decrease the excretion rate of Camptothecin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>Caffeine may decrease the excretion rate of Nilotinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Caffeine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Caffeine may decrease the excretion rate of Apixaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>Caffeine may decrease the excretion rate of Pitavastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>Caffeine may decrease the excretion rate of Ponatinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>Caffeine may decrease the excretion rate of Dabrafenib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>Caffeine may decrease the excretion rate of Afatinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>Caffeine may decrease the excretion rate of Dolutegravir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>Caffeine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>Caffeine may decrease the excretion rate of Idelalisib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>Caffeine may decrease the excretion rate of Palbociclib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>Caffeine may decrease the excretion rate of Fimasartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>Caffeine may decrease the excretion rate of Ombitasvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>Caffeine may decrease the excretion rate of Tenofovir alafenamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>Caffeine may decrease the excretion rate of Moxidectin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>Caffeine may decrease the excretion rate of Venetoclax which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>Caffeine may decrease the excretion rate of Velpatasvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>Caffeine may decrease the excretion rate of Talazoparib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>Caffeine may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>Caffeine may decrease the excretion rate of Revefenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>Caffeine may decrease the excretion rate of Duvelisib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>Caffeine may decrease the excretion rate of Dacomitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>Caffeine may decrease the excretion rate of Glasdegib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>Caffeine may decrease the excretion rate of Abemaciclib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>Caffeine may decrease the excretion rate of Brigatinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>Caffeine may decrease the excretion rate of Copanlisib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>Caffeine may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>Caffeine may decrease the excretion rate of Pibrentasvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>Caffeine may decrease the excretion rate of Glecaprevir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Caffeine may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Caffeine may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Caffeine may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>Caffeine may decrease the excretion rate of Larotrectinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>Caffeine may decrease the excretion rate of Darolutamide which could result in a higher serum level.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.24</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.10e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1,3,7-trimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>caffeine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>194.1906</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>194.080375584</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CN1C=NC2=C1C(=O)N(C)C(=O)N2C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C8H10N4O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RYYVLZVUVIJVGH-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>58.44</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>49.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>18.95</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-0.92</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>2.17 g/100mL</value>
      <source>http://www.inchem.org/documents/icsc/icsc/eics0405.htm</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>235-237</value>
      <source>https://www.sigmaaldrich.com/catalog/product/sial/41019?lang=en&amp;region=US</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>178</value>
      <source>http://www.inchem.org/documents/icsc/icsc/eics0405.htm</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.07</value>
      <source>http://www.inchem.org/documents/icsc/icsc/eics0405.htm</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-0.97</value>
      <source>https://pubchem.ncbi.nlm.nih.gov/compound/Caffeine</source>
    </property>
    <property>
      <kind>caco2 Permeability</kind>
      <value>-4.41</value>
      <source>https://pubs.acs.org/doi/full/10.1021/ci049884m?src=recsys</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>14</value>
      <source>https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma-Aldrich/Product_Information_Sheet/c0750pis.pdf</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>9358</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>9357</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>27732</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>2519</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506408</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07481</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00528</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>2424</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>10849</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448710</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>CFF</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000099</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>407</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>407</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Caffeine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL113</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/caffeine.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/caffeine.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000028</smpdb-id>
      <name>Caffeine Metabolism</name>
      <category>metabolic</category>
      <drugs>
        <drug>
          <drugbank-id>DB00157</drugbank-id>
          <name>NADH</name>
        </drug>
        <drug>
          <drugbank-id>DB00201</drugbank-id>
          <name>Caffeine</name>
        </drug>
        <drug>
          <drugbank-id>DB00277</drugbank-id>
          <name>Theophylline</name>
        </drug>
        <drug>
          <drugbank-id>DB01412</drugbank-id>
          <name>Theobromine</name>
        </drug>
        <drug>
          <drugbank-id>DB02577</drugbank-id>
          <name>Mesoheme</name>
        </drug>
        <drug>
          <drugbank-id>DB03147</drugbank-id>
          <name>Flavin adenine dinucleotide</name>
        </drug>
        <drug>
          <drugbank-id>DB03843</drugbank-id>
          <name>Formaldehyde</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P05177</uniprot-id>
        <uniprot-id>P05181</uniprot-id>
        <uniprot-id>A4Z6T9</uniprot-id>
        <uniprot-id>P08684</uniprot-id>
        <uniprot-id>P10632</uniprot-id>
        <uniprot-id>P11712</uniprot-id>
        <uniprot-id>P47989</uniprot-id>
        <uniprot-id>P11509</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00201</drugbank-id>
        <name>Caffeine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00220</drugbank-id>
        <name>Theobromine</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002433</drugbank-id>
          <name>Cytochrome P450 1A2</name>
          <uniprot-id>P05177</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003533</drugbank-id>
          <name>Cytochrome P450 2E1</name>
          <uniprot-id>P05181</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00201</drugbank-id>
        <name>Caffeine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00221</drugbank-id>
        <name>Theophylline</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002433</drugbank-id>
          <name>Cytochrome P450 1A2</name>
          <uniprot-id>P05177</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003533</drugbank-id>
          <name>Cytochrome P450 2E1</name>
          <uniprot-id>P05181</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002887</drugbank-id>
          <name>Cytochrome P450 2C8</name>
          <uniprot-id>P10632</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002793</drugbank-id>
          <name>Cytochrome P450 2C9</name>
          <uniprot-id>P11712</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00201</drugbank-id>
        <name>Caffeine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00222</drugbank-id>
        <name>1,3,7-Trimethyluric acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002887</drugbank-id>
          <name>Cytochrome P450 2C8</name>
          <uniprot-id>P10632</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002793</drugbank-id>
          <name>Cytochrome P450 2C9</name>
          <uniprot-id>P11712</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002433</drugbank-id>
          <name>Cytochrome P450 1A2</name>
          <uniprot-id>P05177</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003533</drugbank-id>
          <name>Cytochrome P450 2E1</name>
          <uniprot-id>P05181</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00201</drugbank-id>
        <name>Caffeine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00223</drugbank-id>
        <name>Paraxanthine</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002433</drugbank-id>
          <name>Cytochrome P450 1A2</name>
          <uniprot-id>P05177</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET00223</drugbank-id>
        <name>Paraxanthine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00611</drugbank-id>
        <name>1,7-Dimethyluric acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002433</drugbank-id>
          <name>Cytochrome P450 1A2</name>
          <uniprot-id>P05177</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003336</drugbank-id>
          <name>Cytochrome P450 2A6</name>
          <uniprot-id>P11509</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET00221</drugbank-id>
        <name>Theophylline</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00271</drugbank-id>
        <name>1-Methylxanthine</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002433</drugbank-id>
          <name>Cytochrome P450 1A2</name>
          <uniprot-id>P05177</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET00223</drugbank-id>
        <name>Paraxanthine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00612</drugbank-id>
        <name>5-Acetylamino-6-formylamino-3-methyluracil</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0003607</drugbank-id>
          <name>Arylamine N-acetyltransferase 2</name>
          <uniprot-id>P11245</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET00223</drugbank-id>
        <name>Paraxanthine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00271</drugbank-id>
        <name>1-Methylxanthine</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002204</drugbank-id>
          <name>Xanthine dehydrogenase/oxidase</name>
          <uniprot-id>P47989</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET00271</drugbank-id>
        <name>1-Methylxanthine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00560</drugbank-id>
        <name>1-Methyluric acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002204</drugbank-id>
          <name>Xanthine dehydrogenase/oxidase</name>
          <uniprot-id>P47989</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions>
    <reaction>
      <protein-name>Cytochrome P450 1A2</protein-name>
      <gene-symbol>CYP1A2</gene-symbol>
      <uniprot-id>P05177</uniprot-id>
      <rs-id>rs762551</rs-id>
      <allele/>
      <adverse-reaction>C allele</adverse-reaction>
      <description>Patients with this genotype have increased risk of a non-fatal myocardial infarction with caffeine</description>
      <pubmed-id>16522833</pubmed-id>
    </reaction>
  </snp-adverse-drug-reactions>
  <targets>
    <target position="3">
      <id>BE0000013</id>
      <name>Adenosine receptor A1</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>multitarget</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4285</ref-id>
            <pubmed-id>16702031</pubmed-id>
            <citation>Gaytan SP, Saadani-Makki F, Bodineau L, Frugiere A, Larnicol N, Pasaro R: Effect of postnatal exposure to caffeine on the pattern of adenosine A1 receptor distribution in respiration-related nuclei of the rat brainstem. Auton Neurosci. 2006 Jun 30;126-127:339-46. Epub 2006 May 15.</citation>
          </article>
          <article>
            <ref-id>A4286</ref-id>
            <pubmed-id>17372967</pubmed-id>
            <citation>Wang SJ: Caffeine facilitation of glutamate release from rat cerebral cortex nerve terminals (synaptosomes) through activation protein kinase C pathway: an interaction with presynaptic adenosine A1 receptors. Synapse. 2007 Jun;61(6):401-11.</citation>
          </article>
          <article>
            <ref-id>A4287</ref-id>
            <pubmed-id>17126319</pubmed-id>
            <citation>Rieg T, Schnermann J, Vallon V: Adenosine A1 receptors determine effects of caffeine on total fluid intake but not caffeine appetite. Eur J Pharmacol. 2007 Jan 26;555(2-3):174-7. Epub 2006 Oct 25.</citation>
          </article>
          <article>
            <ref-id>A4288</ref-id>
            <pubmed-id>17162470</pubmed-id>
            <citation>Mustafa S, Venkatesh P, Pasha K, Mullangi R, Srinivas NR: Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF? Xenobiotica. 2006 Dec;36(12):1239-58.</citation>
          </article>
          <article>
            <ref-id>A4289</ref-id>
            <pubmed-id>17085856</pubmed-id>
            <citation>Listos J, Malec D, Fidecka S: Adenosine receptor antagonists intensify the benzodiazepine withdrawal signs in mice. Pharmacol Rep. 2006 Sep-Oct;58(5):643-51.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L9851</ref-id>
            <title>Caffeine citrate injection FDA label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20793s1lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P30542" source="Swiss-Prot">
        <name>Adenosine receptor A1</name>
        <general-function>Purine nucleoside binding</general-function>
        <specific-function>Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.</specific-function>
        <gene-name>ADORA1</gene-name>
        <locus>1q32.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>11-33
47-69
81-102
124-146
177-201
236-259
268-292</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.75</theoretical-pi>
        <molecular-weight>36511.325</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:262</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADORA1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S45235</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>256155</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>18</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>18</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P30542</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AA1R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000026|Adenosine receptor A1
MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGA
LVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVT
PRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYM
VYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALIL
FLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFL
KIWNDHFRCQPAPPIDEDLPEERPDD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010133|Adenosine receptor A1 (ADORA1)
ATGCCGCCCTCCATCTCAGCTTTCCAGGCCGCCTACATCGGCATCGAGGTGCTCATCGCC
CTGGTCTCTGTGCCCGGGAACGTGCTGGTGATCTGGGCGGTGAAGGTGAACCAGGCGCTG
CGGGATGCCACCTTCTGCTTCATCGTGTCGCTGGCGGTGGCTGATGTGGCCGTGGGTGCC
CTGGTCATCCCCCTCGCCATCCTCATCAACATTGGGCCACAGACCTACTTCCACACCTGC
CTCATGGTTGCCTGTCCGGTCCTCATCCTCACCCAGAGCTCCATCCTGGCCCTGCTGGCA
ATTGCTGTGGACCGCTACCTCCGGGTCAAGATCCCTCTCCGGTACAAGATGGTGGTGACC
CCCCGGAGGGCGGCGGTGGCCATAGCCGGCTGCTGGATCCTCTCCTTCGTGGTGGGACTG
ACCCCTATGTTTGGCTGGAACAATCTGAGTGCGGTGGAGCGGGCCTGGGCAGCCAACGGC
AGCATGGGGGAGCCCGTGATCAAGTGCGAGTTCGAGAAGGTCATCAGCATGGAGTACATG
GTCTACTTCAACTTCTTTGTGTGGGTGCTGCCCCCGCTTCTCCTCATGGTCCTCATCTAC
CTGGAGGTCTTCTACCTAATCCGCAAGCAGCTCAACAAGAAGGTGTCGGCCTCCTCCGGC
GACCCGCAGAAGTACTATGGGAAGGAGCTGAAGATCGCCAAGTCGCTGGCCCTCATCCTC
TTCCTCTTTGCCCTCAGCTGGCTGCCTTTGCACATCCTCAACTGCATCACCCTCTTCTGC
CCGTCCTGCCACAAGCCCAGCATCCTTACCTACATTGCCATCTTCCTCACGCACGGCAAC
TCGGCCATGAACCCCATTGTCTATGCCTTCCGCATCCAGAAGTTCCGCGTCACCTTCCTT
AAGATTTGGAATGACCATTTCCGCTGCCAGCCTGCACCTCCCATTGACGAGGATCTCCCA
GAAGAGAGGCCTGATGACTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>presynaptic active zone</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>presynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal bouton</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled adenosine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>purine nucleoside binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cognition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of temperature stimulus involved in sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of circadian sleep/wake cycle, non-REM sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glutamate secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of long term synaptic depression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of mucus secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neurotrophin production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of renal sodium excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epidermal growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nucleoside transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptide secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein dephosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein targeting to membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of glomerular filtration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of respiratory gaseous exchange by neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>relaxation of vascular smooth muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0000487</id>
      <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4B</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A10297</ref-id>
            <pubmed-id>17514358</pubmed-id>
            <citation>Daly JW: Caffeine analogs: biomedical impact. Cell Mol Life Sci. 2007 Aug;64(16):2153-69.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q07343" source="Swiss-Prot">
        <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4B</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.</specific-function>
        <gene-name>PDE4B</gene-name>
        <locus>1p31</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.89</theoretical-pi>
        <molecular-weight>83342.695</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8781</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE4B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L20966</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>347122</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1301</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q07343</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE4B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>DPDE4</synonym>
          <synonym>PDE32</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000972|cAMP-specific 3',5'-cyclic phosphodiesterase 4B
MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNLQLPPLSQRQS
ERARTPEGDGISRPTTLPLTTLPSIAITTVSQECFDVENGPSPGRSPLDPQASSSAGLVL
HATFPGHSQRRESFLYRSDSDYDLSPKAMSRNSSLPSEQHGDDLIVTPFAQVLASLRSVR
NNFTILTNLHGTSNKRSPAASQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYR
SVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKK
KQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGLNIFNVAGYSH
NRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSLHAADVAQSTHV
LLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHL
AVGFKLLQEEHCDIFMNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTS
SGVLLLDNYTDRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEI
SPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMIPQSP
SPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHSYFSSTKTLCVIDPENRDSLG
ETDIDIATEDKSPVDT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016107|cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B)
ATGAAGGAGCACGGGGGCACCTTCAGTAGCACCGGAATCAGCGGTGGTAGCGGTGACTCT
GCTATGGACAGCCTGCAGCCGCTCCAGCCTAACTACATGCCTGTGTGTTTGTTTGCAGAA
GAATCTTATCAAAAATTAGCAATGGAAACGCTGGAGGAATTAGACTGGTGTTTAGACCAG
CTAGAGACCATACAGACCTACCGGTCTGTCAGTGAGATGGCTTCTAACAAGTTCAAAAGA
ATGCTGAACCGGGAGCTGACACACCTCTCAGAGATGAGCCGATCAGGGAACCAGGTGTCT
GAATACATTTCAAATACTTTCTTAGACAAGCAGAATGATGTGGAGATCCCATCTCCTACC
CAGAAAGACAGGGAGAAAAAGAAAAAGCAGCAGCTCATGACCCAGATAAGTGGAGTGAAG
AAATTAATGCATAGTTCAAGCCTAAACAATACAAGCATCTCACGCTTTGGAGTCAACACT
GAAAATGAAGATCACCTGGCCAAGGAGCTGGAAGACCTGAACAAATGGGGTCTTAACATC
TTTAATGTGGCTGGATATTCTCACAATAGACCCCTAACATGCATCATGTATGCTATATTC
CAGGAAAGAGACCTCCTAAAGACATTCAGAATCTCATCTGACACATTTATAACCTACATG
ATGACTTTAGAAGACCATTACCATTCTGACGTGGCATATCACAACAGCCTGCACGCTGCT
GATGTAGCCCAGTCGACCCATGTTCTCCTTTCTACACCAGCATTAGACGCTGTCTTCACA
GATTTGGAGATCCTGGCTGCCATTTTTGCAGCTGCCATCCATGACGTTGATCATCCTGGA
GTCTCCAATCAGTTTCTCATCAACACAAATTCAGAACTTGCTTTGATGTATAATGATGAA
TCTGTGTTGGAAAATCATCACCTTGCTGTGGGTTTCAAACTGCTGCAAGAAGAACACTGT
GACATCTTCATGAATCTCACCAAGAAGCAGCGTCAGACACTCAGGAAGATGGTTATTGAC
ATGGTGTTAGCAACTGATATGTCTAAACATATGAGCCTGCTGGCAGACCTGAAGACAATG
GTAGAAACGAAGAAAGTTACAAGTTCAGGCGTTCTTCTCCTAGACAACTATACCGATCGC
ATTCAGGTCCTTCGCAACATGGTACACTGTGCAGACCTGAGCAACCCCACCAAGTCCTTG
GAATTGTATCGGCAATGGACAGACCGCATCATGGAGGAATTTTTCCAGCAGGGAGACAAA
GAGCGGGAGAGGGGAATGGAAATTAGCCCAATGTGTGATAAACACACAGCTTCTGTGGAA
AAATCCCAGGTTGGTTTCATCGACTACATTGTCCATCCATTGTGGGAGACATGGGCAGAT
TTGGTACAGCCTGATGCTCAGGACATTCTCGATACCTTAGAAGATAACAGGAACTGGTAT
CAGAGCATGATACCTCAAAGTCCCTCACCACCACTGGACGAGCAGAACAGGGACTGCCAG
GGTCTGATGGAGAAGTTTCAGTTTGAACTGACTCTCGATGAGGAAGATTCTGAAGGACCT
GAGAAGGAGGGAGAGGGACACAGCTATTTCAGCAGCACAAAGACGCTTTGTGTGATTGAT
CCAGAAAACAGAGATTCCCTGGGAGAGACTGACATAGACATTGCAACAGAAGACAAGTCC
CCCGTGGATACATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell periphery</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>centrosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>excitatory synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>gamma-tubulin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Z disc</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to epinephrine stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of relaxation of cardiac muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-2 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle cell contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0000924</id>
      <name>Adenosine receptor A2a</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>multitarget</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A11743</ref-id>
            <pubmed-id>17558310</pubmed-id>
            <citation>Riksen NP, Franke B, van den Broek P, Smits P, Rongen GA: The 1976C&gt;T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genomics. 2007 Jul;17(7):551-4.</citation>
          </article>
          <article>
            <ref-id>A11744</ref-id>
            <pubmed-id>17577101</pubmed-id>
            <citation>Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, Shryock J, Belardinelli L, Hintze TH: Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol. 2007 Jun;49(6):369-75.</citation>
          </article>
          <article>
            <ref-id>A11745</ref-id>
            <pubmed-id>17616786</pubmed-id>
            <citation>Cornelis MC, El-Sohemy A, Campos H: Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr. 2007 Jul;86(1):240-4.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P29274" source="Swiss-Prot">
        <name>Adenosine receptor A2a</name>
        <general-function>Identical protein binding</general-function>
        <specific-function>Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.</specific-function>
        <gene-name>ADORA2A</gene-name>
        <locus>22q11.23</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>8-32
43-66
78-100
121-143
174-198
235-258
267-290</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.05</theoretical-pi>
        <molecular-weight>44706.925</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:263</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADORA2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M97370</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177892</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>19</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>19</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29274</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AA2AR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADORA2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001840|Adenosine receptor A2a
MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAI
PFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLVTGTR
AKGIIAICWVLSFAIGLTPMLGWNNCGQPKEGKNHSQGCGEGQVACLFEDVVPMNYMVYF
NFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVG
LFALCWLPLHIINCFTFFCPDCSHAPLWLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFR
KIIRSHVLRQQEPFKAAGTSARVLAAHGSDGEQVSLRLNGHPPGVWANGSAPHPERRPNG
YALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGLDDPLAQDGAGVS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016254|Adenosine receptor A2a (ADORA2A)
ATGCCCATCATGGGCTCCTCGGTGTACATCACGGTGGAGCTGGCCATTGCTGTGCTGGCC
ATCCTGGGCAATGTGCTGGTGTGCTGGGCCGTGTGGCTCAACAGCAACCTGCAGAACGTC
ACCAACTACTTTGTGGTGTCACTGGCGGCGGCCGACATCGCAGTGGGTGTGCTCGCCATC
CCCTTTGCCATCACCATCAGCACCGGGTTCTGCGCTGCCTGCCACGGCTGCCTCTTCATT
GCCTGCTTCGTCCTGGTCCTCACGCAGAGCTCCATCTTCAGTCTCCTGGCCATCGCCATT
GACCGCTACATTGCCATCCGCATCCCGCTCCGGTACAATGGCTTGGTGACCGGCACGAGG
GCTAAGGGCATCATTGCCATCTGCTGGGTGCTGTCGTTTGCCATCGGCCTGACTCCCATG
CTAGGTTGGAACAACTGCGGTCAGCCAAAGGAGGGCAAGAACCACTCCCAGGGCTGCGGG
GAGGGCCAAGTGGCCTGTCTCTTTGAGGATGTGGTCCCCATGAACTACATGGTGTACTTC
AACTTCTTTGCCTGTGTGCTGGTGCCCCTGCTGCTCATGCTGGGTGTCTATTTGCGGATC
TTCCTGGCGGCGCGACGACAGCTGAAGCAGATGGAGAGCCAGCCTCTGCCGGGGGAGCGG
GCACGGTCCACACTGCAGAAGGAGGTCCATGCTGCCAAGTCACTGGCCATCATTGTGGGG
CTCTTTGCCCTCTGCTGGCTGCCCCTACACATCATCAACTGCTTCACTTTCTTCTGCCCC
GACTGCAGCCACGCCCCTCTCTGGCTCATGTACCTGGCCATCGTCCTCTCCCACACCAAT
TCGGTTGTGAATCCCTTCATCTACGCCTACCGTATCCGCGAGTTCCGCCAGACCTTCCGC
AAGATCATTCGCAGCCACGTCCTGAGGCAGCAAGAACCTTTCAAGGCAGCTGGCACCAGT
GCCCGGGTCTTGGCAGCTCATGGCAGTGACGGAGAGCAGGTCAGCCTCCGTCTCAACGGC
CACCCGCCAGGAGTGTGGGCCAACGGCAGTGCTCCCCACCCTGAGCGGAGGCCCAATGGC
TATGCCCTGGGGCTGGTGAGTGGAGGGAGTGCCCAAGAGTCCCAGGGGAACACGGGCCTC
CCAGACGTGGAGCTCCTTAGCCATGAGCTCAAGGGAGTGTGCCCAGAGCCCCCTGGCCTA
GATGACCCCCTGGCCCAGGATGGAGCAGGAGTGTCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endomembrane system</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intermediate filament</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>presynaptic active zone</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>presynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled adenosine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>astrocyte activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood circulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>central nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eating behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inhibitory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of alpha-beta T cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron projection morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of acetylcholine secretion, neurotransmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of circadian sleep/wake cycle, sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glutamate secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of renal sodium excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of urine volume</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of mitochondrial membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to caffeine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasodilation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0000739</id>
      <name>Ryanodine receptor 1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A10297</ref-id>
            <pubmed-id>17514358</pubmed-id>
            <citation>Daly JW: Caffeine analogs: biomedical impact. Cell Mol Life Sci. 2007 Aug;64(16):2153-69.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P21817" source="Swiss-Prot">
        <name>Ryanodine receptor 1</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores in neurons, and may thereby promote prolonged Ca(2+) signaling in the brain. Required for normal embryonic development of muscle fibers and skeletal muscle. Required for normal heart morphogenesis, skin development and ossification during embryogenesis (By similarity).</specific-function>
        <gene-name>RYR1</gene-name>
        <locus>19q13.1</locus>
        <cellular-location>Sarcoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>4327-4347
4348-4368
4560-4580
4652-4672
4781-4801
4808-4828
4840-4860
4921-4941</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>4.96</theoretical-pi>
        <molecular-weight>565170.715</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10483</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RYR1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J05200</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>337722</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>747</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21817</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RYR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>RYDR</synonym>
          <synonym>RYR-1</synonym>
          <synonym>Skeletal muscle calcium release channel</synonym>
          <synonym>Skeletal muscle ryanodine receptor</synonym>
          <synonym>Skeletal muscle-type ryanodine receptor</synonym>
          <synonym>Type 1 ryanodine receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001474|Ryanodine receptor 1
MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPD
LAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCL
TTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLH
LSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQ
RRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVV
VDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAA
PDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSF
SGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEE
GMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFS
TNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLD
VLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSK
WYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHL
WTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVV
SFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVG
PSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNK
RLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMM
SNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRL
VPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSY
TVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGR
PWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGH
LNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVD
GTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAED
EARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATT
EKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFA
GQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFV
SPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNV
IQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAG
ERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRV
AHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPE
TRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSP
AIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVK
QILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEE
GLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLL
IKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLA
HCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSH
MVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLG
QIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGES
KEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASV
IDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVF
VNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRD
RRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSL
VPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLH
VLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVD
SMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMP
LKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAM
PCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAE
YTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWE
WTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAE
NYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRG
LKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAK
ILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTD
APAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQART
QVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKN
TYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMC
PDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGA
PPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIP
TIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNR
AQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAK
AGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRY
ALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVS
AVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAA
WILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDY
LYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQ
MISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSV
LDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQN
YLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQV
FNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQK
DMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYV
TDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGF
NVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETN
RAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETD
EDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRL
RRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELL
AGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAV
TDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELE
PEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNF
YTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEA
EGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELAR
KLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAE
LLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMS
LLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFF
RKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDIT
FFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHT
LEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020483|Ryanodine receptor 1 (RYR1)
ATGGGTGACGCAGAAGGCGAAGACGAGGTCCAGTTCCTGCGGACGGACGATGAGGTGGTC
CTGCAGTGCAGCGCTACCGTGCTCAAGGAGCAGCTCAAGCTCTGCCTGGCCGCCGAGGGC
TTCGGCAACCGCCTGTGCTTCCTGGAGCCCACTAGCAACGCGCAGAATGTGCCCCCCGAT
CTGGCCATCTGTTGCTTCGTCCTGGAGCAGTCCCTGTCTGTGCGAGCCCTGCAGGAGATG
CTGGCTAACACGGTGGAGGCTGGCGTGGAGTCATCCCAGGGCGGGGGACACAGGACGCTC
CTGTATGGCCATGCCATCCTGCTCCGGCATGCACACAGCCGCATGTATCTGAGCTGCCTC
ACCACCTCCCGCTCCATGACTGACAAGCTGGCCTTCGATGTGGGACTGCAGGAGGACGCA
ACAGGAGAGGCTTGCTGGTGGACCATGCACCCAGCCTCCAAGCAGAGGTCTGAAGGAGAA
AAGGTCCGCGTTGGGGATGACATCATCCTTGTCAGTGTCTCCTCCGAGCGCTACCTGCAC
CTGTCGACCGCCAGTGGGGAGCTCCAGGTTGACGCTTCCTTCATGCAGACACTATGGAAC
ATGAACCCCATCTGCTCCCGCTGCGAAGAGGGCTTCGTGACGGGAGGTCACGTCCTCCGC
CTCTTTCATGGACATATGGATGAGTGTCTGACCATTTCCCCTGCTGACAGTGATGACCAG
CGCAGACTTGTCTACTATGAGGGGGGAGCTGTGTGCACTCATGCCCGCTCCCTCTGGAGG
CTGGAGCCACTGAGAATCAGCTGGAGTGGGAGCCACCTGCGCTGGGGCCAGCCACTCCGA
GTCCGGCATGTCACTACCGGGCAGTACCTAGCGCTCACCGAGGACCAGGGCCTGGTGGTG
GTTGACGCCAGCAAGGCTCACACCAAGGCTACCTCCTTCTGCTTCCGCATCTCCAAGGAG
AAGCTGGATGTGGCCCCCAAGCGGGATGTGGAGGGCATGGGCCCCCCTGAGATCAAGTAC
GGGGAGTCACTGTGCTTCGTGCAGCATGTGGCCTCAGGACTGTGGCTCACCTATGCTGCT
CCAGACCCCAAGGCCCTGCGGCTCGGCGTGCTCAAGAAGAAGGCCATGCTGCACCAGGAG
GGCCACATGGACGACGCACTGTCGCTGACCCGCTGCCAGCAGGAGGAGTCCCAGGCCGCC
CGCATGATCCACAGCACCAATGGCCTATACAACCAGTTCATCAAGAGCCTGGACAGCTTC
AGCGGGAAGCCACGGGGCTCGGGGCCACCCGCTGGCACGGCGCTGCCCATCGAGGGCGTT
ATCCTGAGCCTGCAGGACCTCATCATCTACTTCGAGCCTCCCTCCGAGGACTTGCAGCAC
GAGGAGAAGCAGAGCAAGCTGCGAAGCCTGCGCAACCGCCAGAGCCTCTTCCAGGAGGAG
GGGATGCTCTCCATGGTCCTGAATTGCATAGACCGCCTAAATGTCTACACCACTGCTGCC
CACTTTGCTGAGTTTGCAGGGGAGGAGGCAGCCGAGTCCTGGAAAGAGATTGTGAATCTT
CTCTATGAACTCCTAGCTTCTCTAATCCGTGGCAATCGTAGCAACTGTGCCCTCTTCTCC
ACAAACTTGGACTGGCTGGTCAGCAAGCTGGATCGGCTGGAGGCCTCGTCTGGCATCCTG
GAGGTCCTGTACTGTGTCCTCATTGAGAGTCCAGAGGTTCTGAACATCATCCAGGAGAAT
CACATCAAGTCCATCATCTCCCTCCTGGACAAGCATGGGAGGAACCACAAGGTCCTGGAC
GTGCTATGCTCCCTGTGTGTGTGTAATGGTGTGGCTGTACGCTCCAACCAAGATCTTATT
ACTGAGAACTTGCTGCCTGGCCGTGAGCTTCTGCTGCAGACAAACCTCATCAACTATGTC
ACCAGCATCCGCCCCAACATCTTTGTGGGCCGAGCGGAAGGCACCACGCAGTACAGCAAA
TGGTACTTTGAGGTGATGGTGGACGAGGTGACTCCATTTCTGACAGCTCAGGCCACCCAC
TTGCGGGTGGGCTGGGCCCTCACCGAGGGCTACACCCCCTACCCTGGGGCCGGCGAGGGC
TGGGGCGGCAACGGGGTCGGCGATGACCTCTATTCCTACGGCTTTGATGGACTGCATCTC
TGGACAGGACACGTGGCACGCCCAGTGACTTCCCCAGGGCAGCACCTCCTGGCCCCTGAA
GACGTGATCAGCTGCTGCCTGGACCTCAGCGTGCCGTCCATCTCCTTCCGCATCAACGGC
TGCCCCGTGCAGGGTGTCTTTGAGTCCTTCAACCTGGACGGGCTCTTCTTCCCTGTTGTC
AGCTTCTCGGCTGGTGTCAAGGTGCGGTTCCTCCTTGGTGGCCGCCATGGTGAATTCAAG
TTCCTGCCCCCACCTGGCTATGCTCCATGCCATGAGGCTGTGCTCCCTCGAGAGCGACTC
CATCTTGAACCCATCAAGGAGTATCGACGGGAGGGGCCCCGGGGGCCTCACCTGGTGGGC
CCCAGTCGCTGCCTCTCACACACCGACTTCGTGCCCTGCCCTGTGGACACTGTCCAGATT
GTCCTGCCGCCCCATCTGGAGCGCATTCGGGAGAAGCTGGCGGAGAACATCCACGAGCTC
TGGGCGCTAACCCGCATCGAGCAGGGCTGGACCTACGGCCCGGTTCGGGATGACAACAAG
AGGCTGCACCCGTGTCTTGTGGACTTCCACAGCCTTCCAGAGCCTGAGAGGAACTACAAC
CTGCAGATGTCTGGGGAGACGCTCAAGACTCTGCTGGCTCTGGGCTGCCACGTGGGCATG
GCGGATGAGAAGGCGGAGGACAACCTGAAGAAGACAAAACTCCCCAAGACGTATATGATG
AGCAATGGGTACAAGCCGGCTCCGCTGGACCTGAGCCACGTGCGGCTGACGCCGGCGCAG
ACGACACTGGTGGACCGTCTGGCAGAAAATGGGCACAACGTGTGGGCCCGAGACCGCGTG
GGCCAGGGCTGGAGCTACAGCGCAGTGCAGGACATCCCAGCGCGCCGAAACCCTCGGCTG
GTGCCCTACCGCCTGCTGGATGAAGCCACCAAGCGCAGCAACCGGGACAGCCTCTGCCAG
GCCGTGCGCACCCTCCTGGGCTACGGCTACAACATCGAGCCTCCTGACCAGGAGCCCAGT
CAGGTGGAGAACCAGTCTCGTTGTGACCGGGTGCGCATCTTCCGGGCAGAGAAATCCTAT
ACAGTGCAGAGCGGCCGCTGGTACTTCGAGTTTGAAGCAGTCACCACAGGCGAGATGCGC
GTGGGCTGGGCGAGGCCCGAGCTGAGGCCTGATGTAGAGCTGGGAGCTGACGAGCTGGCC
TATGTCTTCAATGGGCACCGCGGCCAGCGCTGGCACTTGGGCAGTGAACCATTTGGGCGC
CCCTGGCAGCCGGGCGATGTCGTTGGCTGTATGATCGACCTCACAGAGAACACCATTATC
TTCACCCTCAATGGCGAGGTCCTCATGTCTGACTCAGGCTCCGAAACAGCCTTCCGGGAG
ATTGAGATTGGGGACGGCTTCCTGCCCGTCTGCAGCTTGGGACCTGGCCAGGTGGGTCAT
CTGAACCTGGGCCAGGACGTGAGCTCTCTGAGGTTCTTTGCCATCTGTGGCCTCCAGGAA
GGCTTCGAGCCATTTGCCATCAACATGCAGCGCCCAGTCACCACCTGGTTCAGCAAAGGC
CTGCCCCAGTTTGAGCCAGTGCCCCTTGAACACCCTCACTATGAGGTATCCCGAGTGGAC
GGCACTGTGGACACGCCCCCCTGCCTGCGCCTGACCCACCGCACCTGGGGCTCCCAGAAC
AGCCTGGTGGAGATGCTTTTCCTGCGGCTGAGCCTCCCAGTCCAGTTCCACCAGCACTTC
CGCTGCACTGCAGGGGCCACCCCGCTGGCACCTCCTGGCCTGCAGCCCCCCGCCGAGGAC
GAGGCCCGGGCGGCGGAACCCGACCCTGACTACGAAAACCTGCGCCGCTCAGCTGGGGGC
TGGAGCGAGGCAGAGAACGGCAAAGAAGGGACTGCGAAGGAGGGCGCCCCCGGGGGCACC
CCGCAGGCGGGGGGAGAGGCGCAGCCCGCCAGGGCGGAGAATGAGAAGGATGCCACCACC
GAGAAGAACAAGAAGAGAGGCTTCTTATTCAAGGCCAAGAAGGTCGCCATGATGACCCAG
CCACCGGCCACCCCCACGCTGCCCCGACTCCCTCACGACGTGGTGCCTGCAGACAACCGC
GATGACCCCGAGATCATCCTCAACACCACCACGTACTATTACTCCGTGAGGGTCTTTGCT
GGACAGGAGCCCAGCTGCGTGTGGGCGGGCTGGGTCACCCCTGACTACCATCAGCACGAC
ATGAGCTTCGACCTCAGCAAGGTCCGGGTCGTGACGGTGACCATGGGGGATGAACAAGGC
AACGTCCACAGCAGCCTCAAGTGTAGCAACTGCTACATGGTGTGGGGCGGAGACTTTGTG
AGTCCCGGGCAGCAGGGCCGGATCAGCCACACGGACCTTGTCATTGGGTGCCTGGTGGAC
TTGGCCACTGGCTTAATGACCTTTACAGCCAATGGCAAAGAGAGCAACACCTTTTTCCAG
GTGGAACCCAACACTAAGCTATTTCCTGCCGTCTTCGTCCTGCCCACCCACCAGAACGTC
ATCCAGTTTGAGCTGGGGAAGCAGAAGAACATCATGCCGTTGTCAGCCGCCATGTTCCAA
AGCGAGCGCAAGAACCCGGCCCCGCAGTGCCCACCGCGGCTGGAGATGCAGATGCTGATG
CCAGTGTCCTGGAGCCGCATGCCCAACCACTTCCTGCAGGTGGAGACGAGGCGTGCCGGC
GAGCGGCTGGGCTGGGCCGTGCAGTGCCAGGAGCCGCTGACCATGATGGCGCTGCACATC
CCCGAGGAGAACCGGTGCATGGACATCCTGGAGCTGTCGGAGCGCCTGGACCTGCAGCGC
TTCCACTCGCACACCCTGCGCCTCTACCGCGCTGTGTGCGCCCTGGGCAACAATCGCGTG
GCGCACGCTCTGTGCAGCCACGTAGACCAAGCTCAGCTGCTGCACGCCCTGGAGGACGCG
CACCTGCCAGGCCCACTGCGCGCAGGCTACTATGACCTCCTCATCAGCATCCACCTCGAA
AGTGCCTGCCGCAGCCGCCGCTCCATGCTCTCTGAATACATCGTGCCCCTCACGCCTGAG
ACCCGCGCCATCACGCTCTTCCCTCCTGGAAGGAGCACAGAAAATGGTCACCCCCGGCAT
GGCCTGCCGGGAGTTGGAGTCACCACTTCGCTGAGGCCCCCGCATCATTTCTCGCCCCCC
TGTTTCGTGGCCGCTCTGCCAGCTGCTGGGGCAGCAGAGGCCCCGGCCCGCCTCAGCCCT
GCCATCCCGCTGGAGGCCCTGCGGGACAAGGCACTGAGGATGCTGGGGGAGGCGGTGCGC
GACGGTGGGCAGCACGCTCGCGACCCCGTCGGGGGCTCCGTGGAGTTCCAGTTTGTGCCT
GTGCTCAAGCTCGTGTCCACCCTGCTGGTGATGGGCATCTTTGGCGATGAGGATGTGAAA
CAGATCTTGAAGATGATTGAGCCTGAGGTCTTCACTGAGGAAGAAGAGGAGGAGGACGAG
GAGGAAGAGGGTGAAGAGGAAGATGAGGAGGAGAAGGAGGAGGATGAGGAGGAAACAGCA
CAGGAAAAGGAAGATGAGGAAAAAGAGGAAGAGGAGGCAGCAGAAGGGGAGAAAGAAGAA
GGCTTGGAGGAAGGGCTGCTCCAGATGAAGTTGCCAGAGTCTGTGAAGTTACAGATGTGC
CACCTGCTGGAGTATTTCTGTGACCAAGAGCTGCAGCACCGTGTGGAGTCCCTGGCAGCC
TTTGCGGAGCGCTATGTGGACAAGCTCCAGGCCAACCAGCGGAGCCGCTATGGCCTCCTC
ATAAAAGCCTTCAGCATGACCGCAGCAGAGACTGCAAGACGTACCCGCGAGTTCCGCTCC
CCACCCCAGGAACAGATCAATATGCTATTGCAATTCAAAGATGGTACAGATGAGGAAGAC
TGTCCTCTCCCTGAAGAGATTCGACAGGATTTGCTTGACTTTCATCAAGACCTGCTGGCA
CACTGTGGAATTCAGCTAGATGGAGAGGAGGAGGAACCAGAGGAAGAGACCACCCTGGGC
AGCCGCCTCATGAGCCTGTTGGAGAAAGTGCGGCTGGTGAAGAAGAAGGAAGAGAAACCT
GAGGAGGAGCGGTCAGCAGAGGAGAGCAAACCCCGGTCCCTGCAGGAGCTGGTGTCCCAC
ATGGTGGTGCGCTGGGCCCAAGAGGACTTCGTGCAGAGCCCCGAGCTGGTGCGGGCCATG
TTCAGCCTCCTGCACCGGCAGTACGACGGGCTGGGTGAGCTGCTGCGTGCCCTGCCGCGG
GCGTACACCATCTCACCGTCCTCCGTGGAAGACACCATGAGCCTGCTCGAGTGCCTCGGC
CAGATCCGCTCGCTGCTCATCGTGCAGATGGGCCCCCAGGAGGAGAACCTCATGATCCAG
AGCATCGGGAACATCATGAACAACAAAGTCTTCTACCAACACCCGAACCTGATGAGGGCG
CTGGGCATGCACGAGACGGTCATGGAGGTCATGGTCAACGTCCTCGGGGGCGGCGAGTCC
AAGGAGATCCGCTTCCCCAAGATGGTGACAAGCTGCTGCCGCTTCCTCTGCTATTTCTGC
CGAATCAGCCGGCAGAACCAGCGCTCCATGTTTGACCACCTGAGCTACCTGCTGGAGAAC
AGTGGCATCGGCCTGGGCATGCAGGGCTCCACGCCCCTGGACGTGGCTGCTGCCTCCGTC
ATTGACAACAATGAGCTGGCCTTGGCATTGCAGGAGCAGGACCTGGAAAAGGTTGTGTCC
TACCTGGCAGGCTGTGGCCTCCAGAGCTGCCCCATGCTTGTGGCCAAAGGGTACCCAGAC
ATTGGCTGGAACCCCTGTGGTGGAGAGCGCTACCTGGACTTCCTGCGCTTTGCTGTCTTC
GTCAACGGCGAGAGCGTGGAGGAGAACGCCAATGTGGTGGTGCGGCTGCTCATCCGGAAG
CCTGAGTGCTTCGGACCCGCCCTGCGGGGTGAGGGTGGCTCAGGGCTGCTGGCTGCCATC
GAAGAGGCCATCCGCATCTCCGAGGACCCTGCGAGGGATGGCCCAGGCATCCGCAGGGAC
CGGCGGCGCGAGCACTTTGGTGAGGAACCGCCTGAAGAAAACCGGGTGCACCTGGGACAC
GCCATCATGTCCTTCTATGCCGCCTTGATCGACCTGCTCGGACGCTGTGCACCAGAGATG
CATCTAATCCAAGCCGGCAAGGGTGAGGCCCTGCGGATCCGCGCCATCCTCCGCTCCCTT
GTGCCCTTGGAGGACCTTGTGGGCATCATCAGCCTCCCACTGCAGATTCCCACCCTGGGC
AAAGATGGGGCTCTGGTGCAGCCAAAGATGTCAGCATCCTTCGTGCCGGACCACAAGGCG
TCCATGGTGCTCTTCCTGGACCGTGTGTATGGCATCGAGAACCAGGACTTCTTGCTGCAC
GTGCTGGACGTGGGGTTCCTGCCCGACATGAGGGCAGCCGCCTCGCTGGACACGGCCACT
TTCAGCACCACCGAGATGGCGCTGGCGCTGAACCGCTACCTGTGCCTGGCCGTGCTGCCG
CTCATCACCAAGTGTGCGCCGCTCTTTGCGGGCACAGAACACCGCGCCATCATGGTGGAC
TCTATGCTGCATACCGTGTACCGCCTGTCTCGGGGTCGTTCGCTCACCAAGGCGCAGCGT
GACGTCATCGAGGACTGCCTCATGTCGCTCTGCAGGTACATCCGCCCGTCGATGCTGCAG
CACCTGTTGCGCCGCCTGGTGTTCGACGTGCCCATCCTCAACGAGTTCGCCAAGATGCCA
CTCAAGCTCCTCACCAACCACTATGAGCGCTGTTGGAAGTACTACTGCCTACCCACGGGC
TGGGCCAACTTCGGGGTCACCTCAGAGGAGGAGCTGCACCTCACACGGAAACTCTTCTGG
GGCATCTTTGACTCTCTGGCCCATAAGAAATACGACCCGGAGCTGTACCGCATGGCCATG
CCTTGTCTGTGCGCCATTGCCGGGGCTCTGCCCCCCGACTATGTGGATGCCTCATACTCA
TCTAAGGCAGAGAAAAAGGCCACAGTGGATGCTGAAGGCAACTTTGATCCCCGGCCTGTG
GAGACCCTCAATGTGATCATCCCGGAGAAGCTGGACTCCTTCATTAACAAGTTTGCGGAG
TACACACACGAGAAGTGGGCCTTCGACAAGATCCAGAACAACTGGTCCTATGGAGAGAAC
ATAGACGAGGAGCTGAAGACCCACCCCATGCTGAGGCCCTACAAGACCTTTTCAGAGAAG
GACAAAGAGATTTACCGCTGGCCCATCAAGGAGTCCCTGAAGGCCATGATTGCCTGGGAA
TGGACGATAGAGAAGGCCAGGGAGGGTGAGGAGGAGAAGACGGAAAAGAAAAAAACGCGG
AAGATATCACAAAGTGCCCAGACCTATGATCCTCGAGAAGGCTACAACCCTCAGCCCCCC
GACCTTAGTGCTGTTACCCTGTCCCGGGAGCTGCAGGCCATGGCAGAACAACTGGCAGAA
AATTACCACAACACGTGGGGACGGAAGAAGAAGCAGGAGCTGGAAGCCAAAGGCGGTGGG
ACCCACCCCCTGCTGGTCCCCTACGACACGCTCACGGCCAAGGAGAAGGCACGAGATCGA
GAGAAGGCCCAGGAGCTACTGAAATTCCTGCAGATGAATGGCTACGCGGTTACAAGAGGC
CTTAAGGACATGGAACTGGACTCGTCTTCCATTGAAAAGCGGTTTGCCTTTGGCTTCCTG
CAGCAGCTGCTGCGCTGGATGGACATTTCTCAGGAGTTCATTGCCCACCTGGAGGCTGTG
GTCAGCAGTGGGCGAGTGGAAAAGTCCCCACATGAACAGGAGATTAAATTCTTTGCCAAG
ATCCTGCTCCCTTTGATCAACCAGTACTTCACCAACCACTGCCTCTATTTCTTGTCCACT
CCGGCTAAAGTGCTGGGCAGCGGTGGCCACGCCTCTAACAAGGAGAAGGAAATGATCACC
AGCCTCTTCTGCAAACTTGCTGCTCTCGTCCGCCACCGAGTCTCTCTCTTTGGGACAGAC
GCCCCAGCTGTGGTCAACTGTCTTCACATCCTGGCCCGCTCCCTGGATGCCAGGACAGTG
ATGAAGTCAGGCCCTGAGATCGTGAAGGCTGGCCTCCGCTCCTTCTTCGAGAGTGCCTCG
GAGGACATCGAGAAGATGGTGGAGAACCTGCGGCTGGGCAAGGTGTCGCAGGCGCGCACC
CAGGTGAAAGGCGTGGGCCAGAACCTCACCTACACCACTGTGGCACTGCTGCCGGTCCTC
ACCACCCTCTTCCAGCACATCGCCCAGCACCAGTTCGGAGATGACGTCATCCTGGACGAC
GTCCAGGTCTCTTGCTACCGAACGCTGTGCAGTATCTACTCCCTGGGAACCACCAAGAAC
ACTTATGTGGAAAAGCTTCGGCCAGCCCTCGGGGAGTGCCTGGCCCGTCTGGCAGCAGCC
ATGCCGGTGGCGTTCCTGGAGCCGCAGCTGAACGAGTACAACGCCTGCTCCGTGTACACC
ACCAAGTCTCCGCGGGAGCGGGCCATCCTGGGGCTCCCCAACAGTGTGGAGGAGATGTGT
CCCGACATCCCGGTGCTGGAGCGGCTCATGGCAGACATTGGGGGGCTGGCCGAGTCAGGT
GCCCGCTACACAGAGATGCCGCATGTCATCGAGATCACGCTGCCCATGCTATGCAGCTAC
CTGCCCCGATGGTGGGAGCGCGGGCCCGAGGCACCCCCTTCCGCCCTGCCCGCCGGCGCC
CCCCCACCCTGCACAGCTGTCACCTCTGACCACCTCAACTCCCTGCTGGGGAATATCCTG
AGAATCATCGTCAACAACCTGGGCATTGACGAGGCCTCCTGGATGAAGCGGCTGGCTGTG
TTCGCACAGCCCATTGTGAGCCGTGCACGGCCGGAGCTCCTGCAGTCCCACTTCATCCCA
ACTATCGGGCGGCTGCGCAAGAGGGCAGGGAAGGTGGTGTCCGAGGAGGAGCAGCTGCGC
CTGGAGGCCAAGGCGGAGGCCCAGGAGGGCGAGCTGCTGGTGCGGGACGAGTTCTCTGTG
CTCTGCCGGGACCTCTACGCCCTGTATCCGCTGCTCATCCGCTACGTGGACAACAACAGG
GCGCAGTGGCTGACGGAGCCGAATCCCAGCGCGGAGGAGCTGTTCAGGATGGTGGGCGAG
ATCTTCATCTACTGGTCCAAGTCCCACAACTTCAAGCGCGAGGAGCAGAACTTTGTGGTC
CAGAATGAGATCAACAACATGTCCTTCCTGACTGCTGACAACAAAAGCAAAATGGCTAAG
GCGGGAGATATACAGTCCGGTGGCTCGGACCAGGAACGCACCAAGAAGAAGCGCCGGGGG
GACCGGTACTCTGTGCAGACGTCACTGATCGTGGCCACACTGAAGAAGATGCTGCCCATC
GGCCTGAATATGTGTGCGCCCACCGACCAAGACCTCATCACGCTGGCCAAGACCCGTTAC
GCCCTGAAAGACACAGATGAGGAGGTCCGGGAATTTCTGCACAACAACCTTCACCTTCAG
GGAAAGGTCGAAGGCTCCCCGTCTCTGCGCTGGCAGATGGCTCTGTACCGGGGCGTCCCG
GGTCGCGAGGAGGACGCCGATGACCCCGAGAAAATCGTGCGCAGAGTCCAGGAAGTGTCA
GCCGTGCTCTACTACCTGGACCAGACCGAGCACCCTTACAAGTCTAAGAAGGCCGTGTGG
CACAAGCTTTTGTCCAAACAGCGCCGGCGGGCAGTCGTGGCCTGTTTCCGTATGACGCCC
CTGTACAACCTGCCCACGCACCGGGCATGTAACATGTTCCTGGAGAGCTACAAGGCTGCA
TGGATCCTGACTGAAGACCACAGTTTTGAGGACCGCATGATAGATGACCTTTCAAAAGCT
GGGGAGCAGGAGGAGGAGGAGGAAGAGGTGGAAGAGAAGAAGCCAGACCCCCTGCACCAG
TTGGTCCTGCACTTCAGCCGCACTGCCCTGACGGAAAAGAGCAAACTGGATGAGGATTAC
CTGTACATGGCCTATGCTGATATCATGGCAAAGAGCTGCCACCTGGAGGAGGGAGGGGAG
AACGGTGAAGCTGAAGAGGAGGTTGAGGTCTCCTTTGAGGAGAAACAGATGGAGAAGCAG
AGGCTCTTGTACCAGCAAGCACGGCTGCACACCCGGGGGGCGGCCGAGATGGTGCTGCAG
ATGATCAGTGCCTGCAAAGGAGAGACAGGTGCCATGGTGTCCTCCACCCTGAAGCTGGGC
ATCTCCATCCTCAATGGAGGCAATGCTGAGGTCCAGCAGAAAATGCTGGATTATCTTAAG
GACAAGAAGGAAGTTGGCTTCTTCCAGAGTATCCAGGCACTGATGCAAACATGCAGCGTC
CTGGATCTCAATGCCTTTGAGAGACAGAACAAGGCCGAGGGGCTGGGCATGGTGAATGAG
GATGGCACTGTCATCAATCGCCAGAACGGAGAGAAGGTCATGGCGGATGATGAATTCACA
CAAGACCTGTTCCGATTCCTACAATTGCTCTGTGAGGGGCACAATAATGATTTCCAGAAC
TACCTACGGACACAGACAGGGAACACGACCACTATTAACATCATCATTTGCACTGTGGAC
TACCTCCTGCGGCTGCAGGAATCCATCAGCGACTTCTACTGGTACTACTCGGGCAAGGAT
GTCATTGAAGAGCAGGGCAAGAGGAACTTCTCCAAAGCCATGTCGGTGGCTAAGCAGGTG
TTCAACAGCCTCACTGAGTACATCCAGGGTCCCTGCACCGGGAACCAGCAGAGCCTGGCG
CACAGTCGCCTATGGGACGCAGTGGTGGGATTCCTGCACGTGTTCGCCCACATGATGATG
AAGCTCGCTCAGGACTCAAGCCAGATCGAGCTGCTGAAGGAGCTGCTGGATCTGCAGAAG
GACATGGTGGTGATGTTGCTGTCGCTACTAGAAGGGAACGTGGTGAACGGCATGATCGCC
CGGCAGATGGTGGACATGCTCGTGGAATCCTCATCCAATGTGGAGATGATCCTCAAGTTC
TTCGACATGTTCCTGAAACTCAAGGACATTGTGGGCTCTGAAGCCTTCCAGGACTACGTA
ACGGATCCCCGTGGCCTCATCTCCAAGAAGGACTTCCAGAAGGCCATGGACAGCCAGAAG
CAGTTCAGCGGTCCAGAAATCCAGTTCCTGCTTTCGTGCTCCGAAGCGGATGAGAACGAA
ATGATCAACTGCGAAGAGTTCGCCAACCGCTTCCAGGAGCCAGCACGCGACATCGGCTTC
AACGTGGCGGTGCTGCTGACCAACCTGTCGGAGCATGTGCCGCATGACCCTCGCCTGCAC
AACTTCCTGGAGCTGGCCGAGAGCATCCTTGAGTACTTCCGCCCCTACCTGGGCCGCATC
GAGATCATGGGCGCGTCACGCCGCATCGAGCGCATCTACTTCGAGATCTCAGAGACCAAC
CGCGCCCAGTGGGAGATGCCCCAGGTGAAGGAGTCCAAGCGCCAGTTCATCTTCGACGTG
GTGAACGAGGGCGGCGAGGCTGAGAAGATGGAGCTCTTCGTGAGTTTCTGCGAGGACACC
ATCTTCGAGATGCAGATCGCCGCGCAGATCTCGGAGCCCGAGGGCGAGCCGGAGACCGAC
GAGGACGAGGGCGCGGGCGCGGCGGAGGCGGGCGCGGAAGGCGCGGAGGAGGGCGCGGCG
GGGCTCGAGGGCACGGCGGCCACGGCGGCGGCGGGGGCGACGGCGCGGGTTGTGGCGGCC
GCAGGCCGGGCCCTGCGAGGCCTCAGCTACCGCAGCCTGCGGCGGCGCGTGCGGCGGCTG
CGGCGGCTTACGGCCCGCGAGGCGGCCACCGCAGTGGCGGCGCTGCTCTGGGCAGCAGTG
ACGCGCGCTGGGGCCGCTGGCGCGGGGGCGGCGGCGGGCGCGCTGGGCCTGCTCTGGGGC
TCGCTGTTCGGCGGCGGCCTGGTGGAGGGCGCCAAGAAGGTGACGGTGACCGAGCTCCTG
GCAGGCATGCCCGACCCCACCAGCGACGAGGTGCACGGCGAGCAGCCGGCCGGGCCGGGC
GGAGACGCAGACGGCGAGGGTGCCAGCGAGGGCGCTGGAGACGCCGCGGAGGGCGCTGGA
GACGAGGAGGAGGCGGTGCACGAGGCCGGGCCGGGCGGTGCCGACGGGGCGGTGGCCGTG
ACCGATGGGGGCCCCTTCCGGCCCGAAGGGGCTGGCGGTCTCGGGGACATGGGGGACACG
ACGCCTGCGGAACCGCCCACACCCGAGGGCTCTCCCATCCTCAAGAGGAAATTGGGGGTG
GATGGAGTGGAGGAGGAGCTCCCGCCAGAGCCAGAGCCCGAGCCGGAACCAGAGCTGGAG
CCGGAGAAAGCCGATGCCGAGAATGGGGAGAAGGAAGAAGTTCCCGAGCCCACACCAGAG
CCCCCCAAGAAGCAAGCACCTCCCTCACCCCCTCCAAAGAAGGAGGAAGCTGGAGGCGAA
TTCTGGGGAGAACTGGAGGTGCAGAGGGTGAAGTTCCTGAACTACCTGTCCCGGAACTTT
TACACCCTGCGGTTCCTTGCCCTCTTCTTGGCATTTGCCATCAACTTCATCTTGCTGTTT
TATAAGGTCTCAGACTCTCCACCAGGGGAGGACGACATGGAAGGCTCAGCTGCTGGGGAT
GTGTCAGGTGCAGGCTCTGGTGGCAGCTCTGGCTGGGGCTTGGGGGCCGGAGAGGAGGCA
GAGGGCGATGAGGATGAGAACATGGTGTACTACTTCCTGGAGGAAAGCACAGGCTACATG
GAACCCGCCCTGCGGTGTCTGAGCCTCCTGCATACACTGGTGGCCTTTCTCTGCATCATT
GGCTATAATTGTCTCAAGGTGCCCCTGGTAATCTTTAAGCGGGAGAAGGAGCTGGCCCGG
AAGCTGGAGTTTGATGGCCTGTACATCACGGAGCAGCCTGAGGACGATGACGTGAAGGGG
CAGTGGGACCGACTGGTGCTCAACACGCCGTCTTTCCCTAGCAACTACTGGGACAAGTTT
GTCAAGCGCAAGGTCCTGGACAAACATGGGGACATCTACGGGCGGGAGCGGATTGCTGAG
CTACTGGGCATGGACCTGGCCACACTAGAGATCACAGCCCACAATGAGCGCAAGCCCAAC
CCGCCGCCAGGGCTGCTGACCTGGCTCATGTCCATCGATGTCAAGTACCAGATCTGGAAG
TTCGGGGTCATCTTCACAGACAACTCCTTCCTGTACCTGGGCTGGTATATGGTGATGTCC
CTCTTGGGACACTACAACAACTTCTTCTTTGCTGCCCATCTCCTGGACATCGCCATGGGG
GTCAAGACGCTGCGCACCATCCTGTCCTCTGTCACCCACAATGGGAAACAGCTGGTGATG
ACCGTGGGCCTTCTGGCGGTGGTCGTCTACCTGTACACCGTGGTGGCCTTCAACTTCTTC
CGCAAGTTCTACAACAAGAGCGAGGATGAGGATGAACCTGACATGAAGTGTGATGACATG
ATGACGTGTTACCTGTTTCACATGTACGTGGGTGTCCGGGCTGGCGGAGGCATTGGGGAC
GAGATCGAGGACCCCGCGGGTGACGAATACGAGCTCTACAGGGTGGTCTTCGACATCACC
TTCTTCTTCTTCGTCATCGTCATCCTGTTGGCCATCATCCAGGGTCTGATCATCGACGCT
TTTGGTGAGCTCCGAGACCAACAAGAGCAAGTGAAGGAGGATATGGAGACCAAGTGCTTC
ATCTGTGGAATCGGCAGTGACTACTTTGATACGACACCGCATGGCTTCGAGACTCACACG
CTGGAGGAGCACAACCTGGCCAATTACATGTTTTTCCTGATGTATTTGATAAACAAGGAT
GAGACAGAACACACGGGTCAGGAGTCTTATGTCTGGAAGATGTACCAAGAGAGATGTTGG
GATTTCTTCCCAGCTGGTGATTGTTTCCGTAAGCAGTATGAGGACCAGCTTAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF02815</identifier>
            <name>MIR</name>
          </pfam>
          <pfam>
            <identifier>PF08454</identifier>
            <name>RIH_assoc</name>
          </pfam>
          <pfam>
            <identifier>PF06459</identifier>
            <name>RR_TM4-6</name>
          </pfam>
          <pfam>
            <identifier>PF01365</identifier>
            <name>RYDR_ITPR</name>
          </pfam>
          <pfam>
            <identifier>PF02026</identifier>
            <name>RyR</name>
          </pfam>
          <pfam>
            <identifier>PF00622</identifier>
            <name>SPRY</name>
          </pfam>
          <pfam>
            <identifier>PF13833</identifier>
            <name>EF-hand_8</name>
          </pfam>
          <pfam>
            <identifier>PF08709</identifier>
            <name>Ins145_P3_rec</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell cortex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>I band</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>junctional membrane complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>junctional sarcoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>smooth endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>T-tubule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal cisterna</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ryanodine-sensitive calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to caffeine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytosolic calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ossification involved in bone maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>outflow tract morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol by sarcoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to caffeine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal muscle fiber development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skin development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="13">
      <id>BE0004922</id>
      <name>Cyclic nucleotide phosphodiesterase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18221</ref-id>
            <pubmed-id>20164566</pubmed-id>
            <citation>Ribeiro JA, Sebastiao AM: Caffeine and adenosine. J Alzheimers Dis. 2010;20 Suppl 1:S3-15. doi: 10.3233/JAD-2010-1379.</citation>
          </article>
          <article>
            <ref-id>A16981</ref-id>
            <pubmed-id>11692087</pubmed-id>
            <citation>Essayan DM: Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol. 2001 Nov;108(5):671-80.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P54750" source="Swiss-Prot">
        <name>Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cGMP than for cAMP.</specific-function>
        <gene-name>PDE1A</gene-name>
        <locus>2q32.1</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.02</theoretical-pi>
        <molecular-weight>61251.38</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8774</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U40370</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1151109</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1294</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P54750</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE1A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
          <synonym>61 kDa Cam-PDE</synonym>
          <synonym>Cam-PDE 1A</synonym>
          <synonym>hCam-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006867|Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
MGSSATEIEELENTTFKYLTGEQTEKMWQRLKGILRCLVKQLERGDVNVVDLKKNIEYAA
SVLEAVYIDETRRLLDTEDELSDIQTDSVPSEVRDWLASTFTRKMGMTKKKPEEKPKFRS
IVHAVQAGIFVERMYRKTYHMVGLAYPAAVIVTLKDVDKWSFDVFALNEASGEHSLKFMI
YELFTRYDLINRFKIPVSCLITFAEALEVGYSKYKNPYHNLIHAADVTQTVHYIMLHTGI
MHWLTELEILAMVFAAAIHDYEHTGTTNNFHIQTRSDVAILYNDRSVLENHHVSAAYRLM
QEEEMNILINLSKDDWRDLRNLVIEMVLSTDMSGHFQQIKNIRNSLQQPEGIDRAKTMSL
ILHAADISHPAKSWKLHYRWTMALMEEFFLQGDKEAELGLPFSPLCDRKSTMVAQSQIGF
IDFIVEPTFSLLTDSTEKIVIPLIEEASKAETSSYVASSSTTIVGLHIADALRRSNTKGS
MSDGSYSPDYSLAAVDLKSFKNNLVDIIQQNKERWKELAAQEARTSSQKCEFIHQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017142|Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A (PDE1A)
ATGGGGTCTAGTGCCACAGAGATTGAAGAATTGGAAAACACCACTTTTAAGTATCTTACA
GGAGAACAGACTGAAAAAATGTGGCAGCGCCTGAAAGGAATACTAAGATGCTTGGTGAAG
CAGCTGGAAAGAGGTGATGTTAACGTCGTCGACTTAAAGAAGAATATTGAATATGCGGCA
TCTGTGCTGGAAGCAGTTTATATCGATGAAACAAGAAGACTTCTGGATACTGAAGATGAG
CTCAGTGACATTCAGACTGACTCAGTCCCATCTGAAGTCCGGGACTGGTTGGCTTCTACC
TTTACACGGAAAATGGGGATGACAAAAAAGAAACCTGAGGAAAAACCAAAATTTCGGAGC
ATTGTGCATGCTGTTCAAGCTGGAATTTTTGTGGAAAGAATGTACCGAAAAACATATCAT
ATGGTTGGTTTGGCATATCCAGCAGCTGTCATCGTAACATTAAAGGATGTTGATAAATGG
TCTTTCGATGTATTTGCCCTAAATGAAGCAAGTGGAGAGCATAGTCTGAAGTTTATGATT
TATGAACTGTTTACCAGATATGATCTTATCAACCGTTTCAAGATTCCTGTTTCTTGCCTA
ATCACCTTTGCAGAAGCTTTAGAAGTTGGTTACAGCAAGTACAAAAATCCATATCACAAT
TTGATTCATGCAGCTGATGTCACTCAAACTGTGCATTACATAATGCTTCATACAGGTATC
ATGCACTGGCTCACTGAACTGGAAATTTTAGCAATGGTCTTTGCTGCTGCCATTCATGAT
TATGAGCATACAGGGACAACAAACAACTTTCACATTCAGACAAGGTCAGATGTTGCCATT
TTGTATAATGATCGCTCTGTCCTTGAGAATCACCACGTGAGTGCAGCTTATCGACTTATG
CAAGAAGAAGAAATGAATATCTTGATAAATTTATCCAAAGATGACTGGAGGGATCTTCGG
AACCTAGTGATTGAAATGGTTTTATCTACAGACATGTCAGGTCACTTCCAGCAAATTAAA
AATATAAGAAACAGTTTGCAGCAGCCTGAAGGGATTGACAGAGCCAAAACCATGTCCCTG
ATTCTCCACGCAGCAGACATCAGCCACCCAGCCAAATCCTGGAAGCTGCATTATCGGTGG
ACCATGGCCCTAATGGAGGAGTTTTTCCTGCAGGGAGATAAAGAAGCTGAATTAGGGCTT
CCATTTTCCCCACTTTGTGATCGGAAGTCAACCATGGTGGCCCAGTCACAAATAGGTTTC
ATCGATTTCATAGTAGAGCCAACATTTTCTCTTCTGACAGACTCAACAGAGAAAATTGTT
ATTCCTCTTATAGAGGAAGCCTCAAAAGCCGAAACTTCTTCCTATGTGGCAAGCAGCTCA
ACCACCATTGTGGGGTTACACATTGCTGATGCACTAAGACGATCAAATACAAAAGGCTCC
ATGAGTGATGGGTCCTATTCCCCAGACTACTCCCTTGCAGCAGTGGACCTGAAGAGTTTC
AAGAACAACCTGGTGGACATCATTCAGCAGAACAAAGAGAGGTGGAAAGAGTTAGCTGCA
CAAGAAGCAAGAACCAGTTCACAGAAGTGTGAGTTTATTCATCAGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
          <pfam>
            <identifier>PF08499</identifier>
            <name>PDEase_I_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin-dependent cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q01064" source="Swiss-Prot">
        <name>Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as a substrate.</specific-function>
        <gene-name>PDE1B</gene-name>
        <locus>12q13</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.22</theoretical-pi>
        <molecular-weight>61379.235</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8775</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE1B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U56976</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1295</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q01064</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE1B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
          <synonym>63 kDa Cam-PDE</synonym>
          <synonym>Cam-PDE 1B</synonym>
          <synonym>PDE1B1</synonym>
          <synonym>PDES1B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006483|Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
MELSPRSPPEMLEESDCPSPLELKSAPSKKMWIKLRSLLRYMVKQLENGEINIEELKKNL
EYTASLLEAVYIDETRQILDTEDELQELRSDAVPSEVRDWLASTFTQQARAKGRRAEEKP
KFRSIVHAVQAGIFVERMFRRTYTSVGPTYSTAVLNCLKNLDLWCFDVFSLNQAADDHAL
RTIVFELLTRHNLISRFKIPTVFLMSFLDALETGYGKYKNPYHNQIHAADVTQTVHCFLL
RTGMVHCLSEIELLAIIFAAAIHDYEHTGTTNSFHIQTKSECAIVYNDRSVLENHHISSV
FRLMQDDEMNIFINLTKDEFVELRALVIEMVLATDMSCHFQQVKTMKTALQQLERIDKPK
ALSLLLHAADISHPTKQWLVHSRWTKALMEEFFRQGDKEAELGLPFSPLCDRTSTLVAQS
QIGFIDFIVEPTFSVLTDVAEKSVQPLADEDSKSKNQPSFQWRQPSLDVEVGDPNPDVVS
FRSTWVKRIQENKQKWKERAASGITNQMSIDELSPCEEEAPPSPAEDEHNQNGNLD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017061|Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B (PDE1B)
ATGGAGCTGTCCCCCCGCAGTCCTCCGGAGATGCTGGAGGAGTCGGATTGCCCGTCACCC
CTGGAGCTGAAGTCAGCCCCCAGCAAGAAGATGTGGATTAAGCTTCGGTCTCTGCTGCGC
TACATGGTGAAGCAGTTGGAGAATGGGGAGATAAACATTGAGGAGCTGAAGAAAAATCTG
GAGTACACAGCTTCTCTGCTGGAAGCCGTCTACATAGATGAGACACGGCAAATCTTGGAC
ACGGAGGACGAGCTGCAGGAGCTGCGGTCAGATGCCGTGCCTTCGGAGGTGCGGGACTGG
CTGGCCTCCACCTTCACCCAGCAGGCCCGGGCCAAAGGCCGCCGAGCAGAGGAGAAGCCC
AAGTTCCGAAGCATTGTGCACGCTGTGCAGGCTGGGATCTTCGTGGAACGGATGTTCCGG
AGAACATACACCTCTGTGGGCCCCACTTACTCTACTGCGGTTCTCAACTGTCTCAAGAAC
CTGGATCTCTGGTGCTTTGATGTCTTTTCCTTGAACCAGGCAGCAGATGACCATGCCCTG
AGGACCATTGTTTTTGAGTTGCTGACTCGGCATAACCTCATCAGCCGCTTCAAGATTCCC
ACTGTGTTTTTGATGAGTTTCCTGGATGCCTTGGAGACAGGCTATGGGAAGTACAAGAAT
CCTTACCACAACCAGATCCACGCAGCCGATGTTACCCAGACAGTCCATTGCTTCTTGCTC
CGCACAGGGATGGTGCACTGCCTGTCGGAGATTGAGCTCCTGGCCATCATCTTTGCTGCA
GCTATCCATGATTATGAGCACACGGGCACTACCAACAGCTTCCACATCCAGACCAAGTCA
GAATGTGCCATCGTGTACAATGATCGTTCAGTGCTGGAGAATCACCACATCAGCTCTGTT
TTCCGATTGATGCAGGATGATGAGATGAACATTTTCATCAACCTCACCAAGGATGAGTTT
GTAGAACTCCGAGCCCTGGTCATTGAGATGGTGTTGGCCACAGACATGTCCTGCCATTTC
CAGCAAGTGAAGACCATGAAGACAGCCTTGCAACAGCTGGAGAGGATTGACAAGCCCAAG
GCCCTGTCTCTACTGCTCCATGCTGCTGACATCAGCCACCCAACCAAGCAGTGGTTGGTC
CACAGCCGTTGGACCAAGGCCCTCATGGAGGAATTCTTCCGTCAGGGTGACAAGGAGGCA
GAGTTGGGCCTGCCCTTTTCTCCACTCTGTGACCGCACTTCCACTCTAGTGGCACAGTCT
CAGATAGGGTTCATCGACTTCATTGTGGAGCCCACATTCTCTGTGCTGACTGACGTGGCA
GAGAAGAGTGTTCAGCCCCTGGCGGATGAGGACTCCAAGTCTAAAAACCAGCCCAGCTTT
CAGTGGCGCCAGCCCTCTCTGGATGTGGAAGTGGGAGACCCCAACCCTGATGTGGTCAGC
TTTCGTTCCACCTGGGTCAAGCGCATTCAGGAGAATAAGCAGAAATGGAAGGAACGGGCA
GCAAGTGGCATCACCAACCAGATGTCCATTGACGAGCTGTCCCCCTGTGAAGAAGAGGCC
CCCCCATCCCCTGCCGAAGATGAACACAACCAGAATGGGAATCTGGATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
          <pfam>
            <identifier>PF08499</identifier>
            <name>PDEase_I_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium- and calmodulin-regulated 3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin-dependent cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to granulocyte macrophage colony-stimulating factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to macrophage colony-stimulating factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of neurotransmitter levels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q14123" source="Swiss-Prot">
        <name>Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C</name>
        <general-function>Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a high affinity for both cAMP and cGMP.</general-function>
        <specific-function>Calmodulin binding</specific-function>
        <gene-name>PDE1C</gene-name>
        <locus>7p14.3</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>80759.7</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8776</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1296</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14123</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE1C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
          <synonym>Cam-PDE 1C</synonym>
          <synonym>hCam-3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008692|Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C
MESPTKEIEEFESNSLKYLQPEQIEKIWLRLRGLRKYKKTSQRLRSLVKQLERGEASVVD
LKKNLEYAATVLESVYIDETRRLLDTEDELSDIQSDAVPSEVRDWLASTFTRQMGMMLRR
SDEKPRFKSIVHAVQAGIFVERMYRRTSNMVGLSYPPAVIEALKDVDKWSFDVFSLNEAS
GDHALKFIFYELLTRYDLISRFKIPISALVSFVEALEVGYSKHKNPYHNLMHAADVTQTV
HYLLYKTGVANWLTELEIFAIIFSAAIHDYEHTGTTNNFHIQTRSDPAILYNDRSVLENH
HLSAAYRLLQDDEEMNILINLSKDDWREFRTLVIEMVMATDMSCHFQQIKAMKTALQQPE
AIEKPKALSLMLHTADISHPAKAWDLHHRWTMSLLEEFFRQGDREAELGLPFSPLCDRKS
TMVAQSQVGFIDFIVEPTFTVLTDMTEKIVSPLIDETSQTGGTGQRRSSLNSISSSDAKR
SGVKTSGSEGSAPINNSVISVDYKSFKATWTEVVHINRERWRAKVPKEEKAKKEAEEKAR
LAAEEQQKEMEAKSQAEEGASGKAEKKTSGETKNQVNGTRANKSDNPRGKNSKAEKSSGE
QQQNGDFKDGKNKTDKKDHSNIGNDSKKTDGTKQRSHGSPAPSTSSTCRLTLPVIKPPLR
HFKRPAYASSSYAPSVSKKTDEHPARYKMLDQRIKMKKIQNISHNWNRK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051555|Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C (PDE1C)
ATGGAGTCGCCAACCAAGGAGATTGAAGAATTTGAGAGCAACTCTCTGAAATACCTGCAA
CCGGAACAGATCGAGAAAATCTGGCTTCGGCTCCGCGGGCTGAGGAAATATAAGAAAACG
TCCCAGAGATTACGGTCTTTGGTCAAACAATTAGAGAGAGGGGAAGCTTCAGTGGTAGAT
CTTAAGAAGAATTTGGAATATGCAGCCACAGTGCTTGAATCTGTGTATATTGATGAAACA
AGGAGACTCCTGGATACAGAGGATGAGCTCAGTGACATTCAGTCAGATGCTGTGCCTTCT
GAGGTCCGAGACTGGCTGGCCTCCACCTTCACGCGGCAGATGGGGATGATGCTCAGGAGG
AGCGACGAGAAGCCCCGGTTCAAGAGCATCGTTCACGCAGTGCAGGCTGGGATATTTGTG
GAGAGAATGTATAGACGGACATCAAACATGGTTGGACTGAGCTATCCACCAGCTGTTATT
GAGGCATTAAAGGATGTGGACAAGTGGTCCTTTGACGTCTTTTCCCTCAATGAGGCCAGT
GGGGATCATGCACTGAAATTTATTTTCTATGAACTACTCACACGTTATGATCTGATCAGC
CGTTTCAAGATCCCCATTTCTGCACTTGTCTCATTTGTGGAGGCCCTGGAAGTGGGATAC
AGCAAGCACAAAAATCCTTACCATAACTTAATGCACGCTGCCGATGTTACACAGACAGTG
CATTACCTCCTCTATAAGACAGGAGTGGCGAACTGGCTGACGGAGCTGGAGATCTTTGCT
ATAATCTTCTCAGCTGCCATCCATGACTACGAGCATACCGGAACCACCAACAATTTCCAC
ATTCAGACTCGGTCTGATCCAGCTATTCTGTATAATGACAGATCTGTACTGGAGAATCAC
CATTTAAGTGCAGCTTATCGCCTTCTGCAAGATGACGAGGAAATGAATATTTTGATTAAC
CTCTCAAAGGATGACTGGAGGGAGTTTCGAACCTTGGTAATTGAAATGGTGATGGCCACA
GATATGTCTTGTCACTTCCAACAAATCAAAGCAATGAAGACTGCTCTGCAGCAGCCAGAA
GCCATTGAAAAGCCAAAAGCCTTATCCCTTATGCTGCATACAGCAGATATTAGCCATCCA
GCAAAAGCATGGGACCTCCATCATCGCTGGACAATGTCACTCCTGGAGGAGTTCTTCAGA
CAGGGTGACAGAGAAGCAGAGCTGGGGCTGCCTTTTTCTCCTCTGTGTGACCGAAAGTCC
ACTATGGTTGCTCAGTCACAAGTAGGTTTCATTGATTTCATCGTGGAACCCACCTTCACT
GTGCTTACGGACATGACCGAGAAGATTGTGAGTCCATTAATCGATGAAACCTCTCAAACT
GGTGGGACAGGACAGAGGCGTTCGAGTTTGAATAGCATCAGCTCGTCAGATGCCAAGCGA
TCAGGTGTCAAGACCTCTGGTTCAGAGGGAAGTGCCCCGATCAACAATTCTGTCATCTCC
GTTGACTATAAGAGCTTTAAAGCTACTTGGACGGAAGTGGTGCACATCAATCGGGAGAGA
TGGAGGGCCAAGGTACCCAAAGAGGAGAAGGCCAAGAAGGAAGCAGAGGAAAAGGCTCGC
CTGGCCGCAGAGGAGCAGCAAAAGGAAATGGAAGCCAAAAGCCAGGCTGAAGAAGGCGCA
TCTGGCAAAGCTGAGAAAAAGACGTCTGGAGAAACTAAGAATCAAGTCAATGGAACACGG
GCAAACAAAAGTGACAACCCTCGTGGGAAAAACTCCAAAGCCGAGAAGTCATCAGGAGAA
CAGCAACAGAATGGTGACTTCAAAGATGGTAAAAATAAGACAGACAAGAAGGATCACTCT
AACATCGGAAATGATTCAAAGAAAACAGATGGCACAAAACAGCGTTCTCACGGCTCACCA
GCCCCAAGCACCAGCTCCACGTGTCGCCTTACGTTGCCAGTCATCAAGCCTCCTTTGCGT
CATTTTAAACGCCCTGCTTACGCATCTAGCTCCTATGCACCTTCAGTCTCAAAGAAAACT
GATGAGCATCCTGCAAGGTACAAGATGCTGGATCAGAGGATCAAAATGAAAAAGATTCAG
AACATCTCACATAACTGGAACAGAAAATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
          <pfam>
            <identifier>PF08499</identifier>
            <name>PDEase_I_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin-dependent cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9Y233" source="Swiss-Prot">
        <name>cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.</specific-function>
        <gene-name>PDE10A</gene-name>
        <locus>6q26</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.57</theoretical-pi>
        <molecular-weight>88411.71</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8772</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE10A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB020593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4958858</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1310</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y233</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE10_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001258|cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
MRIEERKSQHLTGLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKNNKSEDESAP
KEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATKADGFALYFLGEC
NNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDILGDERFPRGTGLE
SGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVC
RGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELY
SDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYT
GYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHR
IRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIF
VYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTD
LERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNI
FSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMM
TACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFY
NAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016160|cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A)
ATGGAAGATGGACCTTCTAATAATGCGAGCTGCTTCCGAAGGCTGACCGAGTGCTTCCTG
AGCCCCAGTTTGACAGATGAAAAAGTGAAGGCATATCTTTCTCTTCACCCCCAGGTATTA
GATGAATTTGTATCTGAAAGTGTTAGTGCAGAGACAGTAGAGAAATGGCTGAAGAGGAAG
AACAACAAATCAGAAGATGAATCAGCTCCTAAGGAAGTCAGCAGGTACCAAGATACGAAT
ATGCAGGGAGTTGTATATGAACTAAACAGCTATATAGAACAACGGTTGGACACAGGAGGA
GACAACCAGCTACTCCTCTATGAACTGAGCAGCATCATTAAAATAGCCACAAAAGCCGAT
GGATTTGCACTGTATTTCCTTGGAGAGTGCAATAATAGCCTGTGTATATTCACGCCACCT
GGGATAAAGGAAGGAAAACCCCGCCTCATCCCTGCTGGGCCCATCACTCAGGGCACCACC
GTCTCTGCTTATGTGGCCAAGTCCAGGAAAACACTGCTAGTAGAAGACATCCTTGGAGAT
GAACGATTTCCAAGAGGTACTGGACTGGAATCAGGGACTCGTATCCAGTCTGTTCTTTGC
TTACCAATTGTCACTGCAATTGGTGACTTGATTGGTATTCTCGAGCTGTATCGGCACTGG
GGCAAAGAAGCCTTCTGTCTTAGTCACCAGGAGGTTGCAACAGCAAATCTTGCCTGGGCT
TCAGTAGCAATACATCAGGTGCAGGTATGCAGAGGCCTTGCCAAACAGACAGAATTGAAT
GACTTCCTACTCGACGTATCAAAAACATATTTTGATAACATAGTTGCAATAGATTCTCTA
CTTGAACACATAATGATATATGCAAAAAACCTGGTGAATGCCGATCGTTGTGCGCTTTTC
CAGGTGGACCATAAGAACAAGGAGTTATATTCAGACCTTTTTGATATTGGAGAGGAAAAG
GAAGGAAAACCTGTCTTCAAGAAGACCAAAGAGATAAGATTTTCAATTGAGAAAGGAATT
GCTGGCCAAGTAGCAAGAACAGGGGAAGTCCTGAACATTCCAGATGCCTATGCAGACCCA
CGCTTTAACAGAGAAGTAGACTTGTACACAGGCTACACCACGCGGAACATCCTGTGCATG
CCCATCGTCAGCCGAGGCAGCGTGATAGGTGTGGTGCAGATGGTCAACAAAATCAGTGGC
AGTGCCTTCTCTAAAACAGATGAAAACAACTTCAAAATGTTTGCCGTCTTTTGTGCTTTA
GCCTTACACTGTGCTAATATGTATCATAGAATTCGCCACTCAGAGTGCATTTACCGGGTA
ACGATGGAAAAGCTGTCCTACCATAGCATTTGTACTTCAGAAGAGTGGCAAGGTCTCATG
CAATTCACCCTTCCCGTGCGTCTCTGCAAAGAAATTGAATTATTCCACTTTGACATTGGT
CCTTTTGAAAACATGTGGCCTGGAATTTTTGTCTACATGGTTCATCGGTCCTGTGGGACA
TCCTGCTTTGAGCTTGAAAAGTTGTGTCGTTTTATTATGTCTGTGAAGAAGAACTATCGG
CGGGTTCCTTATCACAACTGGAAGCATGCGGTCACTGTAGCACACTGCATGTATGCCATA
CTTCAGAACAATCACACGCTTTTCACAGACCTTGAGCGCAAAGGACTGCTGATTGCGTGT
CTGTGTCATGACCTGGACCACAGGGGCTTCAGTAACAGCTACCTGCAGAAGTTCGACCAC
CCTCTGGCCGCTCTCTACTCCACTTCCACCATGGAGCAGCACCACTTCTCCCAGACTGTG
TCCATCCTCCAGTTGGAAGGGCACAATATCTTCTCCACTCTGAGCTCCAGTGAATATGAG
CAGGTGCTTGAGATCATCCGCAAAGCCATCATTGCCACAGACCTTGCTTTATACTTTGGA
AACAGGAAGCAGTTGGAAGAGATGTACCAGACCGGATCACTAAACCTTAATAATCAATCA
CATAGAGACCGTGTAATTGGTTTGATGATGACTGCCTGTGACCTTTGTTCTGTGACAAAA
CTGTGGCCCGTTACAAAATTGACGGCAAATGATATATATGCAGAATTCTGGGCTGAGGGT
GATGAAATGAAGAAATTGGGAATACAGCCTATTCCTATGATGGACAGAGACAAGAAGGAT
GAAGTCCCCCAAGGCCAGCTTGGGTTCTACAATGCCGTGGCCATTCCCTGCTATACAACC
CTTACCCAGATCCTCCCTCCCACGGAGCCTCTTCTGAAAGCATGCAGGGATAATCTCAGT
CAGTGGGAGAAGGTGATTCGAGGGGAGGAGACTGCAACCTGGATTTCATCCCCATCCGTG
GCTCAGAAGGCAGCTGCATCTGAAGATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP-stimulated cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein kinase A signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P27815" source="Swiss-Prot">
        <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.</specific-function>
        <gene-name>PDE4A</gene-name>
        <locus>19p13.2</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.87</theoretical-pi>
        <molecular-weight>98142.155</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8780</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE4A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L20965</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>347120</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1300</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P27815</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE4A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>DPDE2</synonym>
          <synonym>PDE46</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002254|cAMP-specific 3',5'-cyclic phosphodiesterase 4A
MEPPTVPSERSLSLSLPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSDSAERAERERQ
PHRPIERADAMDTSDRPGLRTTRMSWPSSFHGTGTGSGGAGGGSSRRFEAENGPTPSPGR
SPLDSQASPGLVLHAGAATSQRRESFLYRSDSDYDMSPKTMSRNSSVTSEAHAEDLIVTP
FAQVLASLRSVRSNFSLLTNVPVPSNKRSPLGGPTPVCKATLSEETCQQLARETLEELDW
CLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEI
PSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQITGLKKLMHSNSLNNSNIPRFGVKTD
QEELLAQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYML
TLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV
SNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDM
VLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLE
LYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADL
VHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEE
ISMAQIPCTAQEALTAQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLT
QQAQSTGSAPVAPDEFSSREEFVVAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLP
STAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016323|cAMP-specific 3',5'-cyclic phosphodiesterase 4A (PDE4A)
ATGGAACCCCCGACCGTCCCCTCGGAAAGGAGCCTGTCTCTGTCACTGCCCGGGCCCCGG
GAGGGCCAGGCCACCCTGAAGCCTCCCCCGCAGCACCTGTGGCGGCAGCCTCGGACCCCC
ATCCGTATCCAGCAGCGCGGCTACTCCGACAGCGCGGAGCGCGCCGAGCGGGAGCGGCAG
CCGCACCGGCCCATAGAGCGCGCCGATGCCATGGACACCAGCGACCGGCCCGGCCTGCGC
ACGACCCGCATGTCCTGGCCCTCGTCCTTCCATGGCACTGGCACCGGCAGCGGCGGCGCG
GGCGGAGGCAGCAGCAGGCGCTTCGAGGCAGAGAATGGGCCGACACCATCTCCTGGCCGC
AGCCCCCTGGACTCGCAGGCGAGCCCAGGACTCGTGCTGCACGCCGGGGCGGCCACCAGC
CAGCGCCGGGAGTCCTTCCTGTACCGCTCAGACAGCGACTATGACATGTCACCCAAGACC
ATGTCCCGGAACTCATCGGTCACCAGCGAGGCGCACGCTGAAGACCTCATCGTAACACCA
TTTGCTCAGGTGCTGGCCAGCCTCCGGAGCGTCCGTAGCAACTTCTCACTCCTGACCAAT
GTGCCCGTTCCCAGTAACAAGCGGTCCCCGCTGGGCGGCCCCACCCCTGTCTGCAAGGCC
ACGCTGTCAGAAGAAACGTGTCAGCAGTTGGCCCGGGAGACTCTGGAGGAGCTGGACTGG
TGTCTGGAGCAGCTGGAGACCATGCAGACCTATCGCTCTGTCAGCGAGATGGCCTCGCAC
AAGTTCAAAAGGATGTTGAACCGTGAGCTCACACACCTGTCAGAAATGAGCAGGTCCGGA
AACCAGGTCTCAGAGTACATTTCCACAACATTCCTGGACAAACAGAATGAAGTGGAGATC
CCATCACCCACGATGAAGGAACGAGAAAAACAGCAAGCGCCGCGACCAAGACCCTCCCAG
CCGCCCCCGCCCCCTGTACCACACTTACAGCCCATGTCCCAAATCACAGGGTTGAAAAAG
TTGATGCATAGTAACAGCCTGAACAACTCTAACATTCCCCGATTTGGGGTGAAGACCGAT
CAAGAAGAGCTCCTGGCCCAAGAACTGGAGAACCTGAACAAGTGGGGCCTGAACATCTTT
TGCGTGTCGGATTACGCTGGAGGCCGCTCACTCACCTGCATCATGTACATGATATTCCAG
GAGCGGGACCTGCTGAAGAAATTCCGCATCCCTGTGGACACGATGGTGACATACATGCTG
ACGCTGGAGGATCACTACCACGCTGACGTGGCCTACCATAACAGCCTGCACGCAGCTGAC
GTGCTGCAGTCCACCCACGTACTGCTGGCCACGCCTGCACTAGATGCAGTGTTCACGGAC
CTGGAGATTCTCGCCGCCCTCTTCGCGGCTGCCATCCACGATGTGGATCACCCTGGGGTC
TCCAACCAGTTCCTCATCAACACCAATTCGGAGCTGGCGCTCATGTACAACGATGAGTCG
GTGCTCGAGAATCACCACCTGGCCGTGGGCTTCAAGCTGCTGCAGGAGGACAACTGCGAC
ATCTTCCAGAACCTCAGCAAGCGCCAGCGGCAGAGCCTACGCAAGATGGTCATCGACATG
GTGCTGGCCACGGACATGTCCAAGCACATGACCCTCCTGGCTGACCTGAAGACCATGGTG
GAGACCAAGAAAGTGACCAGCTCAGGGGTCCTCCTGCTAGATAACTACTCCGACCGCATC
CAGGTCCTCCGGAACATGGTGCACTGTGCCGACCTCAGCAACCCCACCAAGCCGCTGGAG
CTGTACCGCCAGTGGACAGACCGCATCATGGCCGAGTTCTTCCAGCAGGGTGACCGAGAG
CGCGAGCGTGGCATGGAAATCAGCCCCATGTGTGACAAGCACACTGCCTCCGTGGAGAAG
TCTCAGGTGGGTTTTATTGACTACATTGTGCACCCATTGTGGGAGACCTGGGCGGACCTT
GTCCACCCAGATGCCCAGGAGATCTTGGACACTTTGGAGGACAACCGGGACTGGTACTAC
AGCGCCATCCGGCAGAGCCCATCTCCGCCACCCGAGGAGGAGTCAAGGGGGCCAGGCCAC
CCACCCCTGCCTGACAAGTTCCAGTTTGAGCTGACGCTGGAGGAGGAAGAGGAGGAAGAA
ATATCAATGGCCCAGATACCGTGCACAGCCCAAGAGGCATTGACTGCGCAGGGATTGTCA
GGAGTCGAGGAAGCTCTGGATGCAACCATAGCCTGGGAGGCATCCCCGGCCCAGGAGTCG
TTGGAAGTTATGGCACAGGAAGCATCCCTGGAGGCCGAGCTGGAGGCAGTGTATTTGACA
CAGCAGGCACAGTCCACAGGCAGTGCACCTGTGGCTCCGGATGAGTTCTCGTCCCGGGAG
GAATTCGTGGTTGCTGTAAGCCACAGCAGCCCCTCTGCCCTGGCTCTTCAAAGCCCCCTT
CTCCCTGCTTGGAGGACCCTGTCTGTTTCAGAGCATGCCCCGGGCCTCCCGGGCCTCCCC
TCCACGGCGGCCGAGGTGGAGGCCCAACGAGAGCACCAGGCTGCCAAGAGGGCTTGCAGT
GCCTGCGCAGGGACATTTGGGGAGGACACATCCGCACTCCCAGCTCCTGGTGGCGGGGGG
TCAGGTGGAGACCCTACCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ruffle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein kinase A signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of smell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q07343" source="Swiss-Prot">
        <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4B</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.</specific-function>
        <gene-name>PDE4B</gene-name>
        <locus>1p31</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.89</theoretical-pi>
        <molecular-weight>83342.695</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8781</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE4B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L20966</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>347122</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1301</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q07343</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE4B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>DPDE4</synonym>
          <synonym>PDE32</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000972|cAMP-specific 3',5'-cyclic phosphodiesterase 4B
MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNLQLPPLSQRQS
ERARTPEGDGISRPTTLPLTTLPSIAITTVSQECFDVENGPSPGRSPLDPQASSSAGLVL
HATFPGHSQRRESFLYRSDSDYDLSPKAMSRNSSLPSEQHGDDLIVTPFAQVLASLRSVR
NNFTILTNLHGTSNKRSPAASQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYR
SVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKK
KQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGLNIFNVAGYSH
NRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSLHAADVAQSTHV
LLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHL
AVGFKLLQEEHCDIFMNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTS
SGVLLLDNYTDRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEI
SPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMIPQSP
SPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHSYFSSTKTLCVIDPENRDSLG
ETDIDIATEDKSPVDT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016107|cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B)
ATGAAGGAGCACGGGGGCACCTTCAGTAGCACCGGAATCAGCGGTGGTAGCGGTGACTCT
GCTATGGACAGCCTGCAGCCGCTCCAGCCTAACTACATGCCTGTGTGTTTGTTTGCAGAA
GAATCTTATCAAAAATTAGCAATGGAAACGCTGGAGGAATTAGACTGGTGTTTAGACCAG
CTAGAGACCATACAGACCTACCGGTCTGTCAGTGAGATGGCTTCTAACAAGTTCAAAAGA
ATGCTGAACCGGGAGCTGACACACCTCTCAGAGATGAGCCGATCAGGGAACCAGGTGTCT
GAATACATTTCAAATACTTTCTTAGACAAGCAGAATGATGTGGAGATCCCATCTCCTACC
CAGAAAGACAGGGAGAAAAAGAAAAAGCAGCAGCTCATGACCCAGATAAGTGGAGTGAAG
AAATTAATGCATAGTTCAAGCCTAAACAATACAAGCATCTCACGCTTTGGAGTCAACACT
GAAAATGAAGATCACCTGGCCAAGGAGCTGGAAGACCTGAACAAATGGGGTCTTAACATC
TTTAATGTGGCTGGATATTCTCACAATAGACCCCTAACATGCATCATGTATGCTATATTC
CAGGAAAGAGACCTCCTAAAGACATTCAGAATCTCATCTGACACATTTATAACCTACATG
ATGACTTTAGAAGACCATTACCATTCTGACGTGGCATATCACAACAGCCTGCACGCTGCT
GATGTAGCCCAGTCGACCCATGTTCTCCTTTCTACACCAGCATTAGACGCTGTCTTCACA
GATTTGGAGATCCTGGCTGCCATTTTTGCAGCTGCCATCCATGACGTTGATCATCCTGGA
GTCTCCAATCAGTTTCTCATCAACACAAATTCAGAACTTGCTTTGATGTATAATGATGAA
TCTGTGTTGGAAAATCATCACCTTGCTGTGGGTTTCAAACTGCTGCAAGAAGAACACTGT
GACATCTTCATGAATCTCACCAAGAAGCAGCGTCAGACACTCAGGAAGATGGTTATTGAC
ATGGTGTTAGCAACTGATATGTCTAAACATATGAGCCTGCTGGCAGACCTGAAGACAATG
GTAGAAACGAAGAAAGTTACAAGTTCAGGCGTTCTTCTCCTAGACAACTATACCGATCGC
ATTCAGGTCCTTCGCAACATGGTACACTGTGCAGACCTGAGCAACCCCACCAAGTCCTTG
GAATTGTATCGGCAATGGACAGACCGCATCATGGAGGAATTTTTCCAGCAGGGAGACAAA
GAGCGGGAGAGGGGAATGGAAATTAGCCCAATGTGTGATAAACACACAGCTTCTGTGGAA
AAATCCCAGGTTGGTTTCATCGACTACATTGTCCATCCATTGTGGGAGACATGGGCAGAT
TTGGTACAGCCTGATGCTCAGGACATTCTCGATACCTTAGAAGATAACAGGAACTGGTAT
CAGAGCATGATACCTCAAAGTCCCTCACCACCACTGGACGAGCAGAACAGGGACTGCCAG
GGTCTGATGGAGAAGTTTCAGTTTGAACTGACTCTCGATGAGGAAGATTCTGAAGGACCT
GAGAAGGAGGGAGAGGGACACAGCTATTTCAGCAGCACAAAGACGCTTTGTGTGATTGAT
CCAGAAAACAGAGATTCCCTGGGAGAGACTGACATAGACATTGCAACAGAAGACAAGTCC
CCCGTGGATACATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell periphery</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>centrosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>excitatory synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>gamma-tubulin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Z disc</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to epinephrine stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of relaxation of cardiac muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-2 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle cell contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q08493" source="Swiss-Prot">
        <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4C</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.</specific-function>
        <gene-name>PDE4C</gene-name>
        <locus>19p13.11</locus>
        <cellular-location>Cell projection</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.84</theoretical-pi>
        <molecular-weight>79900.795</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8782</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE4C</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z46632</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>727223</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1302</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q08493</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE4C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>DPDE1</synonym>
          <synonym>PDE21</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004621|cAMP-specific 3',5'-cyclic phosphodiesterase 4C
MENLGVGEGAEACSRLSRSRGRHSMTRAPKHLWRQPRRPIRIQQRFYSDPDKSAGCRERD
LSPRPELRKSRLSWPVSSCRRFDLENGLSCGRRALDPQSSPGLGRIMQAPVPHSQRRESF
LYRSDSDYELSPKAMSRNSSVASDLHGEDMIVTPFAQVLASLRTVRSNVAALARQQCLGA
AKQGPVGNPSSSNQLPPAEDTGQKLALETLDELDWCLDQLETLQTRHSVGEMASNKFKRI
LNRELTHLSETSRSGNQVSEYISRTFLDQQTEVELPKVTAEEAPQPMSRISGLHGLCHSA
SLSSATVPRFGVQTDQEEQLAKELEDTNKWGLDVFKVAELSGNRPLTAIIFSIFQERDLL
KTFQIPADTLATYLLMLEGHYHANVAYHNSLHAADVAQSTHVLLATPALEAVFTDLEILA
ALFASAIHDVDHPGVSNQFLINTNSELALMYNDASVLENHHLAVGFKLLQAENCDIFQNL
SAKQRLSLRRMVIDMVLATDMSKHMNLLADLKTMVETKKVTSLGVLLLDNYSDRIQVLQN
LVHCADLSNPTKPLPLYRQWTDRIMAEFFQQGDRERESGLDISPMCDKHTASVEKSQVGF
IDYIAHPLWETWADLVHPDAQDLLDTLEDNREWYQSKIPRSPSDLTNPERDGPDRFQFEL
TLEEAEEEDEEEEEEGEETALAKEALELPDTELLSPEAGPDPGDLPLDNQRT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011691|cAMP-specific 3',5'-cyclic phosphodiesterase 4C (PDE4C)
ATGGAGAACCTGGGGGTCGGCGAAGGGGCAGAGGCTTGCAGCAGGTTGAGTCGCTCTCGC
GGCCGCCACAGCATGACCAGAGCCCCGAAGCACCTGTGGCGGCAACCCCGGCGCCCCATC
CGCATCCAACAGCGCTTCTATTCGGATCCGGACAAGTCCGCGGGCTGCCGCGAGAGGGAC
CTGAGCCCGCGGCCGGAGCTCAGGAAGTCGCGGCTCTCCTGGCCCGTTTCCTCCTGCAGG
CGCTTTGACCTGGAAAATGGGCTCTCGTGTGGGAGGAGGGCCCTGGACCCTCAGTCCAGC
CCTGGCCTGGGCCGGATTATGCAGGCTCCAGTCCCGCACAGCCAGCGGCGCGAGTCCTTC
CTGTACCGCTCAGATAGCGACTATGAACTCTCGCCCAAGGCCATGTCTCGGAACTCCTCT
GTGGCCAGCGACCTACATGGAGAGGACATGATTGTGACGCCCTTTGCCCAGGTCCTGGCC
AGTCTGCGGACCGTTCGGAGCAACGTGGCGGCCCTTGCCCGCCAGCAATGCCTAGGAGCA
GCCAAGCAGGGACCCGTCGGAAACCCTTCATCCAGCAATCAGCTCCCTCCTGCAGAGGAC
ACGGGGCAGAAGCTGGCATTGGAGACGCTAGACGAGCTGGACTGGTGCCTGGATCAGTTG
GAGACGCTGCAGACCCGGCACTCGGTGGGGGAGATGGCCTCCAACAAGTTCAAGCGGATC
CTGAACCGGGAGTTGACCCACCTGTCCGAAACCAGCCGCTCCGGGAACCAGGTGTCCGAG
TACATCTCCCGGACCTTCCTGGACCAGCAGACCGAGGTGGAGCTGCCCAAGGTGACCGCT
GAGGAGGCCCCACAGCCCATGTCCCGGATCAGTGGCCTACATGGGCTCTGCCACAGTGCC
AGCCTCTCCTCAGCCACTGTCCCACGCTTTGGGGTCCAGACTGACCAGGAGGAGCAACTG
GCCAAGGAGCTAGAAGACACCAACAAGTGGGGACTTGATGTGTTCAAGGTGGCGGAGCTA
AGTGGGAACCGGCCCCTCACAGCTATCATATTCAGCATTTTTCAGGAGCGGGACCTGCTG
AAGACATTCCAGATCCCAGCAGACACACTGGCCACCTACCTGCTGATGCTGGAAGGTCAC
TACCACGCCAATGTGGCCTACCACAACAGCCTACATGCCGCCGACGTGGCCCAGTCCACG
CATGTGCTGCTGGCTACGCCCGCCCTCGAGGCTGTGTTCACAGACTTGGAAATCCTGGCT
GCCCTCTTTGCAAGCGCCATCCACGACGTGGACCATCCTGGGGTCTCCAACCAGTTTCTG
ATTAACACCAACTCAGAGCTGGCGCTTATGTACAACGACGCCTCGGTGCTGGAGAACCAT
CACCTGGCTGTGGGCTTCAAGCTGCTGCAGGCAGAGAACTGCGATATCTTCCAGAACCTC
AGCGCCAAGCAGCGACTGAGTCTGCGCAGGATGGTCATTGACATGGTGCTGGCCACAGAC
ATGTCCAAACACATGAACCTCCTGGCCGACCTCAAGACCATGGTGGAGACCAAGAAGGTG
ACAAGCCTCGGTGTCCTCCTCCTGGACAACTATTCCGACCGAATCCAGGTCTTGCAGAAC
CTGGTGCACTGTGCTGATCTGAGCAACCCCACCAAGCCGCTGCCCCTGTACCGCCAGTGG
ACGGACCGCATCATGGCCGAGTTCTTCCAGCAGGGAGACCGCGAGCGTGAGTCGGGCCTG
GACATCAGTCCCATGTGTGACAAGCATACGGCCTCAGTGGAGAAGTCCCAGGTGGGTTTC
ATTGACTACATTGCTCACCCACTGTGGGAGACTTGGGCTGACCTGGTCCACCCAGATGCA
CAGGACCTGCTGGACACGCTGGAGGACAATCGAGAGTGGTACCAGAGCAAGATCCCCCGA
AGTCCCTCAGACCTCACCAACCCCGAGCGGGACGGGCCTGACAGATTCCAGTTTGAACTG
ACTCTGGAGGAGGCAGAGGAAGAGGATGAGGAGGAAGAAGAGGAGGGGGAAGAGACAGCT
TTAGCCAAAGAGGCCTTGGAGTTGCCTGACACTGAACTCCTGTCCCCTGAAGCCGGCCCA
GACCCTGGGGACTTACCCCTCGACAACCAGAGGACTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>primary cilium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q08499" source="Swiss-Prot">
        <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4D</name>
        <general-function>Ubiquitin protein ligase binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.</specific-function>
        <gene-name>PDE4D</gene-name>
        <locus>5q12</locus>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.25</theoretical-pi>
        <molecular-weight>91114.1</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8783</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE4D</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L20970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>347130</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1303</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q08499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE4D_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>DPDE3</synonym>
          <synonym>PDE43</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002560|cAMP-specific 3',5'-cyclic phosphodiesterase 4D
MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQYPLRQPQFRLLHPHHHLPPP
PPPSPQPQPQCPLQPPPPPPLPPPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRA
MDRTSYAVETGHRPGLKKSRMSWPSSFQGLRRFDVDNGTSAGRSPLDPMTSPGSGLILQA
NFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRTVRNNF
AALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQTRHSV
SEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKEKKKRP
MSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELSGNRPL
TVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLST
PALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGF
KLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVL
LLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMC
DKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQSPSPAP
DDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSESTEIPL
DEQVEEEAVGEEEESQPEACVIDDRSPDT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020514|cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D)
ATGGAGGCAGAGGGCAGCAGCGCGCCGGCCCGGGCGGGCAGCGGAGAGGGCAGCGACAGC
GCCGGCGGGGCCACGCTCAAAGCCCCCAAGCATCTCTGGAGGCACGAGCAGCACCACCAG
TACCCGCTCCGGCAGCCCCAGTTCCGCCTCCTGCATCCCCATCACCACCTGCCCCCGCCG
CCGCCACCCTCGCCCCAGCCCCAGCCCCAGTGTCCGCTACAGCCGCCGCCGCCGCCCCCC
CTGCCGCCGCCCCCGCCGCCGCCCGGGGCTGCCCGCGGCCGCTACGCCTCGAGCGGGGCC
ACCGGCCGCGTCCGGCATCGCGGCTACTCGGACACCGAGCGCTACCTGTACTGTCGCGCC
ATGGACCGCACCTCCTACGCGGTGGAGACCGGCCACCGGCCCGGCCTGAAGAAATCCAGG
ATGTCCTGGCCCTCCTCGTTCCAGGGACTCAGGCGTTTTGATGTGGACAATGGCACATCT
GCGGGACGGAGTCCCTTGGATCCCATGACCAGCCCAGGATCCGGGCTAATTCTCCAAGCA
AATTTTGTCCACAGTCAACGACGGGAGTCCTTCCTGTATCGATCCGACAGCGATTATGAC
CTCTCTCCAAAGTCTATGTCCCGGAACTCCTCCATTGCCAGTGATATACACGGAGATGAC
TTGATTGTGACTCCATTTGCTCAGGTCTTGGCCAGTCTGCGAACTGTACGAAACAACTTT
GCTGCATTAACTAATTTGCAAGATCGAGCACCTAGCAAAAGATCACCCATGTGCAACCAA
CCATCCATCAACAAAGCCACCATAACAGAGGAGGCCTACCAGAAACTGGCCAGCGAGACC
CTGGAGGAGCTGGACTGGTGTCTGGACCAGCTAGAGACCCTACAGACCAGGCACTCCGTC
AGTGAGATGGCCTCCAACAAGTTTAAAAGGATGCTTAATCGGGAGCTCACCCATCTCTCT
GAAATGAGTCGGTCTGGAAATCAAGTGTCAGAGTTTATATCAAACACATTCTTAGATAAG
CAACATGAAGTGGAAATTCCTTCTCCAACTCAGAAGGAAAAGGAGAAAAAGAAAAGACCA
ATGTCTCAGATCAGTGGAGTCAAGAAATTGATGCACAGCTCTAGTCTGACTAATTCAAGT
ATCCCAAGGTTTGGAGTTAAAACTGAACAAGAAGATGTCCTTGCCAAGGAACTAGAAGAT
GTGAACAAATGGGGTCTTCATGTTTTCAGAATAGCAGAGTTGTCTGGTAACCGGCCCTTG
ACTGTTATCATGCACACCATTTTTCAGGAACGGGATTTATTAAAAACATTTAAAATTCCA
GTAGATACTTTAATTACATATCTTATGACTCTCGAAGACCATTACCATGCTGATGTGGCC
TATCACAACAATATCCATGCTGCAGATGTTGTCCAGTCTACTCATGTGCTATTATCTACA
CCTGCTTTGGAGGCTGTGTTTACAGATTTGGAGATTCTTGCAGCAATTTTTGCCAGTGCA
ATACATGATGTAGATCATCCTGGTGTGTCCAATCAATTTCTGATCAATACAAACTCTGAA
CTTGCCTTGATGTACAATGATTCCTCAGTCTTAGAGAACCATCATTTGGCTGTGGGCTTT
AAATTGCTTCAGGAAGAAAACTGTGACATTTTCCAGAATTTGACCAAAAAACAAAGACAA
TCTTTAAGGAAAATGGTCATTGACATCGTACTTGCAACAGATATGTCAAAACACATGAAT
CTACTGGCTGATTTGAAGACTATGGTTGAAACTAAGAAAGTGACAAGCTCTGGAGTTCTT
CTTCTTGATAATTATTCCGATAGGATTCAGGTTCTTCAGAATATGGTGCACTGTGCAGAT
CTGAGCAACCCAACAAAGCCTCTCCAGCTGTACCGCCAGTGGACGGACCGGATAATGGAG
GAGTTCTTCCGCCAAGGAGACCGAGAGAGGGAACGTGGCATGGAGATAAGCCCCATGTGT
GACAAGCACAATGCTTCCGTGGAAAAATCACAGGTGGGCTTCATAGACTATATTGTTCAT
CCCCTCTGGGAGACATGGGCAGACCTCGTCCACCCTGACGCCCAGGATATTTTGGACACT
TTGGAGGACAATCGTGAATGGTACCAGAGCACAATCCCTCAGAGCCCCTCTCCTGCACCT
GATGACCCAGAGGAGGGCCGGCAGGGTCAAACTGAGAAATTCCAGTTTGAACTAACTTTA
GAGGAAGATGGTGAGTCAGACACGGAAAAGGACAGTGGCAGTCAAGTGGAAGAAGACACT
AGCTGCAGTGACTCCAAGACTCTTTGTACTCAAGACTCAGAGTCTACTGAAATTCCCCTT
GATGAACAGGTTGAAGAGGAGGCAGTAGGGGAAGAAGAGGAAAGCCAGCCTGAAGCCTGT
GTCATAGATGATCGTTCTCCTGACACGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>centrosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myofibril</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-2 adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>scaffold protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin protein ligase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adrenergic receptor signaling pathway involved in positive regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cAMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to epinephrine stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>establishment of endothelial barrier</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of relaxation of cardiac muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-2 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-5 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle cell contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell communication by electrical coupling involved in cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of G-protein coupled receptor protein signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein kinase A signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ryanodine-sensitive calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9NP56" source="Swiss-Prot">
        <name>cAMP-specific 3',5'-cyclic phosphodiesterase 7B</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in the control of cAMP-mediated neural activity and cAMP metabolism in the brain.</specific-function>
        <gene-name>PDE7B</gene-name>
        <locus>6q23-q24</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.03</theoretical-pi>
        <molecular-weight>51834.855</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE7B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB038040</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>8439497</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1306</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NP56</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE7B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010437|cAMP-specific 3',5'-cyclic phosphodiesterase 7B
MSCLMVERCGEILFENPDQNAKCVCMLGDIRLRGQTGVRAERRGSYPFIDFRLLNSTTYS
GEIGTKKKVKRLLSFQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSKVGMWDFDIF
LFDRLTNGNSLVTLLCHLFNTHGLIHHFKLDMVTLHRFLVMVQEDYHSQNPYHNAVHAAD
VTQAMHCYLKEPKLASFLTPLDIMLGLLAAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS
VLENHHWRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLHN
KDLRLEDAQDRHFMLQIALKCADICNPCRIWEMSKQWSERVCEEFYRQGELEQKFELEIS
PLCNQQKDSIPSIQIGFMSYIVEPLFREWAHFTGNSTLSENMLGHLAHNKAQWKSLLPRQ
HRSRGSSGSGPDHDHAGQGTESEEQEGDSP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010438|cAMP-specific 3',5'-cyclic phosphodiesterase 7B (PDE7B)
ATGTCTTGTTTAATGGTTGAGAGGTGTGGCGAAATCTTGTTTGAGAACCCCGATCAGAAT
GCCAAATGTGTTTGCATGCTGGGAGATATACGACTAAGGGGTCAGACGGGGGTTCGTGCT
GAACGCCGTGGCTCCTACCCATTCATTGACTTCCGCCTACTTAACAGTACAACATACTCA
GGGGAGATTGGCACCAAGAAAAAGGTGAAAAGACTATTAAGCTTTCAAAGATACTTCCAT
GCATCAAGGCTGCTTCGTGGAATTATACCACAAGCCCCTCTGCACCTGCTGGATGAAGAC
TACCTTGGACAAGCAAGGCATATGCTCTCCAAAGTGGGAATGTGGGATTTTGACATTTTC
TTGTTTGATCGCTTGACAAATGGAAACAGCCTGGTAACACTGTTGTGCCACCTCTTCAAT
ACCCATGGACTCATTCACCATTTCAAGTTAGATATGGTGACCTTACACCGATTTTTAGTC
ATGGTTCAAGAAGATTACCACAGCCAAAACCCGTATCACAATGCTGTTCACGCAGCCGAC
GTCACCCAGGCCATGCACTGCTACCTGAAAGAGCCAAAGCTTGCCAGCTTCCTCACGCCT
CTGGACATCATGCTTGGACTGCTGGCTGCAGCAGCACACGATGTGGACCACCCAGGGGTG
AACCAGCCATTTTTGATAAAAACTAACCACCATCTTGCAAACCTATATCAGAATATGTCT
GTGCTGGAGAATCATCACTGGCGATCTACAATTGGCATGCTTCGAGAATCAAGGCTTCTT
GCTCATTTGCCAAAGGAAATGACACAGGATATTGAACAGCAGCTGGGCTCCTTGATCTTG
GCAACAGACATCAACAGGCAGAATGAATTTTTGACCAGATTGAAAGCTCACCTCCACAAT
AAAGACTTAAGACTGGAGGATGCACAGGACAGGCACTTTATGCTTCAGATCGCCTTGAAG
TGTGCTGACATTTGCAATCCTTGTAGAATCTGGGAGATGAGCAAGCAGTGGAGTGAAAGG
GTCTGTGAAGAATTCTACAGGCAAGGTGAACTTGAACAGAAATTTGAACTGGAAATCAGT
CCTCTTTGTAATCAACAGAAAGATTCCATCCCTAGTATACAAATTGGTTTCATGAGCTAC
ATCGTGGAGCCGCTCTTCCGGGAATGGGCCCATTTCACGGGTAACAGCACCCTGTCGGAG
AACATGCTGGGCCACCTCGCACACAACAAGGCCCAGTGGAAGAGCCTGTTGCCCAGGCAG
CACAGAAGCAGGGGCAGCAGTGGCAGCGGGCCTGACCACGACCACGCAGGCCAAGGGACT
GAGAGCGAGGAGCAGGAAGGCGACAGCCCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O00408" source="Swiss-Prot">
        <name>cGMP-dependent 3',5'-cyclic phosphodiesterase</name>
        <general-function>Tpr domain binding</general-function>
        <specific-function>Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.Isoform PDE2A2: Regulates Mitochondrial cAMP Levels and Respiration.</specific-function>
        <gene-name>PDE2A</gene-name>
        <locus>11q13.4</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.08</theoretical-pi>
        <molecular-weight>105715.85</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8777</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U67733</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2108052</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1297</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O00408</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE2A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
          <synonym>CGS-PDE</synonym>
          <synonym>cGSPDE</synonym>
          <synonym>Cyclic GMP-stimulated phosphodiesterase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004088|cGMP-dependent 3',5'-cyclic phosphodiesterase
MGQACGHSILCRSQQYPAARPAEPRGQQVFLKPDEPPPPPQPCADSLQDALLSLGSVIDI
SGLQRAVKEALSAVLPRVETVYTYLLDGESQLVCEDPPHELPQEGKVREAIISQKRLGCN
GLGFSDLPGKPLARLVAPLAPDTQVLVMPLADKEAGAVAAVILVHCGQLSDNEEWSLQAV
EKHTLVALRRVQVLQQRGPREAPRAVQNPPEGTAEDQKGGAAYTDRDRKILQLCGELYDL
DASSLQLKVLQYLQQETRASRCCLLLVSEDNLQLSCKVIGDKVLGEEVSFPLTGCLGQVV
EDKKSIQLKDLTSEDVQQLQSMLGCELQAMLCVPVISRATDQVVALACAFNKLEGDLFTD
EDEHVIQHCFHYTSTVLTSTLAFQKEQKLKCECQALLQVAKNLFTHLDDVSVLLQEIITE
ARNLSNAEICSVFLLDQNELVAKVFDGGVVDDESYEIRIPADQGIAGHVATTGQILNIPD
AYAHPLFYRGVDDSTGFRTRNILCFPIKNENQEVIGVAELVNKINGPWFSKFDEDLATAF
SIYCGISIAHSLLYKKVNEAQYRSHLANEMMMYHMKVSDDEYTKLLHDGIQPVAAIDSNF
ASFTYTPRSLPEDDTSMAILSMLQDMNFINNYKIDCPTLARFCLMVKKGYRDPPYHNWMH
AFSVSHFCYLLYKNLELTNYLEDIEIFALFISCMCHDLDHRGTNNSFQVASKSVLAALYS
SEGSVMERHHFAQAIAILNTHGCNIFDHFSRKDYQRMLDLMRDIILATDLAHHLRIFKDL
QKMAEVGYDRNNKQHHRLLLCLLMTSCDLSDQTKGWKTTRKIAELIYKEFFSQGDLEKAM
GNRPMEMMDREKAYIPELQISFMEHIAMPIYKLLQDLFPKAAELYERVASNREHWTKVSH
KFTIRGLPSNNSLDFLDEEYEVPDLDGTRAPINGCCSLDAE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021934|cGMP-dependent 3',5'-cyclic phosphodiesterase (PDE2A)
ATGGTCCTGGTGCTGCACCACATCCTCATCGCTGTTGTCCAATTCCTCAGGCGGGGCCAG
CAGGTCTTCCTCAAGCCGGACGAGCCGCCGCCGCCGCCGCAGCCATGCGCCGACAGCCTG
CAGGACGCCTTGCTGAGTCTGGGCTCTGTCATCGACATTTCAGGCCTGCAACGTGCTGTC
AAGGAGGCCCTGTCAGCTGTGCTCCCCCGAGTGGAAACTGTCTACACCTACCTACTGGAT
GGTGAGTCCCAGCTGGTGTGTGAGGACCCCCCACATGAGCTGCCCCAGGAGGGGAAAGTC
CGGGAGGCTATCATCTCCCAGAAGCGGCTGGGCTGCAATGGGCTGGGCTTCTCAGACCTG
CCAGGGAAGCCCTTGGCCAGGCTGGTGGCTCCACTGGCTCCTGATACCCAAGTGCTGGTC
ATGCCGCTAGCGGACAAGGAGGCTGGGGCCGTGGCAGCTGTCATCTTGGTGCACTGTGGC
CAGCTGAGTGATAATGAGGAATGGAGCCTGCAGGCGGTGGAGAAGCATACCCTGGTCGCC
CTGCGGAGGGTGCAGGTCCTGCAGCAGCGCGGGCCCAGGGAGGCTCCCCGAGCCGTCCAG
AACCCCCCGGAGGGGACGGCGGAAGACCAGAAGGGCGGGGCGGCGTACACCGACCGCGAC
CGCAAGATCCTCCAACTGTGCGGGGAACTCTACGACCTGGATGCCTCTTCCCTGCAGCTC
AAAGTGCTCCAATACCTGCAGCAGGAGACCCGGGCATCCCGCTGCTGCCTCCTGCTGGTG
TCGGAGGACAATCTCCAGCTTTCTTGCAAGGTCATCGGAGACAAAGTGCTCGGGGAAGAG
GTCAGCTTTCCCTTGACAGGATGCCTGGGCCAGGTGGTGGAAGACAAGAAGTCCATCCAG
CTGAAGGACCTCACCTCCGAGGATGTACAACAGCTGCAGAGCATGTTGGGCTGTGAGCTG
CAGGCCATGCTCTGTGTCCCTGTCATCAGCCGGGCCACTGACCAGGTGGTGGCCTTGGCC
TGCGCCTTCAACAAGCTAGAAGGAGACTTGTTCACCGACGAGGACGAGCATGTGATCCAG
CACTGCTTCCACTACACCAGCACCGTGCTCACCAGCACCCTGGCCTTCCAGAAGGAACAG
AAACTCAAGTGTGAGTGCCAGGCTCTTCTCCAAGTGGCAAAGAACCTCTTCACCCACCTG
GATGACGTCTCTGTCCTGCTCCAGGAGATCATCACGGAGGCCAGAAACCTCAGCAACGCA
GAGATCTGCTCTGTGTTCCTGCTGGATCAGAATGAGCTGGTGGCCAAGGTGTTCGACGGG
GGCGTGGTGGATGATGAGAGCTATGAGATCCGCATCCCGGCCGATCAGGGCATCGCGGGA
CACGTGGCGACCACGGGCCAGATCCTGAACATCCCTGACGCATATGCCCATCCGCTTTTC
TACCGCGGCGTGGACGACAGCACCGGCTTCCGCACGCGCAACATCCTCTGCTTCCCCATC
AAGAACGAGAACCAGGAGGTCATCGGTGTGGCCGAGCTGGTGAACAAGATCAATGGGCCA
TGGTTCAGCAAGTTCGACGAGGACCTGGCGACGGCCTTCTCCATCTACTGCGGCATCAGC
ATCGCCCATTCTCTCCTATACAAAAAAGTGAATGAGGCTCAGTATCGCAGCCACCTGGCC
AATGAGATGATGATGTACCACATGAAGGTCTCCGATGATGAGTATACCAAACTTCTCCAT
GATGGGATCCAGCCTGTGGCTGCCATTGACTCCAATTTTGCAAGTTTCACCTATACCCCT
CGTTCCCTGCCCGAGGATGACACGTCCATGGCCATCCTGAGCATGCTGCAGGACATGAAT
TTCATCAACAACTACAAAATTGACTGCCCGACCCTGGCCCGGTTCTGTTTGATGGTGAAG
AAGGGCTACCGGGATCCCCCCTACCACAACTGGATGCACGCCTTTTCTGTCTCCCACTTC
TGCTACCTGCTCTACAAGAACCTGGAGCTCACCAACTACCTCGAGGACATCGAGATCTTT
GCCTTGTTTATTTCCTGCATGTGTCATGACCTGGACCACAGAGGCACAAACAACTCTTTC
CAGGTGGCCTCGAAATCTGTGCTGGCTGCGCTCTACAGCTCTGAGGGCTCCGTCATGGAG
AGGCACCACTTTGCTCAGGCCATCGCCATCCTCAACACCCACGGCTGCAACATCTTTGAT
CATTTCTCCCGGAAGGACTATCAGCGCATGCTGGATCTGATGCGGGACATCATCTTGGCC
ACAGACCTGGCCCACCATCTCCGCATCTTCAAGGACCTCCAGAAGATGGCTGAGGTGGGC
TACGACCGAAACAACAAGCAGCACCACAGACTTCTCCTCTGCCTCCTCATGACCTCCTGT
GACCTCTCTGACCAGACCAAGGGCTGGAAGACTACGAGAAAGATCGCGGAGCTGATCTAC
AAAGAATTCTTCTCCCAGGGAGACCTGGAGAAGGCCATGGGCAACAGGCCGATGGAGATG
ATGGACCGGGAGAAGGCCTATATCCCTGAGCTGCAAATCAGCTTCATGGAGCACATTGCA
ATGCCCATCTACAAGCTGTTGCAGGACCTGTTCCCCAAAGCGGCAGAGCTGTACGAGCGC
GTGGCCTCCAACCGTGAGCACTGGACCAAGGTGTCCCACAAGTTCACCATCCGCGGCCTC
CCAAGTAACAACTCGCTGGACTTCCTGGATGAGGAGTACGAGGTGCCTGATCTGGATGGC
ACTAGGGCCCCCATCAATGGCTGCTGCAGCCTTGATGCTGAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
          <pfam>
            <identifier>PF13185</identifier>
            <name>GAF_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>presynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP-stimulated cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>TPR domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cGMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to granulocyte macrophage colony-stimulating factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to macrophage colony-stimulating factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to transforming growth factor beta stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>establishment of endothelial barrier</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein import into nucleus, translocation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein targeting to mitochondrion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q14432" source="Swiss-Prot">
        <name>cGMP-inhibited 3',5'-cyclic phosphodiesterase A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.</specific-function>
        <gene-name>PDE3A</gene-name>
        <locus>12p12</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>61-81
130-150
160-180
185-205
210-230
232-252</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.87</theoretical-pi>
        <molecular-weight>124978.06</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8778</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE3A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M91667</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>38201493</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1298</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14432</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE3A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
          <synonym>CGI-PDE A</synonym>
          <synonym>Cyclic GMP-inhibited phosphodiesterase A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021260|cGMP-inhibited 3',5'-cyclic phosphodiesterase A
MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRK
LSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAP
GGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGV
GEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYL
AYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEM
SGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDL
LADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLA
IPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWN
NPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVS
KISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADE
PLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYA
PETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFE
DMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVIN
DHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDH
PGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFL
VIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKEL
HLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAG
LMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLL
QNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPD
Q</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021261|cGMP-inhibited 3',5'-cyclic phosphodiesterase A (PDE3A)
ATGGCAGTGCCCGGCGACGCTGCACGAGTCAGGGACAAGCCCGTCCACAGTGGGGTGAGT
CAAGCCCCCACGGCGGGCCGGGACTGCCACCATCGTGCGGACCCCGCATCGCCGCGGGAC
TCGGGCTGCCGTGGCTGCTGGGGAGACCTGGTGCTGCAGCCGCTCCGGAGCTCTCGGAAA
CTTTCCTCCGCGCTGTGCGCGGGCTCCCTGTCCTTTCTGCTGGCGCTGCTGGTGAGGCTG
GTCCGCGGGGAGGTCGGCTGTGACCTGGAGCAGTGTAAGGAGGCGGCGGCGGCGGAGGAG
GAGGAAGCAGCCCCGGGAGCAGAAGGGGGCGTCTTCCCGGGGCCTCGGGGAGGTGCTCCC
GGGGGCGGTGCGCGGCTCAGCCCCTGGCTGCAGCCCTCGGCGCTGCTCTTCAGTCTCCTG
TGTGCCTTCTTCTGGATGGGCTTGTACCTCCTGCGCGCCGGGGTGCGCCTGCCTCTGGCT
GTCGCGCTGCTGGCCGCCTGCTGCGGGGGGGAAGCGCTCGTCCAGATTGGGCTGGGCGTC
GGGGAGGATCACTTACTCTCACTCCCCGCCGCGGGGGTGGTGCTCAGCTGCTTGGCCGCC
GCGACATGGCTGGTGCTGAGGCTGAGGCTGGGCGTCCTCATGATCGCCTTGACTAGCGCG
GTCAGGACCGTGTCCCTCATTTCCTTAGAGAGGTTCAAGGTCGCCTGGAGACCTTACCTG
GCGTACCTGGCCGGCGTGCTGGGGATCCTCTTGGCCAGGTACGTGGAACAAATCTTGCCG
CAGTCCGCGGAGGCGGCTCCAAGGGAGCATTTGGGGTCCCAGCTGATTGCTGGGACCAAG
GAAGATATCCCGGTGTTTAAGAGGAGGAGGCGGTCCAGCTCCGTCGTGTCCGCCGAGATG
TCCGGCTGCAGCAGCAAGTCCCATCGGAGGACCTCCCTGCCCTGTATACCGAGGGAACAG
CTCATGGGGCATTCAGAATGGGACCACAAACGAGGGCCAAGAGGATCACAGTCTTCAGGA
ACCAGTATTACTGTGGACATCGCCGTCATGGGCGAGGCCCACGGCCTCATTACCGACCTC
CTGGCAGACCCTTCTCTTCCACCAAACGTGTGCACATCCTTGAGAGCCGTGAGCAACTTG
CTCAGCACACAGCTCACCTTCCAGGCCATTCACAAGCCCAGAGTGAATCCCGTCACTTCG
CTCAGTGAAAACTATACCTGTTCTGACTCTGAAGAGAGCTCTGAAAAAGACAAGCTTGCT
ATTCCAAAGCGCCTGAGAAGGAGTTTGCCTCCTGGCTTGTTGAGACGAGTTTCTTCCACT
TGGACCACCACCACCTCGGCCACAGGTCTACCCACCTTGGAGCCTGCACCAGTACGGAGA
GACCGCAGCACCAGCATCAAACTGCAGGAAGCACCTTCATCCAGTCCTGATTCTTGGAAT
AATCCAGTGATGATGACCCTCACCAAAAGCAGATCCTTTACTTCATCCTATGCTATTTCT
GCAGCTAACCATGTAAAGGCTAAAAAGCAAAGTCGACCAGGTGCCCTCGCTAAAATTTCA
CCTCTTTCATCGCCCTGCTCCTCACCTCTCCAAGGGACTCCTGCCAGCAGCCTGGTCAGC
AAAATTTCTGCAGTGCAGTTTCCAGAATCTGCTGACACAACTGCCAAACAAAGCCTAGGT
TCTCACAGGGCCTTAACTTACACTCAGAGTGCCCCAGACCTATCCCCTCAAATCCTGACT
CCACCTGTTATATGTAGCAGCTGTGGCAGACCATATTCCCAAGGGAATCCTGCTGATGAG
CCCCTGGAGAGAAGTGGGGTAGCCACTCGGACACCAAGTAGAACAGATGACACTGCTCAA
GTTACCTCTGATTATGAAACCAATAACAACAGTGACAGCAGTGACATTGTACAGAATGAA
GATGAAACAGAGTGCCTGAGAGAGCCTCTGAGGAAAGCATCGGCTTGCAGCACCTATGCT
CCTGAGACCATGATGTTTCTGGACAAACCAATTCTTGCTCCCGAACCTCTTGTCATGGAT
AACCTGGACTCAATTATGGAGCAGCTAAATACTTGGAATTTTCCAATTTTTGATTTAGTG
GAAAATATAGGAAGAAAATGTGGCCGTATTCTTAGTCAGGTATCTTACAGACTTTTTGAA
GACATGGGCCTCTTTGAAGCTTTTAAAATTCCAATTAGGGAATTTATGAATTATTTTCAT
GCTTTGGAGATTGGATATAGGGATATTCCTTATCATAACAGAATCCATGCCACTGATGTT
TTACATGCTGTTTGGTATCTTACTACACAGCCTATTCCAGGCCTCTCAACTGTGATTAAT
GATCATGGTTCAACCAGTGATTCAGATTCTGACAGTGGATTTACACATGGACATATGGGA
TATGTATTCTCAAAAACGTATAATGTGACAGATGATAAATACGGATGTCTGTCTGGGAAT
ATCCCTGCCTTGGAGTTGATGGCGCTGTATGTGGCTGCAGCCATGCACGATTATGATCAT
CCAGGAAGGACTAATGCTTTCCTGGTTGCAACTAGTGCTCCTCAGGCGGTGCTATATAAC
GATCGTTCAGTTTTGGAGAATCATCACGCAGCTGCTGCATGGAATCTTTTCATGTCCCGG
CCAGAGTATAACTTCTTAATTAACCTTGACCATGTGGAATTTAAGCATTTCCGTTTCCTT
GTCATTGAAGCAATTTTGGCCACTGACCTGAAGAAACACTTTGACTTCGTAGCCAAATTT
AATGGCAAGGTAAATGATGATGTTGGAATAGATTGGACCAATGAAAATGATCGTCTACTG
GTTTGTCAAATGTGTATAAAGTTGGCTGATATCAATGGTCCAGCTAAATGTAAAGAACTC
CATCTTCAGTGGACAGATGGTATTGTCAATGAATTTTATGAACAGGGTGATGAAGAGGCC
AGCCTTGGATTACCCATAAGCCCCTTCATGGATCGTTCTGCTCCTCAGCTGGCCAACCTT
CAGGAATCCTTCATCTCTCACATTGTGGGGCCTCTGTGCAACTCCTATGATTCAGCAGGA
CTAATGCCTGGAAAATGGGTGGAAGACAGCGATGAGTCAGGAGATACTGATGACCCAGAA
GAAGAGGAGGAAGAAGCACCAGCACCAAATGAAGAGGAAACCTGTGAAAATAATGAATCT
CCAAAAAAGAAGACTTTCAAAAGGAGAAAAATCTACTGCCAAATAACTCAGCACCTCTTA
CAGAACCACAAGATGTGGAAGAAAGTCATTGAAGAGGAGCAACGGTTGGCAGGCATAGAA
AATCAATCCCTGGACCAGACCCCTCAGTCGCACTCTTCAGAACAGATCCAGGCTATCAAG
GAAGAAGAAGAAGAGAAAGGGAAACCAAGAGGCGAGGAGATACCAACCCAAAAGCCAGAC
CAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP-inhibited cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cGMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to transforming growth factor beta stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oocyte maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of oocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of meiotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cAMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q13370" source="Swiss-Prot">
        <name>cGMP-inhibited 3',5'-cyclic phosphodiesterase B</name>
        <general-function>Protein kinase b binding</general-function>
        <specific-function>Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. May play a role in fat metabolism. Regulates cAMP binding of RAPGEF3. Through simultaneous binding to RAPGEF3 and PIK3R6 assembles a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis.</specific-function>
        <gene-name>PDE3B</gene-name>
        <locus>11p15.1</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>88-108
117-137
152-172
192-212
220-240
247-267</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.75</theoretical-pi>
        <molecular-weight>124332.145</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8779</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE3B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U38178</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1145302</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1299</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13370</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE3B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
          <synonym>CGI-PDE B</synonym>
          <synonym>CGIP1</synonym>
          <synonym>CGIPDE1</synonym>
          <synonym>Cyclic GMP-inhibited phosphodiesterase B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002435|cGMP-inhibited 3',5'-cyclic phosphodiesterase B
MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELR
PPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLS
PLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGD
AGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSL
PSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSL
GETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEAR
NMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKG
DRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGP
FNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDT
ADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSG
KSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLD
LILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQF
MNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRIN
HGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQ
AVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFD
FLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFY
EQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDN
DTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEE
KCKADGNKLQVENSSLPQADEIQVIEEADEEE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021288|cGMP-inhibited 3',5'-cyclic phosphodiesterase B (PDE3B)
ATGAGGAGGGACGAGCGAGACGCCAAAGCCATGCGGTCCCTGCAGCCGCCGGATGGGGCC
GGCTCGCCCCCCGAGAGTCTGAGGAACGGCTACGTGAAGAGCTGCGTGAGCCCCTTGCGG
CAGGACCCTCCGCGCGGCTTCTTCTTCCACCTCTGCCGCTTCTGCAACGTGGAGCTGCGG
CCGCCGCCGGCCTCTCCCCAGCAGCCGCGGCGCTGCTCCCCCTTCTGCCGGGCGCGCCTC
TCGCTGGGCGCCCTGGCTGCCTTTGTCCTCGCCCTGCTGCTGGGCGCGGAACCCGAGAGC
TGGGCTGCCGGGGCCGCCTGGCTGCGGACGCTGCTGAGCGTGTGTTCGCACAGCTTGAGC
CCCCTCTTCAGCATCGCCTGTGCCTTCTTCTTCCTCACCTGCTTCCTCACCCGGACCAAG
CGGGGACCCGGCCCGGGCCGGAGCTGCGGCTCCTGGTGGCTGCTGGCGCTGCCCGCCTGC
TGTTACCTGGGGGACTTCTTGGTGTGGCAGTGGTGGTCTTGGCCTTGGGGGGATGGCGAC
GCAGGGTCCGCGGCCCCGCACACGCCCCCGGAGGCGGCAGCGGGCAGGTTGCTGCTGGTG
CTGAGCTGCGTAGGGCTGCTGCTGACGCTCGCGCACCCGCTGCGGCTCCGGCACTGCGTT
CTGGTGCTGCTCCTGGCCAGCTTCGTCTGGTGGGTCTCCTTCACCAGCCTCGGGTCGCTG
CCCTCCGCCCTCAGGCCGCTGCTCTCCGGCCTGGTGGGGGGCGCTGGCTGCCTGCTGGCC
CTGGGGTTGGATCACTTCTTTCAAATCAGGGAAGCGCCTCTTCATCCTCGACTGTCCAGT
GCCGCCGAAGAAAAAGTGCCTGTGATCCGACCCCGGAGGAGGTCCAGCTGCGTGTCGTTA
GGAGAAACTGCAGCCAGTTACTATGGCAGTTGCAAAATATTCAGGAGACCGTCGTTGCCT
TGTATTTCCAGAGAACAGATGATTCTTTGGGATTGGGACTTAAAACAATGGTATAAGCCT
CATTATCAAAATTCTGGAGGTGGAAATGGAGTTGATCTTTCAGTGCTAAATGAGGCTCGC
AATATGGTGTCAGATCTTCTGACTGATCCAAGCCTTCCACCACAAGTCATTTCCTCTCTA
CGGAGTATTAGTAGCTTAATGGGTGCTTTCTCAGGTTCCTGTAGGCCAAAGATTAATCCT
CTCACACCATTTCCTGGATTTTACCCCTGTTCTGAAATAGAGGACCCAGCTGAGAAAGGG
GATAGAAAACTTAACAAGGGACTAAATAGGAATAGTTTGCCAACTCCACAGCTGAGGAGA
AGCTCAGGAACTTCAGGATTGCTACCTGTTGAACAGTCTTCAAGGTGGGATCGTAATAAT
GGCAAAAGACCTCACCAAGAATTTGGCATTTCAAGTCAAGGATGCTATCTAAATGGGCCT
TTTAATTCAAATCTACTGACTATCCCGAAGCAAAGGTCATCTTCTGTATCACTGACTCAC
CATGTAGGTCTCAGAAGAGCTGGTGTTTTGTCCAGTCTGAGTCCTGTGAATTCTTCCAAC
CATGGACCAGTGTCTACTGGCTCTCTAACTAATCGATCACCCATAGAATTTCCTGATACT
GCTGATTTTCTTAATAAGCCAAGCGTTATCTTGCAGAGATCTCTGGGCAATGCACCTAAT
ACTCCAGATTTTTATCAGCAACTTAGAAATTCTGATAGCAATCTGTGTAACAGCTGTGGA
CATCAAATGCTGAAATATGTTTCAACATCTGAATCAGATGGTACAGATTGCTGCAGTGGA
AAATCAGGTGAAGAAGAAAACATTTTCTCGAAAGAATCATTCAAACTTATGGAAACTCAA
CAAGAAGAGGAAACAGAGAAGAAAGACAGCAGAAAATTATTTCAGGAAGGTGATAAGTGG
CTAACAGAAGAGGCACAGAGTGAACAGCAAACAAATATTGAACAGGAAGTATCACTGGAC
CTGATTTTAGTAGAAGAGTATGACTCATTAATAGAAAAGATGAGCAACTGGAATTTTCCA
ATTTTTGAACTTGTAGAAAAGATGGGAGAGAAATCAGGAAGGATTCTCAGTCAGGTTATG
TATACCTTATTTCAAGACACTGGTTTATTGGAAATATTTAAAATTCCCACTCAACAATTT
ATGAACTATTTTCGTGCATTAGAAAATGGCTATCGAGACATTCCTTATCACAATCGTATA
CATGCCACAGATGTGCTACATGCAGTTTGGTATCTGACAACACGGCCAGTTCCTGGCTTA
CAGCAGATCCACAATGGTTGTGGAACAGGAAATGAAACAGATTCTGATGGTAGAATTAAC
CATGGGCGAATTGCTTATATTTCTTCGAAGAGCTGCTCTAATCCTGATGAGAGTTATGGC
TGCCTGTCTTCAAACATTCCTGCATTAGAATTGATGGCTCTATACGTGGCAGCTGCCATG
CATGATTATGATCACCCAGGGAGGACAAATGCATTTCTAGTGGCTACAAATGCCCCTCAG
GCAGTTTTATACAATGACAGATCTGTTCTGGAAAATCATCATGCTGCGTCAGCTTGGAAT
CTATATCTTTCTCGCCCAGAATACAACTTCCTTCTTCATCTTGATCATGTGGAATTCAAG
CGCTTTCGTTTTTTAGTCATTGAAGCAATCCTTGCTACGGATCTTAAAAAGCATTTTGAT
TTTCTCGCAGAATTCAATGCCAAGGCAAATGATGTAAATAGTAATGGCATAGAATGGAGT
AATGAAAATGATCGCCTCTTGGTATGCCAGGTGTGCATCAAACTGGCAGATATAAATGGC
CCAGCAAAAGTTCGAGACTTGCATTTGAAATGGACAGAAGGCATTGTCAATGAATTTTAT
GAGCAGGGAGATGAAGAAGCAAATCTTGGTCTGCCCATCAGTCCATTCATGGATCGTTCT
TCTCCTCAACTAGCAAAACTCCAAGAATCTTTTATCACCCACATAGTGGGTCCCCTGTGT
AACTCCTATGATGCTGCTGGTTTGCTACCAGGTCAGTGGTTAGAAGCAGAAGAGGATAAT
GATACTGAAAGTGGTGATGATGAAGACGGTGAAGAATTAGATACAGAAGATGAAGAAATG
GAAAACAATCTAAATCCAAAACCACCAAGAAGGAAAAGCAGACGGCGAATATTTTGTCAG
CTAATGCACCACCTCACTGAAAACCACAAGATATGGAAGGAAATCGTAGAGGAAGAAGAA
AAATGTAAAGCTGATGGGAATAAACTGCAGGTGGAGAATTCCTCCTTACCTCAAGCAGAT
GAGATTCAGGTAATTGAAGAGGCAGATGAAGAGGAATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>guanyl-nucleotide exchange factor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP-inhibited cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase B binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endocrine pancreas development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell adhesion mediated by integrin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O76074" source="Swiss-Prot">
        <name>cGMP-specific 3',5'-cyclic phosphodiesterase</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).</specific-function>
        <gene-name>PDE5A</gene-name>
        <locus>4q25-q27</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.0</theoretical-pi>
        <molecular-weight>99984.14</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8784</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE5A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF043731</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3420185</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1304</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O76074</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE5A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.35</synonym>
          <synonym>CGB-PDE</synonym>
          <synonym>cGMP-binding cGMP-specific phosphodiesterase</synonym>
          <synonym>PDE5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036966|cGMP-specific 3',5'-cyclic phosphodiesterase
MERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKATREMVNAWFAE
RVHTIPVCKEGIRGHTESCSCPLQQSPRADNSAPGTPTRKISASEFDRPLRPIVVKDSEG
TVSFLSDSEKKEQMPLTPPRFDHDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLI
SADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEVSNNCIRLEWNKGIVGHVAALGEPL
NIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDE
KDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIIS
FMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKSSDTLTREHDANKINYMYAQYVKNTME
PLNIPDVSKDKRFPWTTENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGK
VKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETREL
QSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWIL
SVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGV
NNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAI
LATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAE
LVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCF
PLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009989|cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A)
ATGGAGCGGGCCGGCCCCAGCTTCGGGCAGCAGCGACAGCAGCAGCAGCCCCAGCAGCAG
AAGCAGCAGCAGAGGGATCAGGACTCGGTCGAAGCATGGCTGGACGATCACTGGGACTTT
ACCTTCTCATACTTTGTTAGAAAAGCCACCAGAGAAATGGTCAATGCATGGTTTGCTGAG
AGAGTTCACACCATCCCTGTGTGCAAGGAAGGTATCAGAGGCCACACCGAATCTTGCTCT
TGTCCCTTGCAGCAGAGTCCTCGTGCAGATAACAGTGCCCCTGGAACACCAACCAGGAAA
ATCTCTGCCTCTGAATTTGACCGGCCTCTTAGACCCATTGTTGTCAAGGATTCTGAGGGA
ACTGTGAGCTTCCTCTCTGACTCAGAAAAGAAGGAACAGATGCCTCTAACCCCTCCAAGG
TTTGATCATGATGAAGGGGACCAGTGCTCAAGACTCTTGGAATTAGTGAAGGATATTTCT
AGTCATTTGGATGTCACAGCCTTATGTCACAAAATTTTCTTGCATATCCATGGACTGATA
TCTGCTGACCGCTATTCCCTGTTCCTTGTCTGTGAAGACAGCTCCAATGACAAGTTTCTT
ATCAGCCGCCTCTTTGATGTTGCTGAAGGTTCAACACTGGAAGAAGTTTCAAATAACTGT
ATCCGCTTAGAATGGAACAAAGGCATTGTGGGACATGTGGCAGCGCTTGGTGAGCCCTTG
AACATCAAAGATGCATATGAGGATCCTCGGTTCAATGCAGAAGTTGACCAAATTACAGGC
TACAAGACACAAAGCATTCTTTGTATGCCAATTAAGAATCATAGGGAAGAGGTTGTTGGT
GTAGCCCAGGCCATCAACAAGAAATCAGGAAACGGTGGGACATTTACTGAAAAAGATGAA
AAGGACTTTGCTGCTTATTTGGCATTTTGTGGTATTGTTCTTCATAATGCTCAGCTCTAT
GAGACTTCACTGCTGGAGAACAAGAGAAATCAGGTGCTGCTTGACCTTGCTAGTTTAATT
TTTGAAGAACAACAATCATTAGAAGTAATTTTGAAGAAAATAGCTGCCACTATTATCTCT
TTCATGCAAGTGCAGAAATGCACCATTTTCATAGTGGATGAAGATTGCTCCGATTCTTTT
TCTAGTGTGTTTCACATGGAGTGTGAGGAATTAGAAAAATCATCTGATACATTAACAAGG
GAACATGATGCAAACAAAATCAATTACATGTATGCTCAGTATGTCAAAAATACTATGGAA
CCACTTAATATCCCAGATGTCAGTAAGGATAAAAGATTTCCCTGGACAACTGAAAATACA
GGAAATGTAAACCAGCAGTGCATTAGAAGTTTGCTTTGTACACCTATAAAAAATGGAAAG
AAGAATAAAGTTATAGGGGTTTGCCAACTTGTTAATAAGATGGAGGAGAATACTGGCAAG
GTTAAGCCTTTCAACCGAAATGACGAACAGTTTCTGGAAGCTTTTGTCATCTTTTGTGGC
TTGGGGATCCAGAACACGCAGATGTATGAAGCAGTGGAGAGAGCCATGGCCAAGCAAATG
GTCACATTGGAGGTTCTGTCGTATCATGCTTCAGCAGCAGAGGAAGAAACAAGAGAGCTA
CAGTCGTTAGCGGCTGCTGTGGTGCCATCTGCCCAGACCCTTAAAATTACTGACTTTAGC
TTCAGTGACTTTGAGCTGTCTGATCTGGAAACAGCACTGTGTACAATTCGGATGTTTACT
GACCTCAACCTTGTGCAGAACTTCCAGATGAAACATGAGGTTCTTTGCAGATGGATTTTA
AGTGTTAAGAAGAATTATCGGAAGAATGTTGCCTATCATAATTGGAGACATGCCTTTAAT
ACAGCTCAGTGCATGTTTGCTGCTCTAAAAGCAGGCAAAATTCAGAACAAGCTGACTGAC
CTGGAGATACTTGCATTGCTGATTGCTGCACTAAGCCACGATTTGGATCACCGTGGTGTG
AATAACTCTTACATACAGCGAAGTGAACATCCACTTGCCCAGCTTTACTGCCATTCAATC
ATGGAACACCATCATTTTGACCAGTGCCTGATGATTCTTAATAGTCCAGGCAATCAGATT
CTCAGTGGCCTCTCCATTGAAGAATATAAGACCACGTTGAAAATAATCAAGCAAGCTATT
TTAGCTACAGACCTAGCACTGTACATTAAGAGGCGAGGAGAATTTTTTGAACTTATAAGA
AAAAATCAATTCAATTTGGAAGATCCTCATCAAAAGGAGTTGTTTTTGGCAATGCTGATG
ACAGCTTGTGATCTTTCTGCAATTACAAAACCCTGGCCTATTCAACAACGGATAGCAGAA
CTTGTAGCAACTGAATTTTTTGATCAAGGAGACAGAGAGAGAAAAGAACTCAACATAGAA
CCCACTGATCTAATGAACAGGGAGAAGAAAAACAAAATCCCAAGTATGCAAGTTGGGTTC
ATAGATGCCATCTGCTTGCAACTGTATGAGGCCCTGACCCACGTGTCAGAGGACTGTTTC
CCTTTGCTAGATGGCTGCAGAAAGAACAGGCAGAAATGGCAGGCCCTTGCAGAACAGCAG
GAGAAGATGCTGATTAATGGGGAAAGCGGCCAGGCCAAGCGGAACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cardiac muscle hypertrophy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of oocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cGMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>relaxation of cardiac muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P51160" source="Swiss-Prot">
        <name>Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'</name>
        <general-function>As cone-specific cGMP phosphodiesterase, it plays an essential role in light detection and cone phototransduction by rapidly decreasing intracellular levels of cGMP.</general-function>
        <specific-function>3',5'-cyclic-gmp phosphodiesterase activity</specific-function>
        <gene-name>PDE6C</gene-name>
        <locus>10q23.33</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>99146.095</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8787</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1314</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P51160</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE6C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.35</synonym>
          <synonym>cGMP phosphodiesterase 6C</synonym>
          <synonym>PDEA2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013359|Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'
MGEINQVAVEKYLEENPQFAKEYFDRKLRVEVLGEIFKNSQVPVQSSMSFSELTQVEESA
LCLELLWTVQEEGGTPEQGVHRALQRLAHLLQADRCSMFLCRSRNGIPEVASRLLDVTPT
SKFEDNLVGPDKEVVFPLDIGIVGWAAHTKKTHNVPDVKKNSHFSDFMDKQTGYVTKNLL
ATPIVVGKEVLAVIMAVNKVNASEFSKQDEEVFSKYLNFVSIILRLHHTSYMYNIESRRS
QILMWSANKVFEELTDVERQFHKALYTVRSYLNCERYSIGLLDMTKEKEFYDEWPIKLGE
VEPYKGPKTPDGREVNFYKIIDYILHGKEEIKVIPTPPADHWTLISGLPTYVAENGFICN
MMNAPADEYFTFQKGPVDETGWVIKNVLSLPIVNKKEDIVGVATFYNRKDGKPFDEHDEY
ITETLTQFLGWSLLNTDTYDKMNKLENRKDIAQEMLMNQTKATPEEIKSILKFQEKLNVD
VIDDCEEKQLVAILKEDLPDPRSAELYEFRFSDFPLTEHGLIKCGIRLFFEINVVEKFKV
PVEVLTRWMYTVRKGYRAVTYHNWRHGFNVGQTMFTLLMTGRLKKYYTDLEAFAMLAAAF
CHDIDHRGTNNLYQMKSTSPLARLHGSSILERHHLEYSKTLLQDESLNIFQNLNKRQFET
VIHLFEVAIIATDLALYFKKRTMFQKIVDACEQMQTEEEAIKYVTVDPTKKEIIMAMMMT
ACDLSAITKPWEVQSQVALMVANEFWEQGDLERTVLQQQPIPMMDRNKRDELPKLQVGFI
DFVCTFVYKEFSRFHKEITPMLSGLQNNRVEWKSLADEYDAKMKVIEEEAKKQEGGAEKA
AEDSGGGDDKKSKTCLML</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013360|Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' (PDE6C)
ATGGGTGAGATCAACCAAGTTGCCGTGGAGAAATACCTGGAGGAGAACCCTCAGTTTGCC
AAGGAGTACTTTGACAGGAAGTTGCGGGTGGAGGTGCTGGGAGAAATCTTCAAGAACAGC
CAGGTGCCAGTCCAGTCCAGCATGTCCTTCTCTGAGCTGACCCAGGTGGAGGAGTCAGCC
CTGTGCTTGGAGCTGCTGTGGACCGTGCAGGAGGAGGGGGGCACCCCAGAGCAGGGGGTT
CACAGGGCCCTGCAGAGGCTGGCCCACCTGCTCCAGGCTGACCGCTGCAGCATGTTCCTG
TGCCGGTCCCGGAACGGCATACCTGAGGTGGCCTCTAGGTTGCTGGATGTCACCCCCACC
TCCAAGTTTGAGGACAACCTGGTGGGCCCTGACAAAGAAGTTGTGTTTCCATTGGACATT
GGGATAGTGGGTTGGGCTGCTCACACGAAGAAAACTCATAATGTCCCAGATGTGAAAAAG
AACAGCCATTTTTCTGACTTCATGGACAAGCAAACTGGGTATGTCACTAAGAACCTGCTG
GCAACCCCGATCGTGGTGGGCAAGGAGGTTCTTGCTGTGATCATGGCAGTTAACAAAGTA
AATGCATCTGAATTTTCCAAACAGGATGAAGAGGTCTTTTCCAAATACCTCAACTTTGTG
TCTATCATCCTAAGGCTTCATCACACCAGCTACATGTACAATATTGAATCCCGAAGAAGC
CAGATCCTTATGTGGTCAGCCAATAAAGTATTTGAAGAACTCACAGATGTTGAGCGACAG
TTTCACAAAGCGCTCTACACGGTTAGATCATATCTGAACTGTGAACGATACTCCATTGGA
CTGCTGGACATGACCAAGGAGAAGGAATTCTACGATGAATGGCCAATCAAGCTTGGAGAA
GTAGAGCCTTATAAAGGTCCAAAGACACCTGATGGCAGGGAAGTCAACTTTTATAAAATC
ATTGATTACATTTTACATGGAAAAGAAGAGATCAAAGTGATTCCGACGCCTCCTGCAGAC
CACTGGACACTCATTAGTGGGTTGCCAACATATGTTGCTGAAAATGGATTTATCTGTAAC
ATGATGAATGCCCCTGCGGATGAATACTTCACATTTCAGAAAGGACCTGTAGACGAAACT
GGTTGGGTCATTAAGAATGTTTTGTCCCTGCCTATTGTCAACAAGAAAGAAGATATTGTG
GGAGTGGCTACATTTTACAACAGGAAGGATGGAAAACCTTTCGATGAGCATGATGAATAC
ATTACCGAGACTCTCACACAATTTCTTGGATGGTCTCTTTTAAATACTGACACCTACGAT
AAGATGAATAAGCTAGAAAACAGAAAGGACATTGCTCAGGAAATGCTCATGAACCAAACC
AAAGCCACTCCTGAAGAAATTAAGTCCATTTTGAAATTTCAAGAGAAGTTAAATGTTGAT
GTAATTGACGACTGTGAAGAAAAACAACTTGTTGCAATTTTGAAAGAGGACTTGCCAGAC
CCACGCTCAGCAGAACTGTACGAATTCCGCTTCAGTGACTTCCCCCTTACAGAGCACGGA
TTGATTAAATGTGGAATACGACTGTTTTTTGAAATAAATGTGGTGGAGAAATTCAAAGTA
CCTGTAGAGGTTCTTACCAGATGGATGTACACTGTGAGGAAAGGGTACCGAGCTGTCACT
TACCACAATTGGCGGCATGGGTTCAACGTGGGGCAGACCATGTTTACTTTGCTGATGACA
GGAAGATTAAAGAAGTACTACACAGATCTCGAAGCCTTTGCCATGCTTGCTGCTGCTTTC
TGCCATGATATTGACCACAGAGGCACCAATAATTTGTACCAGATGAAATCCACGTCTCCA
TTAGCAAGACTTCATGGTTCTTCTATTTTGGAGAGGCACCACCTGGAGTACAGTAAGACT
CTGTTGCAGGATGAGAGTTTAAACATCTTCCAGAACCTAAATAAGCGGCAGTTTGAAACA
GTTATTCATTTGTTCGAGGTCGCAATAATAGCAACTGACCTGGCTTTATATTTCAAGAAG
AGGACCATGTTTCAAAAAATTGTTGATGCCTGTGAACAAATGCAAACGGAAGAAGAAGCC
ATCAAATATGTAACTGTTGATCCAACCAAGAAAGAGATTATCATGGCAATGATGATGACG
GCATGTGACTTGTCTGCTATTACCAAGCCCTGGGAGGTGCAAAGTCAGGTAGCACTTATG
GTTGCAAATGAATTTTGGGAACAAGGAGATCTGGAGAGAACAGTGTTGCAGCAACAACCC
ATTCCTATGATGGACAGAAACAAAAGAGATGAATTACCTAAACTTCAAGTTGGATTTATT
GATTTTGTTTGTACTTTTGTATATAAGGAGTTCTCACGGTTTCACAAAGAAATCACACCT
ATGCTGAGTGGTCTTCAGAATAACAGAGTAGAATGGAAATCACTAGCTGATGAGTATGAT
GCAAAGATGAAGGTCATTGAAGAGGAGGCAAAAAAGCAAGAAGGAGGAGCCGAAAAAGCT
GCTGAAGATTCAGGAGGTGGTGATGACAAAAAGTCCAAAACATGTTTAATGTTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinal cone cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9HCR9" source="Swiss-Prot">
        <name>Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP. Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively.</specific-function>
        <gene-name>PDE11A</gene-name>
        <locus>2q31.2</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.51</theoretical-pi>
        <molecular-weight>104750.64</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8773</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB036704</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>10716052</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1311</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9HCR9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE11_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.35</synonym>
          <synonym>cAMP and cGMP phosphodiesterase 11A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037245|Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
MAASRLDFGEVETFLDRHPELFEDYLMRKGKQEMVEKWLQRHSQGQGALGPRPSLAGTSS
LAHSTCRGGSSVGGGTGPNGSAHSQPLPGGGDCGGVPLSPSWAGGSRGDGNLQRRASQKE
LRKSFARSKAIHVNRTYDEQVTSRAQEPLSSVRRRALLRKASSLPPTTAHILSALLESRV
NLPRYPPTAIDYKCHLKKHNERQFFLELVKDISNDLDLTSLSYKILIFVCLMVDADRCSL
FLVEGAAAGKKTLVSKFFDVHAGTPLLPCSSTENSNEVQVPWGKGIIGYVGEHGETVNIP
DAYQDRRFNDEIDKLTGYKTKSLLCMPIRSSDGEIIGVAQAINKIPEGAPFTEDDEKVMQ
MYLPFCGIAISNAQLFAASRKEYERSRALLEVVNDLFEEQTDLEKIVKKIMHRAQTLLKC
ERCSVLLLEDIESPVVKFTKSFELMSPKCSADAENSFKESMEKSSYSDWLINNSIAELVA
STGLPVNISDAYQDPRFDAEADQISGFHIRSVLCVPIWNSNHQIIGVAQVLNRLDGKPFD
DADQRLFEAFVIFCGLGINNTIMYDQVKKSWAKQSVALDVLSYHATCSKAEVDKFKAANI
PLVSELAIDDIHFDDFSLDVDAMITAALRMFMELGMVQKFKIDYETLCRWLLTVRKNYRM
VLYHNWRHAFNVCQLMFAMLTTAGFQDILTEVEILAVIVGCLCHDLDHRGTNNAFQAKSG
SALAQLYGTSATLEHHHFNHAVMILQSEGHNIFANLSSKEYSDLMQLLKQSILATDLTLY
FERRTEFFELVSKGEYDWNIKNHRDIFRSMLMTACDLGAVTKPWEISRQVAELVTSEFFE
QGDRERLELKLTPSAIFDRNRKDELPRLQLEWIDSICMPLYQALVKVNVKLKPMLDSVAT
NRSKWEELHQKRLLASTASSSPASVMVAKEDRN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012476|Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (PDE11A)
ATGTCCCCAAAGTGCAGTGCTGATGCTGAGAACAGTTTCAAAGAAAGCATGGAGAAATCA
TCATACTCCGACTGGCTAATAAATAACAGCATTGCTGAGCTGGTTGCTTCAACAGGCCTT
CCAGTGAACATCAGTGATGCCTACCAGGATCCGCGCTTTGATGCAGAGGCAGACCAGATA
TCTGGTTTTCACATAAGATCTGTTCTTTGTGTCCCTATTTGGAATAGCAACCACCAAATA
ATTGGAGTGGCTCAAGTGTTAAACAGACTTGATGGGAAACCTTTTGATGATGCAGATCAA
CGACTTTTTGAGGCTTTTGTCATCTTTTGTGGACTTGGCATCAACAACACAATTATGTAT
GATCAAGTGAAGAAGTCCTGGGCCAAGCAGTCTGTGGCTCTTGATGTGCTATCATACCAT
GCAACATGTTCAAAAGCTGAAGTTGACAAGTTTAAGGCAGCCAACATCCCTCTGGTGTCA
GAACTTGCCATCGATGACATTCATTTTGATGACTTTTCTCTCGACGTTGATGCCATGATC
ACAGCTGCTCTCCGGATGTTCATGGAGCTGGGGATGGTACAGAAATTTAAAATTGACTAT
GAGACACTGTGTAGGTGGCTTTTGACAGTGAGGAAAAACTATCGGATGGTTCTATACCAC
AACTGGAGACATGCCTTCAACGTGTGTCAGCTGATGTTCGCGATGTTAACCACTGCTGGG
TTTCAAGACATTCTGACCGAGGTGGAAATTTTAGCGGTGATTGTGGGATGCCTGTGTCAT
GACCTCGACCACAGGGGAACCAACAATGCCTTCCAAGCTAAGAGTGGCTCTGCCCTGGCC
CAACTCTATGGAACCTCTGCTACCTTGGAGCATCACCATTTCAACCACGCCGTGATGATC
CTTCAAAGTGAGGGTCACAATATCTTTGCTAACCTGTCCTCCAAGGAATATAGTGACCTT
ATGCAGCTTTTGAAGCAGTCAATATTGGCAACAGACCTCACGCTGTACTTTGAGAGGAGA
ACTGAATTCTTTGAACTTGTCAGTAAAGGAGAATACGATTGGAACATCAAAAACCATCGT
GATATATTTCGATCAATGTTAATGACAGCCTGTGACCTTGGAGCCGTGACCAAACCGTGG
GAGATCTCCAGACAGGTGGCAGAACTTGTAACCAGTGAGTTCTTCGAACAAGGAGATCGG
GAGAGATTAGAGCTCAAACTCACTCCTTCAGCAATTTTTGATCGGAACCGGAAGGATGAA
CTGCCTCGGTTGCAACTGGAGTGGATTGATAGCATCTGCATGCCTTTGTATCAGGCACTG
GTGAAGGTCAACGTGAAACTGAAGCCGATGCTAGATTCAGTAGCTACAAACAGAAGTAAG
TGGGAAGAGCTACACCAAAAACGACTGCTGGCCTCAACTGCCTCATCCTCCCCTGCCAGT
GTTATGGTAGCCAAGGAAGACAGGAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP-stimulated cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q13946" source="Swiss-Prot">
        <name>High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May have a role in muscle signal transduction.</specific-function>
        <gene-name>PDE7A</gene-name>
        <locus>8q13</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.53</theoretical-pi>
        <molecular-weight>55504.475</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8791</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE7A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L12052</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5566609</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1305</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13946</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE7A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>HCP1</synonym>
          <synonym>TM22</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001408|High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A
MEVCYQLPVLPLDRPVPQHVLSRRGAISFSSSSALFGCPNPRQLSQRRGAISYDSSDQTA
LYIRMLGDVRVRSRAGFESERRGSHPYIDFRIFHSQSEIEVSVSARNIRRLLSFQRYLRS
SRFFRGTAVSNSLNILDDDYNGQAKCMLEKVGNWNFDIFLFDRLTNGNSLVSLTFHLFSL
HGLIEYFHLDMMKLRRFLVMIQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLANSVTPW
DILLSLIAAATHDLDHPGVNQPFLIKTNHYLATLYKNTSVLENHHWRSAVGLLRESGLFS
HLPLESRQQMETQIGALILATDISRQNEYLSLFRSHLDRGDLCLEDTRHRHLVLQMALKC
ADICNPCRTWELSKQWSEKVTEEFFHQGDIEKKYHLGVSPLCDRHTESIANIQIGFMTYL
VEPLFTEWARFSNTRLSQTMLGHVGLNKASWKGLQREQSSSEDTDAAFELNSQLLPQENR
LS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010496|High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A (PDE7A)
ATGGAAGTGTGTTACCAGCTGCCGGTACTGCCCCTGGACAGGCCGGTCCCCCAGCACGTC
CTCAGCCGCCGAGGAGCCATCAGCTTCAGCTCCAGCTCCGCTCTCTTCGGCTGCCCCAAT
CCCCGGCAGCTCTCTCAGAGGCGTGGAGCTATTTCCTATGACAGTTCTGATCAGACTGCA
TTATACATTCGTATGCTAGGAGATGTACGTGTAAGGAGCCGAGCAGGATTTGAATCAGAA
AGAAGAGGTTCTCACCCATATATTGATTTTCGTATTTTCCACTCTCAATCTGAAATTGAA
GTGTCTGTCTCTGCAAGGAATATCAGAAGGCTACTAAGTTTCCAGCGATATCTTAGATCT
TCACGCTTTTTTCGTGGTACTGCGGTTTCAAATTCCCTAAACATTTTAGATGATGATTAT
AATGGACAAGCCAAGTGTATGCTGGAAAAAGTTGGAAATTGGAATTTTGATATCTTTCTA
TTTGATAGACTAACAAATGGAAATAGTCTAGTAAGCTTAACCTTTCATTTATTTAGTCTT
CATGGATTAATTGAGTACTTCCATTTAGATATGATGAAACTTCGTAGATTTTTAGTTATG
ATTCAAGAAGATTACCACAGTCAAAATCCTTACCATAACGCAGTCCACGCTGCGGATGTT
ACTCAGGCCATGCACTGTTACTTAAAGGAACCTAAGCTTGCCAATTCTGTAACTCCTTGG
GATATCTTGCTGAGCTTAATTGCAGCTGCCACTCATGATCTGGATCATCCAGGTGTTAAT
CAACCTTTCCTTATTAAAACTAACCATTACTTGGCAACTTTATACAAGAATACCTCAGTA
CTGGAAAATCACCACTGGAGATCTGCAGTGGGCTTATTGAGAGAATCAGGCTTATTCTCA
CATCTGCCATTAGAAAGCAGGCAACAAATGGAGACACAGATAGGTGCTCTGATACTAGCC
ACAGACATCAGTCGCCAGAATGAGTATCTGTCTTTGTTTAGGTCCCATTTGGATAGAGGT
GATTTATGCCTAGAAGACACCAGACACAGACATTTGGTTTTACAGATGGCTTTGAAATGT
GCTGATATTTGTAACCCATGTCGGACGTGGGAATTAAGCAAGCAGTGGAGTGAAAAAGTA
ACGGAGGAATTCTTCCATCAAGGAGATATAGAAAAAAAATATCATTTGGGTGTGAGTCCA
CTTTGCGATCGTCACACTGAATCTATTGCCAACATCCAGATTGGTTTTATGACTTACCTA
GTGGAGCCTTTATTTACAGAATGGGCCAGGTTTTCCAATACAAGGCTATCCCAGACAATG
CTTGGACACGTGGGGCTGAATAAAGCCAGCTGGAAGGGACTGCAGAGAGAACAGTCGAGC
AGTGAGGACACTGATGCTGCATTTGAGTTGAACTCACAGTTATTACCTCAGGAAAATCGG
TTATCATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP-mediated signaling</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O60658" source="Swiss-Prot">
        <name>High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in maintaining basal levels of the cyclic nucleotide and/or in the cAMP regulation of germ cell development.</specific-function>
        <gene-name>PDE8A</gene-name>
        <locus>15q25.3</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.03</theoretical-pi>
        <molecular-weight>93303.05</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8793</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF388183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>16417190</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1307</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60658</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE8A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007139|High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A
MGCAPSIHISERLVAEDAPSPAAPPLSSGGPRLPQGQKTAALPRTRGAGLLESELRDGSG
KKVAVADVQFGPMRFHQDQLQVLLVFTKEDNQCNGFCRACEKAGFKCTVTKEAQAVLACF
LDKHHDIIIIDHRNPRQLDAEALCRSIRSSKLSENTVIVGVVRRVDREELSVMPFISAGF
TRRYVENPNIMACYNELLQLEFGEVRSQLKLRACNSVFTALENSEDAIEITSEDRFIQYA
NPAFETTMGYQSGELIGKELGEVPINEKKADLLDTINSCIRIGKEWQGIYYAKKKNGDNI
QQNVKIIPVIGQGGKIRHYVSIIRVCNGNNKAEKISECVQSDTHTDNQTGKHKDRRKGSL
DVKAVASRATEVSSQRRHSSMARIHSMTIEAPITKVINIINAAQESSPMPVTEALDRVLE
ILRTTELYSPQFGAKDDDPHANDLVGGLMSDGLRRLSGNEYVLSTKNTQMVSSNIITPIS
LDDVPPRIARAMENEEYWDFDIFELEAATHNRPLIYLGLKMFARFGICEFLHCSESTLRS
WLQIIEANYHSSNPYHNSTHSADVLHATAYFLSKERIKETLDPIDEVAALIAATIHDVDH
PGRTNSFLCNAGSELAILYNDTAVLESHHAALAFQLTTGDDKCNIFKNMERNDYRTLRQG
IIDMVLATEMTKHFEHVNKFVNSINKPLATLEENGETDKNQEVINTMLRTPENRTLIKRM
LIKCADVSNPCRPLQYCIEWAARISEEYFSQTDEEKQQGLPVVMPVFDRNTCSIPKSQIS
FIDYFITDMFDAWDAFVDLPDLMQHLDNNFKYWKGLDEMKLRNLRPPPE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020711|High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A)
ATGAGATTTCATCAAGATCAACTTCAGGTACTTTTAGTGTTTACCAAAGAAGATAACCAA
TGTAATGGATTCTGCAGGGCATGTGAAAAAGCAGGGTTTAAGTGTACAGTTACCAAGGAG
GCTCAGGCTGTCCTTGCCTGTTTCCTGGACAAACATCATGACATTATCATCATAGACCAC
AGAAATCCTCGACAGCTGGATGCAGAGGCACTGTGCAGGTCTATCAGATCATCAAAACTC
TCAGAAAACACAGTTATTGTTGGTGTAGTACGCAGGGTGGATAGAGAAGAGTTGTCCGTA
ATGCCTTTCATTTCTGCTGGATTTACAAGGAGGTATGTAGAAAACCCCAACATCATGGCC
TGCTACAATGAACTGCTCCAGCTGGAGTTTGGAGAGGTGCGATCACAACTGAAACTCAGG
GCTTGTAACTCAGTATTCACTGCATTAGAAAACAGTGAAGATGCAATTGAAATTACAAGC
GAAGACCGTTTTATACAGTATGCAAATCCTGCATTTGAAACAACAATGGGCTATCAGTCA
GGTGAATTAATAGGGAAGGAGTTAGGAGAAGTGCCTATAAATGAAAAAAAGGCTGACTTG
CTCGATACTATAAATTCATGCATCAGGATAGGCAAGGAGTGGCAAGGAATTTACTATGCC
AAAAAGAAAAACGGAGATAATATACAACAAAATGTGAAGATAATACCTGTCATTGGACAG
GGAGGAAAAATTAGACACTATGTGTCCATTATCAGAGTGTGCAATGGCAACAATAAGGCT
GAGAAAATATCCGAATGTGTTCAGTCTGACACTCATACAGATAATCAGACAGGCAAACAT
AAAGACAGGAGAAAAGGCTCACTAGACGTCAAAGCTGTTGCCTCCCGTGCAACTGAAGTT
TCCAGCCAGAGACGACACTCTTCCATGGCCCGGATACATTCCATGACAATTGAGGCGCCC
ATCACCAAGGTAATCAATATTATCAATGCTGCCCAGGAAAGTAGTCCCATGCCTGTGACA
GAAGCCCTAGACCGTGTGCTGGAAATTCTAAGAACCACTGAGTTATATTCACCACAGTTT
GGTGCTAAAGATGATGATCCCCATGCCAATGACCTTGTTGGGGGCTTAATGTCTGATGGT
TTGCGAAGACTATCAGGGAATGAATATGTTCTTTCAACAAAAAACACTCAAATGGTTTCA
AGCAATATAATCACTCCCATCTCCCTTGATGATGTCCCACCACGGATAGCTCGGGCCATG
GAAAATGAGGAATACTGGGACTTTGATATTTTTGAACTGGAGGCTGCCACCCACAATAGG
CCTTTGATTTATCTTGGTCTCAAAATGTTTGCTCGCTTTGGAATCTGTGAATTCTTACAC
TGCTCCGAGTCAACGCTAAGATCATGGTTACAAATTATCGAAGCCAATTATCATTCCTCC
AATCCCTACCACAATTCTACACATTCTGCTGATGTGCTTCATGCCACTGCCTATTTTCTC
TCCAAGGAGAGGATAAAGGAAACTTTAGATCCAATTGATGAGGTCGCTGCACTCATCGCA
GCCACCATTCATGATGTGGATCACCCTGGGAGAACCAACTCCTTCCTGTGTAATGCTGGA
AGTGAGCTGGCCATTTTGTACAATGACACTGCTGTGCTGGAGAGCCACCATGCGGCCTTG
GCCTTCCAGCTGACCACTGGAGATGATAAATGCAATATATTTAAAAACATGGAGAGGAAT
GATTATCGGACACTGCGCCAGGGGATTATCGACATGGTCTTAGCCACAGAAATGACAAAG
CACTTTGAGCATGTCAACAAATTTGTCAACAGCATCAACAAACCCTTGGCAACACTAGAA
GAAAATGGGGAAACTGATAAAAACCAGGAAGTGATAAACACTATGCTTAGGACTCCAGAG
AACCGGACCCTAATCAAACGAATGCTGATTAAATGTGCTGATGTGTCCAATCCCTGCCGA
CCCCTGCAGTACTGCATCGAGTGGGCTGCACGCATTTCGGAAGAATATTTTTCTCAGACT
GATGAAGAGAAGCAGCAGGGCTTACCTGTGGTGATGCCAGTGTTTGACAGAAATACCTGC
AGCATCCCCAAATCCCAAATCTCTTTCATTGATTACTTCATCACAGACATGTTTGATGCT
TGGGATGCCTTTGTAGACCTGCCTGATTTAATGCAGCATCTTGACAACAACTTTAAATAC
TGGAAAGGACTGGACGAAATGAAGCTGCGGAACCTCCGACCACCTCCTGAATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00989</identifier>
            <name>PAS</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cyclic nucleotide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O95263" source="Swiss-Prot">
        <name>High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B</name>
        <general-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in specific signaling in the thyroid gland.</general-function>
        <specific-function>3',5'-cyclic-amp phosphodiesterase activity</specific-function>
        <gene-name>PDE8B</gene-name>
        <locus>5q13.3</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.81</theoretical-pi>
        <molecular-weight>98977.9</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8794</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AY129948</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>32261241</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1308</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95263</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE8B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>Cell proliferation-inducing gene 22 protein</synonym>
          <synonym>HsPDE8B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007141|High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B
MGCAPSIHVSQSGVIYCRDSDESSSPRQTTSVSQGPAAPLPGLFVQTDAADAIPPSRASG
PPSVARVRRARTELGSGSSAGSAAPAATTSRGRRRHCCSSAEAETQTCYTSVKQVSSAEV
RIGPMRLTQDPIQVLLIFAKEDSQSDGFWWACDRAGYRCNIARTPESALECFLDKHHEII
VIDHRQTQNFDAEAVCRSIRATNPSEHTVILAVVSRVSDDHEEASVLPLLHAGFNRRFME
NSSIIACYNELIQIEHGEVRSQFKLRACNSVFTALDHCHEAIEITSDDHVIQYVNPAFER
MMGYHKGELLGKELADLPKSDKNRADLLDTINTCIKKGKEWQGVYYARRKSGDSIQQHVK
ITPVIGQGGKIRHFVSLKKLCCTTDNNKQIHKIHRDSGDNSQTEPHSFRYKNRRKESIDV
KSISSRGSDAPSLQNRRYPSMARIHSMTIEAPITKVINIINAAQENSPVTVAEALDRVLE
ILRTTELYSPQLGTKDEDPHTSDLVGGLMTDGLRRLSGNEYVFTKNVHQSHSHLAMPITI
NDVPPCISQLLDNEESWDFNIFELEAITHKRPLVYLGLKVFSRFGVCEFLNCSETTLRAW
FQVIEANYHSSNAYHNSTHAADVLHATAFFLGKERVKGSLDQLDEVAALIAATVHDVDHP
GRTNSFLCNAGSELAVLYNDTAVLESHHTALAFQLTVKDTKCNIFKNIDRNHYRTLRQAI
IDMVLATEMTKHFEHVNKFVNSINKPMAAEIEGSDCECNPAGKNFPENQILIKRMMIKCA
DVANPCRPLDLCIEWAGRISEEYFAQTDEEKRQGLPVVMPVFDRNTCSIPKSQISFIDYF
ITDMFDAWDAFAHLPALMQHLADNYKHWKTLDDLKCKSLRLPSDS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051552|High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B (PDE8B)
ATGGGCTGCGCCCCCAGCATCCATGTCTCGCAGAGCGGCGTGATCTACTGCCGGGACTCG
GACGAGTCCAGCTCGCCCCGCCAGACCACCAGCGTGTCGCAGGGCCCGGCGGCACCCCTG
CCCGGCCTCTTCGTCCAGACCGACGCCGCCGACGCCATCCCCCCGAGCCGCGCGTCGGGA
CCCCCCAGCGTAGCCCGCGTCCGCAGGGCCCGCACCGAGCTGGGCAGCGGTAGCAGCGCG
GGTTCCGCAGCCCCCGCCGCGACCACCAGCAGGGGCCGGAGGCGCCACTGCTGCAGCAGC
GCCGAGGCCGAGACTCAGACCTGCTACACCAGCGTGAAGCAGGTGTCTTCTGCGGAGGTG
CGCATCGGGCCCATGAGACTGACGCAGGACCCTATTCAGGTTTTGCTGATCTTTGCAAAG
GAAGATAGTCAGAGCGATGGCTTCTGGTGGGCCTGCGACAGAGCTGGTTATAGATGCAAT
ATTGCTCGGACTCCAGAGTCAGCCCTTGAATGCTTTCTTGATAAGCATCATGAAATTATT
GTAATTGATCATAGACAAACTCAGAACTTCGATGCAGAAGCAGTGTGCAGGTCGATCCGG
GCCACAAATCCCTCCGAGCACACGGTGATCCTCGCAGTGGTTTCGCGAGTATCGGATGAC
CATGAAGAGGCGTCAGTCCTTCCTCTTCTCCACGCAGGCTTCAACAGGAGATTTATGGAG
AATAGCAGCATAATTGCTTGCTATAATGAACTGATTCAAATAGAACATGGGGAAGTTCGC
TCCCAGTTCAAATTACGGGCCTGTAATTCAGTGTTTACAGCATTAGATCACTGTCATGAA
GCCATAGAAATAACAAGCGATGACCACGTGATTCAGTATGTCAACCCAGCCTTCGAAAGG
ATGATGGGCTACCACAAAGGTGAGCTCCTGGGAAAAGAACTCGCTGATCTGCCCAAAAGC
GATAAGAACCGGGCAGACCTTCTCGACACCATCAATACATGCATCAAGAAGGGAAAGGAG
TGGCAGGGGGTTTACTATGCCAGACGGAAATCCGGGGACAGCATCCAACAGCACGTGAAG
ATCACCCCAGTGATTGGCCAAGGAGGGAAAATTAGGCATTTTGTCTCGCTCAAGAAACTG
TGTTGTACCACTGACAATAATAAGCAGATTCACAAGATTCATCGTGATTCAGGAGACAAT
TCTCAGACAGAGCCTCATTCATTCAGATATAAGAACAGGAGGAAAGAGTCCATTGACGTG
AAATCGATATCATCTCGAGGCAGTGATGCACCAAGCCTGCAGAATCGTCGCTATCCGTCC
ATGGCGAGGATCCACTCCATGACCATCGAGGCTCCCATCACAAAGGTTATAAATATAATC
AATGCAGCCCAAGAAAACAGCCCAGTCACAGTAGCGGAAGCCTTGGACAGAGTTCTAGAG
ATTTTACGGACCACAGAACTGTACTCCCCTCAGCTGGGTACCAAAGATGAAGATCCCCAC
ACCAGTGATCTTGTTGGAGGCCTGATGACTGACGGCTTGAGAAGACTGTCAGGAAACGAG
TATGTGTTTACTAAGAATGTGCACCAGAGTCACAGTCACCTTGCAATGCCAATAACCATC
AATGATGTTCCCCCTTGTATCTCTCAATTACTTGATAATGAGGAGAGTTGGGACTTCAAC
ATCTTTGAATTGGAAGCCATTACGCATAAAAGGCCATTGGTTTATCTGGGCTTAAAGGTC
TTCTCTCGGTTTGGAGTATGTGAATTTTTAAACTGTTCTGAAACCACTCTTCGGGCCTGG
TTCCAAGTGATCGAAGCCAACTACCACTCTTCCAATGCCTACCACAACTCCACCCATGCT
GCCGACGTCCTGCACGCCACCGCTTTCTTTCTTGGAAAGGAAAGAGTAAAGGGAAGCCTC
GATCAGTTGGATGAGGTGGCAGCCCTCATTGCTGCCACAGTCCATGACGTGGATCACCCG
GGAAGGACCAACTCTTTCCTCTGCAATGCAGGCAGTGAGCTTGCTGTGCTCTACAATGAC
ACTGCTGTTCTGGAGAGTCACCACACCGCCCTGGCCTTCCAGCTCACGGTCAAGGACACC
AAATGCAACATTTTCAAGAATATTGACAGGAACCATTATCGAACGCTGCGCCAGGCTATT
ATTGACATGGTTTTGGCAACAGAGATGACAAAACACTTTGAACATGTGAATAAGTTTGTG
AACAGCATCAACAAGCCAATGGCAGCTGAGATTGAAGGCAGCGACTGTGAATGCAACCCT
GCTGGGAAGAACTTCCCTGAAAACCAAATCCTGATCAAACGCATGATGATTAAGTGTGCT
GACGTGGCCAACCCATGCCGCCCCTTGGACCTGTGCATTGAATGGGCTGGGAGGATCTCT
GAGGAGTATTTTGCACAGACTGATGAAGAGAAGAGACAGGGACTACCTGTGGTGATGCCA
GTGTTTGACCGGAATACCTGTAGCATCCCCAAGTCTCAGATCTCTTTCATTGACTACTTC
ATAACAGACATGTTTGATGCTTGGGATGCCTTTGCACATCTGCCAGCCCTGATGCAACAT
TTGGCTGACAACTACAAACACTGGAAGACACTAGATGACCTAAAGTGCAAAAGTTTGAGG
CTTCCATCTGACAGCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
          <pfam>
            <identifier>PF08629</identifier>
            <name>PDE8</name>
          </pfam>
          <pfam>
            <identifier>PF13426</identifier>
            <name>PAS_9</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cyclic nucleotide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O76083" source="Swiss-Prot">
        <name>High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP (PubMed:9624146, PubMed:18757755, PubMed:21483814). Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. Does not regulate nitric oxide-dependent cGMP in heart (PubMed:25799991). Additional experiments are required to confirm whether its ability to hydrolyze natriuretic-peptide-dependent cGMP is specific to heart or is a general feature of the protein (Probable). In brain, involved in cognitive function, such as learning and long-term memory (By similarity).</specific-function>
        <gene-name>PDE9A</gene-name>
        <locus/>
        <cellular-location>Cell projection</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.1</theoretical-pi>
        <molecular-weight>68491.95</molecular-weight>
        <chromosome-location>21</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8795</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE9A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF048837</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1309</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O76083</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE9A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.35</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006116|High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDDAM
VSIDPTMPANSERTPYKVRPVAIKQLSAGVEDKRTTSRGQSAERPLRDRRVVGLEQPRRE
GAFESGQVEPRPREPQGCYQEGQRIPPEREELIQSVLAQVAEQFSRAFKINELKAEVANH
LAVLEKRVELEGLKVVEIEKCKSDIKKMREELAARSSRTNCPCKYSFLDNHKKLTPRRDV
PTYPKYLLSPETIEALRKPTFDVWLWEPNEMLSCLEHMYHDLGLVRDFSINPVTLRRWLF
CVHDNYRNNPFHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTAAICHDLDHPGYN
NTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPPDGFKQIRQGMITLI
LATDMARHAEIMDSFKEKMENFDYSNEEHMTLLKMILIKCCDISNEVRPMEVAEPWVDCL
LEEYFMQSDREKSEGLPVAPFMDRDKVTKATAQIGFIKFVLIPMFETVTKLFPMVEEIML
QPLWESRDRYEELKRIDDAMKELQKKTDSLTSGATEKSRERSRDVKNSEGDCA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021351|High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A)
ATGGGATCCGGCTCCTCCAGCTACCGGCCCAAGGCCATCTACCTGGACATCGATGGACGC
ATTCAGAAGGTAATCTTCAGCAAGTACTGCAACTCCAGCGACATCATGGACCTGTTCTGC
ATCGCCACCGGCCTGCCTCGGAACACGACCATCTCCCTGCTGACCACCGACGACGCCATG
GTCTCCATCGACCCCACCATGCCCGCGAATTCAGAACGCACTCCGTACAAAGTGAGACCT
GTGGCCATCAAGCAACTCTCCGAGAGAGAAGAATTAATCCAGAGCGTGCTGGCGCAGGTT
GCAGAGCAGTTCTCAAGAGCATTCAAAATCAATGAACTGAAAGCTGAAGTTGCAAATCAC
TTGGCTGTCCTAGAGAAACGCGTGGAATTGGAAGGACTAAAAGTGGTGGAGATTGAGAAA
TGCAAGAGTGACATTAAGAAGATGAGGGAGGAGCTGGCGGCCAGAAGCAGCAGGACCAAC
TGCCCCTGTAAGTACAGTTTTTTGGATAACCACAAGAAGTTGACTCCTCGACGCGATGTT
CCCACTTACCCCAAGTACCTGCTCTCTCCAGAGACCATCGAGGCCCTGCGGAAGCCGACC
TTTGACGTCTGGCTTTGGGAGCCCAATGAGATGCTGAGCTGCCTGGAGCACATGTACCAC
GACCTCGGGCTGGTCAGGGACTTCAGCATCAACCCTGTCACCCTCAGGAGGTGGCTGTTC
TGCGTCCACGACAACTACAGAAACAACCCCTTCCACAACTTCCGGCACTGCTTCTGCGTG
GCCCAGATGATGTACAGCATGGTCTGGCTCTGCAGTCTCCAGGAGAAGTTCTCACAAACG
GATATCCTGATCCTAATGACAGCGGCCATCTGCCACGATCTGGACCATCCCGGCTACAAC
AACACGTACCAGATCAATGCCCGCACAGAGCTGGCGGTCCGCTACAATGACATCTCACCG
CTGGAGAACCACCACTGCGCCGTGGCCTTCCAGATCCTCGCCGAGCCTGAGTGCAACATC
TTCTCCAACATCCCACCTGATGGGTTCAAGCAGATCCGACAGGGAATGATCACATTAATC
TTGGCCACTGACATGGCAAGACATGCAGAAATTATGGATTCTTTCAAAGAGAAAATGGAG
AATTTTGACTACAGCAACGAGGAGCACATGACCCTGCTGAAGATGATTTTGATAAAATGC
TGTGATATCTCTAACGAGGTCCGTCCAATGGAAGTCGCAGAGCCTTGGGTGGACTGTTTA
TTAGAGGAATATTTTATGCAGAGCGACCGTGAGAAGTCAGAAGGCCTTCCTGTGGCACCG
TTCATGGACCGAGACAAAGTGACCAAGGCCACAGCCCAGATTGGGTTCATCAAGTTTGTC
CTGATCCCAATGTTTGAAACAGTGACCAAGCTCTTCCCCATGGTTGAGGAGATCATGCTG
CAGCCACTTTGGGAATCCCGAGATCGCTACGAGGAGCTGAAGCGGATAGATGACGCCATG
AAAGAGTTACAGAAGAAGACTGACAGCTTGACGTCTGGGGCCACCGAGAAGTCCAGAGAG
AGAAGCAGAGATGTGAAAAACAGTGAAGGAGACTGTGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ruffle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cardiac muscle hypertrophy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P16499" source="Swiss-Prot">
        <name>Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha</name>
        <general-function>This protein participates in processes of transmission and amplification of the visual signal.</general-function>
        <specific-function>3',5'-cyclic-gmp phosphodiesterase activity</specific-function>
        <gene-name>PDE6A</gene-name>
        <locus>5q32</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>99546.595</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8785</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1312</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE6A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.35</synonym>
          <synonym>GMP-PDE alpha</synonym>
          <synonym>PDE V-B1</synonym>
          <synonym>PDEA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013357|Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha
MGEVTAEEVEKFLDSNIGFAKQYYNLHYRAKLISDLLGAKEAAVDFSNYHSPSSMEESEI
IFDLLRDFQENLQTEKCIFNVMKKLCFLLQADRMSLFMYRTRNGIAELATRLFNVHKDAV
LEDCLVMPDQEIVFPLDMGIVGHVAHSKKIANVPNTEEDEHFCDFVDILTEYKTKNILAS
PIMNGKDVVAIIMAVNKVDGSHFTKRDEEILLKYLNFANLIMKVYHLSYLHNCETRRGQI
LLWSGSKVFEELTDIERQFHKALYTVRAFLNCDRYSVGLLDMTKQKEFFDVWPVLMGEVP
PYSGPRTPDGREINFYKVIDYILHGKEDIKVIPNPPPDHWALVSGLPAYVAQNGLICNIM
NAPAEDFFAFQKEPLDESGWMIKNVLSMPIVNKKEEIVGVATFYNRKDGKPFDEMDETLM
ESLTQFLGWSVLNPDTYESMNKLENRKDIFQDIVKYHVKCDNEEIQKILKTREVYGKEPW
ECEEEELAEILQAELPDADKYEINKFHFSDLPLTELELVKCGIQMYYELKVVDKFHIPQE
ALVRFMYSLSKGYRKITYHNWRHGFNVGQTMFSLLVTGKLKRYFTDLEALAMVTAAFCHD
IDHRGTNNLYQMKSQNPLAKLHGSSILERHHLEFGKTLLRDESLNIFQNLNRRQHEHAIH
MMDIAIIATDLALYFKKRTMFQKIVDQSKTYESEQEWTQYMMLEQTRKEIVMAMMMTACD
LSAITKPWEVQSQVALLVAAEFWEQGDLERTVLQQNPIPMMDRNKADELPKLQVGFIDFV
CTFVYKEFSRFHEEITPMLDGITNNRKEWKALADEYDAKMKVQEEKKQKQQSAKSAAAGN
QPGGNPSPGGATTSKSCCIQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013358|Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha (PDE6A)
ATGGGCGAGGTGACAGCAGAGGAGGTGGAGAAGTTCCTGGACTCGAATATTGGCTTTGCC
AAACAGTACTACAACCTCCACTACCGGGCCAAGCTCATCTCCGACCTCCTTGGGGCCAAG
GAGGCTGCCGTGGACTTCAGCAACTACCACTCCCCGAGCAGCATGGAGGAGAGCGAAATC
ATCTTTGATCTCCTGCGGGACTTTCAGGAGAATTTACAGACAGAGAAATGCATCTTCAAT
GTCATGAAGAAGCTGTGCTTCCTCCTGCAGGCAGACCGCATGAGCCTGTTCATGTACCGG
ACCCGCAATGGCATCGCAGAGCTGGCCACCAGGCTTTTCAATGTCCACAAGGATGCTGTC
CTCGAGGACTGCCTGGTGATGCCCGACCAAGAGATCGTCTTCCCTTTGGACATGGGCATC
GTGGGCCATGTCGCACACTCTAAGAAGATTGCTAACGTCCCCAACACAGAGGAGGATGAG
CATTTCTGTGACTTTGTGGACATCCTCACAGAGTACAAGACCAAGAACATCTTGGCTTCC
CCCATAATGAATGGGAAGGATGTGGTGGCCATAATCATGGCTGTGAATAAAGTGGATGGA
TCCCACTTCACCAAGAGAGATGAAGAGATTCTTCTCAAGTACCTCAATTTTGCAAATCTA
ATCATGAAGGTGTACCACCTGAGTTACCTGCACAACTGTGAAACTCGACGTGGCCAGATA
CTGCTGTGGTCTGGGAGCAAAGTCTTTGAAGAACTTACGGACATCGAACGACAGTTCCAC
AAAGCCCTGTACACAGTCCGTGCTTTCCTCAACTGTGACAGATACTCTGTGGGTCTCTTA
GACATGACCAAGCAGAAGGAATTTTTTGATGTGTGGCCGGTTCTGATGGGTGAAGTTCCA
CCTTACTCTGGTCCCAGGACTCCGGATGGAAGAGAAATTAACTTTTACAAGGTCATTGAC
TACATCCTGCATGGCAAAGAGGACATCAAAGTCATCCCGAATCCACCTCCTGACCATTGG
GCTTTAGTAAGCGGTCTCCCAGCTTATGTTGCCCAGAATGGCCTGATTTGCAACATCATG
AATGCGCCTGCGGAGGACTTTTTTGCATTTCAGAAAGAACCTCTGGATGAGTCTGGATGG
ATGATTAAAAATGTGCTTTCAATGCCGATTGTGAACAAGAAGGAAGAAATTGTTGGAGTG
GCCACATTTTACAATCGTAAAGATGGGAAGCCCTTTGATGAAATGGATGAGACGCTCATG
GAGTCTTTGACTCAATTTCTGGGCTGGTCTGTCTTAAATCCTGACACCTATGAGTCAATG
AATAAACTTGAAAATAGGAAGGATATTTTCCAGGACATAGTAAAATATCATGTGAAGTGT
GACAATGAAGAAATTCAGAAAATCTTGAAAACCAGAGAGGTGTATGGGAAGGAGCCATGG
GAGTGTGAGGAAGAGGAGCTGGCTGAGATCCTGCAAGCGGAGCTGCCAGATGCAGATAAA
TACGAAATTAATAAATTTCACTTCAGTGACTTACCCCTAACAGAACTGGAGCTGGTAAAA
TGTGGAATACAGATGTATTATGAGCTCAAAGTGGTGGATAAATTTCACATTCCACAAGAG
GCCCTGGTGCGGTTCATGTACTCCCTGAGTAAGGGCTACCGCAAGATCACCTACCACAAC
TGGCGGCACGGCTTCAACGTGGGGCAGACCATGTTCTCCCTGCTGGTGACGGGAAAGCTG
AAGCGCTACTTCACGGACCTAGAGGCCTTGGCCATGGTCACTGCTGCTTTCTGCCATGAC
ATTGACCACAGAGGCACCAATAACCTCTACCAGATGAAATCCCAGAACCCACTGGCCAAG
CTCCATGGGTCCTCTATCTTGGAAAGACACCACTTGGAGTTTGGCAAAACACTGCTCAGA
GACGAGAGCCTGAATATCTTTCAAAACCTCAATCGTCGACAGCATGAGCATGCCATCCAC
ATGATGGACATTGCAATCATTGCCACAGACCTCGCCCTGTATTTCAAGAAGAGGACGATG
TTCCAAAAGATCGTGGATCAGTCTAAGACATATGAGAGTGAACAGGAGTGGACACAGTAC
ATGATGCTGGAGCAGACACGGAAGGAAATCGTTATGGCCATGATGATGACCGCCTGTGAT
CTCTCAGCCATCACCAAACCCTGGGAGGTGCAGAGCCAGGTAGCTCTGCTGGTGGCTGCT
GAATTCTGGGAACAAGGTGACCTGGAGCGCACGGTGCTGCAACAGAATCCCATTCCCATG
ATGGACAGAAACAAAGCAGATGAACTCCCTAAGCTTCAAGTCGGCTTCATTGACTTTGTT
TGCACCTTCGTCTACAAGGAATTCTCCCGTTTCCACGAGGAGATCACCCCAATGTTGGAC
GGGATCACCAACAATCGCAAGGAGTGGAAGGCGCTTGCTGATGAGTACGATGCCAAGATG
AAGGTGCAGGAGGAGAAGAAGCAGAAACAGCAGTCGGCCAAGTCAGCAGCCGCAGGAAAT
CAGCCGGGGGGAAACCCCAGCCCAGGGGGTGCAACTACATCCAAGTCCTGCTGCATCCAG
TAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>photoreceptor disc membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>GMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of rhodopsin mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhodopsin mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Wnt signaling pathway, calcium modulating pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P35913" source="Swiss-Prot">
        <name>Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta</name>
        <general-function>This protein participates in processes of transmission and amplification of the visual signal. Necessary for the formation of a functional phosphodiesterase holoenzyme.</general-function>
        <specific-function>3',5'-cyclic-gmp phosphodiesterase activity</specific-function>
        <gene-name>PDE6B</gene-name>
        <locus>4p16.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>98334.935</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8786</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35913</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE6B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.35</synonym>
          <synonym>GMP-PDE beta</synonym>
          <synonym>PDEB</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008694|Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta
MSLSEEQARSFLDQNPDFARQYFGKKLSPENVAAACEDGCPPDCDSLRDLCQVEESTALL
ELVQDMQESINMERVVFKVLRRLCTLLQADRCSLFMYRQRNGVAELATRLFSVQPDSVLE
DCLVPPDSEIVFPLDIGVVGHVAQTKKMVNVEDVAECPHFSSFADELTDYKTKNMLATPI
MNGKDVVAVIMAVNKLNGPFFTSEDEDVFLKYLNFATLYLKIYHLSYLHNCETRRGQVLL
WSANKVFEELTDIERQFHKAFYTVRAYLNCERYSVGLLDMTKEKEFFDVWSVLMGESQPY
SGPRTPDGREIVFYKVIDYVLHGKEEIKVIPTPSADHWALASGLPSYVAESGFICNIMNA
SADEMFKFQEGALDDSGWLIKNVLSMPIVNKKEEIVGVATFYNRKDGKPFDEQDEVLMES
LTQFLGWSVMNTDTYDKMNKLENRKDIAQDMVLYHVKCDRDEIQLILPTRARLGKEPADC
DEDELGEILKEELPGPTTFDIYEFHFSDLECTELDLVKCGIQMYYELGVVRKFQIPQEVL
VRFLFSISKGYRRITYHNWRHGFNVAQTMFTLLMTGKLKSYYTDLEAFAMVTAGLCHDID
HRGTNNLYQMKSQNPLAKLHGSSILERHHLEFGKFLLSEETLNIYQNLNRRQHEHVIHLM
DIAIIATDLALYFKKRAMFQKIVDESKNYQDKKSWVEYLSLETTRKEIVMAMMMTACDLS
AITKPWEVQSKVALLVAAEFWEQGDLERTVLDQQPIPMMDRNKAAELPKLQVGFIDFVCT
FVYKEFSRFHEEILPMFDRLQNNRKEWKALADEYEAKVKALEEKEEEERVAAKKVGTEIC
NGGPAPKSSTCCIL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019645|Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta (PDE6B)
ATGAGCCTCAGTGAGGAGCAGGCCCGGAGCTTTCTGGACCAGAACCCCGATTTTGCCCGC
CAGTACTTTGGGAAGAAACTGAGCCCTGAGAATGTGGCCGCGGCCTGCGAGGACGGGTGC
CCGCCGGACTGCGACAGCCTCCGGGACCTCTGCCAGGTGGAGGAGAGCACGGCGCTGCTG
GAGCTGGTGCAGGATATGCAGGAGAGCATCAACATGGAGCGCGTGGTCTTCAAGGTCCTG
CGGCGCCTCTGCACCCTCCTGCAGGCCGACCGCTGCAGCCTCTTCATGTACCGCCAGCGC
AACGGCGTGGCCGAGCTGGCCACCAGGCTTTTCAGCGTGCAGCCGGACAGCGTCCTGGAG
GACTGCCTGGTGCCCCCCGACTCCGAGATCGTCTTCCCACTGGACATCGGGGTCGTGGGC
CACGTGGCTCAGACCAAAAAGATGGTGAACGTCGAGGACGTGGCCGAGTGCCCTCACTTC
AGCTCATTTGCTGACGAGCTCACTGACTACAAGACAAAGAATATGCTGGCCACACCCATC
ATGAATGGCAAAGACGTCGTGGCGGTGATCATGGCAGTGAACAAGCTCAACGGCCCATTC
TTCACCAGCGAAGACGAAGATGTGTTCTTGAAGTACCTGAATTTTGCCACGTTGTACCTG
AAGATCTATCACCTGAGCTACCTCCACAACTGCGAGACGCGCCGCGGCCAGGTGCTGCTG
TGGTCGGCCAACAAGGTGTTTGAGGAGCTGACGGACATCGAGAGGCAGTTCCACAAGGCC
TTCTACACGGTGCGGGCCTACCTCAACTGCGAGCGGTACTCCGTGGGCCTCCTGGACATG
ACCAAGGAGAAGGAATTTTTTGACGTGTGGTCTGTGCTGATGGGAGAGTCCCAGCCGTAC
TCGGGCCCACGCACGCCTGATGGCCGGGAAATTGTCTTCTACAAAGTGATCGACTACATC
CTCCACGGCAAGGAGGAGATCAAGGTCATTCCCACACCCTCAGCCGATCACTGGGCCCTG
GCCAGCGGCCTTCCAAGCTACGTGGCAGAAAGCGGCTTTATTTGTAACATCATGAATGCT
TCCGCTGACGAAATGTTCAAATTTCAGGAAGGGGCCCTGGACGACTCCGGGTGGCTCATC
AAGAATGTGCTGTCCATGCCCATCGTCAACAAGAAGGAGGAGATTGTGGGAGTCGCCACA
TTTTACAACAGGAAAGACGGGAAGCCCTTTGACGAACAGGACGAGGTTCTCATGGAGTCC
CTGACACAGTTCCTGGGCTGGTCAGTGATGAACACCGACACCTACGACAAGATGAACAAG
CTGGAGAACCGCAAGGACATCGCACAGGACATGGTCCTTTACCACGTGAAGTGCGACAGG
GACGAGATCCAGCTCATCCTGCCAACCAGAGCGCGCCTGGGGAAGGAGCCTGCTGACTGC
GATGAGGACGAGCTGGGCGAAATCCTGAAGGAGGAGCTGCCAGGGCCCACCACATTTGAC
ATCTACGAATTCCACTTCTCTGACCTGGAGTGCACCGAACTGGACCTGGTCAAATGTGGC
ATCCAGATGTACTACGAGCTGGGCGTGGTCCGAAAGTTCCAGATCCCCCAGGAGGTCCTG
GTGCGGTTCCTGTTCTCCATCAGCAAAGGGTACCGGAGAATCACCTACCACAACTGGCGC
CACGGCTTCAACGTGGCCCAGACGATGTTCACGCTGCTCATGACCGGCAAACTGAAGAGC
TACTACACGGACCTGGAGGCCTTCGCCATGGTGACAGCCGGCCTGTGCCATGACATCGAC
CACCGCGGCACCAACAACCTGTACCAGATGAAGTCCCAGAACCCCTTGGCTAAGCTCCAC
GGCTCCTCGATTTTGGAGCGGCACCACCTGGAGTTTGGGAAGTTCCTGCTCTCGGAGGAG
ACCCTGAACATCTACCAGAACCTGAACCGGCGGCAGCACGAGCACGTGATCCACCTGATG
GACATCGCCATCATCGCCACGGACCTGGCCCTGTACTTCAAGAAGAGAGCGATGTTTCAG
AAGATCGTGGATGAGTCCAAGAACTACCAGGACAAGAAGAGCTGGGTGGAGTACCTGTCC
CTGGAGACGACCCGGAAGGAGATCGTCATGGCCATGATGATGACAGCCTGCGACCTGTCT
GCCATCACCAAGCCCTGGGAAGTCCAGAGCAAGGTCGCACTTCTCGTGGCTGCTGAGTTC
TGGGAGCAAGGTGACTTGGAAAGGACAGTCTTGGATCAGCAGCCCATTCCTATGATGGAC
CGGAACAAGGCGGCCGAGCTCCCCAAGCTGCAAGTGGGCTTCATCGACTTCGTGTGCACA
TTCGTGTACAAGGAGTTCTCTCGTTTCCACGAAGAGATCCTGCCCATGTTCGACCGACTG
CAGAACAATAGGAAAGAGTGGAAGGCGCTGGCTGATGAGTATGAGGCCAAAGTGAAGGCT
CTGGAGGAGAAGGAGGAGGAGGAGAGGGTGGCAGCCAAGAAAGTAGGCACAGAAATTTGC
AATGGCGGCCCAGCACCCAAGTCTTCAACCTGCTGTATCCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>photoreceptor disc membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>GMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of rhodopsin mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhodopsin mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Wnt signaling pathway, calcium modulating pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="14">
      <id>BE0002385</id>
      <name>DNA-dependent protein kinase catalytic subunit</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18222</ref-id>
            <pubmed-id>12145276</pubmed-id>
            <citation>Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR: Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem. 2002 Oct 4;277(40):37124-30. Epub 2002 Jul 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P78527" source="Swiss-Prot">
        <name>DNA-dependent protein kinase catalytic subunit</name>
        <general-function>Transcription factor binding</general-function>
        <specific-function>Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D. Contributes to the determination of the circadian period length by antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1 protein stability, most likely through an indirect machanism. Interacts with CRY1 and CRY2; negatively regulates CRY1 phosphorylation.</specific-function>
        <gene-name>PRKDC</gene-name>
        <locus>8q11</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.12</theoretical-pi>
        <molecular-weight>469084.155</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9413</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PRKDC</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U47077</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2800</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P78527</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PRKDC_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.11.1</synonym>
          <synonym>DNA-PK catalytic subunit</synonym>
          <synonym>DNPK1</synonym>
          <synonym>HYRC</synonym>
          <synonym>HYRC1</synonym>
          <synonym>p460</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004685|DNA-dependent protein kinase catalytic subunit
MAGSGAGVRCSLLRLQETLSAADRCGAALAGHQLIRGLGQECVLSSSPAVLALQTSLVFS
RDFGLLVFVRKSLNSIEFRECREEILKFLCIFLEKMGQKIAPYSVEIKNTCTSVYTKDRA
AKCKIPALDLLIKLLQTFRSSRLMDEFKIGELFSKFYGELALKKKIPDTVLEKVYELLGL
LGEVHPSEMINNAENLFRAFLGELKTQMTSAVREPKLPVLAGCLKGLSSLLCNFTKSMEE
DPQTSREIFNFVLKAIRPQIDLKRYAVPSAGLRLFALHASQFSTCLLDNYVSLFEVLLKW
CAHTNVELKKAALSALESFLKQVSNMVAKNAEMHKNKLQYFMEQFYGIIRNVDSNNKELS
IAIRGYGLFAGPCKVINAKDVDFMYVELIQRCKQMFLTQTDTGDDRVYQMPSFLQSVASV
LLYLDTVPEVYTPVLEHLVVMQIDSFPQYSPKMQLVCCRAIVKVFLALAAKGPVLRNCIS
TVVHQGLIRICSKPVVLPKGPESESEDHRASGEVRTGKWKVPTYKDYVDLFRHLLSSDQM
MDSILADEAFFSVNSSSESLNHLLYDEFVKSVLKIVEKLDLTLEIQTVGEQENGDEAPGV
WMIPTSDPAANLHPAKPKDFSAFINLVEFCREILPEKQAEFFEPWVYSFSYELILQSTRL
PLISGFYKLLSITVRNAKKIKYFEGVSPKSLKHSPEDPEKYSCFALFVKFGKEVAVKMKQ
YKDELLASCLTFLLSLPHNIIELDVRAYVPALQMAFKLGLSYTPLAEVGLNALEEWSIYI
DRHVMQPYYKDILPCLDGYLKTSALSDETKNNWEVSALSRAAQKGFNKVVLKHLKKTKNL
SSNEAISLEEIRIRVVQMLGSLGGQINKNLLTVTSSDEMMKSYVAWDREKRLSFAVPFRE
MKPVIFLDVFLPRVTELALTASDRQTKVAACELLHSMVMFMLGKATQMPEGGQGAPPMYQ
LYKRTFPVLLRLACDVDQVTRQLYEPLVMQLIHWFTNNKKFESQDTVALLEAILDGIVDP
VDSTLRDFCGRCIREFLKWSIKQITPQQQEKSPVNTKSLFKRLYSLALHPNAFKRLGASL
AFNNIYREFREEESLVEQFVFEALVIYMESLALAHADEKSLGTIQQCCDAIDHLCRIIEK
KHVSLNKAKKRRLPRGFPPSASLCLLDLVKWLLAHCGRPQTECRHKSIELFYKFVPLLPG
NRSPNLWLKDVLKEEGVSFLINTFEGGGCGQPSGILAQPTLLYLRGPFSLQATLCWLDLL
LAALECYNTFIGERTVGALQVLGTEAQSSLLKAVAFFLESIAMHDIIAAEKCFGTGAAGN
RTSPQEGERYNYSKCTVVVRIMEFTTTLLNTSPEGWKLLKKDLCNTHLMRVLVQTLCEPA
SIGFNIGDVQVMAHLPDVCVNLMKALKMSPYKDILETHLREKITAQSIEELCAVNLYGPD
AQVDRSRLAAVVSACKQLHRAGLLHNILPSQSTDLHHSVGTELLSLVYKGIAPGDERQCL
PSLDLSCKQLASGLLELAFAFGGLCERLVSLLLNPAVLSTASLGSSQGSVIHFSHGEYFY
SLFSETINTELLKNLDLAVLELMQSSVDNTKMVSAVLNGMLDQSFRERANQKHQGLKLAT
TILQHWKKCDSWWAKDSPLETKMAVLALLAKILQIDSSVSFNTSHGSFPEVFTTYISLLA
DTKLDLHLKGQAVTLLPFFTSLTGGSLEELRRVLEQLIVAHFPMQSREFPPGTPRFNNYV
DCMKKFLDALELSQSPMLLELMTEVLCREQQHVMEELFQSSFRRIARRGSCVTQVGLLES
VYEMFRKDDPRLSFTRQSFVDRSLLTLLWHCSLDALREFFSTIVVDAIDVLKSRFTKLNE
STFDTQITKKMGYYKILDVMYSRLPKDDVHAKESKINQVFHGSCITEGNELTKTLIKLCY
DAFTENMAGENQLLERRRLYHCAAYNCAISVICCVFNELKFYQGFLFSEKPEKNLLIFEN
LIDLKRRYNFPVEVEVPMERKKKYIEIRKEAREAANGDSDGPSYMSSLSYLADSTLSEEM
SQFDFSTGVQSYSYSSQDPRPATGRFRRREQRDPTVHDDVLELEMDELNRHECMAPLTAL
VKHMHRSLGPPQGEEDSVPRDLPSWMKFLHGKLGNPIVPLNIRLFLAKLVINTEEVFRPY
AKHWLSPLLQLAASENNGGEGIHYMVVEIVATILSWTGLATPTGVPKDEVLANRLLNFLM
KHVFHPKRAVFRHNLEIIKTLVECWKDCLSIPYRLIFEKFSGKDPNSKDNSVGIQLLGIV
MANDLPPYDPQCGIQSSEYFQALVNNMSFVRYKEVYAAAAEVLGLILRYVMERKNILEES
LCELVAKQLKQHQNTMEDKFIVCLNKVTKSFPPLADRFMNAVFFLLPKFHGVLKTLCLEV
VLCRVEGMTELYFQLKSKDFVQVMRHRDDERQKVCLDIIYKMMPKLKPVELRELLNPVVE
FVSHPSTTCREQMYNILMWIHDNYRDPESETDNDSQEIFKLAKDVLIQGLIDENPGLQLI
IRNFWSHETRLPSNTLDRLLALNSLYSPKIEVHFLSLATNFLLEMTSMSPDYPNPMFEHP
LSECEFQEYTIDSDWRFRSTVLTPMFVETQASQGTLQTRTQEGSLSARWPVAGQIRATQQ
QHDFTLTQTADGRSSFDWLTGSSTDPLVDHTSPSSDSLLFAHKRSERLQRAPLKSVGPDF
GKKRLGLPGDEVDNKVKGAAGRTDLLRLRRRFMRDQEKLSLMYARKGVAEQKREKEIKSE
LKMKQDAQVVLYRSYRHGDLPDIQIKHSSLITPLQAVAQRDPIIAKQLFSSLFSGILKEM
DKFKTLSEKNNITQKLLQDFNRFLNTTFSFFPPFVSCIQDISCQHAALLSLDPAAVSAGC
LASLQQPVGIRLLEEALLRLLPAELPAKRVRGKARLPPDVLRWVELAKLYRSIGEYDVLR
GIFTSEIGTKQITQSALLAEARSDYSEAAKQYDEALNKQDWVDGEPTEAEKDFWELASLD
CYNHLAEWKSLEYCSTASIDSENPPDLNKIWSEPFYQETYLPYMIRSKLKLLLQGEADQS
LLTFIDKAMHGELQKAILELHYSQELSLLYLLQDDVDRAKYYIQNGIQSFMQNYSSIDVL
LHQSRLTKLQSVQALTEIQEFISFISKQGNLSSQVPLKRLLNTWTNRYPDAKMDPMNIWD
DIITNRCFFLSKIEEKLTPLPEDNSMNVDQDGDPSDRMEVQEQEEDISSLIRSCKFSMKM
KMIDSARKQNNFSLAMKLLKELHKESKTRDDWLVSWVQSYCRLSHCRSRSQGCSEQVLTV
LKTVSLLDENNVSSYLSKNILAFRDQNILLGTTYRIIANALSSEPACLAEIEEDKARRIL
ELSGSSSEDSEKVIAGLYQRAFQHLSEAVQAAEEEAQPPSWSCGPAAGVIDAYMTLADFC
DQQLRKEEENASVIDSAELQAYPALVVEKMLKALKLNSNEARLKFPRLLQIIERYPEETL
SLMTKEISSVPCWQFISWISHMVALLDKDQAVAVQHSVEEITDNYPQAIVYPFIISSESY
SFKDTSTGHKNKEFVARIKSKLDQGGVIQDFINALDQLSNPELLFKDWSNDVRAELAKTP
VNKKNIEKMYERMYAALGDPKAPGLGAFRRKFIQTFGKEFDKHFGKGGSKLLRMKLSDFN
DITNMLLLKMNKDSKPPGNLKECSPWMSDFKVEFLRNELEIPGQYDGRGKPLPEYHVRIA
GFDERVTVMASLRRPKRIIIRGHDEREHPFLVKGGEDLRQDQRVEQLFQVMNGILAQDSA
CSQRALQLRTYSVVPMTSRLGLIEWLENTVTLKDLLLNTMSQEEKAAYLSDPRAPPCEYK
DWLTKMSGKHDVGAYMLMYKGANRTETVTSFRKRESKVPADLLKRAFVRMSTSPEAFLAL
RSHFASSHALICISHWILGIGDRHLNNFMVAMETGGVIGIDFGHAFGSATQFLPVPELMP
FRLTRQFINLMLPMKETGLMYSIMVHALRAFRSDPGLLTNTMDVFVKEPSFDWKNFEQKM
LKKGGSWIQEINVAEKNWYPRQKICYAKRKLAGANPAVITCDELLLGHEKAPAFRDYVAV
ARGSKDHNIRAQEPESGLSEETQVKCLMDQATDPNILGRTWEGWEPWM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016774|DNA-dependent protein kinase catalytic subunit (PRKDC)
ATGGCGGGCTCCGGAGCCGGTGTGCGTTGCTCCCTGCTGCGGCTGCAGGAGACCTTGTCC
GCTGCGGACCGCTGCGGTGCTGCCCTGGCCGGTCATCAACTGATCCGCGGCCTGGGGCAG
GAATGCGTCCTGAGCAGCAGCCCCGCGGTGCTGGCATTACAGACATCTTTAGTTTTTTCC
AGAGATTTCGGTTTGCTTGTATTTGTCCGGAAGTCACTCAACAGTATTGAATTTCGTGAA
TGTAGAGAAGAAATCCTAAAGTTTTTATGTATTTTCTTAGAAAAAATGGGCCAGAAGATC
GCACCTTACTCTGTTGAAATTAAGAACACTTGTACCAGTGTTTATACAAAAGATAGAGCT
GCTAAATGTAAAATTCCAGCCCTGGACCTTCTTATTAAGTTACTTCAGACTTTTAGAAGT
TCTAGACTCATGGATGAATTTAAAATTGGAGAATTATTTAGTAAATTCTATGGAGAACTT
GCATTGAAAAAAAAAATACCAGATACAGTTTTAGAAAAAGTATATGAGCTCCTAGGATTA
TTGGGTGAAGTTCATCCTAGTGAGATGATAAATAATGCAGAAAACCTGTTCCGCGCTTTT
CTGGGTGAACTTAAGACCCAGATGACATCAGCAGTAAGAGAGCCCAAACTACCTGTTCTG
GCAGGATGTCTGAAGGGGTTGTCCTCACTTCTGTGCAACTTCACTAAGTCCATGGAAGAA
GATCCCCAGACTTCAAGGGAGATTTTTAATTTTGTACTAAAGGCAATTCGTCCTCAGATT
GATCTGAAGAGATATGCTGTGCCCTCAGCTGGCTTGCGCCTATTTGCCCTGCATGCATCT
CAGTTTAGCACCTGCCTTCTGGACAACTACGTGTCTCTATTTGAAGTCTTGTTAAAGTGG
TGTGCCCACACAAATGTAGAATTGAAAAAAGCTGCACTTTCAGCCCTGGAATCCTTTCTG
AAACAGGTTTCTAATATGGTGGCGAAAAATGCAGAAATGCATAAAAATAAACTGCAGTAC
TTTATGGAGCAGTTTTATGGAATCATCAGAAATGTGGATTCGAACAACAAGGAGTTATCT
ATTGCTATCCGTGGATATGGACTTTTTGCAGGACCGTGCAAGGTTATAAACGCAAAAGAT
GTTGACTTCATGTACGTTGAGCTCATTCAGCGCTGCAAGCAGATGTTCCTCACCCAGACA
GACACTGGTGACGACCGTGTTTATCAGATGCCAAGCTTCCTCCAGTCTGTTGCAAGCGTC
TTGCTGTACCTTGACACAGTTCCTGAGGTGTATACTCCAGTTCTGGAGCACCTCGTGGTG
ATGCAGATAGACAGTTTCCCACAGTACAGTCCAAAAATGCAGCTGGTGTGTTGCAGAGCC
ATAGTGAAGGTGTTCCTAGCTTTGGCAGCAAAAGGGCCAGTTCTCAGGAATTGCATTAGT
ACTGTGGTGCATCAGGGTTTAATCAGAATATGTTCTAAACCAGTGGTCCTTCCAAAGGGC
CCTGAGTCTGAATCTGAAGACCACCGTGCTTCAGGGGAAGTCAGAACTGGCAAATGGAAG
GTGCCCACATACAAAGACTACGTGGATCTCTTCAGACATCTCCTGAGCTCTGACCAGATG
ATGGATTCTATTTTAGCAGATGAAGCATTTTTCTCTGTGAATTCCTCCAGTGAAAGTCTG
AATCATTTACTTTATGATGAATTTGTAAAATCCGTTTTGAAGATTGTTGAGAAATTGGAT
CTTACACTTGAAATACAGACTGTTGGGGAACAAGAGAATGGAGATGAGGCGCCTGGTGTT
TGGATGATCCCAACTTCAGATCCAGCGGCTAACTTGCATCCAGCTAAACCTAAAGATTTT
TCGGCTTTCATTAACCTGGTGGAATTTTGCAGAGAGATTCTCCCTGAGAAACAAGCAGAA
TTTTTTGAACCATGGGTGTACTCATTTTCATATGAATTAATTTTGCAATCTACAAGGTTG
CCCCTCATCAGTGGTTTCTACAAATTGCTTTCTATTACAGTAAGAAATGCCAAGAAAATA
AAATATTTCGAGGGAGTTAGTCCAAAGAGTCTGAAACACTCTCCTGAAGACCCAGAAAAG
TATTCTTGCTTTGCTTTATTTGTGAAATTTGGCAAAGAGGTGGCAGTTAAAATGAAGCAG
TACAAAGATGAACTTTTGGCCTCTTGTTTGACCTTTCTTCTGTCCTTGCCACACAACATC
ATTGAACTCGATGTTAGAGCCTACGTTCCTGCACTGCAGATGGCTTTCAAACTGGGCCTG
AGCTATACCCCCTTGGCAGAAGTAGGCCTGAATGCTCTAGAAGAATGGTCAATTTATATT
GACAGACATGTAATGCAGCCTTATTACAAAGACATTCTCCCCTGCCTGGATGGATACCTG
AAGACTTCAGCCTTGTCAGATGAGACCAAGAATAACTGGGAAGTGTCAGCTCTTTCTCGG
GCTGCCCAGAAAGGATTTAATAAAGTGGTGTTAAAGCATCTGAAGAAGACAAAGAACCTT
TCATCAAACGAAGCAATATCCTTAGAAGAAATAAGAATTAGAGTAGTACAAATGCTTGGA
TCTCTAGGAGGACAAATAAACAAAAATCTTCTGACAGTCACGTCCTCAGATGAGATGATG
AAGAGCTATGTGGCCTGGGACAGAGAGAAGCGGCTGAGCTTTGCAGTGCCCTTTAGAGAG
ATGAAACCTGTCATTTTCCTGGATGTGTTCCTGCCTCGAGTCACAGAATTAGCGCTCACA
GCCAGTGACAGACAAACTAAAGTTGCAGCCTGTGAACTTTTACATAGCATGGTTATGTTT
ATGTTGGGCAAAGCCACGCAGATGCCAGAAGGGGGACAGGGAGCCCCACCCATGTACCAG
CTCTATAAGCGGACGTTTCCTGTGCTGCTTCGACTTGCGTGTGATGTTGATCAGGTGACA
AGGCAACTGTATGAGCCACTAGTTATGCAGCTGATTCACTGGTTCACTAACAACAAGAAA
TTTGAAAGTCAGGATACTGTTGCCTTACTAGAAGCTATATTGGATGGAATTGTGGACCCT
GTTGACAGTACTTTAAGAGATTTTTGTGGTCGGTGTATTCGAGAATTCCTTAAATGGTCC
ATTAAGCAAATAACACCACAGCAGCAGGAGAAGAGTCCAGTAAACACCAAATCGCTTTTC
AAGCGACTTTATAGCCTTGCGCTTCACCCCAATGCTTTCAAGAGGCTGGGAGCATCACTT
GCCTTTAATAATATCTACAGGGAATTCAGGGAAGAAGAGTCTCTGGTGGAACAGTTTGTG
TTTGAAGCCTTGGTGATATACATGGAGAGTCTGGCCTTAGCACATGCAGATGAGAAGTCC
TTAGGTACAATTCAACAGTGTTGTGATGCCATTGATCACCTATGCCGCATCATTGAAAAG
AAGCATGTTTCTTTAAATAAAGCAAAGAAACGACGTTTGCCGCGAGGATTTCCACCTTCC
GCATCATTGTGTTTATTGGATCTGGTCAAGTGGCTTTTAGCTCATTGTGGGAGGCCCCAG
ACAGAATGTCGACACAAATCCATTGAACTCTTTTATAAATTCGTTCCTTTATTGCCAGGC
AACAGATCCCCTAATTTGTGGCTGAAAGATGTTCTCAAGGAAGAAGGTGTCTCTTTTCTC
ATCAACACCTTTGAGGGGGGTGGCTGTGGCCAGCCCTCGGGCATCCTGGCCCAGCCCACC
CTCTTGTACCTTCGGGGGCCATTCAGCCTGCAGGCCACGCTATGCTGGCTGGACCTGCTC
CTGGCCGCGTTGGAGTGCTACAACACGTTCATTGGCGAGAGAACTGTAGGAGCGCTCCAG
GTCCTAGGTACTGAAGCCCAGTCTTCACTTTTGAAAGCAGTGGCTTTCTTCTTAGAAAGC
ATTGCCATGCATGACATTATAGCAGCAGAAAAGTGCTTTGGCACTGGGGCAGCAGGTAAC
AGAACAAGCCCACAAGAGGGAGAAAGGTACAACTACAGCAAATGCACCGTTGTGGTCCGG
ATTATGGAGTTTACCACGACTCTGCTAAACACCTCCCCGGAAGGATGGAAGCTCCTGAAG
AAGGACTTGTGTAATACACACCTGATGAGAGTCCTGGTGCAGACGCTGTGTGAGCCCGCA
AGCATAGGTTTCAACATCGGAGACGTCCAGGTTATGGCTCATCTTCCTGATGTTTGTGTG
AATCTGATGAAAGCTCTAAAGATGTCCCCATACAAAGATATCCTAGAGACCCATCTGAGA
GAGAAAATAACAGCACAGAGCATTGAGGAGCTTTGTGCCGTCAACTTGTATGGCCCTGAC
GCGCAAGTGGACAGGAGCAGGCTGGCTGCTGTTGTGTCTGCCTGTAAACAGCTTCACAGA
GCTGGGCTTCTGCATAATATATTACCGTCTCAGTCCACAGATTTGCATCATTCTGTTGGC
ACAGAACTTCTTTCCCTGGTTTATAAAGGCATTGCCCCTGGAGATGAGAGACAGTGTCTG
CCTTCTCTAGACCTCAGTTGTAAGCAGCTGGCCAGCGGACTTCTGGAGTTAGCCTTTGCT
TTTGGAGGACTGTGTGAGCGCCTTGTGAGTCTTCTCCTGAACCCAGCGGTGCTGTCCACG
GCGTCCTTGGGCAGCTCACAGGGCAGCGTCATCCACTTCTCCCATGGGGAGTATTTCTAT
AGCTTGTTCTCAGAAACGATCAACACGGAATTATTGAAAAATCTGGATCTTGCTGTATTG
GAGCTCATGCAGTCTTCAGTGGATAATACCAAAATGGTGAGTGCCGTTTTGAACGGCATG
TTAGACCAGAGCTTCAGGGAGCGAGCAAACCAGAAACACCAAGGACTGAAACTTGCGACT
ACAATTCTGCAACACTGGAAGAAGTGTGATTCATGGTGGGCCAAAGATTCCCCTCTCGAA
ACTAAAATGGCAGTGCTGGCCTTACTGGCAAAAATTTTACAGATTGATTCATCTGTATCT
TTTAATACAAGTCATGGTTCATTCCCTGAAGTCTTTACAACATATATTAGTCTACTTGCT
GACACAAAGCTGGATCTACATTTAAAGGGCCAAGCTGTCACTCTTCTTCCATTCTTCACC
AGCCTCACTGGAGGCAGTCTGGAGGAACTTAGACGTGTTCTGGAGCAGCTCATCGTTGCT
CACTTCCCCATGCAGTCCAGGGAATTTCCTCCAGGAACTCCGCGGTTCAATAATTATGTG
GACTGCATGAAAAAGTTTCTAGATGCATTGGAATTATCTCAAAGCCCTATGTTGTTGGAA
TTGATGACAGAAGTTCTTTGTCGGGAACAGCAGCATGTCATGGAAGAATTATTTCAATCC
AGTTTCAGGAGGATTGCCAGAAGGGGTTCATGTGTCACACAAGTAGGCCTTCTGGAAAGC
GTGTATGAAATGTTCAGGAAGGATGACCCCCGCCTAAGTTTCACACGCCAGTCCTTTGTG
GACCGCTCCCTCCTCACTCTGCTGTGGCACTGTAGCCTGGATGCTTTGAGAGAATTCTTC
AGCACAATTGTGGTGGATGCCATTGATGTGTTGAAGTCCAGGTTTACAAAGCTAAATGAA
TCTACCTTTGATACTCAAATCACCAAGAAGATGGGCTACTATAAGATTCTAGACGTGATG
TATTCTCGCCTTCCCAAAGATGATGTTCATGCTAAGGAATCAAAAATTAATCAAGTTTTC
CATGGCTCGTGTATTACAGAAGGAAATGAACTTACAAAGACATTGATTAAATTGTGCTAC
GATGCATTTACAGAGAACATGGCAGGAGAGAATCAGCTGCTGGAGAGGAGAAGACTTTAC
CATTGTGCAGCATACAACTGCGCCATATCTGTCATCTGCTGTGTCTTCAATGAGTTAAAA
TTTTACCAAGGTTTTCTGTTTAGTGAAAAACCAGAAAAGAACTTGCTTATTTTTGAAAAT
CTGATCGACCTGAAGCGCCGCTATAATTTTCCTGTAGAAGTTGAGGTTCCTATGGAAAGA
AAGAAAAAGTACATTGAAATTAGGAAAGAAGCCAGAGAAGCAGCAAATGGGGATTCAGAT
GGTCCTTCCTATATGTCTTCCCTGTCATATTTGGCAGACAGTACCCTGAGTGAGGAAATG
AGTCAATTTGATTTCTCAACCGGAGTTCAGAGCTATTCATACAGCTCCCAAGACCCTAGA
CCTGCCACTGGTCGTTTTCGGAGACGGGAGCAGCGGGACCCCACGGTGCATGATGATGTG
CTGGAGCTGGAGATGGACGAGCTCAATCGGCATGAGTGCATGGCGCCCCTGACGGCCCTG
GTCAAGCACATGCACAGAAGCCTGGGCCCGCCTCAAGGAGAAGAGGATTCAGTGCCAAGA
GATCTTCCTTCTTGGATGAAATTCCTCCATGGCAAACTGGGAAATCCAATAGTACCATTA
AATATCCGTCTCTTCTTAGCCAAGCTTGTTATTAATACAGAAGAGGTCTTTCGCCCTTAC
GCGAAGCACTGGCTTAGCCCCTTGCTGCAGCTGGCTGCTTCTGAAAACAATGGAGGAGAA
GGAATTCACTACATGGTGGTTGAGATAGTGGCCACTATTCTTTCATGGACAGGCTTGGCC
ACTCCAACAGGGGTCCCTAAAGATGAAGTGTTAGCAAATCGATTGCTTAATTTCCTAATG
AAACATGTCTTTCATCCAAAAAGAGCTGTGTTTAGACACAACCTTGAAATTATAAAGACC
CTTGTCGAGTGCTGGAAGGATTGTTTATCCATCCCTTATAGGTTAATATTTGAAAAGTTT
TCCGGTAAAGATCCTAATTCTAAAGACAACTCAGTAGGGATTCAATTGCTAGGCATCGTG
ATGGCCAATGACCTGCCTCCCTATGACCCACAGTGTGGCATCCAGAGTAGCGAATACTTC
CAGGCTTTGGTGAATAATATGTCCTTTGTAAGATATAAAGAAGTGTATGCCGCTGCAGCA
GAAGTTCTAGGACTTATACTTCGATATGTTATGGAGAGAAAAAACATACTGGAGGAGTCT
CTGTGTGAACTGGTTGCGAAACAATTGAAGCAACATCAGAATACTATGGAGGACAAGTTT
ATTGTGTGCTTGAACAAAGTGACCAAGAGCTTCCCTCCTCTTGCAGACAGGTTCATGAAT
GCTGTGTTCTTTCTGCTGCCAAAATTTCATGGAGTGTTGAAAACACTCTGTCTGGAGGTG
GTACTTTGTCGTGTGGAGGGAATGACAGAGCTGTACTTCCAGTTAAAGAGCAAGGACTTC
GTTCAAGTCATGAGACATAGAGATGATGAAAGACAAAAAGTATGTTTGGACATAATTTAT
AAGATGATGCCAAAGTTAAAACCAGTAGAACTCCGAGAACTTCTGAACCCCGTTGTGGAA
TTCGTTTCCCATCCTTCTACAACATGTAGGGAACAAATGTATAATATTCTCATGTGGATT
CATGATAATTACAGAGATCCAGAAAGTGAGACAGATAATGACTCCCAGGAAATATTTAAG
TTGGCAAAAGATGTGCTGATTCAAGGATTGATCGATGAGAACCCTGGACTTCAATTAATT
ATTCGAAATTTCTGGAGCCATGAAACTAGGTTACCTTCAAATACCTTGGACCGGTTGCTG
GCACTAAATTCCTTATATTCTCCTAAGATAGAAGTGCACTTTTTAAGTTTAGCAACAAAT
TTTCTGCTCGAAATGACCAGCATGAGCCCAGATTATCCAAACCCCATGTTCGAGCATCCT
CTGTCAGAATGCGAATTTCAGGAATATACCATTGATTCTGATTGGCGTTTCCGAAGTACT
GTTCTCACTCCGATGTTTGTGGAGACCCAGGCCTCCCAGGGCACTCTCCAGACCCGTACC
CAGGAAGGGTCCCTCTCAGCTCGCTGGCCAGTGGCAGGGCAGATAAGGGCCACCCAGCAG
CAGCATGACTTCACACTGACACAGACTGCAGATGGAAGAAGCTCATTTGATTGGCTGACC
GGGAGCAGCACTGACCCGCTGGTCGACCACACCAGTCCCTCATCTGACTCCTTGCTGTTT
GCCCACAAGAGGAGTGAAAGGTTACAGAGAGCACCCTTGAAGTCAGTGGGGCCTGATTTT
GGGAAAAAAAGGCTGGGCCTTCCAGGGGACGAGGTGGATAACAAAGTGAAAGGTGCGGCC
GGCCGGACGGACCTACTACGACTGCGCAGACGGTTTATGAGGGACCAGGAGAAGCTCAGT
TTGATGTATGCCAGAAAAGGCGTTGCTGAGCAAAAACGAGAGAAGGAAATCAAGAGTGAG
TTAAAAATGAAGCAGGATGCCCAGGTCGTTCTGTACAGAAGCTACCGGCACGGAGACCTT
CCTGACATTCAGATCAAGCACAGCAGCCTCATCACCCCGTTACAGGCCGTGGCCCAGAGG
GACCCAATAATTGCAAAACAGCTCTTTAGCAGCTTGTTTTCTGGAATTTTGAAAGAGATG
GATAAATTTAAGACACTGTCTGAAAAAAACAACATCACTCAAAAGTTGCTTCAAGACTTC
AATCGTTTTCTTAATACCACCTTCTCTTTCTTTCCACCCTTTGTCTCTTGTATTCAGGAC
ATTAGCTGTCAGCACGCAGCCCTGCTGAGCCTCGACCCAGCGGCTGTTAGCGCTGGTTGC
CTGGCCAGCCTACAGCAGCCCGTGGGCATCCGCCTGCTAGAGGAGGCTCTGCTCCGCCTG
CTGCCTGCTGAGCTGCCTGCCAAGCGAGTCCGTGGGAAGGCCCGCCTCCCTCCTGATGTC
CTCAGATGGGTGGAGCTTGCTAAGCTGTATAGATCAATTGGAGAATACGACGTCCTCCGT
GGGATTTTTACCAGTGAGATAGGAACAAAGCAAATCACTCAGAGTGCATTATTAGCAGAA
GCCAGAAGTGATTATTCTGAAGCTGCTAAGCAGTATGATGAGGCTCTCAATAAACAAGAC
TGGGTAGATGGTGAGCCCACAGAAGCCGAGAAGGATTTTTGGGAACTTGCATCCCTTGAC
TGTTACAACCACCTTGCTGAGTGGAAATCACTTGAATACTGTTCTACAGCCAGTATAGAC
AGTGAGAACCCCCCAGACCTAAATAAAATCTGGAGTGAACCATTTTATCAGGAAACATAT
CTACCTTACATGATCCGCAGCAAGCTGAAGCTGCTGCTCCAGGGAGAGGCTGACCAGTCC
CTGCTGACATTTATTGACAAAGCTATGCACGGGGAGCTCCAGAAGGCGATTCTAGAGCTT
CATTACAGTCAAGAGCTGAGTCTGCTTTACCTCCTGCAAGATGATGTTGACAGAGCCAAA
TATTACATTCAAAATGGCATTCAGAGTTTTATGCAGAATTATTCTAGTATTGATGTCCTC
TTACACCAAAGTAGACTCACCAAATTGCAGTCTGTACAGGCTTTAACAGAAATTCAGGAG
TTCATCAGCTTTATAAGCAAACAAGGCAATTTATCATCTCAAGTTCCCCTTAAGAGACTT
CTGAACACCTGGACAAACAGATATCCAGATGCTAAAATGGACCCAATGAACATCTGGGAT
GACATCATCACAAATCGATGTTTCTTTCTCAGCAAAATAGAGGAGAAGCTTACCCCTCTT
CCAGAAGATAATAGTATGAATGTGGATCAAGATGGAGACCCCAGTGACAGGATGGAAGTG
CAAGAGCAGGAAGAAGATATCAGCTCCCTGATCAGGAGTTGCAAGTTTTCCATGAAAATG
AAGATGATAGACAGTGCCCGGAAGCAGAACAATTTCTCACTTGCTATGAAACTACTGAAG
GAGCTGCATAAAGAGTCAAAAACCAGAGACGATTGGCTGGTGAGCTGGGTGCAGAGCTAC
TGCCGCCTGAGCCACTGCCGGAGCCGGTCCCAGGGCTGCTCTGAGCAGGTGCTCACTGTG
CTGAAAACAGTCTCTTTGTTGGATGAGAACAACGTGTCAAGCTACTTAAGCAAAAATATT
CTGGCTTTCCGTGACCAGAACATTCTCTTGGGTACAACTTACAGGATCATAGCGAATGCT
CTCAGCAGTGAGCCAGCCTGCCTTGCTGAAATCGAGGAGGACAAGGCTAGAAGAATCTTA
GAGCTTTCTGGATCCAGTTCAGAGGATTCAGAGAAGGTGATCGCGGGTCTGTACCAGAGA
GCATTCCAGCACCTCTCTGAGGCTGTGCAGGCGGCTGAGGAGGAGGCCCAGCCTCCCTCC
TGGAGCTGTGGGCCTGCAGCTGGGGTGATTGATGCTTACATGACGCTGGCAGATTTCTGT
GACCAACAGCTGCGCAAGGAGGAAGAGAATGCATCAGTTATTGATTCTGCAGAACTGCAG
GCGTATCCAGCACTTGTGGTGGAGAAAATGTTGAAAGCTTTAAAATTAAATTCCAATGAA
GCCAGATTGAAGTTTCCTAGATTACTTCAGATTATAGAACGGTATCCAGAGGAGACTTTG
AGCCTCATGACAAAAGAGATCTCTTCCGTTCCCTGCTGGCAGTTCATCAGCTGGATCAGC
CACATGGTGGCCTTACTGGACAAAGACCAAGCCGTTGCTGTTCAGCACTCTGTGGAAGAA
ATCACTGATAACTACCCGCAGGCTATTGTTTATCCCTTCATCATAAGCAGCGAAAGCTAT
TCCTTCAAGGATACTTCTACTGGTCATAAGAATAAGGAGTTTGTGGCAAGGATTAAAAGT
AAGTTGGATCAAGGAGGAGTGATTCAAGATTTTATTAATGCCTTAGATCAGCTCTCTAAT
CCTGAACTGCTCTTTAAGGATTGGAGCAATGATGTAAGAGCTGAACTAGCAAAAACCCCT
GTAAATAAAAAAAACATTGAAAAAATGTATGAAAGAATGTATGCAGCCTTGGGTGACCCA
AAGGCTCCAGGCCTGGGGGCCTTTAGAAGGAAGTTTATTCAGACTTTTGGAAAAGAATTT
GATAAACATTTTGGGAAAGGAGGTTCTAAACTACTGAGAATGAAGCTCAGTGACTTCAAC
GACATTACCAACATGCTACTTTTAAAAATGAACAAAGACTCAAAGCCCCCTGGGAATCTG
AAAGAATGTTCACCCTGGATGAGCGACTTCAAAGTGGAGTTCCTGAGAAATGAGCTGGAG
ATTCCCGGTCAGTATGACGGTAGGGGAAAGCCATTGCCAGAGTACCACGTGCGAATCGCC
GGGTTTGATGAGCGGGTGACAGTCATGGCGTCTCTGCGAAGGCCCAAGCGCATCATCATC
CGTGGCCATGACGAGAGGGAACACCCTTTCCTGGTGAAGGGTGGCGAGGACCTGCGGCAG
GACCAGCGCGTGGAGCAGCTCTTCCAGGTCATGAATGGGATCCTGGCCCAAGACTCCGCC
TGCAGCCAGAGGGCCCTGCAGCTGAGGACCTATAGCGTTGTGCCCATGACCTCCAGTGAT
CCCAGGGCACCGCCGTGTGAATATAAAGATTGGCTGACAAAAATGTCAGGAAAACATGAT
GTTGGAGCTTACATGCTAATGTATAAGGGCGCTAATCGTACTGAAACAGTCACGTCTTTT
AGAAAACGAGAAAGTAAAGTGCCTGCTGATCTCTTAAAGCGGGCCTTCGTGAGGATGAGT
ACAAGCCCTGAGGCTTTCCTGGCGCTCCGCTCCCACTTCGCCAGCTCTCACGCTCTGATA
TGCATCAGCCACTGGATCCTCGGGATTGGAGACAGACATCTGAACAACTTTATGGTGGCC
ATGGAGACTGGCGGCGTGATCGGGATCGACTTTGGGCATGCGTTTGGATCCGCTACACAG
TTTCTGCCAGTCCCTGAGTTGATGCCTTTTCGGCTAACTCGCCAGTTTATCAATCTGATG
TTACCAATGAAAGAAACGGGCCTTATGTACAGCATCATGGTACACGCACTCCGGGCCTTC
CGCTCAGACCCTGGCCTGCTCACCAACACCATGGATGTGTTTGTCAAGGAGCCCTCCTTT
GATTGGAAAAATTTTGAACAGAAAATGCTGAAAAAAGGAGGGTCATGGATTCAAGAAATA
AATGTTGCTGAAAAAAATTGGTACCCCCGACAGAAAATATGTTACGCTAAGAGAAAGTTA
GCAGGTGCCAATCCAGCAGTCATTACTTGTGATGAGCTACTCCTGGGTCATGAGAAGGCC
CCTGCCTTCAGAGACTATGTGGCTGTGGCACGAGGAAGCAAAGATCACAACATTCGTGCC
CAAGAACCAGAGAGTGGGCTTTCAGAAGAGACTCAAGTGAAGTGCCTGATGGACCAGGCA
ACAGACCCCAACATCCTTGGCAGAACCTGGGAAGGATGGGAGCCCTGGATGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00454</identifier>
            <name>PI3_PI4_kinase</name>
          </pfam>
          <pfam>
            <identifier>PF02259</identifier>
            <name>FAT</name>
          </pfam>
          <pfam>
            <identifier>PF02260</identifier>
            <name>FATC</name>
          </pfam>
          <pfam>
            <identifier>PF08163</identifier>
            <name>NUC194</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>DNA-dependent protein kinase-DNA ligase 4 complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nonhomologous end joining complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear chromosome, telomeric region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transcription factor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA-dependent protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>double-stranded DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>poly(A) RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein serine/threonine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell lineage commitment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein modification process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA repair</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>double-strand break repair</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>double-strand break repair via homologous recombination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>double-strand break repair via nonhomologous end joining</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ectopic germ cell programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immunoglobulin V(D)J recombination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intrinsic apoptotic signaling pathway in response to DNA damage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular senescence</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of immunoglobulin production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of response to gamma radiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of developmental growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fibroblast proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of immune system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of type I interferon production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pro-B cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein destabilization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to gamma radiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhythmic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction involved in mitotic G1 DNA damage checkpoint</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>somitogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spleen development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell differentiation in thymus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell lineage commitment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor V(D)J recombination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thymus development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="15">
      <id>BE0002406</id>
      <name>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18222</ref-id>
            <pubmed-id>12145276</pubmed-id>
            <citation>Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR: Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem. 2002 Oct 4;277(40):37124-30. Epub 2002 Jul 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O00329" source="Swiss-Prot">
        <name>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform</name>
        <general-function>Phosphatidylinositol-4,5-bisphosphate 3-kinase activity</general-function>
        <specific-function>Phosphoinositide-3-kinase (PI3K) that phosphorylates PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity.</specific-function>
        <gene-name>PIK3CD</gene-name>
        <locus>1p36.2</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.18</theoretical-pi>
        <molecular-weight>119478.065</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8977</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PIK3CD</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Y10055</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2155</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O00329</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PK3CD_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.1.153</synonym>
          <synonym>p110delta</synonym>
          <synonym>Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta</synonym>
          <synonym>PI3-kinase subunit delta</synonym>
          <synonym>PtdIns-3-kinase subunit p110-delta</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004726|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
MPPGVDCPMEFWTKEENQSVVVDFLLPTGVYLNFPVSRNANLSTIKQLLWHRAQYEPLFH
MLSGPEAYVFTCINQTAEQQELEDEQRRLCDVQPFLPVLRLVAREGDRVKKLINSQISLL
IGKGLHEFDSLCDPEVNDFRAKMCQFCEEAAARRQQLGWEAWLQYSFPLQLEPSAQTWGP
GTLRLPNRALLVNVKFEGSEESFTFQVSTKDVPLALMACALRKKATVFRQPLVEQPEDYT
LQVNGRHEYLYGSYPLCQFQYICSCLHSGLTPHLTMVHSSSILAMRDEQSNPAPQVQKPR
AKPPPIPAKKPSSVSLWSLEQPFRIELIQGSKVNADERMKLVVQAGLFHGNEMLCKTVSS
SEVSVCSEPVWKQRLEFDINICDLPRMARLCFALYAVIEKAKKARSTKKKSKKADCPIAW
ANLMLFDYKDQLKTGERCLYMWPSVPDEKGELLNPTGTVRSNPNTDSAAALLICLPEVAP
HPVYYPALEKILELGRHSECVHVTEEEQLQLREILERRGSGELYEHEKDLVWKLRHEVQE
HFPEALARLLLVTKWNKHEDVAQMLYLLCSWPELPVLSALELLDFSFPDCHVGSFAIKSL
RKLTDDELFQYLLQLVQVLKYESYLDCELTKFLLDRALANRKIGHFLFWHLRSEMHVPSV
ALRFGLILEAYCRGSTHHMKVLMKQGEALSKLKALNDFVKLSSQKTPKPQTKELMHLCMR
QEAYLEALSHLQSPLDPSTLLAEVCVEQCTFMDSKMKPLWIMYSNEEAGSGGSVGIIFKN
GDDLRQDMLTLQMIQLMDVLWKQEGLDLRMTPYGCLPTGDRTGLIEVVLRSDTIANIQLN
KSNMAATAAFNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIM
IRESGQLFHIDFGHFLGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYC
ERAYTILRRHGLLFLHLFALMRAAGLPELSCSKDIQYLKDSLALGKTEEEALKHFRVKFN
EALRESWKTKVNWLAHNVSKDNRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019281|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD)
ATGCCCCCTGGGGTGGACTGCCCCATGGAATTCTGGACCAAGGAGGAGAATCAGAGCGTT
GTGGTTGACTTCCTGCTGCCCACAGGGGTCTACCTGAACTTCCCTGTGTCCCGCAATGCC
AACCTCAGCACCATCAAGCAGCTGCTGTGGCACCGCGCCCAGTATGAGCCGCTCTTCCAC
ATGCTCAGTGGCCCCGAGGCCTATGTGTTCACCTGCATCAACCAGACAGCGGAGCAGCAA
GAGCTGGAGGACGAGCAACGGCGTCTGTGTGACGTGCAGCCCTTCCTGCCCGTCCTGCGC
CTGGTGGCCCGTGAGGGCGACCGCGTGAAGAAGCTCATCAACTCACAGATCAGCCTCCTC
ATCGGCAAAGGCCTCCACGAGTTTGACTCCTTGTGCGACCCAGAAGTGAACGACTTTCGC
GCCAAGATGTGCCAATTCTGCGAGGAGGCGGCCGCCCGCCGGCAGCAGCTGGGCTGGGAG
GCCTGGCTGCAGTACAGTTTCCCCCTGCAGCTGGAGCCCTCGGCTCAAACCTGGGGGCCT
GGTACCCTGCGGCTCCCGAACCGGGCCCTTCTGGTCAACGTTAAGTTTGAGGGCAGCGAG
GAGAGCTTCACCTTCCAGGTGTCCACCAAGGACGTGCCGCTGGCGCTGATGGCCTGTGCC
CTGCGGAAGAAGGCCACAGTGTTCCGGCAGCCGCTGGTGGAGCAGCCGGAAGACTACACG
CTGCAGGTGAACGGCAGGCATGAGTACCTGTATGGCAGCTACCCGCTCTGCCAGTTCCAG
TACATCTGCAGCTGCCTGCACAGTGGGTTGACCCCTCACCTGACCATGGTCCATTCCTCC
TCCATCCTCGCCATGCGGGATGAGCAGAGCAACCCTGCCCCCCAGGTCCAGAAACCGCGT
GCCAAACCACCTCCCATTCCTGCGAAGAAGCCTTCCTCTGTGTCCCTGTGGTCCCTGGAG
CAGCCGTTCCGCATCGAGCTCATCCAGGGCAGCAAAGTGAACGCCGACGAGCGGATGAAG
CTGGTGGTGCAGGCCGGGCTTTTCCACGGCAACGAGATGCTGTGCAAGACGGTGTCCAGC
TCGGAGGTGAGCGTGTGCTCGGAGCCCGTGTGGAAGCAGCGGCTGGAGTTCGACATCAAC
ATCTGCGACCTGCCCCGCATGGCCCGTCTCTGCTTTGCGCTGTACGCCGTGATCGAGAAA
GCCAAGAAGGCTCGCTCCACCAAGAAGAAGTCCAAGAAGGCGGACTGCCCCATTGCCTGG
GCCAACCTCATGCTGTTTGACTACAAGGACCAGCTTAAGACCGGGGAACGCTGCCTCTAC
ATGTGGCCCTCCGTCCCAGATGAGAAGGGCGAGCTGCTGAACCCCACGGGCACTGTGCGC
AGTAACCCCAACACGGATAGCGCCGCTGCCCTGCTCATCTGCCTGCCCGAGGTGGCCCCG
CACCCCGTGTACTACCCCGCCCTGGAGAAGATCTTGGAGCTGGGGCGACACAGCGAGTGT
GTGCATGTCACCGAGGAGGAGCAGCTGCAGCTGCGGGAAATCCTGGAGCGGCGGGGGTCT
GGGGAGCTGTATGAGCACGAGAAGGACCTGGTGTGGAAGCTGCGGCATGAAGTCCAGGAG
CACTTCCCGGAGGCGCTAGCCCGGCTGCTGCTGGTCACCAAGTGGAACAAGCATGAGGAT
GTGGCCCAGATGCTCTACCTGCTGTGCTCCTGGCCGGAGCTGCCCGTCCTGAGCGCCCTG
GAGCTGCTAGACTTCAGCTTCCCCGATTGCCACGTAGGCTCCTTCGCCATCAAGTCGCTG
CGGAAACTGACGGACGATGAGCTGTTCCAGTACCTGCTGCAGCTGGTGCAGGTGCTCAAG
TACGAGTCCTACCTGGACTGCGAGCTGACCAAATTCCTGCTGGACCGGGCCCTGGCCAAC
CGCAAGATCGGCCACTTCCTTTTCTGGCACCTCCGCTCCGAGATGCACGTGCCGTCGGTG
GCCCTGCGCTTCGGCCTCATCCTGGAGGCCTACTGCAGGGGCAGCACCCACCACATGAAG
GTGCTGATGAAGCAGGGGGAAGCACTGAGCAAACTGAAGGCCCTGAATGACTTCGTCAAG
CTGAGCTCTCAGAAGACCCCCAAGCCCCAGACCAAGGAGCTGATGCACTTGTGCATGCGG
CAGGAGGCCTACCTAGAGGCCCTCTCCCACCTGCAGTCCCCACTCGACCCCAGCACCCTG
CTGGCTGAAGTCTGCGTGGAGCAGTGCACCTTCATGGACTCCAAGATGAAGCCCCTGTGG
ATCATGTACAGCAACGAGGAGGCAGGCAGCGGCGGCAGCGTGGGCATCATCTTTAAGAAC
GGGGATGACCTCCGGCAGGACATGCTGACCCTGCAGATGATCCAGCTCATGGACGTCCTG
TGGAAGCAGGAGGGGCTGGACCTGAGGATGACCCCCTATGGCTGCCTCCCCACCGGGGAC
CGCACAGGCCTCATTGAGGTGGTACTCCGTTCAGACACCATCGCCAACATCCAACTCAAC
AAGAGCAACATGGCAGCCACAGCCGCCTTCAACAAGGATGCCCTGCTCAACTGGCTGAAG
TCCAAGAACCCGGGGGAGGCCCTGGATCGAGCCATTGAGGAGTTCACCCTCTCCTGTGCT
GGCTATTGTGTGGCCACATATGTGCTGGGCATTGGCGATCGGCACAGCGACAACATCATG
ATCCGAGAGAGTGGGCAGCTGTTCCACATTGATTTTGGCCACTTTCTGGGGAATTTCAAG
ACCAAGTTTGGAATCAACCGCGAGCGTGTCCCATTCATCCTCACCTACGACTTTGTCCAT
GTGATTCAGCAGGGGAAGACTAATAATAGTGAGAAATTTGAACGGTTCCGGGGCTACTGT
GAAAGGGCCTACACCATCCTGCGGCGCCACGGGCTTCTCTTCCTCCACCTCTTTGCCCTG
ATGCGGGCGGCAGGCCTGCCTGAGCTCAGCTGCTCCAAAGACATCCAGTATCTCAAGGAC
TCCCTGGCACTGGGGAAAACAGAGGAGGAGGCACTGAAGCACTTCCGAGTGAAGTTTAAC
GAAGCCCTCCGTGAGAGCTGGAAAACCAAAGTGAACTGGCTGGCCCACAACGTGTCCAAA
GACAACAGGCAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00454</identifier>
            <name>PI3_PI4_kinase</name>
          </pfam>
          <pfam>
            <identifier>PF00792</identifier>
            <name>PI3K_C2</name>
          </pfam>
          <pfam>
            <identifier>PF00794</identifier>
            <name>PI3K_rbd</name>
          </pfam>
          <pfam>
            <identifier>PF00613</identifier>
            <name>PI3Ka</name>
          </pfam>
          <pfam>
            <identifier>PF02192</identifier>
            <name>PI3K_p85B</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mast cell granule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phosphatidylinositol 3-kinase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-4-phosphate 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol-4,5-bisphosphate 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adaptive immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to fungus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mast cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mast cell degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mast cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>natural killer cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>natural killer cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>natural killer cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil extravasation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-3-phosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>respiratory burst involved in defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="16">
      <id>BE0002379</id>
      <name>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18222</ref-id>
            <pubmed-id>12145276</pubmed-id>
            <citation>Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR: Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem. 2002 Oct 4;277(40):37124-30. Epub 2002 Jul 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P42336" source="Swiss-Prot">
        <name>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform</name>
        <general-function>Protein serine/threonine kinase activity</general-function>
        <specific-function>Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation in breast cancer cells through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Has also serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS.</specific-function>
        <gene-name>PIK3CA</gene-name>
        <locus>3q26.3</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.23</theoretical-pi>
        <molecular-weight>124283.025</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8975</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PIK3CA</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z29090</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2153</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P42336</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PK3CA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.1.153</synonym>
          <synonym>p110alpha</synonym>
          <synonym>Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha</synonym>
          <synonym>Phosphoinositide-3-kinase catalytic alpha polypeptide</synonym>
          <synonym>PI3-kinase subunit alpha</synonym>
          <synonym>PtdIns-3-kinase subunit p110-alpha</synonym>
          <synonym>Serine/threonine protein kinase PIK3CA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011705|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQ
LLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFA
IGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKH
IYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLK
LCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMD
CFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGI
YHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHC
PLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWF
SSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPL
SEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAME
LLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTN
QRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILK
QEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLW
LNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLS
IGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRS
CAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDF
LIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIA
YIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011706|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)
ATGCCTCCACGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATGCCCCCAAGAATC
CTAGTAGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGCCTCCGTGAGGCT
ACATTAATAACCATAAAGCATGAACTATTTAAAGAAGCAAGAAAATACCCCCTCCATCAA
CTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACTCAAGAAGCAGAAAGGGAA
GAATTTTTTGATGAAACAAGACGACTTTGTGACCTTCGGCTTTTTCAACCCTTTTTAAAA
GTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAAATTGGTTTTGCT
ATCGGCATGCCAGTGTGTGAATTTGATATGGTTAAAGATCCAGAAGTACAGGACTTCCGA
AGAAATATTCTGAACGTTTGTAAAGAAGCTGTGGATCTTAGGGACCTCAATTCACCTCAT
AGTAGAGCAATGTATGTCTATCCTCCAAATGTAGAATCTTCACCAGAATTGCCAAAGCAC
ATATATAATAAATTAGATAAAGGGCAAATAATAGTGGTGATCTGGGTAATAGTTTCTCCA
AATAATGACAAGCAGAAGTATACTCTGAAAATCAACCATGACTGTGTACCAGAACAAGTA
ATTGCTGAAGCAATCAGGAAAAAAACTCGAAGTATGTTGCTATCCTCTGAACAACTAAAA
CTCTGTGTTTTAGAATATCAGGGCAAGTATATTTTAAAAGTGTGTGGATGTGATGAATAC
TTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGTATAATGCTTGGG
AGGATGCCCAATTTGATGTTGATGGCTAAAGAAAGCCTTTATTCTCAACTGCCAATGGAC
TGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCATATATGAATGGA
GAAACATCTACAAAATCCCTTTGGGTTATAAATAGTGCACTCAGAATAAAAATTCTTTGT
GCAACCTACGTGAATGTAAATATTCGAGACATTGATAAGATCTATGTTCGAACAGGTATC
TACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTACCTTGTTCCAAT
CCCAGGTGGAATGAATGGCTGAATTATGATATATACATTCCTGATCTTCCTCGTGCTGCT
CGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAAGAGGAACACTGT
CCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTAGTATCTGGAAAA
ATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTGAACCCTATTGGT
GTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAGTTTGACTGGTTC
AGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCCAATTGGTCTGTA
TCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGACTAGCTAGAGAC
AATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGATCCTCTC
TCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGTGTAACT
ATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGATGAAGTA
GCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCTATGGAA
CTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCGGTGCTTGGAA
AAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTCCTAAAA
TATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTGACTAAT
CAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCACAATAAAACAGTT
AGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTATTTGAAG
CACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACTGACATTCTCAAA
CAGGAGAAGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTTGAGCAAATGAGG
CGACCAGATTTCATGGATGCTCTACAGGGCTTTCTGTCTCCTCTAAACCCTGCTCATCAA
CTAGGAAACCTCAGGCTTGAAGAGTGTCGAATTATGTCCTCTGCAAAAAGGCCACTGTGG
TTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAACAATGAGATCATC
TTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATTATTCGTATTATG
GAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTATGGTTGTCTGTCA
ATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACTATTATGCAAATT
CAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACACTACATCAGTGG
CTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTGTTTACACGTTCA
TGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGTCACAATAGTAAC
ATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACACTTTTTGGATCAC
AAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTGACACAGGATTTC
TTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAATTTGAGAGGTTT
CAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAATCTCTTCATAAAT
CTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTTGATGACATTGCA
TACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTGGAGTATTTCATG
AAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGATTGGATCTTCCAC
ACAATTAAACAGCATGCATTGAACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00454</identifier>
            <name>PI3_PI4_kinase</name>
          </pfam>
          <pfam>
            <identifier>PF00792</identifier>
            <name>PI3K_C2</name>
          </pfam>
          <pfam>
            <identifier>PF00794</identifier>
            <name>PI3K_rbd</name>
          </pfam>
          <pfam>
            <identifier>PF00613</identifier>
            <name>PI3Ka</name>
          </pfam>
          <pfam>
            <identifier>PF02192</identifier>
            <name>PI3K_p85B</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lamellipodium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phosphatidylinositol 3-kinase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phosphatidylinositol 3-kinase complex, class IA</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-4-phosphate 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol-4,5-bisphosphate 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase activator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein serine/threonine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adipose tissue development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endothelial cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hypomethylation of CpG island</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway via phosphatidylinositol 3-kinase</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>liver development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of anoikis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fibroblast apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-3-phosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of genetic imprinting</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell costimulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasculature development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="17">
      <id>BE0002407</id>
      <name>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18222</ref-id>
            <pubmed-id>12145276</pubmed-id>
            <citation>Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR: Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem. 2002 Oct 4;277(40):37124-30. Epub 2002 Jul 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P42338" source="Swiss-Prot">
        <name>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform</name>
        <general-function>Phosphatidylinositol-4,5-bisphosphate 3-kinase activity</general-function>
        <specific-function>Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors.</specific-function>
        <gene-name>PIK3CB</gene-name>
        <locus>3q22.3</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.09</theoretical-pi>
        <molecular-weight>122761.225</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8976</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PIK3CB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S67334</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2154</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P42338</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PK3CB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.1.153</synonym>
          <synonym>p110beta</synonym>
          <synonym>Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta</synonym>
          <synonym>PI3-kinase subunit beta</synonym>
          <synonym>PIK3C1</synonym>
          <synonym>PtdIns-3-kinase subunit p110-beta</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011722|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
MCFSFIMPPAMADILDIWAVDSQIASDGSIPVDFLLPTGIYIQLEVPREATISYIKQMLW
KQVHNYPMFNLLMDIDSYMFACVNQTAVYEELEDETRRLCDVRPFLPVLKLVTRSCDPGE
KLDSKIGVLIGKGLHEFDSLKDPEVNEFRRKMRKFSEEKILSLVGLSWMDWLKQTYPPEH
EPSIPENLEDKLYGGKLIVAVHFENCQDVFSFQVSPNMNPIKVNELAIQKRLTIHGKEDE
VSPYDYVLQVSGRVEYVFGDHPLIQFQYIRNCVMNRALPHFILVECCKIKKMYEQEMIAI
EAAINRNSSNLPLPLPPKKTRIISHVWENNNPFQIVLVKGNKLNTEETVKVHVRAGLFHG
TELLCKTIVSSEVSGKNDHIWNEPLEFDINICDLPRMARLCFAVYAVLDKVKTKKSTKTI
NPSKYQTIRKAGKVHYPVAWVNTMVFDFKGQLRTGDIILHSWSSFPDELEEMLNPMGTVQ
TNPYTENATALHVKFPENKKQPYYYPPFDKIIEKAAEIASSDSANVSSRGGKKFLPVLKE
ILDRDPLSQLCENEMDLIWTLRQDCREIFPQSLPKLLLSIKWNKLEDVAQLQALLQIWPK
LPPREALELLDFNYPDQYVREYAVGCLRQMSDEELSQYLLQLVQVLKYEPFLDCALSRFL
LERALGNRRIGQFLFWHLRSEVHIPAVSVQFGVILEAYCRGSVGHMKVLSKQVEALNKLK
TLNSLIKLNAVKLNRAKGKEAMHTCLKQSAYREALSDLQSPLNPCVILSELYVEKCKYMD
SKMKPLWLVYNNKVFGEDSVGVIFKNGDDLRQDMLTLQMLRLMDLLWKEAGLDLRMLPYG
CLATGDRSGLIEVVSTSETIADIQLNSSNVAAAAAFNKDALLNWLKEYNSGDDLDRAIEE
FTLSCAGYCVASYVLGIGDRHSDNIMVKKTGQLFHIDFGHILGNFKSKFGIKRERVPFIL
TYDFIHVIQQGKTGNTEKFGRFRQCCEDAYLILRRHGNLFITLFALMLTAGLPELTSVKD
IQYLKDSLALGKSEEEALKQFKQKFDEALRESWTTKVNWMAHTVRKDYRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0004727|3213 bp
ATGTGCTTCAGTTTCATAATGCCTCCTGCTATGGCAGACATCCTTGACATCTGGGCGGTG
GATTCACAGATAGCATCTGATGGCTCCATACCTGTGGATTTCCTTTTGCCCACTGGGATT
TATATCCAGTTGGAGGTACCTCGGGAAGCTACCATTTCTTATATTAAGCAGATGTTATGG
AAGCAAGTTCACAATTACCCAATGTTCAACCTCCTTATGGATATTGACTCCTATATGTTT
GCATGTGTGAATCAGACTGCTGTATATGAGGAGCTTGAAGATGAAACACGAAGACTCTGT
GATGTCAGACCTTTTCTTCCAGTTCTCAAATTAGTGACAAGAAGTTGTGACCCAGGGGAA
AAATTAGACTCAAAAATTGGAGTCCTTATAGGAAAAGGTCTGCATGAATTTGATTCCTTG
AAGGATCCTGAAGTAAATGAATTTCGAAGAAAAATGCGCAAATTCAGCGAGGAAAAAATC
CTGTCACTTGTGGGATTGTCTTGGATGGACTGGCTAAAACAAACATATCCACCAGAGCAT
GAACCATCCATCCCTGAAAACTTAGAAGATAAACTTTATGGGGGAAAGCTCATCGTAGCT
GTTCATTTTGAAAACTGCCAGGACGTGTTTAGCTTTCAAGTGTCTCCTAATATGAATCCT
ATCAAAGTAAATGAATTGGCAATCCAAAAACGTTTGACTATTCATGGGAAGGAAGATGAA
GTTAGCCCCTATGATTATGTGTTGCAAGTCAGCGGGAGAGTAGAATATGTTTTTGGTGAT
CATCCACTAATTCAGTTCCAGTATATCCGGAACTGTGTGATGAACAGAGCCCTGCCCCAT
TTTATACTTGTGGAATGCTGCAAGATCAAGAAAATGTATGAACAAGAAATGATTGCCATA
GAGGCTGCCATAAATCGAAATTCATCTAATCTTCCTCTTCCATTACCACCAAAGAAAACA
CGAATTATTTCTCATGTTTGGGAAAATAACAACCCTTTCCAAATTGTCTTGGTTAAGGGA
AATAAACTTAACACAGAGGAAACTGTAAAAGTTCATGTCAGGGCTGGTCTTTTTCATGGT
ACTGAGCTCCTGTGTAAAACCATCGTAAGCTCAGAGGTATCAGGGAAAAATGATCATATT
TGGAATGAACCACTGGAATTTGATATTAATATTTGTGACTTACCAAGAATGGCTCGATTA
TGTTTTGCTGTTTATGCAGTTTTGGATAAAGTAAAAACGAAGAAATCAACGAAAACTATT
AATCCCTCTAAATATCAGACCATCAGGAAAGCTGGAAAAGTGCATTATCCTGTAGCGTGG
GTAAATACGATGGTTTTTGACTTTAAAGGACAATTGAGAACTGGAGACATAATATTACAC
AGCTGGTCTTCATTTCCTGATGAACTCGAAGAAATGTTGAATCCAATGGGAACTGTTCAA
ACAAATCCATATACTGAAAATGCAACAGCTTTGCATGTTAAATTTCCAGAGAATAAAAAA
CAACCTTATTATTACCCTCCCTTCGATAAGATTATTGAAAAGGCAGCTGAGATTGCAAGC
AGTGATAGTGCTAATGTGTCAAGTCGAGGTGGAAAAAAGTTTCTTCCTGTATTGAAAGAA
ATCTTGGACAGGGATCCCTTGTCTCAACTGTGTGAAAATGAAATGGATCTTATTTGGACT
TTGCGACAAGACTGCCGAGAGATTTTCCCACAATCACTGCCAAAATTACTGCTGTCAATC
AAGTGGAATAAACTTGAGGATGTTGCTCAGCTTCAGGCGCTGCTTCAGATTTGGCCTAAA
CTGCCCCCCCGGGAGGCCCTAGAGCTTCTGGATTTCAACTATCCAGACCAGTACGTTCGA
GAATATGCTGTAGGCTGCCTGCGACAGATGAGTGATGAAGAACTTTCTCAATATCTTTTA
CAACTGGTGCAAGTGTTAAAATATGAGCCTTTTCTTGATTGTGCCCTCTCTAGATTCCTA
TTAGAAAGAGCACTTGGTAATCGGAGGATAGGGCAGTTTCTATTTTGGCATCTTAGGTCA
GAAGTGCACATTCCTGCTGTCTCAGTACAATTTGGTGTCATCCTTGAAGCATACTGCCGG
GGAAGTGTGGGGCACATGAAAGTGCTTTCTAAGCAGGTTGAAGCACTCAATAAGTTAAAA
ACTTTAAATAGTTTAATCAAACTGAATGCCGTGAAGTTAAACAGAGCCAAAGGGAAGGAG
GCCATGCATACCTGTTTAAAACAGAGTGCTTACCGGGAAGCCCTCTCTGACCTGCAGTCA
CCCCTGAACCCATGTGTTATCCTCTCAGAACTCTATGTTGAAAAGTGCAAATACATGGAT
TCCAAAATGAAGCCTTTGTGGCTGGTATACAATAACAAGGTATTTGGTGAGGATTCAGTT
GGAGTGATTTTTAAAAATGGTGATGATTTACGACAGGATATGTTGACACTCCAAATGTTG
CGCTTGATGGATTTACTCTGGAAAGAAGCTGGTTTGGATCTTCGGATGTTGCCTTATGGC
TGTTTAGCAACAGGAGATCGCTCTGGCCTCATTGAAGTTGTGAGCACCTCTGAAACAATT
GCTGACATTCAGCTGAACAGTAGCAATGTGGCTGCTGCAGCAGCCTTCAACAAAGATGCC
CTTCTGAACTGGCTTAAAGAATACAACTCTGGGGATGACCTGGACCGAGCCATTGAGGAA
TTTACACTGTCCTGTGCTGGCTACTGTGTAGCTTCTTATGTCCTTGGGATTGGTGACAGA
CATAGTGACAACATCATGGTCAAAAAAACTGGCCAGCTCTTCCACATTGACTTTGGACAT
ATTCTTGGAAATTTCAAATCTAAGTTTGGCATTAAAAGGGAGCGAGTGCCTTTTATTCTT
ACCTATGATTTCATCCATGTCATTCAACAAGGAAAAACAGGAAATACAGAAAAGTTTGGC
CGGTTCCGCCAGTGTTGTGAGGATGCATATCTGATTTTACGACGGCATGGGAATCTCTTC
ATCACTCTCTTTGCGCTGATGTTGACTGCAGGGCTTCCTGAACTCACATCAGTCAAAGAT
ATACAGTATCTTAAGGACTCTCTTGCATTAGGGAAGAGTGAAGAAGAAGCACTCAAACAG
TTTAAGCAAAAATTTGATGAGGCGCTCAGGGAAAGCTGGACTACTAAAGTGAACTGGATG
GCCCACACAGTTCGGAAAGACTACAGATCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00454</identifier>
            <name>PI3_PI4_kinase</name>
          </pfam>
          <pfam>
            <identifier>PF00792</identifier>
            <name>PI3K_C2</name>
          </pfam>
          <pfam>
            <identifier>PF00794</identifier>
            <name>PI3K_rbd</name>
          </pfam>
          <pfam>
            <identifier>PF00613</identifier>
            <name>PI3Ka</name>
          </pfam>
          <pfam>
            <identifier>PF02192</identifier>
            <name>PI3K_p85B</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intercellular bridge</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phosphatidylinositol 3-kinase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-4-phosphate 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol-4,5-bisphosphate 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis involved in wound healing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic cleavage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endothelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>homophilic cell adhesion via plasma membrane adhesion molecules</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet aggregation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell-matrix adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of clathrin-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="18">
      <id>BE0004914</id>
      <name>Inositol 1,4,5-trisphosphate receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18223</ref-id>
            <pubmed-id>1844813</pubmed-id>
            <citation>Parker I, Ivorra I: Caffeine inhibits inositol trisphosphate-mediated liberation of intracellular calcium in Xenopus oocytes. J Physiol. 1991 Feb;433:229-40.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q14643" source="Swiss-Prot">
        <name>Inositol 1,4,5-trisphosphate receptor type 1</name>
        <general-function>Phosphatidylinositol binding</general-function>
        <specific-function>Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate. Involved in the regulation of epithelial secretion of electrolytes and fluid through the interaction with AHCYL1 (By similarity). Plays a role in ER stress-induced apoptosis. Cytoplasmic calcium released from the ER triggers apoptosis by the activation of CaM kinase II, eventually leading to the activation of downstream apoptosis pathways (By similarity).</specific-function>
        <gene-name>ITPR1</gene-name>
        <locus/>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2283-2303
2315-2335
2362-2382
2406-2426
2449-2469
2578-2598</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>313926.375</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>743</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14643</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ITPR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>INSP3R1</synonym>
          <synonym>IP3 receptor isoform 1</synonym>
          <synonym>IP3R 1</synonym>
          <synonym>Type 1 inositol 1,4,5-trisphosphate receptor</synonym>
          <synonym>Type 1 InsP3 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009443|Inositol 1,4,5-trisphosphate receptor type 1
MSDKMSSFLHIGDICSLYAEGSTNGFISTLGLVDDRCVVQPETGDLNNPPKKFRDCLFKL
CPMNRYSAQKQFWKAAKPGANSTTDAVLLNKLHHAADLEKKQNETENRKLLGTVIQYGNV
IQLLHLKSNKYLTVNKRLPALLEKNAMRVTLDEAGNEGSWFYIQPFYKLRSIGDSVVIGD
KVVLNPVNAGQPLHASSHQLVDNPGCNEVNSVNCNTSWKIVLFMKWSDNKDDILKGGDVV
RLFHAEQEKFLTCDEHRKKQHVFLRTTGRQSATSATSSKALWEVEVVQHDPCRGGAGYWN
SLFRFKHLATGHYLAAEVDPDFEEECLEFQPSVDPDQDASRSRLRNAQEKMVYSLVSVPE
GNDISSIFELDPTTLRGGDSLVPRNSYVRLRHLCTNTWVHSTNIPIDKEEEKPVMLKIGT
SPVKEDKEAFAIVPVSPAEVRDLDFANDASKVLGSIAGKLEKGTITQNERRSVTKLLEDL
VYFVTGGTNSGQDVLEVVFSKPNRERQKLMREQNILKQIFKLLQAPFTDCGDGPMLRLEE
LGDQRHAPFRHICRLCYRVLRHSQQDYRKNQEYIAKQFGFMQKQIGYDVLAEDTITALLH
NNRKLLEKHITAAEIDTFVSLVRKNREPRFLDYLSDLCVSMNKSIPVTQELICKAVLNPT
NADILIETKLVLSRFEFEGVSSTGENALEAGEDEEEVWLFWRDSNKEIRSKSVRELAQDA
KEGQKEDRDVLSYYRYQLNLFARMCLDRQYLAINEISGQLDVDLILRCMSDENLPYDLRA
SFCRLMLHMHVDRDPQEQVTPVKYARLWSEIPSEIAIDDYDSSGASKDEIKERFAQTMEF
VEEYLRDVVCQRFPFSDKEKNKLTFEVVNLARNLIYFGFYNFSDLLRLTKILLAILDCVH
VTTIFPISKMAKGEENKGNNDVEKLKSSNVMRSIHGVGELMTQVVLRGGGFLPMTPMAAA
PEGNVKQAEPEKEDIMVMDTKLKIIEILQFILNVRLDYRISCLLCIFKREFDESNSQTSE
TSSGNSSQEGPSNVPGALDFEHIEEQAEGIFGGSEENTPLDLDDHGGRTFLRVLLHLTMH
DYPPLVSGALQLLFRHFSQRQEVLQAFKQVQLLVTSQDVDNYKQIKQDLDQLRSIVEKSE
LWVYKGQGPDETMDGASGENEHKKTEEGNNKPQKHESTSSYNYRVVKEILIRLSKLCVQE
SASVRKSRKQQQRLLRNMGAHAVVLELLQIPYEKAEDTKMQEIMRLAHEFLQNFCAGNQQ
NQALLHKHINLFLNPGILEAVTMQHIFMNNFQLCSEINERVVQHFVHCIETHGRNVQYIK
FLQTIVKAEGKFIKKCQDMVMAELVNSGEDVLVFYNDRASFQTLIQMMRSERDRMDENSP
LMYHIHLVELLAVCTEGKNVYTEIKCNSLLPLDDIVRVVTHEDCIPEVKIAYINFLNHCY
VDTEVEMKEIYTSNHMWKLFENFLVDICRACNNTSDRKHADSILEKYVTEIVMSIVTTFF
SSPFSDQSTTLQTRQPVFVQLLQGVFRVYHCNWLMPSQKASVESCIRVLSDVAKSRAIAI
PVDLDSQVNNLFLKSHSIVQKTAMNWRLSARNAARRDSVLAASRDYRNIIERLQDIVSAL
EDRLRPLVQAELSVLVDVLHRPELLFPENTDARRKCESGGFICKLIKHTKQLLEENEEKL
CIKVLQTLREMMTKDRGYGEKLISIDELDNAELPPAPDSENATEELEPSPPLRQLEDHKR
GEALRQVLVNRYYGNVRPSGRRESLTSFGNGPLSAGGPGKPGGGGGGSGSSSMSRGEMSL
AEVQCHLDKEGASNLVIDLIMNASSDRVFHESILLAIALLEGGNTTIQHSFFCRLTEDKK
SEKFFKVFYDRMKVAQQEIKATVTVNTSDLGNKKKDDEVDRDAPSRKKAKEPTTQITEEV
RDQLLEASAATRKAFTTFRREADPDDHYQPGEGTQATADKAKDDLEMSAVITIMQPILRF
LQLLCENHNRDLQNFLRCQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEKNVAL
INQTLESLTEYCQGPCHENQNCIATHESNGIDIITALILNDINPLGKKRMDLVLELKNNA
SKLLLAIMESRHDSENAERILYNMRPKELVEVIKKAYMQGEVEFEDGENGEDGAASPRNV
GHNIYILAHQLARHNKELQSMLKPGGQVDGDEALEFYAKHTAQIEIVRLDRTMEQIVFPV
PSICEFLTKESKLRIYYTTERDEQGSKINDFFLRSEDLFNEMNWQKKLRAQPVLYWCARN
MSFWSSISFNLAVLMNLLVAFFYPFKGVRGGTLEPHWSGLLWTAMLISLAIVIALPKPHG
IRALIASTILRLIFSVGLQPTLFLLGAFNVCNKIIFLMSFVGNCGTFTRGYRAMVLDVEF
LYHLLYLVICAMGLFVHEFFYSLLLFDLVYREETLLNVIKSVTRNGRSIILTAVLALILV
YLFSIVGYLFFKDDFILEVDRLPNETAVPETGESLASEFLFSDVCRVESGENCSSPAPRE
ELVPAEETEQDKEHTCETLLMCIVTVLSHGLRSGGGVGDVLRKPSKEEPLFAARVIYDLL
FFFMVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVTFEEHI
KEEHNMWHYLCFIVLVKVKDSTEYTGPESYVAEMIKERNLDWFPRMRAMSLVSSDSEGEQ
NELRNLQEKLESTMKLVTNLSGQLSELKDQMTEQRKQKQRIGLLGHPPHMNVNPQQPA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013163|Inositol 1,4,5-trisphosphate receptor type 1 (ITPR1)
ATGTCTGACAAAATGTCTAGCTTCCTACATATTGGAGACATTTGTTCTCTGTACGCGGAG
GGATCGACAAATGGATTTATTAGCACCTTGGGCCTGGTTGATGATCGTTGTGTTGTACAG
CCAGAAACCGGGGACCTTAACAATCCACCTAAGAAATTCAGAGACTGCCTCTTTAAGCTA
TGTCCCATGAACCGCTACTCTGCCCAAAAGCAGTTCTGGAAAGCCGCTAAGCCTGGGGCC
AACAGCACCACAGACGCAGTGCTACTCAACAAACTGCACCACGCTGCAGACTTGGAAAAG
AAGCAGAATGAGACAGAAAACAGGAAATTGCTGGGGACCGTAATCCAGTATGGCAATGTG
ATCCAGCTCCTGCATTTGAAAAGTAATAAATACCTAACAGTGAATAAGAGGCTTCCTGCT
CTGTTGGAGAAGAATGCCATGAGAGTCACATTGGACGAGGCTGGAAATGAAGGGTCCTGG
TTTTATATTCAGCCATTCTACAAGCTGCGATCCATTGGAGACAGCGTGGTCATAGGTGAC
AAGGTGGTTCTGAACCCCGTCAATGCTGGTCAGCCCCTACATGCTAGCAGCCATCAACTG
GTAGATAACCCAGGCTGCAATGAGGTCAATTCCGTCAACTGCAATACAAGCTGGAAAATA
GTCCTTTTCATGAAATGGAGTGATAACAAAGACGACATATTAAAGGGGGGTGACGTGGTG
AGGCTGTTTCATGCTGAGCAGGAGAAGTTTCTCACCTGTGACGAACACAGGAAGAAGCAG
CACGTCTTCCTGAGAACCACGGGCCGGCAGTCGGCCACATCTGCCACCAGTTCAAAAGCC
CTGTGGGAGGTGGAGGTGGTCCAGCATGACCCATGTCGGGGCGGAGCAGGGTATTGGAAC
AGCCTTTTCCGTTTCAAGCATCTGGCCACGGGGCATTACTTGGCAGCAGAGGTAGACCCT
GACTTTGAGGAAGAATGCCTGGAGTTTCAGCCCTCAGTGGACCCTGATCAGGACGCCTCT
CGAAGTAGGTTGCGGAATGCCCAAGAAAAGATGGTATACTCCCTGGTCTCTGTGCCTGAA
GGCAATGACATCTCCTCCATTTTCGAGCTAGATCCCACCACTCTGCGTGGAGGTGACAGC
CTTGTCCCAAGGAACTCTTATGTTCGGCTCAGACACCTATGTACTAATACCTGGGTTCAC
AGCACAAATATTCCTATTGACAAGGAAGAAGAAAAGCCCGTGATGCTGAAAATTGGCACC
TCTCCTGTGAAGGAGGATAAGGAAGCATTTGCCATAGTTCCGGTTTCTCCTGCTGAAGTT
CGGGACCTGGACTTTGCCAATGATGCCAGCAAGGTGCTGGGCTCCATTGCTGGGAAGCTA
GAGAAGGGCACCATCACCCAGAATGAAAGGAGGTCTGTAACCAAGCTGCTAGAAGATTTG
GTTTACTTCGTCACTGGTGGAACTAATTCTGGTCAAGATGTTCTCGAAGTTGTCTTCTCC
AAGCCCAACAGAGAACGGCAGAAACTGATGAGAGAACAGAATATTCTCAAGCAGATCTTC
AAGTTGTTACAAGCCCCATTCACAGACTGCGGTGATGGCCCAATGCTTCGGCTGGAAGAG
CTCGGGGACCAGCGGCACGCTCCTTTCAGACACATCTGCCGGCTCTGCTACAGGGTGCTG
AGACACTCGCAGCAAGACTACAGGAAGAACCAGGAGTATATAGCCAAGCAGTTTGGCTTC
ATGCAGAAGCAGATTGGCTATGATGTGTTGGCTGAAGACACTATCACTGCCCTGCTCCAC
AATAATCGGAAACTCCTGGAAAAACACATTACCGCGGCAGAGATTGACACATTTGTCAGC
CTGGTGCGAAAGAACAGGGAGCCCAGATTCTTAGATTACCTCTCCGACCTCTGTGTCTCC
ATGAACAAATCAATTCCAGTGACCCAGGAACTGATATGTAAAGCTGTGCTGAACCCCACC
AACGCTGACATCCTGATTGAGACCAAGTTGGTTCTTTCTCGTTTTGAATTTGAAGGTGTC
TCTTCCACTGGAGAGAATGCTCTGGAGGCAGGAGAAGACGAGGAAGAGGTGTGGCTGTTT
TGGAGGGACAGCAACAAAGAGATTCGCAGCAAGAGTGTGAGGGAATTGGCTCAGGATGCT
AAAGAAGGGCAGAAGGAGGACCGAGACGTTCTCAGCTACTACAGATATCAGCTGAACCTC
TTTGCGAGGATGTGTCTGGACCGCCAATACCTGGCCATCAACGAAATCTCAGGCCAGCTG
GATGTCGATCTCATTCTCCGCTGCATGTCTGACGAGAACCTGCCCTATGACCTCAGGGCG
TCCTTCTGCCGCCTCATGCTTCACATGCATGTGGACCGAGATCCCCAGGAACAAGTCACC
CCCGTGAAATATGCCCGCCTCTGGTCGGAGATTCCCTCGGAGATCGCCATTGACGACTAT
GATAGTAGTGGAGCTTCCAAAGATGAAATTAAGGAGAGATTTGCTCAGACCATGGAGTTT
GTGGAGGAGTATTTAAGAGATGTGGTTTGTCAGAGGTTCCCTTTCTCTGATAAAGAGAAG
AATAAGCTTACGTTTGAGGTTGTAAATTTAGCTAGGAATCTCATATACTTTGGTTTCTAC
AACTTCTCTGACCTTCTACGATTAACTAAGATCCTTCTGGCCATATTGGACTGTGTACAT
GTGACAACAATCTTCCCCATTAGCAAGATGGCGAAAGGAGAAGAGAATAAAGGCAGTAAC
GTGATGAGATCTATTCATGGCGTGGGAGAGCTGATGACCCAGGTGGTGCTCCGGGGAGGA
GGCTTTTTGCCCATGACTCCCATGGCTGCTGCCCCTGAAGGCAATGTGAAGCAGGCAGAG
CCTGAGAAGGAGGACATCATGGTCATGGACACCAAGCTGAAGATCATTGAGATACTCCAG
TTTATTTTGAATGTGAGGTTGGATTATAGGATCTCCTGCCTCCTGTGTATATTTAAGCGA
GAGTTTGATGAAAGCAATTCCCAGACTTCAGAAACATCCTCCGGAAACAGCAGCCAAGAA
GGGCCAAGTAATGTACCAGGTGCTCTTGACTTTGAACACATTGAAGAACAAGCAGAAGGC
ATCTTTGGAGGAAGTGAGGAGAACACCCCACTGGACTTGGATGACCACGGCGGCAGAACC
TTTCTCCGTGTCCTGCTCCACTTGACGATGCATGACTACCCACCCCTGGTGTCAGGGGCC
CTGCAGCTCCTCTTCCGGCACTTCAGCCAGAGGCAGGAGGTGCTCCAGGCCTTCAAACAG
GTTCAACTGCTGGTTACCAGCCAAGATGTGGACAACTACAAACAGATCAAACAAGACTTG
GATCAACTGAGGTCCATCGTGGAAAAGTCAGAGCTTTGGGTGTACAAAGGGCAGGGCCCC
GATGAGACTATGGATGGTGCATCTGGAGAAAATGAACATAAGAAAACGGAGGAGGGAAAT
AACAAGCCACAAAAGCATGAAAGCACCAGCAGCTACAACTACAGAGTGGTCAAAGAGATT
TTGATTCGGCTTAGCAAACTCTGTGTTCAAGAGAGTGCCTCAGTGAGAAAGAGCAGGAAG
CAGCAACAGCGTCTGCTCCGGAACATGGGCGCGCACGCCGTGGTGCTGGAGCTGCTGCAG
ATTCCCTATGAGAAGGCCGAAGATACCAAGATGCAAGAGATAATGAGGTTGGCTCATGAA
TTTTTGCAGAATTTCTGCGCAGGCAACCAGCAGAATCAAGCTTTGCTACATAAACACATA
AACCTGTTTCTCAACCCAGGGATCCTGGAGGCAGTAACCATGCAGCACATCTTCATGAAC
AATTTCCAGCTTTGCAGTGAGATCAACGAGAGAGTTGTTCAGCACTTCGTTCACTGCATA
GAGACTCACGGTCGGAATGTCCAGTATATAAAGTTCTTACAGACAATTGTCAAGGCAGAA
GGGAAATTTATTAAAAAATGCCAAGACATGGTTATGGCCGAGCTGGTCAATTCGGGAGAG
GATGTCCTCGTGTTCTACAACGACAGAGCCTCTTTCCAGACTCTGATCCAGATGATGCGG
TCAGAACGGGATCGGATGGATGAGAACAGCCCTCTCATGTACCACATCCACTTGGTCGAG
CTCCTGGCTGTGTGCACGGAGGGTAAGAATGTCTACACAGAGATCAAGTGCAACTCCCTG
CTCCCGCTGGATGACATCGTTCGCGTGGTGACCCACGAGGACTGCATCCCTGAGGTTAAA
ATTGCATACATTAACTTCCTGAATCACTGCTATGTGGATACAGAGGTGGAAATGAAGGAG
ATTTATACCAGCAATCACATGTGGAAATTGTTTGAGAATTTCCTTGTAGACATCTGCAGG
GCCTGTAACAACACTAGTGACAGGAAACATGCAGACTCGATTTTGGAGAAGTATGTCACC
GAAATCGTCATGAGTATTGTTACTACTTTCTTCAGCTCTCCCTTCTCAGACCAGAGTACG
ACTTTGCAGACTCGCCAGCCTGTCTTTGTGCAACTGCTGCAAGGCGTGTTCAGGGTTTAC
CACTGCAACTGGTTAATGCCAAGCCAAAAAGCCTCCGTGGAGAGCTGTATTCGGGTGCTG
TCTGATGTAGCCAAGAGCCGGGCCATTGCCATTCCCGTGGACCTGGACAGCCAAGTCAAC
AACCTCTTTCTCAAGTCCCACAGCATTGTGCAGAAAACAGCCATGAACTGGCGGCTCTCA
GCCCGCAATGCCGCACGCAGGGACTCTGTTCTGGCAGCTTCCAGAGACTACCGGAATATC
ATTGAGAGATTGCAGGACATCGTCTCCGCGCTGGAGGACCGTCTCAGGCCCCTGGTGCAG
GCAGAGTTATCTGTGCTCGTGGATGTTCTCCACAGACCCGAGCTGCTTTTCCCAGAGAAC
ACAGACGCCAGAAGGAAATGTGAAAGTGGCGGTTTCATTTGCAAGTTAATAAAGCATACA
AAACAGCTGCTAGAAGAAAATGAAGAGAAGCTCTGCATTAAGGTCCTACAGACCCTGAGG
GAAATGATGACCAAAGATAGAGGCTATGGAGAAAAGGGTGAGGCGCTCAGGCAAGTTCTG
GTCAACCGTTACTATGGAAACGTCAGACCTTCGGGACGAAGAGAGAGCCTTACCAGCTTT
GGCAATGGCCCACTGTCAGCAGGAGGACCCGGCAAGCCCGGGGGAGGAGGGGGAGGTTCC
GGATCCAGCTCTATGAGCAGGGGTGAGATGAGTCTGGCCGAGGTTCAGTGTCACCTTGAC
AAGGAGGGGGCTTCCAATCTAGTTATCGACCTCATCATGAACGCATCCAGTGACCGAGTG
TTCCATGAAAGCATTCTCCTGGCCATTGCCCTTCTGGAAGGAGGCAACACCACCATCCAG
CACTCCTTTTTCTGTCGCTTGACAGAAGATAAGAAGTCAGAGAAATTCTTTAAGGTGTTT
TATGACCGGATGAAGGTGGCCCAGCAAGAAATCAAAGCAACAGTGACAGTGAACACCAGT
GACTTGGGAAATAAAAAGAAAGACGATGAGGTAGACAGGGATGCCCCATCACGGAAAAAA
GCTAAAGAGCCCACAACACAGATAACAGAAGAGGTCCGGGATCAGCTCCTGGAGGCCTCC
GCTGCCACCAGGAAAGCCTTCACCACTTTCAGGAGGGAGGCTGATCCCGACGACCACTAC
CAGCCTGGAGAGGGCACCCAGGCCACTGCCGACAAGGCCAAGGACGACCTGGAGATGAGC
GCGGTCATCACCATCATGCAGCCCATCCTCCGCTTCCTTCAGCTCCTGTGTGAAAACCAC
AACCGAGACCTGCAGAACTTCCTCCGTTGCCAAAATAACAAGACCAACTACAATTTGGTA
TGTGAGACCCTGCAGTTTCTGGACTGTATTTGTGGAAGCACAACTGGAGGCCTTGGTCTT
CTGGGCTTGTATATAAATGAAAAGAACGTAGCGCTTATCAACCAAACCCTGGAAAGTCTG
ACCGAATACTGTCAAGGACCTTGCCATGAGAACCAGAACTGCATAGCCACCCATGAATCC
AATGGCATTGACATCATCACAGCCCTGATCCTCAATGATATCAATCCTTTGGGAAAGAAG
AGGATGGACCTTGTGTTAGAACTGAAGAACAATGCCTCGAAGTTGCTCCTGGCCATCATG
GAAAGCAGGCACGACAGTGAAAACGCAGAGAGGATACTTTATAACATGAGGCCCAAGGAA
CTGGTGGAAGTGATCAAGAAAGCCTACATGCAAGGTGAAGTGGAATTTGAGGATGGAGAA
AACGGTGAGGATGGGGCGGCGTCCCCCAGGAACGTGGGGCACAACATCTACATATTAGCC
CATCAGTTGGCTCGGCATAACAAAGAACTTCAGAGCATGCTGAAACCTGGTGGCCAAGTG
GACGGAGATGAAGCCCTGGAGTTTTATGCCAAGCACACGGCGCAGATAGAGATTGTCAGA
TTAGACCGAACAATGGAACAGATAGTCTTTCCCGTGCCCAGCATATGTGAATTCCTAACC
AAGGAGTCAAAACTACGAATTTACTATACTACAGAGAGAGACGAACAAGGCAGCAAAATC
AATGATTTCTTTCTGCGGTCTGAAGACCTCTTCAATGAAATGAATTGGCAGAAGAAACTG
AGAGCCCAGCCCGTGTTGTACTGGTGTGCCCGCAACATGTCTTTCTGGAGCAGCATTTCG
TTTAACCTGGCCGTCCTGATGAACCTGCTGGTGGCGTTTTTCTACCCGTTTAAGGGAGTC
CGAGGAGGAACCCTGGAGCCCCACTGGTCGGGACTCCTGTGGACAGCCATGCTCATCTCT
CTGGCCATCGTCATTGCCCTCCCCAAGCCCCATGGCATCCGGGCCTTAATTGCCTCCACA
ATTCTACGACTGATATTTTCAGTCGGGTTACAACCCACGTTGTTTCTTCTGGGCGCTTTC
AATGTATGCAATAAAATCATCTTTCTAATGAGCTTTGTGGGCAACTGTGGGACATTCACA
AGAGGCTACCGAGCCATGGTTCTGGATGTTGAGTTCCTCTATCATTTGTTGTATCTGGTG
ATCTGTGCCATGGGGCTCTTTGTCCATGAATTCTTCTACAGTCTGCTGCTTTTTGATTTA
GTGTACAGAGAAGAGACTTTGCTTAATGTCATTAAAAGTGTCACTCGCAATGGACGGTCC
ATCATCCTGACAGCAGTTCTGGCTCTGATCCTCGTTTACCTGTTCTCAATAGTGGGCTAT
CTTTTCTTCAAGGATGACTTTATCTTGGAAGTAGATAGGCTGCCCAATGAAACAGCTGTT
CCAGAAACCGGCGAGAGTTTGGCAAGCGAGTTCCTGTTCTCCGATGTGTGTAGGGTGGAG
AGTGGGGAGAACTGCTCCTCTCCTGCACCCAGAGAAGAGCTGGTCCCTGCAGAAGAGACG
GAACAGGATAAAGAGCACACATGTGAGACGCTGCTGATGTGCATTGTCACTGTGCTGAGT
CACGGGCTGCGGAGCGGGGGTGGAGTAGGAGATGTACTCAGGAAGCCGTCCAAAGAGGAA
CCCCTGTTTGCTGCTAGAGTTATTTATGACCTCTTGTTCTTCTTCATGGTCATCATCATT
GTTCTTAACCTGATTTTTGGGGTTATCATTGACACTTTTGCTGACCTGAGGAGTGAGAAG
CAGAAGAAGGAAGAGATCTTGAAGACCACGTGCTTTATCTGTGGCTTGGAAAGAGACAAG
TTTGACAACAAGACTGTCACCTTTGAAGAGCACATCAAGGAAGAACACAACATGTGGCAC
TATCTGTGCTTCATCGTCCTGGTGAAAGTAAAGGACTCCACCGAATATACTGGGCCTGAG
AGTTACGTGGCAGAAATGATCAAGGAAAGAAACCTTGACTGGTTCCCCAGGATGAGAGCC
ATGTCATTGGTCAGCAGTGATTCTGAAGGAGAACAGAATGAGCTGAGAAACCTGCAGGAG
AAGCTGGAGTCCACCATGAAACTTGTCACGAACCTTTCTGGCCAGCTGTCGGAATTAAAG
GATCAGATGACAGAACAAAGGAAGCAGAAACAAAGAATTGGTCTTCTAGGACATCCTCCT
CACATGAATGTCAACCCACAACAACCAGCATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF02815</identifier>
            <name>MIR</name>
          </pfam>
          <pfam>
            <identifier>PF08454</identifier>
            <name>RIH_assoc</name>
          </pfam>
          <pfam>
            <identifier>PF01365</identifier>
            <name>RYDR_ITPR</name>
          </pfam>
          <pfam>
            <identifier>PF08709</identifier>
            <name>Ins145_P3_rec</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>calcineurin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet dense granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet dense tubular network</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet dense tubular network membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>intracellular ligand-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endoplasmic reticulum calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial fluid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inositol phosphate-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stimulatory C-type lectin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>voluntary musculoskeletal movement</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q14571" source="Swiss-Prot">
        <name>Inositol 1,4,5-trisphosphate receptor type 2</name>
        <general-function>Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium. This release is regulated by cAMP both dependently and independently of PKA (By similarity).</general-function>
        <specific-function>Calcium ion binding</specific-function>
        <gene-name>ITPR2</gene-name>
        <locus>12p11.23</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2228-2248
2261-2281
2308-2328
2352-2372
2395-2415
2522-2542</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>308061.11</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6181</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14571</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ITPR2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>InsP3R2</synonym>
          <synonym>IP3 receptor isoform 2</synonym>
          <synonym>IP3R 2</synonym>
          <synonym>Type 2 inositol 1,4,5-trisphosphate receptor</synonym>
          <synonym>Type 2 InsP3 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008690|Inositol 1,4,5-trisphosphate receptor type 2
MTEKMSSFLYIGDIVSLYAEGSVNGFISTLGLVDDRCVVHPEAGDLANPPKKFRDCLFKV
CPMNRYSAQKQYWKAKQAKQGNHTEAALLKKLQHAAELEQKQNESENKKLLGEIVKYSNV
IQLLHIKSNKYLTVNKRLPALLEKNAMRVSLDAAGNEGSWFYIHPFWKLRSEGDNIVVGD
KVVLMPVNAGQPLHASNIELLDNPGCKEVNAVNCNTSWKITLFMKYSSYREDVLKGGDVV
RLFHAEQEKFLTCDEYEKKQHIFLRTTLRQSATSATSSKALWEIEVVHHDPCRGGAGQWN
SLFRFKHLATGNYLAAELNPDYRDAQNEGKNVRDGVPPTSKKKRQAGEKIMYTLVSVPHG
NDIASLFELDATTLQRADCLVPRNSYVRLRHLCTNTWVTSTSIPIDTDEERPVMLKIGTC
QTKEDKEAFAIVSVPLSEVRDLDFANDANKVLATTVKKLENGTITQNERRFVTKLLEDLI
FFVADVPNNGQEVLDVVITKPNRERQKLMREQNILAQVFGILKAPFKEKAGEGSMLRLED
LGDQRYAPYKYMLRLCYRVLRHSQQDYRKNQEYIAKNFCVMQSQIGYDILAEDTITALLH
NNRKLLEKHITAKEIETFVSLLRRNREPRFLDYLSDLCVSNTTAIPVTQELICKFMLSPG
NADILIQTKVVSMQADNPMESSILSDDIDDEEVWLYWIDSNKEPHGKAIRHLAQEAKEGT
KADLEVLTYYRYQLNLFARMCLDRQYLAINQISTQLSVDLILRCVSDESLPFDLRASFCR
LMLHMHVDRDPQESVVPVRYARLWTEIPTKITIHEYDSITDSSRNDMKRKFALTMEFVEE
YLKEVVNQPFPFGDKEKNKLTFEVVHLARNLIYFGFYSFSELLRLTRTLLAILDIVQAPM
SSYFERLSKFQDGGNNVMRTIHGVGEMMTQMVLSRGSIFPMSVPDVPPSIHPSKQGSPTE
HEDVTVMDTKLKIIEILQFILSVRLDYRISYMLSIYKKEFGEDNDNAETSASGSPDTLLP
SAIVPDIDEIAAQAETMFAGRKEKNPVQLDDEGGRTFLRVLIHLIMHDYPPLLSGALQLL
FKHFSQRAEVLQAFKQVQLLVSNQDVDNYKQIKADLDQLRLTVEKSELWVEKSSNYENGE
IGESQVKGGEEPIEESNILSPVQDGTKKPQIDSNKSNNYRIVKEILIRLSKLCVQNKKCR
NQHQRLLKNMGAHSVVLDLLQIPYEKNDEKMNEVMNLAHTFLQNFCRGNPQNQVLLHKHL
NLFLTPGLLEAETMRHIFMNNYHLCNEISERVVQHFVHCIETHGRHVEYLRFLQTIVKAD
GKYVKKCQDMVMTELINGGEDVLIFYNDRASFPILLHMMCSERDRGDESGPLAYHITLVE
LLAACTEGKNVYTEIKCNSLLPLDDIVRVVTHDDCIPEVKIAYVNFVNHCYVDTEVEMKE
IYTSNHIWKLFENFLVDMARVCNTTTDRKHADIFLEKCVTESIMNIVSGFFNSPFSDNST
SLQTHQPVFIQLLQSAFRIYNCTWPNPAQKASVESCIRTLAEVAKNRGIAIPVDLDSQVN
TLFMKSHSNMVQRAAMGWRLSARSGPRFKEALGGPAWDYRNIIEKLQDVVASLEHQFSPM
MQAEFSVLVDVLYSPELLFPEGSDARIRCGAFMSKLINHTKKLMEKEEKLCIKILQTLRE
MLEKKDSFVEEGNTLRKILLNRYFKGDYSIGVNGHLSGAYSKTAQVGGSFSGQDSDKMGI
SMSDIQCLLDKEGASELVIDVIVNTKNDRIFSEGIFLGIALLEGGNTQTQYSFYQQLHEQ
KKSEKFFKVLYDRMKAAQKEIRSTVTVNTIDLGNKKRDDDNELMTSGPRMRVRDSTLHLK
EGMKGQLTEASSATSKAYCVYRREMDPEIDIMCTGPEAGNTEEKSAEEVTMSPAIAIMQP
ILRFLQLLCENHNRELQNFLRNQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEK
NVALVNQNLESLTEYCQGPCHENQTCIATHESNGIDIIIALILNDINPLGKYRMDLVLQL
KNNASKLLLAIMESRHDSENAERILFNMRPRELVDVMKNAYNQGLECDHGDDEGGDDGVS
PKDVGHNIYILAHQLARHNKLLQQMLKPGSDPDEGDEALKYYANHTAQIEIVRHDRTMEQ
IVFPVPNICEYLTRESKCRVFNTTERDEQGSKVNDFFQQTEDLYNEMKWQKKIRNNPALF
WFSRHISLWGSISFNLAVFINLAVALFYPFGDDGDEGTLSPLFSVLLWIAVAICTSMLFF
FSKPVGIRPFLVSIMLRSIYTIGLGPTLILLGAANLCNKIVFLVSFVGNRGTFTRGYRAV
ILDMAFLYHVAYVLVCMLGLFVHEFFYSFLLFDLVYREETLLNVIKSVTRNGRSIILTAV
LALILVYLFSIIGFLFLKDDFTMEVDRLKNRTPVTGSHQVPTMTLTTMMEACAKENCSPT
IPASNTADEEYEDGIERTCDTLLMCIVTVLNQGLRNGGGVGDVLRRPSKDEPLFAARVVY
DLLFYFIVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVSFE
EHIKSEHNMWHYLYFIVLVKVKDPTEYTGPESYVAQMIVEKNLDWFPRMRAMSLVSNEGD
SEQNEIRSLQEKLESTMSLVKQLSGQLAELKEQMTEQRKNKQRLGFLGSNTPHVNHHMPP
H</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013356|Inositol 1,4,5-trisphosphate receptor type 2 (ITPR2)
ATGACTGAGAAAATGTCCAGCTTCCTCTACATAGGGGACATCGTGTCCCTGTACGCGGAG
GGCTCGGTCAACGGCTTCATCAGCACCTTGGGGTTAGTGGATGACAGATGTGTGGTGCAC
CCAGAGGCCGGGGACCTTGCCAACCCTCCCAAGAAGTTCAGAGACTGCCTTTTCAAGGTG
TGCCCTATGAACAGATATTCTGCCCAGAAGCAATATTGGAAAGCAAAGCAAGCCAAACAA
GGGAACCACACCGAGGCAGCCTTGCTGAAGAAACTACAGCACGCTGCAGAACTGGAACAA
AAACAAAATGAATCGGAGAATAAGAAACTGTTGGGAGAAATTGTAAAATACAGTAATGTT
ATACAACTACTGCATATAAAAAGCAACAAATATCTTACTGTCAACAAGAGATTACCTGCT
TTACTGGAGAAGAATGCCATGCGTGTGTCCTTGGATGCTGCAGGAAATGAAGGGTCTTGG
TTTTATATTCATCCGTTCTGGAAACTGAGAAGCGAGGGTGACAATATTGTTGTAGGAGAT
AAAGTTGTTTTGATGCCTGTGAATGCAGGGCAGCCACTACATGCCAGCAACATAGAGCTT
CTTGATAACCCAGGGTGTAAAGAGGTGAATGCTGTCAATTGCAACACCAGCTGGAAAATC
ACTTTATTCATGAAATATAGTTCCTATCGAGAGGATGTATTAAAAGGAGGGGACGTTGTT
AGATTATTTCATGCGGAACAAGAGAAGTTTTTGACTTGTGATGAATATGAGAAAAAACAG
CACATTTTCCTTCGTACGACCTTGCGCCAATCAGCTACTTCTGCTACTAGTTCTAAAGCA
CTCTGGGAAATAGAGGTGGTTCATCATGACCCATGCCGTGGGGGTGCAGGACAGTGGAAC
AGCTTGTTCAGATTTAAGCATCTTGCAACTGGAAACTATTTAGCTGCAGAGCTTAATCCT
GATTATCGAGATGCCCAAAATGAAGGAAAAAATGTGAGAGATGGAGTCCCTCCAACTTCA
AAGAAAAAACGCCAGGCAGGGGAGAAGATCATGTATACTTTGGTTTCAGTCCCGCATGGC
AATGACATTGCATCCCTTTTTGAACTAGATGCCACAACTCTTCAGAGAGCTGACTGCCTG
GTTCCAAGGAACTCATATGTTCGGTTAAGGCATTTATGCACCAACACATGGGTAACCAGT
ACTAGTATCCCCATAGACACAGATGAAGAGAGGCCTGTTATGTTAAAGATTGGAACCTGC
CAAACCAAAGAAGATAAAGAAGCGTTCGCAATCGTGTCTGTTCCACTGTCTGAAGTTCGA
GACTTAGACTTTGCCAATGATGCCAATAAAGTACTAGCGACCACAGTTAAAAAGCTAGAA
AACGGCACAATAACTCAGAATGAAAGGAGGTTTGTAACCAAATTATTGGAAGATCTCATA
TTCTTTGTTGCTGATGTGCCTAATAATGGACAAGAAGTTCTGGATGTGGTTATCACTAAG
CCAAACCGAGAGCGTCAAAAATTGATGAGGGAACAAAACATACTGGCACAGGTATTTGGA
ATTCTTAAAGCACCCTTTAAAGAGAAAGCAGGAGAAGGCTCGATGCTGAGACTTGAAGAT
CTGGGGGATCAAAGATATGCACCCTACAAGTACATGCTGCGGCTCTGTTACCGCGTCCTG
AGACACTCGCAGCAGGATTACCGGAAAAATCAGGAATATATTGCTAAGAATTTCTGTGTC
ATGCAGTCCCAGATTGGCTATGATATTTTGGCAGAAGATACTATCACAGCTTTGTTGCAC
AACAACAGAAAACTACTAGAGAAACATATCACAGCAAAAGAAATAGAAACATTTGTCAGT
TTACTCAGGAGAAATCGGGAGCCAAGGTTTTTGGATTATTTGTCAGATCTGTGTGTGTCT
AATACCACTGCTATCCCTGTAACTCAAGAACTCATCTGTAAATTTATGTTGAGTCCAGGC
AATGCAGACATTCTCATTCAAACTAAGGTGGTCTCAATGCAAGCAGACAACCCCATGGAG
AGCTCCATCCTTTCAGATGACATTGATGATGAAGAAGTTTGGCTCTATTGGATTGACAGC
AACAAGGAACCTCATGGCAAAGCTATCAGGCACCTTGCTCAAGAGGCAAAAGAAGGCACC
AAAGCTGACTTAGAAGTTCTTACCTATTACAGGTACCAGCTAAACCTCTTTGCAAGGATG
TGCTTGGATCGCCAGTATCTGGCCATAAACCAGATTTCTACACAGCTGTCTGTAGACCTG
ATCCTGCGGTGTGTGTCGGATGAGAGCCTGCCGTTCGACCTCCGAGCGTCCTTCTGTCGC
CTCATGCTCCACATGCACGTTGACCGGGATCCCCAGGAGTCCGTGGTGCCTGTTCGCTAT
GCCAGGCTCTGGACAGAAATCCCCACAAAGATCACAATTCATGAATATGATTCTATAACA
GACTCTTCCAGAAATGATATGAAGAGGAAATTTGCCCTGACAATGGAATTTGTTGAAGAA
TATTTGAAAGAAGTTGTAAACCAGCCCTTTCCTTTTGGGGATAAAGAAAAAAATAAACTG
ACATTTGAGGTGGTCCACTTGGCTCGGAATCTTATATACTTTGGATTTTATAGTTTCAGT
GAGTTATTAAGGCTAACAAGAACACTTCTGGCTATTTTAGACATTGTACAGGCCCCCATG
TCATCATACTTTGAAAGATTAAGCAAATTTCAAGATGGAGGAAACAATGTGATGAGAACC
ATTCATGGGGTGGGAGAGATGATGACCCAGATGGTACTCAGTAGAGGCTCCATCTTCCCC
ATGAGCGTGCCGGATGTGCCACCCAGCATCCACCCGAGCAAGCAAGGGAGCCCCACCGAG
CACGAGGATGTGACTGTGATGGACACCAAGCTGAAGATCATTGAGATTTTGCAGTTTATC
CTGAGTGTCAGACTGGATTATAGGATCTCATATATGCTGTCAATATATAAGAAGGAGTTT
GGAGAGGACAATGACAATGCGGAGACATCTGCCAGTGGATCTCCAGACACTTTACTACCA
TCAGCTATTGTTCCTGATATAGATGAAATTGCAGCTCAGGCAGAAACTATGTTTGCGGGA
AGAAAAGAAAAAAATCCAGTTCAACTTGACGATGAAGGAGGCAGGACGTTTTTACGGGTC
CTCATTCATCTGATCATGCACGACTACCCGCCTTTGCTGTCTGGAGCCCTGCAGCTGTTG
TTTAAGCACTTCAGCCAGAGGGCAGAGGTTTTACAGGCATTTAAGCAGGTGCAATTACTG
GTGTCTAATCAAGACGTAGATAACTACAAGCAAATCAAGGCAGATCTAGACCAGCTTCGA
CTGACAGTAGAAAAGTCTGAGCTATGGGTGGAGAAGAGCAGCAACTATGAGAATGGAGAA
ATAGGGGAAAGTCAAGTGAAAGGTGGTGAAGAGCCAATTGAGGAATCAAACATTTTAAGT
CCAGTGCAGGATGGAACAAAGAAACCTCAGATTGACAGCAACAAGAGCAATAACTACCGG
ATTGTAAAGGAGATTTTGATCAGGCTAAGTAAACTCTGTGTGCAGAATAAAAAGTGTCGG
AATCAACATCAACGATTACTGAAAAATATGGGGGCGCATTCGGTGGTGTTGGATCTTCTG
CAGATACCCTATGAAAAGAATGATGAAAAGATGAATGAAGTAATGAATCTAGCCCATACA
TTTCTGCAGAATTTCTGTCGAGGAAATCCACAGAATCAAGTTCTTCTTCATAAACATCTG
AATTTGTTTTTAACTCCAGGTCTCCTTGAAGCAGAAACCATGCGGCACATCTTCATGAAC
AATTACCATCTGTGCAACGAAATTAGCGAGAGAGTTGTACAACACTTTGTGCACTGCATT
GAGACACATGGCCGCCACGTGGAGTACCTGAGGTTTTTGCAAACAATTGTAAAAGCAGAT
GGTAAATATGTGAAGAAATGCCAGGATATGGTAATGACAGAGTTGATAAATGGGGGTGAA
GACGTGCTGATATTTTACAATGATAGAGCATCATTTCCAATCCTTCTCCATATGATGTGT
TCAGAGAGAGACCGAGGGGATGAGAGTGGCCCCTTAGCCTACCACATCACCCTGGTGGAG
TTGCTGGCAGCATGCACAGAGGGGAAAAATGTCTACACTGAAATCAAGTGTAATTCCCTT
CTCCCGCTGGACGACATAGTGAGGGTGGTGACCCATGACGACTGCATCCCTGAGGTTAAA
ATTGCTTATGTGAACTTTGTTAATCACTGTTATGTTGACACTGAAGTGGAAATGAAAGAA
ATCTATACAAGTAACCACATTTGGAAATTATTTGAGAACTTCTTGGTGGATATGGCAAGG
GTTTGCAACACAACTACAGACAGGAAACATGCAGACATCTTTTTGGAAAAGTGTGTTACT
GAGTCAATAATGAATATTGTGAGCGGCTTCTTTAATTCTCCCTTTTCAGACAATAGTACC
AGCCTCCAGACACATCAGCCAGTTTTTATTCAGCTACTGCAATCTGCCTTCAGAATTTAC
AATTGCACCTGGCCAAACCCAGCGCAGAAAGCCTCAGTGGAATCCTGTATCAGAACTTTG
GCTGAAGTGGCAAAAAATCGTGGAATTGCCATTCCAGTGGATTTGGACAGCCAAGTTAAT
ACTCTTTTCATGAAGAGCCATTCAAATATGGTGCAGAGAGCAGCAATGGGTTGGAGACTA
TCAGCTCGCTCTGGGCCACGCTTTAAGGAAGCTCTTGGAGGGCCTGCTTGGGATTACAGA
AATATTATTGAAAAGTTACAGGATGTAGTGGCCTCCTTGGAGCACCAGTTCAGCCCAATG
ATGCAGGCTGAATTCTCAGTGTTGGTTGATGTATTGTACAGTCCAGAACTGCTGTTCCCT
GAGGGAAGCGATGCAAGAATAAGATGTGGCGCTTTCATGTCGAAGTTGATTAATCATACA
AAGAAACTAATGGAGAAAGAAGAAAAACTGTGCATTAAAATTCTTCAGACATTACGAGAA
ATGTTAGAGAAGAAAGACAGCTTTGTGGAAGAGGGTAACACATTAAGAAAGATACTTCTG
AATCGATACTTTAAAGGTGATTATAGTATTGGTGTGAATGGACACCTATCAGGAGCCTAC
TCCAAAACTGCACAGGTGGGAGGAAGCTTTTCTGGACAAGATTCAGATAAGATGGGGATA
TCAATGTCAGACATTCAGTGTCTGCTGGATAAAGAAGGTGCATCAGAACTTGTCATCGAT
GTTATAGTGAACACCAAAAATGACAGAATTTTTTCAGAAGGCATTTTCCTCGGCATTGCC
TTGCTTGAAGGAGGAAATACACAAACACAGTATTCTTTCTACCAGCAGTTGCATGAACAA
AAAAAGTCAGAAAAATTCTTTAAAGTTCTCTATGATCGAATGAAGGCTGCTCAGAAAGAA
ATAAGATCAACAGTGACAGTTAATACCATAGATTTAGGTAACAAAAAAAGGGACGATGAC
AATGAATTGATGACATCTGGTCCACGAATGAGAGTAAGAGATTCAACACTACATTTAAAA
GAGGGAATGAAAGGGCAATTAACAGAAGCTTCTTCAGCAACATCCAAAGCATATTGTGTA
TACAGAAGAGAAATGGATCCAGAAATAGACATTATGTGCACAGGACCAGAAGCGGGAAAC
ACTGAGGAAAAATCCGCAGAGGAAGTAACAATGAGTCCCGCAATTGCCATCATGCAGCCA
ATACTGAGATTTCTTCAGTTACTGTGTGAGAATCACAACCGGGAATTGCAGAACTTCTTG
AGGAATCAAAACAACAAAACAAATTACAACCTAGTCTGTGAGACCCTTCAGTTTCTGGAC
TGCATTTGTGGAAGTACAACCGGTGGCCTGGGCCTGTTGGGTCTCTACATCAATGAGAAG
AATGTAGCGCTGGTCAACCAGAACCTGGAGAGCTTGACTGAGTATTGCCAGGGCCCTTGC
CATGAAAATCAGACCTGTATCGCTACACATGAGTCTAATGGGATTGATATCATCATTGCT
TTGATTCTGAATGACATAAACCCTCTTGGTAAATACCGAATGGACCTGGTGCTCCAGCTA
AAGAACAATGCATCTAAACTTTTGCTGGCCATTATGGAAAGCAGACATGACAGTGAGAAT
GCAGAAAGAATTCTTTTTAACATGAGACCCAGAGAACTGGTGGATGTGATGAAGAATGCC
TATAACCAAGGATTGGAATGTGACCATGGGGATGATGAGGGTGGAGATGATGGTGTTTCT
CCAAAAGATGTTGGACACAATATCTATATTCTGGCCCATCAGTTGGCCCGCCACAATAAA
CTGTTGCAGCAGATGCTCAAACCAGGATCGGATCCAGATGAAGGAGATGAAGCCTTAAAG
TATTATGCCAACCACACTGCACAGATTGAGATTGTCCGGCATGATAGGACCATGGAACAA
ATAGTTTTTCCTGTCCCCAATATATGTGAATACCTCACTCGAGAATCCAAGTGCCGTGTG
TTCAATACAACTGAAAGGGATGAACAAGGAAGTAAAGTGAATGACTTTTTCCAGCAAACA
GAAGATCTCTACAATGAAATGAAGTGGCAGAAGAAAATCAGGAATAACCCTGCACTGTTC
TGGTTCTCGAGGCACATCTCTCTCTGGGGGAGCATTTCCTTCAACCTGGCTGTGTTCATC
AATTTAGCTGTTGCTCTCTTCTACCCATTTGGGGATGATGGAGATGAAGGTACACTTTCT
CCATTGTTCTCGGTTCTTCTTTGGATAGCAGTTGCGATCTGCACATCTATGCTGTTTTTC
TTCTCCAAGCCTGTGGGTATTCGGCCGTTTCTTGTATCAATAATGCTCAGATCAATATAT
ACAATAGGTCTTGGGCCTACATTAATACTTCTTGGTGCAGCTAATCTTTGTAATAAAATT
GTTTTTCTGGTGAGTTTTGTTGGAAATCGTGGCACGTTCACCCGTGGGTACCGAGCAGTC
ATCCTGGATATGGCCTTTCTCTATCACGTGGCGTATGTCCTGGTTTGCATGCTGGGCCTT
TTTGTCCATGAATTCTTCTATAGCTTCCTGCTTTTTGATTTGGTGTACAGGGAAGAGACT
TTGCTGAATGTCATAAAAAGTGTCACACGAAATGGCCGCTCTATTATTCTAACTGCAGTC
CTGGCTCTCATCCTCGTCTACCTGTTTTCCATTATTGGGTTCCTTTTTTTGAAGGATGAC
TTCACTATGGAAGTTGATAGGCTGAAAAACCGAACTCCTGTTACAGGCAGTCATCAAGTG
CCTACTATGACTTTAACTACCATGATGGAAGCATGTGCCAAGGAGAACTGTTCACCCACA
ATTCCAGCTTCAAATACAGCTGATGAAGAGTATGAAGATGGAATTGAAAGGACGTGTGAC
ACTCTCCTTATGTGCATTGTCACCGTGCTGAACCAGGGCCTCAGGAATGGCGGTGGTGTG
GGGGATGTGCTAAGAAGGCCATCGAAAGATGAGCCCTTGTTTGCTGCCCGAGTGGTTTAT
GACCTTCTTTTTTATTTCATTGTTATCATTATTGTTCTGAACTTGATTTTTGGTGTTATC
ATCGATACTTTTGCTGATCTCAGAAGCGAAAAACAGAAAAAAGAAGAAATTCTAAAGACA
ACTTGTTTCATCTGTGGACTTGAGAGAGACAAGTTTGATAATAAAACGGTTTCATTTGAG
GAGCACATTAAGTCAGAACACAATATGTGGCATTATTTGTACTTCATAGTCCTGGTGAAA
GTTAAAGACCCAACAGAATACACTGGACCTGAAAGTTATGTGGCTCAAATGATTGTGGAG
AAGAATTTGGATTGGTTTCCTCGGATGCGAGCCATGTCCCTCGTTAGCAATGAAGGCGAC
AGTGAGCAAAATGAAATTCGGAGCCTTCAGGAGAAGTTGGAATCGACCATGAGTCTGGTC
AAACAGCTGTCGGGTCAGCTGGCGGAGCTCAAGGAGCAGATGACAGAACAAAGGAAGAAT
AAGCAGAGACTGGGCTTCCTCGGATCAAACACACCCCATGTGAATCATCACATGCCACCA
CACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF02815</identifier>
            <name>MIR</name>
          </pfam>
          <pfam>
            <identifier>PF08454</identifier>
            <name>RIH_assoc</name>
          </pfam>
          <pfam>
            <identifier>PF01365</identifier>
            <name>RYDR_ITPR</name>
          </pfam>
          <pfam>
            <identifier>PF08709</identifier>
            <name>Ins145_P3_rec</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell cortex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet dense tubular network membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inositol 1,4,5 trisphosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>scaffold protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cAMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q14573" source="Swiss-Prot">
        <name>Inositol 1,4,5-trisphosphate receptor type 3</name>
        <general-function>Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium.</general-function>
        <specific-function>Calcium ion binding</specific-function>
        <gene-name>ITPR3</gene-name>
        <locus>6p21.31</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2203-2223
2236-2256
2265-2285
2326-2346
2369-2389
2497-2517</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>304103.96</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6182</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14573</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ITPR3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>InsP3R3</synonym>
          <synonym>IP3 receptor isoform 3</synonym>
          <synonym>IP3R 3</synonym>
          <synonym>Type 3 inositol 1,4,5-trisphosphate receptor</synonym>
          <synonym>Type 3 InsP3 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019643|Inositol 1,4,5-trisphosphate receptor type 3
MSEMSSFLHIGDIVSLYAEGSVNGFISTLGLVDDRCVVEPAAGDLDNPPKKFRDCLFKVC
PMNRYSAQKQYWKAKQTKQDKEKIADVVLLQKLQHAAQMEQKQNDTENKKVHGDVVKYGS
VIQLLHMKSNKYLTVNKRLPALLEKNAMRVTLDATGNEGSWLFIQPFWKLRSNGDNVVVG
DKVILNPVNAGQPLHASNYELSDNAGCKEVNSVNCNTSWKINLFMQFRDHLEEVLKGGDV
VRLFHAEQEKFLTCDEYKGKLQVFLRTTLRQSATSATSSNALWEVEVVHHDPCRGGAGHW
NGLYRFKHLATGNYLAAEENPSYKGDASDPKAAGMGAQGRTGRRNAGEKIKYCLVAVPHG
NDIASLFELDPTTLQKTDSFVPRNSYVRLRHLCTNTWIQSTNVPIDIEEERPIRLMLGTC
PTKEDKEAFAIVSVPVSEIRDLDFANDASSMLASAVEKLNEGFISQNDRRFVIQLLEDLV
FFVSDVPNNGQNVLDIMVTKPNRERQKLMREQNILKQVFGILKAPFREKGGEGPLVRLEE
LSDQKNAPYQHMFRLCYRVLRHSQEDYRKNQEHIAKQFGMMQSQIGYDILAEDTITALLH
NNRKLLEKHITKTEVETFVSLVRKNREPRFLDYLSDLCVSNHIAIPVTQELICKCVLDPK
NSDILIRTELRPVKEMAQSHEYLSIEYSEEEVWLTWTDKNNEHHEKSVRQLAQEARAGNA
HDENVLSYYRYQLKLFARMCLDRQYLAIDEISQQLGVDLIFLCMADEMLPFDLRASFCHL
MLHVHVDRDPQELVTPVKFARLWTEIPTAITIKDYDSNLNASRDDKKNKFANTMEFVEDY
LNNVVSEAVPFANEEKNKLTFEVVSLAHNLIYFGFYSFSELLRLTRTLLGIIDCVQGPPA
MLQAYEDPGGKNVRRSIQGVGHMMSTMVLSRKQSVFSAPSLSAGASAAEPLDRSKFEENE
DIVVMETKLKILEILQFILNVRLDYRISYLLSVFKKEFVEVFPMQDSGADGTAPAFDSTT
ANMNLDRIGEQAEAMFGVGKTSSMLEVDDEGGRMFLRVLIHLTMHDYAPLVSGALQLLFK
HFSQRQEAMHTFKQVQLLISAQDVENYKVIKSELDRLRTMVEKSELWVDKKGSGKGEEVE
AGAAKDKKERPTDEEGFLHPPGEKSSENYQIVKGILERLNKMCGVGEQMRKKQQRLLKNM
DAHKVMLDLLQIPYDKGDAKMMEILRYTHQFLQKFCAGNPGNQALLHKHLHLFLTPGLLE
AETMQHIFLNNYQLCSEISEPVLQHFVHLLATHGRHVQYLDFLHTVIKAEGKYVKKCQDM
IMTELTNAGDDVVVFYNDKASLAHLLDMMKAARDGVEDHSPLMYHISLVDLLAACAEGKN
VYTEIKCTSLLPLEDVVSVVTHEDCITEVKMAYVNFVNHCYVDTEVEMKEIYTSNHIWTL
FENFTLDMARVCSKREKRVADPTLEKYVLSVVLDTINAFFSSPFSENSTSLQTHQTIVVQ
LLQSTTRLLECPWLQQQHKGSVEACIRTLAMVAKGRAILLPMDLDAHISSMLSSGASCAA
AAQRNASSYKATTRAFPRVTPTANQWDYKNIIEKLQDIITALEERLKPLVQAELSVLVDV
LHWPELLFLEGSEAYQRCESGGFLSKLIQHTKDLMESEEKLCIKVLRTLQQMLLKKTKYG
DRGNQLRKMLLQNYLQNRKSTSRGDLPDPIGTGLDPDWSAIAATQCRLDKEGATKLVCDL
ITSTKNEKIFQESIGLAIHLLDGGNTEIQKSFHNLMMSDKKSERFFKVLHDRMKRAQQET
KSTVAVNMNDLGSQPHEDREPVDPTTKGRVASFSIPGSSSRYSLGPSLRRGHEVSERVQS
SEMGTSVLIMQPILRFLQLLCENHNRDLQNFLRCQNNKTNYNLVCETLQFLDIMCGSTTG
GLGLLGLYINEDNVGLVIQTLETLTEYCQGPCHENQTCIVTHESNGIDIITALILNDISP
LCKYRMDLVLQLKDNASKLLLALMESRHDSENAERILISLRPQELVDVIKKAYLQEEERE
NSEVSPREVGHNIYILALQLSRHNKQLQHLLKPVKRIQEEEAEGISSMLSLNNKQLSQML
KSSAPAQEEEEDPLAYYENHTSQIEIVRQDRSMEQIVFPVPGICQFLTEETKHRLFTTTE
QDEQGSKVSDFFDQSSFLHNEMEWQRKLRSMPLIYWFSRRMTLWGSISFNLAVFINIIIA
FFYPYMEGASTGVLDSPLISLLFWILICFSIAALFTKRYSIRPLIVALILRSIYYLGIGP
TLNILGALNLTNKIVFVVSFVGNRGTFIRGYKAMVMDMEFLYHVGYILTSVLGLFAHELF
YSILLFDLIYREETLFNVIKSVTRNGRSILLTALLALILVYLFSIVGFLFLKDDFILEVD
RLPNNHSTASPLGMPHGAAAFVDTCSGDKMDCVSGLSVPEVLEEDRELDSTERACDTLLM
CIVTVMNHGLRNGGGVGDILRKPSKDESLFPARVVYDLLFFFIVIIIVLNLIFGVIIDTF
ADLRSEKQKKEEILKTTCFICGLERDKFDNKTVSFEEHIKLEHNMWNYLYFIVLVRVKNK
TDYTGPESYVAQMIKNKNLDWFPRMRAMSLVSNEGEGEQNEIRILQDKLNSTMKLVSHLT
AQLNELKEQMTEQRKRRQRLGFVDVQNCISR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019644|Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3)
ATGAGTGAAATGTCCAGCTTTCTTCACATCGGGGACATCGTCTCCCTGTACGCCGAGGGC
TCCGTCAATGGCTTCATCAGCACTTTGGGGCTGGTGGATGACCGCTGTGTGGTGGAGCCC
GCGGCCGGGGACCTGGACAACCCCCCTAAGAAGTTCCGTGACTGCCTCTTCAAGGTGTGC
CCCATGAACCGCTACTCGGCCCAGAAGCAGTACTGGAAGGCCAAGCAGACTAAGCAGGAC
AAGGAGAAGATCGCTGATGTGGTGTTGCTGCAGAAGCTGCAGCATGCGGCGCAGATGGAG
CAGAAGCAAAATGACACGGAGAACAAGAAGGTGCATGGGGATGTCGTGAAGTATGGCAGT
GTGATCCAGCTCCTGCACATGAAGAGCAACAAGTACCTGACAGTGAACAAGCGGCTTCCG
GCCTTGCTGGAGAAGAACGCCATGCGGGTGACTCTGGATGCCACAGGCAACGAGGGTTCC
TGGCTCTTCATCCAGCCCTTCTGGAAGCTGCGGAGCAACGGGGACAACGTGGTCGTGGGG
GACAAGGTGATCCTGAATCCTGTCAATGCCGGGCAGCCTCTGCATGCCAGCAATTACGAG
CTCAGCGACAACGCCGGCTGCAAGGAGGTCAATTCTGTGAACTGCAACACCAGCTGGAAG
ATCAACCTGTTTATGCAGTTTCGGGACCACCTGGAGGAGGTGTTGAAAGGGGGAGACGTG
GTGCGGCTGTTCCATGCGGAGCAGGAGAAGTTCCTGACGTGTGACGAGTACAAGGGCAAG
CTGCAGGTGTTCCTGCGAACTACACTGCGCCAGTCTGCCACCTCGGCCACCAGCTCCAAT
GCTCTCTGGGAGGTGGAGGTGGTCCACCACGACCCCTGCCGTGGAGGAGCTGGGCACTGG
AATGGCTTGTACCGCTTCAAGCACCTGGCTACAGGCAACTACCTGGCTGCTGAGGAGAAC
CCCAGTTACAAAGGTGATGCCTCAGATCCCAAGGCAGCAGGAATGGGGGCACAGGGCCGC
ACAGGCCGCAGGAATGCTGGGGAGAAGATCAAGTACTGCCTGGTGGCTGTGCCTCATGGC
AATGACATCGCCTCTCTCTTTGAGCTGGACCCCACCACCTTGCAGAAAACCGACTCTTTC
GTGCCCCGGAACTCGTACGTCCGGCTGCGGCACCTCTGCACCAACACGTGGATTCAGAGC
ACCAATGTGCCCATTGACATCGAGGAGGAGCGGCCCATCCGGCTCATGCTGGGCACCTGC
CCCACCAAGGAGGACAAGGAGGCCTTTGCCATCGTGTCAGTGCCCGTGTCTGAGATCCGA
GACCTGGACTTTGCCAATGACGCCAGCTCCATGCTGGCCAGTGCCGTGGAGAAACTCAAC
GAGGGCTTCATCAGCCAGAATGACCGCAGGTTTGTCATCCAGCTGCTGGAAGACCTGGTG
TTCTTTGTCAGCGATGTCCCCAACAATGGGCAGAATGTCCTGGACATCATGGTCACTAAG
CCCAACCGGGAACGGCAGAAGCTGATGAGGGAGCAGAACATCCTCAAACAGGTCTTTGGC
ATTCTGAAGGCCCCGTTCCGTGAGAAGGGGGGTGAAGGTCCCCTGGTGCGGCTGGAGGAG
CTGTCAGACCAGAAGAACGCCCCCTACCAGCACATGTTCCGCCTGTGCTACCGCGTGTTG
CGGCATTCCCAGGAGGACTACCGCAAGAACCAGGAGCACATTGCCAAGCAGTTTGGGATG
ATGCAGTCCCAGATTGGCTACGACATCCTGGCCGAGGACACCATCACTGCCCTGCTGCAC
AACAACCGCAAGCTCCTGGAAAAGCACATCACCAAGACCGAGGTGGAGACCTTCGTCAGC
CTTGTGCGCAAGAACCGGGAGCCCAGGTTCCTGGACTACCTCTCTGACCTGTGTGTGTCC
AACCACATCGCCATCCCCGTCACCCAAGAGCTCATCTGCAAGTGTGTGCTGGACCCCAAG
AACAGTGACATTCTCATCCGGACCGAGCTTCGGCCCGTGAAGGAGATGGCCCAATCCCAC
GAGTACCTGAGCATCGAGTACTCAGAAGAGGAAGTGTGGCTCACGTGGACTGACAAGAAT
AACGAGCATCATGAGAAGAGTGTGAGGCAGCTGGCCCAGGAGGCGCGGGCCGGCAACGCC
CACGACGAGAATGTGCTCAGCTACTACAGGTACCAGCTGAAGCTCTTTGCCCGCATGTGC
TTGGACCGCCAGTACTTGGCCATCGACGAGATCTCCCAGCAGCTGGGCGTGGACCTGATT
TTCCTGTGCATGGCAGACGAGATGCTGCCCTTTGACCTGCGCGCCTCCTTCTGCCACCTG
ATGCTGCACGTGCACGTGGACCGTGACCCCCAGGAGCTGGTCACGCCGGTCAAGTTTGCC
CGTCTCTGGACTGAGATCCCCACAGCCATCACCATCAAGGACTATGATTCCAACCTCAAC
GCGTCCCGAGATGACAAGAAGAACAAGTTTGCCAACACCATGGAGTTCGTGGAGGACTAC
CTCAACAATGTAGTCAGCGAGGCCGTGCCCTTTGCCAACGAGGAGAAGAACAAGCTCACT
TTTGAGGTGGTCAGCCTGGCGCACAATCTCATCTACTTCGGCTTCTACAGCTTCAGCGAG
CTGCTGCGGCTCACTCGCACACTGCTGGGCATCATCGACTGTGTGCAGGGGCCCCCGGCC
ATGCTGCAGGCCTATGAGGACCCCGGTGGCAAGAATGTGCGGCGGTCCATCCAGGGCGTG
GGGCACATGATGTCCACCATGGTGCTGAGCCGCAAGCAGTCCGTCTTCAGTGCCCCCAGC
CTGTCTGCTGGGGCCAGTGCTGCTGAGCCGCTGGACAGAAGCAAGTTTGAGGAGAATGAG
GACATTGTGGTGATGGAGACCAAGCTGAAGATCCTGGAAATCCTTCAGTTCATCCTCAAT
GTCCGCCTGGATTACCGCATATCCTACCTGCTGTCTGTCTTCAAGAAGGAGTTTGTGGAG
GTGTTTCCCATGCAGGACAGTGGGGCTGATGGCACAGCCCCTGCCTTCGACTCTACCACT
GCCAACATGAACCTGGATCGCATCGGGGAGCAGGCGGAGGCCATGTTTGGAGTGGGGAAG
ACAAGCAGCATGCTGGAGGTGGATGACGAGGGCGGCCGCATGTTCCTGCGCGTGCTCATC
CACCTCACCATGCACGACTATGCGCCGCTGGTCTCGGGTGCCCTGCAGCTGCTCTTCAAG
CACTTCAGCCAGCGCCAGGAGGCCATGCACACCTTCAAGCAGGTTCAGCTGCTGATCTCA
GCGCAGGACGTGGAGAACTACAAGGTGATCAAGTCGGAGCTGGACCGGCTGCGGACCATG
GTGGAGAAGTCAGAGCTGTGGGTGGACAAGAAGGGCAGTGGCAAGGGTGAGGAGGTGGAG
GCAGGCGCCGCCAAGGACAAGAAAGAGCGTCCCACGGACGAGGAGGGCTTTCTGCACCCA
CCAGGGGAGAAAAGCAGTGAGAACTACCAGATCGTCAAGGGCATCCTGGAAAGGCTGAAC
AAGATGTGCGGGGTTGGGGAGCAAATGAGGAAGAAGCAGCAACGGCTGCTGAAGAACATG
GATGCCCACAAGGTCATGCTGGACCTGCTGCAGATCCCCTATGACAAGGGTGATGCCAAG
ATGATGGAGATCCTGCGCTACACGCACCAGTTCCTGCAGAAGTTCTGTGCAGGGAACCCC
GGCAACCAGGCCCTGCTGCACAAACACCTGCACCTCTTCCTCACGCCAGGGCTCCTGGAG
GCAGAGACCATGCAGCACATCTTCCTGAACAACTATCAGCTCTGCTCCGAGATCAGCGAG
CCTGTGTTGCAGCACTTCGTGCACCTGCTGGCCACGCACGGGCGCCATGTGCAGTACCTG
GACTTCCTGCACACCGTCATTAAGGCCGAGGGCAAGTACGTCAAGAAGTGCCAGGACATG
ATCATGACTGAGCTGACCAATGCAGGTGACGATGTGGTCGTGTTCTACAATGATAAGGCA
TCGCTGGCCCACCTGCTGGACATGATGAAGGCCGCCCGCGACGGCGTGGAGGACCACAGC
CCCCTCATGTACCACATTTCCCTGGTGGACCTGCTGGCCGCCTGTGCCGAGGGCAAAAAC
GTCTACACTGAGATCAAGTGCACCTCCCTGCTGCCGCTGGAGGACGTGGTGTCTGTGGTG
ACGCATGAGGACTGCATCACTGAGGTGAAAATGGCCTATGTGAACTTCGTGAACCACTGC
TACGTGGACACGGAGGTGGAGATGAAGGAGATCTACACCAGCAACCACATCTGGACGCTC
TTTGAGAACTTCACCCTGGACATGGCTCGGGTCTGCAGCAAGCGTGAGAAGCGCGTGGCT
GACCCCACCTTGGAGAAGTACGTGCTGAGCGTTGTGCTGGACACCATCAACGCCTTCTTC
AGCTCCCCATTCTCTGAGAACAGCACTTCCCTGCAGACACACCAGACGATTGTGGTGCAG
CTGCTGCAGTCTACCACACGCCTCCTCGAGTGTCCGTGGCTACAGCAGCAGCACAAGGGC
TCCGTGGAGGCCTGCATCCGGACCCTCGCCATGGTGGCCAAGGGCCGGGCCATCTTGCTG
CCCATGGACCTGGATGCCCACATCAGCTCGATGCTCAGCAGTGGAGCCAGCTGTGCAGCT
GCCGCCCAGCGGAACGCCTCCAGCTACAAGGCAACCACGCGGGCCTTCCCCCGCGTCACC
CCCACCGCCAACCAGTGGGACTACAAGAACATCATTGAGAAGCTGCAGGACATCATCACA
GCCCTGGAGGAGCGGCTGAAGCCCCTGGTACAGGCTGAGCTGTCCGTGCTGGTGGATGTC
CTGCACTGGCCTGAGCTGCTCTTCCTGGAGGGCAGTGAGGCCTACCAGCGCTGCGAGAGT
GGGGGCTTCCTGTCCAAGCTGATCCAGCACACCAAGGACCTCATGGAGTCGGAGGAGAAG
CTGTGCATCAAGGTGCTGCGGACCCTGCAGCAGATGCTGCTCAAGAAGACCAAGTACGGG
GACCGGGGCAACCAGCTGCGCAAGATGCTGCTGCAAAACTACCTCCAGAACCGGAAGTCC
ACCTCGCGGGGGGACCTTCCCGACCCCATAGGCACTGGCCTGGACCCAGACTGGTCGGCA
ATCGCAGCCACCCAGTGCCGGCTGGACAAGGAGGGGGCCACCAAGTTGGTATGCGACCTC
ATCACCAGCACCAAGAACGAGAAGATCTTCCAGGAGAGCATCGGCCTGGCCATCCACCTG
CTGGATGGTGGCAACACAGAGATCCAGAAATCCTTCCACAACCTGATGATGAGTGACAAG
AAGTCAGAGCGCTTCTTCAAGGTGCTGCACGACCGCATGAAGCGGGCCCAGCAGGAGACC
AAGTCCACGGTGGCAGTCAACATGAATGACCTGGGCAGCCAGCCACATGAGGACCGCGAG
CCAGTCGACCCCACCACCAAAGGCCGCGTGGCCTCCTTCTCGATACCTGGCTCCTCATCC
CGCTACTCGCTGGGCCCCAGCCTGCGCCGGGGGCACGAGGTGAGCGAACGTGTGCAGAGC
AGTGAGATGGGCACATCCGTGCTCATCATGCAGCCCATCCTGCGCTTTCTGCAGCTGCTG
TGTGAGAACCACAACCGGGACCTGCAGAACTTCCTGCGCTGTCAGAACAACAAAACCAAC
TACAACTTGGTATGCGAGACGCTGCAGTTCCTGGACATCATGTGCGGCAGCACCACGGGC
GGCCTGGGGCTGCTGGGGCTCTACATCAATGAGGACAACGTGGGCCTCGTCATCCAGACC
TTGGAGACCCTCACTGAGTACTGCCAGGGCCCCTGCCATGAGAACCAGACTTGCATTGTG
ACTCACGAGTCCAATGGCATAGACATCATCACCGCACTGATCCTCAATGACATCAGCCCC
CTGTGCAAGTACCGCATGGATCTGGTGCTGCAGCTCAAGGACAATGCCTCCAAGCTGCTC
CTGGCTCTGATGGAGAGCCGGCATGACAGTGAAAATGCTGAGCGAATCCTCATCAGCCTG
CGGCCCCAGGAGCTGGTGGACGTCATCAAGAAGGCCTACCTGCAGGAGGAAGAGCGTGAG
AACTCGGAGGTGAGCCCACGTGAAGTGGGCCATAACATCTATATCCTGGCGCTGCAGCTC
TCCAGGCACAATAAACAGCTGCAGCACCTGCTGAAGCCGGTGAAGCGCATTCAAGAGGAG
GAGGCCGAGGGTATCTCTTCCATGCTCAGCCTCAACAACAAGCAGCTGTCACAGATGCTC
AAGTCCTCAGCGCCAGCACAGGAGGAGGAGGAAGACCCCCTGGCCTACTATGAGAACCAC
ACGTCCCAGATCGAGATTGTGCGGCAGGACCGCAGCATGGAGCAGATCGTGTTCCCAGTG
CCCGGCATCTGCCAGTTCCTGACGGAGGAAACCAAGCACCGGCTCTTCACCACTACTGAG
CAGGACGAGCAGGGCAGCAAAGTGAGCGACTTCTTCGACCAGTCCTCCTTCCTGCACAAC
GAGATGGAGTGGCAGCGCAAGCTCCGCAGCATGCCGCTGATCTACTGGTTCTCCCGCCGC
ATGACCCTGTGGGGCAGCATCTCCTTCAACCTGGCCGTGTTTATCAACATCATCATTGCC
TTCTTCTACCCTTACATGGAGGGCGCGTCCACAGGCGTGCTGGACTCCCCTCTCATCTCA
TTGCTCTTCTGGATCCTCATCTGCTTCTCCATCGCGGCCCTGTTCACCAAGCGCTACAGC
ATCCGCCCCCTCATCGTGGCGCTCATCCTGCGCTCCATCTACTATCTGGGCATCGGGCCC
ACACTCAACATCCTGGGTGCCCTCAATCTGACCAACAAGATCGTGTTTGTGGTGAGCTTC
GTGGGCAACCGTGGCACCTTCATCCGGGGCTATAAGGCCATGGTCATGGACATGGAATTC
CTCTACCACGTGGGCTACATCCTGACCAGTGTCCTGGGCCTCTTTGCTCATGAGCTGTTC
TACAGCATCCTGCTCTTTGACCTCATCTACCGCGAGGAGACGCTGTTCAACGTCATCAAG
AGTGTGACCCGCAATGGCCGCTCCATCCTGCTGACAGCCCTGCTGGCCCTCATCCTGGTC
TACCTCTTCTCCATCGTCGGCTTCCTCTTCCTCAAGGATGACTTCATTCTCGAGGTCGAC
CGGCTGCCCAACAACCACTCCACAGCCAGCCCCCTGGGGATGCCACATGGAGCTGCTGCA
TTTGTGGACACCTGCAGTGGGGACAAGATGGACTGTGTCTCAGGGCTCTCGGTGCCTGAG
GTCCTGGAAGAGGACAGGGAGCTGGACAGCACAGAGCGGGCCTGTGACACTCTGTTGATG
TGCATCGTCACTGTCATGAACCATGGGCTACGCAACGGTGGTGGCGTGGGCGACATTCTC
CGCAAGCCCTCCAAAGATGAGTCTCTCTTCCCAGCCCGAGTGGTCTATGACCTCCTGTTC
TTCTTCATCGTCATCATCATTGTGCTGAACCTCATCTTTGGGGTAATCATCGACACCTTC
GCTGACCTGCGTAGTGAGAAGCAGAAGAAGGAGGAGATTCTTAAGACGACATGCTTCATC
TGTGGTCTGGAGAGGGACAAGTTTGATAACAAGACAGTGTCATTTGAGGAACACATCAAG
CTGGAGCACAACATGTGGAACTACTTGTACTTCATTGTGCTGGTCCGCGTGAAGAACAAG
ACCGACTACACGGGCCCTGAGAGCTACGTGGCCCAGATGATCAAGAACAAGAACCTGGAC
TGGTTCCCCCGGATGCGGGCCATGTCCCTTGTCAGCAATGAGGGCGAGGGGGAGCAGAAT
GAGATTCGGATTCTCCAGGACAAGCTCAACTCCACCATGAAGCTGGTGTCCCACCTCACT
GCCCAGCTCAACGAGCTCAAGGAGCAGATGACGGAGCAGCGGAAACGCAGGCAACGCCTA
GGCTTTGTGGATGTCCAGAACTGCATTAGCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF02815</identifier>
            <name>MIR</name>
          </pfam>
          <pfam>
            <identifier>PF08454</identifier>
            <name>RIH_assoc</name>
          </pfam>
          <pfam>
            <identifier>PF01365</identifier>
            <name>RYDR_ITPR</name>
          </pfam>
          <pfam>
            <identifier>PF08709</identifier>
            <name>Ins145_P3_rec</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear outer membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet dense tubular network membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inositol 1,3,4,5 tetrakisphosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inositol 1,4,5 trisphosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inositol hexakisphosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-term synaptic potentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to calcium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of bitter taste</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sweet taste</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of umami taste</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="19">
      <id>BE0004874</id>
      <name>Serine-protein kinase ATM</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18224</ref-id>
            <pubmed-id>10485486</pubmed-id>
            <citation>Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT: Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999 Sep 1;59(17):4375-82.</citation>
          </article>
          <article>
            <ref-id>A18225</ref-id>
            <pubmed-id>10531013</pubmed-id>
            <citation>Blasina A, Price BD, Turenne GA, McGowan CH: Caffeine inhibits the checkpoint kinase ATM. Curr Biol. 1999 Oct 7;9(19):1135-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q13315" source="Swiss-Prot">
        <name>Serine-protein kinase ATM</name>
        <general-function>Protein serine/threonine kinase activity</general-function>
        <specific-function>Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in response to genotoxic stress prevents its MDM2-mediated ubiquitination and subsequent proteasome degradation. Phosphorylates ATF2 which stimulates its function in DNA damage response.</specific-function>
        <gene-name>ATM</gene-name>
        <locus/>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>350684.105</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:795</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1934</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13315</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ATM_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.11.1</synonym>
          <synonym>A-T mutated</synonym>
          <synonym>Ataxia telangiectasia mutated</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008666|Serine-protein kinase ATM
MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAV
FRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQEL
LNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQ
DVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFL
KTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEK
GAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNED
TRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLI
SKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDL
LKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVC
CLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILH
SNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKM
DFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSR
LLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMM
QLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMED
DTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDM
LKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYP
LPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLT
VIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLAD
NHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAEN
PETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSET
FGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLV
IRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYD
MLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPH
FPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILK
IYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQ
VCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIK
LLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQ
LELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGP
IDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNI
LATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSE
NHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRN
LLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQK
RPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEG
SQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEA
MWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHY
QAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCK
RSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQ
EPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQ
YNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRV
CGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQR
IENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRK
RFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLM
YQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARR
SRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKT
QRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPK
IIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPL
SQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVF
MDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINE
QSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRN
SQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQ
SFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013341|Serine-protein kinase ATM (ATM)
ATGAGTCTAGTACTTAATGATCTGCTTATCTGCTGCCGTCAACTAGAACATGATAGAGCT
ACAGAACGAAAGAAAGAAGTTGAGAAATTTAAGCGCCTGATTCGAGATCCTGAAACAATT
AAACATCTAGATCGGCATTCAGATTCCAAACAAGGAAAATATTTGAATTGGGATGCTGTT
TTTAGATTTTTACAGAAATATATTCAGAAAGAAACAGAATGTCTGAGAATAGCAAAACCA
AATGTATCAGCCTCAACACAAGCCTCCAGGCAGAAAAAGATGCAGGAAATCAGTAGTTTG
GTCAAATACTTCATCAAATGTGCAAACAGAAGAGCACCTAGGCTAAAATGTCAAGAACTC
TTAAATTATATCATGGATACAGTGAAAGATTCATCTAATGGTGCTATTTACGGAGCTGAT
TGTAGCAACATACTACTCAAAGACATTCTTTCTGTGAGAAAATACTGGTGTGAAATATCT
CAGCAACAGTGGTTAGAATTGTTCTCTGTGTACTTCAGGCTCTATCTGAAACCTTCACAA
GATGTTCATAGAGTTTTAGTGGCTAGAATAATTCATGCTGTTACCAAAGGATGCTGTTCT
CAGACTGACGGATTAAATTCCAAATTTTTGGACTTTTTTTCCAAGGCTATTCAGTGTGCG
AGACAAGAAAAGAGCTCTTCAGGTCTAAATCATATCTTAGCAGCTCTTACTATCTTCCTC
AAGACTTTGGCTGTCAACTTTCGAATTCGAGTGTGTGAATTAGGAGATGAAATTCTTCCC
ACTTTGCTTTATATTTGGACTCAACATAGGCTTAATGATTCTTTAAAAGAAGTCATTATT
GAATTATTTCAACTGCAAATTTATATCCATCATCCGAAAGGAGCCAAAACCCAAGAAAAA
GGTGCTTATGAATCAACAAAATGGAGAAGTATTTTATACAACTTATATGATCTGCTAGTG
AATGAGATAAGTCATATAGGAAGTAGAGGAAAGTATTCTTCAGGATTTCGTAATATTGCC
GTCAAAGAAAATTTGATTGAATTGATGGCAGATATCTGTCACCAGGTTTTTAATGAAGAT
ACCAGATCCTTGGAGATTTCTCAATCTTACACTACTACACAAAGAGAATCTAGTGATTAC
AGTGTCCCTTGCAAAAGGAAGAAAATAGAACTAGGCTGGGAAGTAATAAAAGATCACCTT
CAGAAGTCACAGAATGATTTTGATCTTGTGCCTTGGCTACAGATTGCAACCCAATTAATA
TCAAAGTATCCTGCAAGTTTACCTAACTGTGAGCTGTCTCCATTACTGATGATACTATCT
CAGCTTCTACCCCAACAGCGACATGGGGAACGTACACCATATGTGTTACGATGCCTTACG
GAAGTTGCATTGTGTCAAGACAAGAGGTCAAACCTAGAAAGCTCACAAAAGTCAGATTTA
TTAAAACTCTGGAATAAAATTTGGTGTATTACCTTTCGTGGTATAAGTTCTGAGCAAATA
CAAGCTGAAAACTTTGGCTTACTTGGAGCCATAATTCAGGGTAGTTTAGTTGAGGTTGAC
AGAGAATTCTGGAAGTTATTTACTGGGTCAGCCTGCAGACCTTCATGTCCTGCAGTATGC
TGTTTGACTTTGGCACTGACCACCAGTATAGTTCCAGGAACGGTAAAAATGGGAATAGAG
CAAAATATGTGTGAAGTAAATAGAAGCTTTTCTTTAAAGGAATCAATAATGAAATGGCTC
TTATTCTATCAGTTAGAGGGTGACTTAGAAAATAGCACAGAAGTGCCTCCAATTCTTCAC
AGTAATTTTCCTCATCTTGTACTGGAGAAAATTCTTGTGAGTCTCACTATGAAAAACTGT
AAAGCTGCAATGAATTTTTTCCAAAGCGTGCCAGAATGTGAACACCACCAAAAAGATAAA
GAAGAACTTTCATTCTCAGAAGTAGAAGAACTATTTCTTCAGACAACTTTTGACAAGATG
GACTTTTTAACCATTGTGAGAGAATGTGGTATAGAAAAGCACCAGTCCAGTATTGGCTTC
TCTGTCCACCAGAATCTCAAGGAATCACTGGATCGCTGTCTTCTGGGATTATCAGAACAG
CTTCTGAATAATTACTCATCTGAGATTACAAATTCAGAAACTCTTGTCCGGTGTTCACGT
CTTTTGGTGGGTGTCCTTGGCTGCTACTGTTACATGGGTGTAATAGCTGAAGAGGAAGCA
TATAAGTCAGAATTATTCCAGAAAGCCAAGTCTCTAATGCAATGTGCAGGAGAAAGTATC
ACTCTGTTTAAAAATAAGACAAATGAGGAATTCAGAATTGGTTCCTTGAGAAATATGATG
CAGCTATGTACACGTTGCTTGAGCAACTGTACCAAGAAGAGTCCAAATAAGATTGCATCT
GGCTTTTTCCTGCGATTGTTAACATCAAAGCTAATGAATGACATTGCAGATATTTGTAAA
AGTTTAGCATCCTTCATCAAAAAGCCATTTGACCGTGGAGAAGTAGAATCAATGGAAGAT
GATACTAATGGAAATCTAATGGAGGTGGAGGATCAGTCATCCATGAATCTATTTAACGAT
TACCCTGATAGTAGTGTTAGTGATGCAAACGAACCTGGAGAGAGCCAAAGTACCATAGGT
GCCATTAATCCTTTAGCTGAAGAATATCTGTCAAAGCAAGATCTACTTTTCTTAGACATG
CTCAAGTTCTTGTGTTTGTGTGTAACTACTGCTCAGACCAATACTGTGTCCTTTAGGGCA
GCTGATATTCGGAGGAAATTGTTAATGTTAATTGATTCTAGCACGCTAGAACCTACCAAA
TCCCTCCACCTGCATATGTATCTAATGCTTTTAAAGGAGCTTCCTGGAGAAGAGTACCCC
TTGCCAATGGAAGATGTTCTTGAACTTCTGAAACCACTATCCAATGTGTGTTCTTTGTAT
CGTCGTGACCAAGATGTTTGTAAAACTATTTTAAACCATGTCCTTCATGTAGTGAAAAAC
CTAGGTCAAAGCAATATGGACTCTGAGAACACAAGGGATGCTCAAGGACAGTTTCTTACA
GTAATTGGAGCATTTTGGCATCTAACAAAGGAGAGGAAATATATATTCTCTGTAAGAATG
GCCCTAGTAAATTGCCTTAAAACTTTGCTTGAGGCTGATCCTTATTCAAAATGGGCCATT
CTTAATGTAATGGGAAAAGACTTTCCTGTAAATGAAGTATTTACACAATTTCTTGCTGAC
AATCATCACCAAGTTCGCATGTTGGCTGCAGAGTCAATCAATAGATTGTTCCAGGACACG
AAGGGAGATTCTTCCAGGTTACTGAAAGCACTTCCTTTGAAGCTTCAGCAAACAGCTTTT
GAAAATGCATACTTGAAAGCTCAGGAAGGAATGAGAGAAATGTCCCATAGTGCTGAGAAC
CCTGAAACTTTGGATGAAATTTATAATAGAAAATCTGTTTTACTGACGTTGATAGCTGTG
GTTTTATCCTGTAGCCCTATCTGCGAAAAACAGGCTTTGTTTGCCCTGTGTAAATCTGTG
AAAGAGAATGGATTAGAACCTCACCTTGTGAAAAAGGTTTTAGAGAAAGTTTCTGAAACT
TTTGGATATAGACGTTTAGAAGACTTTATGGCATCTCATTTAGATTATCTGGTTTTGGAA
TGGCTAAATCTTCAAGATACTGAATACAACTTATCTTCTTTTCCTTTTATTTTATTAAAC
TACACAAATATTGAGGATTTCTATAGATCTTGTTATAAGGTTTTGATTCCACATCTGGTG
ATTAGAAGTCATTTTGATGAGGTGAAGTCCATTGCTAATCAGATTCAAGAGGACTGGAAA
AGTCTTCTAACAGACTGCTTTCCAAAGATTCTTGTAAATATTCTTCCTTATTTTGCCTAT
GAGGGTACCAGAGACAGTGGGATGGCACAGCAAAGAGAGACTGCTACCAAGGTCTATGAT
ATGCTTAAAAGTGAAAACTTATTGGGAAAACAGATTGATCACTTATTCATTAGTAATTTA
CCAGAGATTGTGGTGGAGTTATTGATGACGTTACATGAGCCAGCAAATTCTAGTGCCAGT
CAGAGCACTGACCTCTGTGACTTTTCAGGGGATTTGGATCCTGCTCCTAATCCACCTCAT
TTTCCATCGCATGTGATTAAAGCAACATTTGCCTATATCAGCAATTGTCATAAAACCAAG
TTAAAAAGCATTTTAGAAATTCTTTCCAAAAGCCCTGATTCCTATCAGAAAATTCTTCTT
GCCATATGTGAGCAAGCAGCTGAAACAAATAATGTTTATAAGAAGCACAGAATTCTTAAA
ATATATCACCTGTTTGTTAGTTTATTACTGAAAGATATAAAAAGTGGCTTAGGAGGAGCT
TGGGCCTTTGTTCTTCGAGACGTTATTTATACTTTGATTCACTATATCAACCAAAGGCCT
TCTTGTATCATGGATGTGTCATTACGTAGCTTCTCCCTTTGTTGTGACTTATTAAGTCAG
GTTTGCCAGACAGCCGTGACTTACTGTAAGGATGCTCTAGAAAACCATCTTCATGTTATT
GTTGGTACACTTATACCCCTTGTGTATGAGCAGGTGGAGGTTCAGAAACAGGTATTGGAC
TTGTTGAAATACTTAGTGATAGATAACAAGGATAATGAAAACCTCTATATCACGATTAAG
CTTTTAGATCCTTTTCCTGACCATGTTGTTTTTAAGGATTTGCGTATTACTCAGCAAAAA
ATCAAATACAGTAGAGGACCCTTTTCACTCTTGGAGGAAATTAACCATTTTCTCTCAGTA
AGTGTTTATGATGCACTTCCATTGACAAGACTTGAAGGACTAAAGGATCTTCGAAGACAA
CTGGAACTACATAAAGATCAGATGGTGGACATTATGAGAGCTTCTCAGGATAATCCGCAA
GATGGGATTATGGTGAAACTAGTTGTCAATTTGTTGCAGTTATCCAAGATGGCAATAAAC
CACACTGGTGAAAAAGAAGTTCTAGAGGCTGTTGGAAGCTGCTTGGGAGAAGTGGGTCCT
ATAGATTTCTCTACCATAGCTATACAACATAGTAAAGATGCATCTTATACCAAGGCCCTT
AAGTTATTTGAAGATAAAGAACTTCAGTGGACCTTCATAATGCTGACCTACCTGAATAAC
ACACTGGTAGAAGATTGTGTCAAAGTTCGATCAGCAGCTGTTACCTGTTTGAAAAACATT
TTAGCCACAAAGACTGGACATAGTTTCTGGGAGATTTATAAGATGACAACAGATCCAATG
CTGGCCTATCTACAGCCTTTTAGAACATCAAGAAAAAAGTTTTTAGAAGTACCCAGATTT
GACAAAGAAAACCCTTTTGAAGGCCTGGATGATATAAATCTGTGGATTCCTCTAAGTGAA
AATCATGACATTTGGATAAAGACACTGACTTGTGCTTTTTTGGACAGTGGAGGCACAAAA
TGTGAAATTCTTCAATTATTAAAGCCAATGTGTGAAGTGAAAACTGACTTTTGTCAGACT
GTACTTCCATACTTGATTCATGATATTTTACTCCAAGATACAAATGAATCATGGAGAAAT
CTGCTTTCTACACATGTTCAGGGATTTTTCACCAGCTGTCTTCGACACTTCTCGCAAACG
AGCCGATCCACAACCCCTGCAAACTTGGATTCAGAGTCAGAGCACTTTTTCCGATGCTGT
TTGGATAAAAAATCACAAAGAACAATGCTTGCTGTTGTGGACTACATGAGAAGACAAAAG
AGACCTTCTTCAGGAACAATTTTTAATGATGCTTTCTGGCTGGATTTAAATTATCTAGAA
GTTGCCAAGGTAGCTCAGTCTTGTGCTGCTCACTTTACAGCTTTACTCTATGCAGAAATC
TATGCAGATAAGAAAAGTATGGATGATCAAGAGAAAAGAAGTCTTGCATTTGAAGAAGGA
AGCCAGAGTACAACTATTTCTAGCTTGAGTGAAAAAAGTAAAGAAGAAACTGGAATAAGT
TTACAGGATCTTCTCTTAGAAATCTACAGAAGTATAGGGGAGCCAGATAGTTTGTATGGC
TGTGGTGGAGGGAAGATGTTACAACCCATTACTAGACTACGAACATATGAACACGAAGCA
ATGTGGGGCAAAGCCCTAGTAACATATGACCTCGAAACAGCAATCCCCTCATCAACACGC
CAGGCAGGAATCATTCAGGCCTTGCAGAATTTGGGACTCTGCCATATTCTTTCCGTCTAT
TTAAAAGGATTGGATTATGAAAATAAAGACTGGTGTCCTGAACTAGAAGAACTTCATTAC
CAAGCAGCATGGAGGAATATGCAGTGGGACCATTGCACTTCCGTCAGCAAAGAAGTAGAA
GGAACCAGTTACCATGAATCATTGTACAATGCTCTACAATCTCTAAGAGACAGAGAATTC
TCTACATTTTATGAAAGTCTCAAATATGCCAGAGTAAAAGAAGTGGAAGAGATGTGTAAG
CGCAGCCTTGAGTCTGTGTATTCGCTCTATCCCACACTTAGCAGGTTGCAGGCCATTGGA
GAGCTGGAAAGCATTGGGGAGCTTTTCTCAAGATCAGTCACACATAGACAACTCTCTGAA
GTATATATTAAGTGGCAGAAACACTCCCAGCTTCTCAAGGACAGTGATTTTAGTTTTCAG
GAGCCTATCATGGCTCTACGCACAGTCATTTTGGAGATCCTGATGGAAAAGGAAATGGAC
AACTCACAAAGAGAATGTATTAAGGACATTCTCACCAAACACCTTGTAGAACTCTCTATA
CTGGCCAGAACTTTCAAGAACACTCAGCTCCCTGAAAGGGCAATATTTCAAATTAAACAG
TACAATTCAGTTAGCTGTGGAGTCTCTGAGTGGCAGCTGGAAGAAGCACAAGTATTCTGG
GCAAAAAAGGAGCAGAGTCTTGCCCTGAGTATTCTCAAGCAAATGATCAAGAAGTTGGAT
GCCAGCTGTGCAGCGAACAATCCCAGCCTAAAACTTACATACACAGAATGTCTGAGGGTT
TGTGGCAACTGGTTAGCAGAAACGTGCTTAGAAAATCCTGCGGTCATCATGCAGACCTAT
CTAGAAAAGGCAGTAGAAGTTGCTGGAAATTATGATGGAGAAAGTAGTGATGAGCTAAGA
AATGGAAAAATGAAGGCATTTCTCTCATTAGCCCGGTTTTCAGATACTCAATACCAAAGA
ATTGAAAACTACATGAAATCATCGGAATTTGAAAACAAGCAAGCTCTCCTGAAAAGAGCC
AAAGAGGAAGTAGGTCTCCTTAGGGAACATAAAATTCAGACAAACAGATACACAGTAAAG
GTTCAGCGAGAGCTGGAGTTGGATGAATTAGCCCTGCGTGCACTGAAAGAGGATCGTAAA
CGCTTCTTATGTAAAGCAGTTGAAAATTATATCAACTGCTTATTAAGTGGAGAAGAACAT
GATATGTGGGTATTCCGACTTTGTTCCCTCTGGCTTGAAAATTCTGGAGTTTCTGAAGTC
AATGGCATGATGAAGAGAGACGGAATGAAGATTCCAACATATAAATTTTTGCCTCTTATG
TACCAATTGGCTGCTAGAATGGGGACCAAGATGATGGGAGGCCTAGGATTTCATGAAGTC
CTCAATAATCTAATCTCTAGAATTTCAATGGATCACCCCCATCACACTTTGTTTATTATA
CTGGCCTTAGCAAATGCAAACAGAGATGAATTTCTGACTAAACCAGAGGTAGCCAGAAGA
AGCAGAATAACTAAAAATGTGCCTAAACAAAGCTCTCAGCTTGATGAGGATCGAACAGAG
GCTGCAAATAGAATAATATGTACTATCAGAAGTAGGAGACCTCAGATGGTCAGAAGTGTT
GAGGCACTTTGTGATGCTTATATTATATTAGCAAACTTAGATGCCACTCAGTGGAAGACT
CAGAGAAAAGGCATAAATATTCCAGCAGACCAGCCAATTACTAAACTTAAGAATTTAGAA
GATGTTGTTGTCCCTACTATGGAAATTAAGGTGGACCACACAGGAGAATATGGAAATCTG
GTGACTATACAGTCATTTAAAGCAGAATTTCGCTTAGCAGGAGGTGTAAATTTACCAAAA
ATAATAGATTGTGTAGGTTCCGATGGCAAGGAGAGGAGACAGCTTGTTAAGGGCCGTGAT
GACCTGAGACAAGATGCTGTCATGCAACAGGTCTTCCAGATGTGTAATACATTACTGCAG
AGAAACACGGAAACTAGGAAGAGGAAATTAACTATCTGTACTTATAAGGTGGTTCCCCTC
TCTCAGCGAAGTGGTGTTCTTGAATGGTGCACAGGAACTGTCCCCATTGGTGAATTTCTT
GTTAACAATGAAGATGGTGCTCATAAAAGATACAGGCCAAATGATTTCAGTGCCTTTCAG
TGCCAAAAGAAAATGATGGAGGTGCAAAAAAAGTCTTTTGAAGAGAAATATGAAGTCTTC
ATGGATGTTTGCCAAAATTTTCAACCAGTTTTCCGTTACTTCTGCATGGAAAAATTCTTG
GATCCAGCTATTTGGTTTGAGAAGCGATTGGCTTATACGCGCAGTGTAGCTACTTCTTCT
ATTGTTGGTTACATACTTGGACTTGGTGATAGACATGTACAGAATATCTTGATAAATGAG
CAGTCAGCAGAACTTGTACATATAGATCTAGGTGTTGCTTTTGAACAGGGCAAAATCCTT
CCTACTCCTGAGACAGTTCCTTTTAGACTCACCAGAGATATTGTGGATGGCATGGGCATT
ACGGGTGTTGAAGGTGTCTTCAGAAGATGCTGTGAGAAAACCATGGAAGTGATGAGAAAC
TCTCAGGAAACTCTGTTAACCATTGTAGAGGTCCTTCTATATGATCCACTCTTTGACTGG
ACCATGAATCCTTTGAAAGCTTTGTATTTACAGCAGAGGCCGGAAGATGAAACTGAGCTT
CACCCTACTCTGAATGCAGATGACCAAGAATGCAAACGAAATCTCAGTGATATTGACCAG
AGTTTCAACAAAGTAGCTGAACGTGTCTTAATGAGACTACAAGAGAAACTGAAAGGAGTG
GAAGAAGGCACTGTGCTCAGTGTTGGTGGACAAGTGAATTTGCTCATACAGCAGGCCATA
GACCCCAAAAATCTCAGCCGACTTTTCCCAGGATGGAAAGCTTGGGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00454</identifier>
            <name>PI3_PI4_kinase</name>
          </pfam>
          <pfam>
            <identifier>PF02259</identifier>
            <name>FAT</name>
          </pfam>
          <pfam>
            <identifier>PF02260</identifier>
            <name>FATC</name>
          </pfam>
          <pfam>
            <identifier>PF11640</identifier>
            <name>TAN</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic membrane-bounded vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>DNA repair complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>spindle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA-dependent protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histone serine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein complex binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein dimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein N-terminus binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein serine/threonine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle arrest</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to DNA damage stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to gamma radiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>determination of adult lifespan</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA damage induced protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA repair</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>double-strand break repair</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>double-strand break repair via homologous recombination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>double-strand break repair via nonhomologous end joining</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>double-strand break repair via synthesis-dependent strand annealing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>histone mRNA catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intrinsic apoptotic signaling pathway in response to DNA damage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>meiotic telomere clustering</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic spindle assembly checkpoint</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of B cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-serine autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-3-phosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of DNA damage response, signal transduction by p53 class mediator</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pre-B cell allelic exclusion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>reciprocal meiotic recombination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cellular response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>replicative senescence</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ionizing radiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction involved in mitotic G2 DNA damage checkpoint</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>somitogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>V(D)J recombination</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="21">
      <id>BE0000241</id>
      <name>Adenosine receptor A2b</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18221</ref-id>
            <pubmed-id>20164566</pubmed-id>
            <citation>Ribeiro JA, Sebastiao AM: Caffeine and adenosine. J Alzheimers Dis. 2010;20 Suppl 1:S3-15. doi: 10.3233/JAD-2010-1379.</citation>
          </article>
        </articles>
        <textbooks>
          <textbook>
            <ref-id>T716</ref-id>
            <isbn/>
            <citation>Justin Evans; Amanda S. Battisti (2019). Caffeine. Stat Pearls Publishing.</citation>
          </textbook>
        </textbooks>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P29275" source="Swiss-Prot">
        <name>Adenosine receptor A2b</name>
        <general-function>G-protein coupled adenosine receptor activity</general-function>
        <specific-function>Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.</specific-function>
        <gene-name>ADORA2B</gene-name>
        <locus>17p12-p11.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>9-33
44-67
79-101
122-144
179-203
236-259
268-291</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.31</theoretical-pi>
        <molecular-weight>36332.655</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:264</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADORA2B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M97759</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178150</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>20</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>20</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29275</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AA2BR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010028|Adenosine receptor A2b
MLLETQDALYVALELVIAALSVAGNVLVCAAVGTANTLQTPTNYFLVSLAAADVAVGLFA
IPFAITISLGFCTDFYGCLFLACFVLVLTQSSIFSLLAVAVDRYLAICVPLRYKSLVTGT
RARGVIAVLWVLAFGIGLTPFLGWNSKDSATNNCTEPWDGTTNESCCLVKCLFENVVPMS
YMVYFNFFGCVLPPLLIMLVIYIKIFLVACRQLQRTELMDHSRTTLQREIHAAKSLAMIV
GIFALCWLPVHAVNCVTLFQPAQGKNKPKWAMNMAILLSHANSVVNPIVYAYRNRDFRYT
FHKIISRYLLCQADVKSGNGQAGVQPALGVGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010029|Adenosine receptor A2b (ADORA2B)
ATGCTGCTGGAGACACAGGACGCGCTGTACGTGGCGCTGGAGCTGGTCATCGCCGCGCTT
TCGGTGGCGGGCAACGTGCTGGTGTGCGCCGCGGTGGGCACGGCGAACACTCTGCAGACG
CCCACCAACTACTTCCTGGTGTCCCTGGCTGCGGCCGACGTGGCCGTGGGGCTCTTCGCC
ATCCCCTTTGCCATCACCATCAGCCTGGGCTTCTGCACTGACTTCTACGGCTGCCTCTTC
CTCGCCTGCTTCGTGCTGGTGCTCACGCAGAGCTCCATCTTCAGCCTTCTGGCCGTGGCA
GTCGACAGATACCTGGCCATCTGTGTCCCGCTCAGGTATAAAAGTTTGGTCACGGGGACC
CGAGCAAGAGGGGTCATTGCTGTCCTCTGGGTCCTTGCCTTTGGCATCGGATTGACTCCA
TTCCTGGGGTGGAACAGTAAAGACAGTGCCACCAACAACTGCACAGAACCCTGGGATGGA
ACCACGAATGAAAGCTGCTGCCTTGTGAAGTGTCTCTTTGAGAATGTGGTCCCCATGAGC
TACATGGTATATTTCAATTTCTTTGGGTGTGTTCTGCCCCCACTGCTTATAATGCTGGTG
ATCTACATTAAGATCTTCCTGGTGGCCTGCAGGCAGCTTCAGCGCACTGAGCTGATGGAC
CACTCGAGGACCACCCTCCAGCGGGAGATCCATGCAGCCAAGTCACTGGCCATGATTGTG
GGGATTTTTGCCCTGTGCTGGTTACCTGTGCATGCTGTTAACTGTGTCACTCTTTTCCAG
CCAGCTCAGGGTAAAAATAAGCCCAAGTGGGCAATGAATATGGCCATTCTTCTGTCACAT
GCCAATTCAGTTGTCAATCCCATTGTCTATGCTTACCGGAACCGAGACTTCCGCTACACT
TTTCACAAAATTATCTCCAGGTATCTTCTCTGCCAAGCAGATGTCAAGAGTGGGAATGGT
CAGGCTGGGGTACAGCCTGCTCTCGGTGTGGGCCTATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled adenosine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to extracellular stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>JNK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of chemokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of chronic inflammatory response to non-antigenic stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of guanylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mast cell degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>relaxation of vascular smooth muscle</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="22">
      <id>BE0000354</id>
      <name>Adenosine receptor A3</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18221</ref-id>
            <pubmed-id>20164566</pubmed-id>
            <citation>Ribeiro JA, Sebastiao AM: Caffeine and adenosine. J Alzheimers Dis. 2010;20 Suppl 1:S3-15. doi: 10.3233/JAD-2010-1379.</citation>
          </article>
        </articles>
        <textbooks>
          <textbook>
            <ref-id>T716</ref-id>
            <isbn/>
            <citation>Justin Evans; Amanda S. Battisti (2019). Caffeine. Stat Pearls Publishing.</citation>
          </textbook>
        </textbooks>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0DMS8" source="Swiss-Prot">
        <name>Adenosine receptor A3</name>
        <general-function>G-protein coupled adenosine receptor activity</general-function>
        <specific-function>Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction.</specific-function>
        <gene-name>ADORA3</gene-name>
        <locus>1p13.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>15-37
49-72
85-106
127-148
178-198
232-255
262-284</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.04</theoretical-pi>
        <molecular-weight>36184.175</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:268</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADORA3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L20463</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>349449</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>21</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>21</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0DMS8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AA3R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000705|Adenosine receptor A3
MPNNSTALSLANVTYITMEIFIGLCAIVGNVLVICVVKLNPSLQTTTFYFIVSLALADIA
VGVLVMPLAIVVSLGITIHFYSCLFMTCLLLIFTHASIMSLLAIAVDRYLRVKLTVRYKR
VTTHRRIWLALGLCWLVSFLVGLTPMFGWNMKLTSEYHRNVTFLSCQFVSVMRMDYMVYF
SFLTWIFIPLVVMCAIYLDIFYIIRNKLSLNLSNSKETGAFYGREFKTAKSLFLVLFLFA
LSWLPLSIINCIIYFNGEVPQLVLYMGILLSHANSMMNPIVYAYKIKKFKETYLLILKAC
VVCHPSDSLDTSIEKNSE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010106|Adenosine receptor A3 (ADORA3)
ATGCCCAACAACAGCACTGCTCTGTCATTGGCCAATGTTACCTACATCACCATGGAAATT
TTCATTGGACTCTGCGCCATAGTGGGCAACGTGCTGGTCATCTGCGTGGTCAAGCTGAAC
CCCAGCCTGCAGACCACCACCTTCTATTTCATTGTCTCTCTAGCCCTGGCTGACATTGCT
GTTGGGGTGCTGGTCATGCCTTTGGCCATTGTTGTCAGCCTGGGCATCACAATCCACTTC
TACAGCTGCCTTTTTATGACTTGCCTACTGCTTATCTTTACCCACGCCTCCATCATGTCC
TTGCTGGCCATCGCTGTGGACCGATACTTGCGGGTCAAGCTTACCGTCAGATACAAGAGG
GTCACCACTCACAGAAGAATATGGCTGGCCCTGGGCCTTTGCTGGCTGGTGTCATTCCTG
GTGGGATTGACCCCCATGTTTGGCTGGAACATGAAACTGACCTCAGAGTACCACAGAAAT
GTCACCTTCCTTTCATGCCAATTTGTTTCCGTCATGAGAATGGACTACATGGTATACTTC
AGCTTCCTCACCTGGATTTTCATCCCCCTGGTTGTCATGTGCGCCATCTATCTTGACATC
TTTTACATCATTCGGAACAAACTCAGTCTGAACTTATCTAACTCCAAAGAGACAGGTGCA
TTTTATGGACGGGAGTTCAAGACGGCTAAGTCCTTGTTTCTGGTTCTTTTCTTGTTTGCT
CTGTCATGGCTGCCTTTATCTATCATCAACTGCATCATCTACTTTAATGGTGAGGTACCA
CAGCTTGTGCTGTACATGGGCATCCTGCTGTCCCATGCCAACTCCATGATGAACCCTATC
GTCTATGCCTATAAAATAAAGAAGTTCAAGGAAACCTACCTTTTGATCCTCAAAGCTTGT
GTGGTCTGCCATCCCTCTGATTCTTTGGACACAAGCATTGAGAAGAATTCTGAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled adenosine receptor activity</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="23">
      <id>BE0009789</id>
      <name>Phosphodiesterase enzymes</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187724</ref-id>
            <pubmed-id>16402111</pubmed-id>
            <citation>Boswell-Smith V, Spina D, Page CP: Phosphodiesterase inhibitors. Br J Pharmacol. 2006 Jan;147 Suppl 1:S252-7. doi: 10.1038/sj.bjp.0706495.</citation>
          </article>
          <article>
            <ref-id>A187769</ref-id>
            <pubmed-id>7689104</pubmed-id>
            <citation>Howell LL: Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther. 1993 Aug;266(2):894-903.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L9851</ref-id>
            <title>Caffeine citrate injection FDA label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20793s1lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q01064" source="Swiss-Prot">
        <name>Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as a substrate.</specific-function>
        <gene-name>PDE1B</gene-name>
        <locus>12q13</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.22</theoretical-pi>
        <molecular-weight>61379.235</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8775</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE1B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U56976</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1295</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q01064</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE1B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
          <synonym>63 kDa Cam-PDE</synonym>
          <synonym>Cam-PDE 1B</synonym>
          <synonym>PDE1B1</synonym>
          <synonym>PDES1B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006483|Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
MELSPRSPPEMLEESDCPSPLELKSAPSKKMWIKLRSLLRYMVKQLENGEINIEELKKNL
EYTASLLEAVYIDETRQILDTEDELQELRSDAVPSEVRDWLASTFTQQARAKGRRAEEKP
KFRSIVHAVQAGIFVERMFRRTYTSVGPTYSTAVLNCLKNLDLWCFDVFSLNQAADDHAL
RTIVFELLTRHNLISRFKIPTVFLMSFLDALETGYGKYKNPYHNQIHAADVTQTVHCFLL
RTGMVHCLSEIELLAIIFAAAIHDYEHTGTTNSFHIQTKSECAIVYNDRSVLENHHISSV
FRLMQDDEMNIFINLTKDEFVELRALVIEMVLATDMSCHFQQVKTMKTALQQLERIDKPK
ALSLLLHAADISHPTKQWLVHSRWTKALMEEFFRQGDKEAELGLPFSPLCDRTSTLVAQS
QIGFIDFIVEPTFSVLTDVAEKSVQPLADEDSKSKNQPSFQWRQPSLDVEVGDPNPDVVS
FRSTWVKRIQENKQKWKERAASGITNQMSIDELSPCEEEAPPSPAEDEHNQNGNLD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017061|Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B (PDE1B)
ATGGAGCTGTCCCCCCGCAGTCCTCCGGAGATGCTGGAGGAGTCGGATTGCCCGTCACCC
CTGGAGCTGAAGTCAGCCCCCAGCAAGAAGATGTGGATTAAGCTTCGGTCTCTGCTGCGC
TACATGGTGAAGCAGTTGGAGAATGGGGAGATAAACATTGAGGAGCTGAAGAAAAATCTG
GAGTACACAGCTTCTCTGCTGGAAGCCGTCTACATAGATGAGACACGGCAAATCTTGGAC
ACGGAGGACGAGCTGCAGGAGCTGCGGTCAGATGCCGTGCCTTCGGAGGTGCGGGACTGG
CTGGCCTCCACCTTCACCCAGCAGGCCCGGGCCAAAGGCCGCCGAGCAGAGGAGAAGCCC
AAGTTCCGAAGCATTGTGCACGCTGTGCAGGCTGGGATCTTCGTGGAACGGATGTTCCGG
AGAACATACACCTCTGTGGGCCCCACTTACTCTACTGCGGTTCTCAACTGTCTCAAGAAC
CTGGATCTCTGGTGCTTTGATGTCTTTTCCTTGAACCAGGCAGCAGATGACCATGCCCTG
AGGACCATTGTTTTTGAGTTGCTGACTCGGCATAACCTCATCAGCCGCTTCAAGATTCCC
ACTGTGTTTTTGATGAGTTTCCTGGATGCCTTGGAGACAGGCTATGGGAAGTACAAGAAT
CCTTACCACAACCAGATCCACGCAGCCGATGTTACCCAGACAGTCCATTGCTTCTTGCTC
CGCACAGGGATGGTGCACTGCCTGTCGGAGATTGAGCTCCTGGCCATCATCTTTGCTGCA
GCTATCCATGATTATGAGCACACGGGCACTACCAACAGCTTCCACATCCAGACCAAGTCA
GAATGTGCCATCGTGTACAATGATCGTTCAGTGCTGGAGAATCACCACATCAGCTCTGTT
TTCCGATTGATGCAGGATGATGAGATGAACATTTTCATCAACCTCACCAAGGATGAGTTT
GTAGAACTCCGAGCCCTGGTCATTGAGATGGTGTTGGCCACAGACATGTCCTGCCATTTC
CAGCAAGTGAAGACCATGAAGACAGCCTTGCAACAGCTGGAGAGGATTGACAAGCCCAAG
GCCCTGTCTCTACTGCTCCATGCTGCTGACATCAGCCACCCAACCAAGCAGTGGTTGGTC
CACAGCCGTTGGACCAAGGCCCTCATGGAGGAATTCTTCCGTCAGGGTGACAAGGAGGCA
GAGTTGGGCCTGCCCTTTTCTCCACTCTGTGACCGCACTTCCACTCTAGTGGCACAGTCT
CAGATAGGGTTCATCGACTTCATTGTGGAGCCCACATTCTCTGTGCTGACTGACGTGGCA
GAGAAGAGTGTTCAGCCCCTGGCGGATGAGGACTCCAAGTCTAAAAACCAGCCCAGCTTT
CAGTGGCGCCAGCCCTCTCTGGATGTGGAAGTGGGAGACCCCAACCCTGATGTGGTCAGC
TTTCGTTCCACCTGGGTCAAGCGCATTCAGGAGAATAAGCAGAAATGGAAGGAACGGGCA
GCAAGTGGCATCACCAACCAGATGTCCATTGACGAGCTGTCCCCCTGTGAAGAAGAGGCC
CCCCCATCCCCTGCCGAAGATGAACACAACCAGAATGGGAATCTGGATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
          <pfam>
            <identifier>PF08499</identifier>
            <name>PDEase_I_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium- and calmodulin-regulated 3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin-dependent cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to granulocyte macrophage colony-stimulating factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to macrophage colony-stimulating factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of neurotransmitter levels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q08499" source="Swiss-Prot">
        <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4D</name>
        <general-function>Ubiquitin protein ligase binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.</specific-function>
        <gene-name>PDE4D</gene-name>
        <locus>5q12</locus>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.25</theoretical-pi>
        <molecular-weight>91114.1</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8783</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE4D</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L20970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>347130</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1303</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q08499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE4D_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>DPDE3</synonym>
          <synonym>PDE43</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002560|cAMP-specific 3',5'-cyclic phosphodiesterase 4D
MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQYPLRQPQFRLLHPHHHLPPP
PPPSPQPQPQCPLQPPPPPPLPPPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRA
MDRTSYAVETGHRPGLKKSRMSWPSSFQGLRRFDVDNGTSAGRSPLDPMTSPGSGLILQA
NFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRTVRNNF
AALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQTRHSV
SEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKEKKKRP
MSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELSGNRPL
TVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLST
PALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGF
KLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVL
LLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMC
DKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQSPSPAP
DDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSESTEIPL
DEQVEEEAVGEEEESQPEACVIDDRSPDT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020514|cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D)
ATGGAGGCAGAGGGCAGCAGCGCGCCGGCCCGGGCGGGCAGCGGAGAGGGCAGCGACAGC
GCCGGCGGGGCCACGCTCAAAGCCCCCAAGCATCTCTGGAGGCACGAGCAGCACCACCAG
TACCCGCTCCGGCAGCCCCAGTTCCGCCTCCTGCATCCCCATCACCACCTGCCCCCGCCG
CCGCCACCCTCGCCCCAGCCCCAGCCCCAGTGTCCGCTACAGCCGCCGCCGCCGCCCCCC
CTGCCGCCGCCCCCGCCGCCGCCCGGGGCTGCCCGCGGCCGCTACGCCTCGAGCGGGGCC
ACCGGCCGCGTCCGGCATCGCGGCTACTCGGACACCGAGCGCTACCTGTACTGTCGCGCC
ATGGACCGCACCTCCTACGCGGTGGAGACCGGCCACCGGCCCGGCCTGAAGAAATCCAGG
ATGTCCTGGCCCTCCTCGTTCCAGGGACTCAGGCGTTTTGATGTGGACAATGGCACATCT
GCGGGACGGAGTCCCTTGGATCCCATGACCAGCCCAGGATCCGGGCTAATTCTCCAAGCA
AATTTTGTCCACAGTCAACGACGGGAGTCCTTCCTGTATCGATCCGACAGCGATTATGAC
CTCTCTCCAAAGTCTATGTCCCGGAACTCCTCCATTGCCAGTGATATACACGGAGATGAC
TTGATTGTGACTCCATTTGCTCAGGTCTTGGCCAGTCTGCGAACTGTACGAAACAACTTT
GCTGCATTAACTAATTTGCAAGATCGAGCACCTAGCAAAAGATCACCCATGTGCAACCAA
CCATCCATCAACAAAGCCACCATAACAGAGGAGGCCTACCAGAAACTGGCCAGCGAGACC
CTGGAGGAGCTGGACTGGTGTCTGGACCAGCTAGAGACCCTACAGACCAGGCACTCCGTC
AGTGAGATGGCCTCCAACAAGTTTAAAAGGATGCTTAATCGGGAGCTCACCCATCTCTCT
GAAATGAGTCGGTCTGGAAATCAAGTGTCAGAGTTTATATCAAACACATTCTTAGATAAG
CAACATGAAGTGGAAATTCCTTCTCCAACTCAGAAGGAAAAGGAGAAAAAGAAAAGACCA
ATGTCTCAGATCAGTGGAGTCAAGAAATTGATGCACAGCTCTAGTCTGACTAATTCAAGT
ATCCCAAGGTTTGGAGTTAAAACTGAACAAGAAGATGTCCTTGCCAAGGAACTAGAAGAT
GTGAACAAATGGGGTCTTCATGTTTTCAGAATAGCAGAGTTGTCTGGTAACCGGCCCTTG
ACTGTTATCATGCACACCATTTTTCAGGAACGGGATTTATTAAAAACATTTAAAATTCCA
GTAGATACTTTAATTACATATCTTATGACTCTCGAAGACCATTACCATGCTGATGTGGCC
TATCACAACAATATCCATGCTGCAGATGTTGTCCAGTCTACTCATGTGCTATTATCTACA
CCTGCTTTGGAGGCTGTGTTTACAGATTTGGAGATTCTTGCAGCAATTTTTGCCAGTGCA
ATACATGATGTAGATCATCCTGGTGTGTCCAATCAATTTCTGATCAATACAAACTCTGAA
CTTGCCTTGATGTACAATGATTCCTCAGTCTTAGAGAACCATCATTTGGCTGTGGGCTTT
AAATTGCTTCAGGAAGAAAACTGTGACATTTTCCAGAATTTGACCAAAAAACAAAGACAA
TCTTTAAGGAAAATGGTCATTGACATCGTACTTGCAACAGATATGTCAAAACACATGAAT
CTACTGGCTGATTTGAAGACTATGGTTGAAACTAAGAAAGTGACAAGCTCTGGAGTTCTT
CTTCTTGATAATTATTCCGATAGGATTCAGGTTCTTCAGAATATGGTGCACTGTGCAGAT
CTGAGCAACCCAACAAAGCCTCTCCAGCTGTACCGCCAGTGGACGGACCGGATAATGGAG
GAGTTCTTCCGCCAAGGAGACCGAGAGAGGGAACGTGGCATGGAGATAAGCCCCATGTGT
GACAAGCACAATGCTTCCGTGGAAAAATCACAGGTGGGCTTCATAGACTATATTGTTCAT
CCCCTCTGGGAGACATGGGCAGACCTCGTCCACCCTGACGCCCAGGATATTTTGGACACT
TTGGAGGACAATCGTGAATGGTACCAGAGCACAATCCCTCAGAGCCCCTCTCCTGCACCT
GATGACCCAGAGGAGGGCCGGCAGGGTCAAACTGAGAAATTCCAGTTTGAACTAACTTTA
GAGGAAGATGGTGAGTCAGACACGGAAAAGGACAGTGGCAGTCAAGTGGAAGAAGACACT
AGCTGCAGTGACTCCAAGACTCTTTGTACTCAAGACTCAGAGTCTACTGAAATTCCCCTT
GATGAACAGGTTGAAGAGGAGGCAGTAGGGGAAGAAGAGGAAAGCCAGCCTGAAGCCTGT
GTCATAGATGATCGTTCTCCTGACACGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>centrosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myofibril</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated calcium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-2 adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>scaffold protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin protein ligase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adrenergic receptor signaling pathway involved in positive regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cAMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to epinephrine stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>establishment of endothelial barrier</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of relaxation of cardiac muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-2 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-5 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle cell contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell communication by electrical coupling involved in cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of G-protein coupled receptor protein signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein kinase A signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ryanodine-sensitive calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q13370" source="Swiss-Prot">
        <name>cGMP-inhibited 3',5'-cyclic phosphodiesterase B</name>
        <general-function>Protein kinase b binding</general-function>
        <specific-function>Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. May play a role in fat metabolism. Regulates cAMP binding of RAPGEF3. Through simultaneous binding to RAPGEF3 and PIK3R6 assembles a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis.</specific-function>
        <gene-name>PDE3B</gene-name>
        <locus>11p15.1</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>88-108
117-137
152-172
192-212
220-240
247-267</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.75</theoretical-pi>
        <molecular-weight>124332.145</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8779</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE3B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U38178</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1145302</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1299</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13370</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE3B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
          <synonym>CGI-PDE B</synonym>
          <synonym>CGIP1</synonym>
          <synonym>CGIPDE1</synonym>
          <synonym>Cyclic GMP-inhibited phosphodiesterase B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002435|cGMP-inhibited 3',5'-cyclic phosphodiesterase B
MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELR
PPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLS
PLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGD
AGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSL
PSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSL
GETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEAR
NMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKG
DRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGP
FNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDT
ADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSG
KSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLD
LILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQF
MNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRIN
HGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQ
AVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFD
FLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFY
EQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDN
DTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEE
KCKADGNKLQVENSSLPQADEIQVIEEADEEE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021288|cGMP-inhibited 3',5'-cyclic phosphodiesterase B (PDE3B)
ATGAGGAGGGACGAGCGAGACGCCAAAGCCATGCGGTCCCTGCAGCCGCCGGATGGGGCC
GGCTCGCCCCCCGAGAGTCTGAGGAACGGCTACGTGAAGAGCTGCGTGAGCCCCTTGCGG
CAGGACCCTCCGCGCGGCTTCTTCTTCCACCTCTGCCGCTTCTGCAACGTGGAGCTGCGG
CCGCCGCCGGCCTCTCCCCAGCAGCCGCGGCGCTGCTCCCCCTTCTGCCGGGCGCGCCTC
TCGCTGGGCGCCCTGGCTGCCTTTGTCCTCGCCCTGCTGCTGGGCGCGGAACCCGAGAGC
TGGGCTGCCGGGGCCGCCTGGCTGCGGACGCTGCTGAGCGTGTGTTCGCACAGCTTGAGC
CCCCTCTTCAGCATCGCCTGTGCCTTCTTCTTCCTCACCTGCTTCCTCACCCGGACCAAG
CGGGGACCCGGCCCGGGCCGGAGCTGCGGCTCCTGGTGGCTGCTGGCGCTGCCCGCCTGC
TGTTACCTGGGGGACTTCTTGGTGTGGCAGTGGTGGTCTTGGCCTTGGGGGGATGGCGAC
GCAGGGTCCGCGGCCCCGCACACGCCCCCGGAGGCGGCAGCGGGCAGGTTGCTGCTGGTG
CTGAGCTGCGTAGGGCTGCTGCTGACGCTCGCGCACCCGCTGCGGCTCCGGCACTGCGTT
CTGGTGCTGCTCCTGGCCAGCTTCGTCTGGTGGGTCTCCTTCACCAGCCTCGGGTCGCTG
CCCTCCGCCCTCAGGCCGCTGCTCTCCGGCCTGGTGGGGGGCGCTGGCTGCCTGCTGGCC
CTGGGGTTGGATCACTTCTTTCAAATCAGGGAAGCGCCTCTTCATCCTCGACTGTCCAGT
GCCGCCGAAGAAAAAGTGCCTGTGATCCGACCCCGGAGGAGGTCCAGCTGCGTGTCGTTA
GGAGAAACTGCAGCCAGTTACTATGGCAGTTGCAAAATATTCAGGAGACCGTCGTTGCCT
TGTATTTCCAGAGAACAGATGATTCTTTGGGATTGGGACTTAAAACAATGGTATAAGCCT
CATTATCAAAATTCTGGAGGTGGAAATGGAGTTGATCTTTCAGTGCTAAATGAGGCTCGC
AATATGGTGTCAGATCTTCTGACTGATCCAAGCCTTCCACCACAAGTCATTTCCTCTCTA
CGGAGTATTAGTAGCTTAATGGGTGCTTTCTCAGGTTCCTGTAGGCCAAAGATTAATCCT
CTCACACCATTTCCTGGATTTTACCCCTGTTCTGAAATAGAGGACCCAGCTGAGAAAGGG
GATAGAAAACTTAACAAGGGACTAAATAGGAATAGTTTGCCAACTCCACAGCTGAGGAGA
AGCTCAGGAACTTCAGGATTGCTACCTGTTGAACAGTCTTCAAGGTGGGATCGTAATAAT
GGCAAAAGACCTCACCAAGAATTTGGCATTTCAAGTCAAGGATGCTATCTAAATGGGCCT
TTTAATTCAAATCTACTGACTATCCCGAAGCAAAGGTCATCTTCTGTATCACTGACTCAC
CATGTAGGTCTCAGAAGAGCTGGTGTTTTGTCCAGTCTGAGTCCTGTGAATTCTTCCAAC
CATGGACCAGTGTCTACTGGCTCTCTAACTAATCGATCACCCATAGAATTTCCTGATACT
GCTGATTTTCTTAATAAGCCAAGCGTTATCTTGCAGAGATCTCTGGGCAATGCACCTAAT
ACTCCAGATTTTTATCAGCAACTTAGAAATTCTGATAGCAATCTGTGTAACAGCTGTGGA
CATCAAATGCTGAAATATGTTTCAACATCTGAATCAGATGGTACAGATTGCTGCAGTGGA
AAATCAGGTGAAGAAGAAAACATTTTCTCGAAAGAATCATTCAAACTTATGGAAACTCAA
CAAGAAGAGGAAACAGAGAAGAAAGACAGCAGAAAATTATTTCAGGAAGGTGATAAGTGG
CTAACAGAAGAGGCACAGAGTGAACAGCAAACAAATATTGAACAGGAAGTATCACTGGAC
CTGATTTTAGTAGAAGAGTATGACTCATTAATAGAAAAGATGAGCAACTGGAATTTTCCA
ATTTTTGAACTTGTAGAAAAGATGGGAGAGAAATCAGGAAGGATTCTCAGTCAGGTTATG
TATACCTTATTTCAAGACACTGGTTTATTGGAAATATTTAAAATTCCCACTCAACAATTT
ATGAACTATTTTCGTGCATTAGAAAATGGCTATCGAGACATTCCTTATCACAATCGTATA
CATGCCACAGATGTGCTACATGCAGTTTGGTATCTGACAACACGGCCAGTTCCTGGCTTA
CAGCAGATCCACAATGGTTGTGGAACAGGAAATGAAACAGATTCTGATGGTAGAATTAAC
CATGGGCGAATTGCTTATATTTCTTCGAAGAGCTGCTCTAATCCTGATGAGAGTTATGGC
TGCCTGTCTTCAAACATTCCTGCATTAGAATTGATGGCTCTATACGTGGCAGCTGCCATG
CATGATTATGATCACCCAGGGAGGACAAATGCATTTCTAGTGGCTACAAATGCCCCTCAG
GCAGTTTTATACAATGACAGATCTGTTCTGGAAAATCATCATGCTGCGTCAGCTTGGAAT
CTATATCTTTCTCGCCCAGAATACAACTTCCTTCTTCATCTTGATCATGTGGAATTCAAG
CGCTTTCGTTTTTTAGTCATTGAAGCAATCCTTGCTACGGATCTTAAAAAGCATTTTGAT
TTTCTCGCAGAATTCAATGCCAAGGCAAATGATGTAAATAGTAATGGCATAGAATGGAGT
AATGAAAATGATCGCCTCTTGGTATGCCAGGTGTGCATCAAACTGGCAGATATAAATGGC
CCAGCAAAAGTTCGAGACTTGCATTTGAAATGGACAGAAGGCATTGTCAATGAATTTTAT
GAGCAGGGAGATGAAGAAGCAAATCTTGGTCTGCCCATCAGTCCATTCATGGATCGTTCT
TCTCCTCAACTAGCAAAACTCCAAGAATCTTTTATCACCCACATAGTGGGTCCCCTGTGT
AACTCCTATGATGCTGCTGGTTTGCTACCAGGTCAGTGGTTAGAAGCAGAAGAGGATAAT
GATACTGAAAGTGGTGATGATGAAGACGGTGAAGAATTAGATACAGAAGATGAAGAAATG
GAAAACAATCTAAATCCAAAACCACCAAGAAGGAAAAGCAGACGGCGAATATTTTGTCAG
CTAATGCACCACCTCACTGAAAACCACAAGATATGGAAGGAAATCGTAGAGGAAGAAGAA
AAATGTAAAGCTGATGGGAATAAACTGCAGGTGGAGAATTCCTCCTTACCTCAAGCAGAT
GAGATTCAGGTAATTGAAGAGGCAGATGAAGAGGAATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>guanyl-nucleotide exchange factor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP-inhibited cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase B binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endocrine pancreas development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell adhesion mediated by integrin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O76074" source="Swiss-Prot">
        <name>cGMP-specific 3',5'-cyclic phosphodiesterase</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).</specific-function>
        <gene-name>PDE5A</gene-name>
        <locus>4q25-q27</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.0</theoretical-pi>
        <molecular-weight>99984.14</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8784</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE5A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF043731</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3420185</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1304</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O76074</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE5A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.35</synonym>
          <synonym>CGB-PDE</synonym>
          <synonym>cGMP-binding cGMP-specific phosphodiesterase</synonym>
          <synonym>PDE5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036966|cGMP-specific 3',5'-cyclic phosphodiesterase
MERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKATREMVNAWFAE
RVHTIPVCKEGIRGHTESCSCPLQQSPRADNSAPGTPTRKISASEFDRPLRPIVVKDSEG
TVSFLSDSEKKEQMPLTPPRFDHDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLI
SADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEVSNNCIRLEWNKGIVGHVAALGEPL
NIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDE
KDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIIS
FMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKSSDTLTREHDANKINYMYAQYVKNTME
PLNIPDVSKDKRFPWTTENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGK
VKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETREL
QSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWIL
SVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGV
NNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAI
LATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAE
LVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCF
PLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009989|cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A)
ATGGAGCGGGCCGGCCCCAGCTTCGGGCAGCAGCGACAGCAGCAGCAGCCCCAGCAGCAG
AAGCAGCAGCAGAGGGATCAGGACTCGGTCGAAGCATGGCTGGACGATCACTGGGACTTT
ACCTTCTCATACTTTGTTAGAAAAGCCACCAGAGAAATGGTCAATGCATGGTTTGCTGAG
AGAGTTCACACCATCCCTGTGTGCAAGGAAGGTATCAGAGGCCACACCGAATCTTGCTCT
TGTCCCTTGCAGCAGAGTCCTCGTGCAGATAACAGTGCCCCTGGAACACCAACCAGGAAA
ATCTCTGCCTCTGAATTTGACCGGCCTCTTAGACCCATTGTTGTCAAGGATTCTGAGGGA
ACTGTGAGCTTCCTCTCTGACTCAGAAAAGAAGGAACAGATGCCTCTAACCCCTCCAAGG
TTTGATCATGATGAAGGGGACCAGTGCTCAAGACTCTTGGAATTAGTGAAGGATATTTCT
AGTCATTTGGATGTCACAGCCTTATGTCACAAAATTTTCTTGCATATCCATGGACTGATA
TCTGCTGACCGCTATTCCCTGTTCCTTGTCTGTGAAGACAGCTCCAATGACAAGTTTCTT
ATCAGCCGCCTCTTTGATGTTGCTGAAGGTTCAACACTGGAAGAAGTTTCAAATAACTGT
ATCCGCTTAGAATGGAACAAAGGCATTGTGGGACATGTGGCAGCGCTTGGTGAGCCCTTG
AACATCAAAGATGCATATGAGGATCCTCGGTTCAATGCAGAAGTTGACCAAATTACAGGC
TACAAGACACAAAGCATTCTTTGTATGCCAATTAAGAATCATAGGGAAGAGGTTGTTGGT
GTAGCCCAGGCCATCAACAAGAAATCAGGAAACGGTGGGACATTTACTGAAAAAGATGAA
AAGGACTTTGCTGCTTATTTGGCATTTTGTGGTATTGTTCTTCATAATGCTCAGCTCTAT
GAGACTTCACTGCTGGAGAACAAGAGAAATCAGGTGCTGCTTGACCTTGCTAGTTTAATT
TTTGAAGAACAACAATCATTAGAAGTAATTTTGAAGAAAATAGCTGCCACTATTATCTCT
TTCATGCAAGTGCAGAAATGCACCATTTTCATAGTGGATGAAGATTGCTCCGATTCTTTT
TCTAGTGTGTTTCACATGGAGTGTGAGGAATTAGAAAAATCATCTGATACATTAACAAGG
GAACATGATGCAAACAAAATCAATTACATGTATGCTCAGTATGTCAAAAATACTATGGAA
CCACTTAATATCCCAGATGTCAGTAAGGATAAAAGATTTCCCTGGACAACTGAAAATACA
GGAAATGTAAACCAGCAGTGCATTAGAAGTTTGCTTTGTACACCTATAAAAAATGGAAAG
AAGAATAAAGTTATAGGGGTTTGCCAACTTGTTAATAAGATGGAGGAGAATACTGGCAAG
GTTAAGCCTTTCAACCGAAATGACGAACAGTTTCTGGAAGCTTTTGTCATCTTTTGTGGC
TTGGGGATCCAGAACACGCAGATGTATGAAGCAGTGGAGAGAGCCATGGCCAAGCAAATG
GTCACATTGGAGGTTCTGTCGTATCATGCTTCAGCAGCAGAGGAAGAAACAAGAGAGCTA
CAGTCGTTAGCGGCTGCTGTGGTGCCATCTGCCCAGACCCTTAAAATTACTGACTTTAGC
TTCAGTGACTTTGAGCTGTCTGATCTGGAAACAGCACTGTGTACAATTCGGATGTTTACT
GACCTCAACCTTGTGCAGAACTTCCAGATGAAACATGAGGTTCTTTGCAGATGGATTTTA
AGTGTTAAGAAGAATTATCGGAAGAATGTTGCCTATCATAATTGGAGACATGCCTTTAAT
ACAGCTCAGTGCATGTTTGCTGCTCTAAAAGCAGGCAAAATTCAGAACAAGCTGACTGAC
CTGGAGATACTTGCATTGCTGATTGCTGCACTAAGCCACGATTTGGATCACCGTGGTGTG
AATAACTCTTACATACAGCGAAGTGAACATCCACTTGCCCAGCTTTACTGCCATTCAATC
ATGGAACACCATCATTTTGACCAGTGCCTGATGATTCTTAATAGTCCAGGCAATCAGATT
CTCAGTGGCCTCTCCATTGAAGAATATAAGACCACGTTGAAAATAATCAAGCAAGCTATT
TTAGCTACAGACCTAGCACTGTACATTAAGAGGCGAGGAGAATTTTTTGAACTTATAAGA
AAAAATCAATTCAATTTGGAAGATCCTCATCAAAAGGAGTTGTTTTTGGCAATGCTGATG
ACAGCTTGTGATCTTTCTGCAATTACAAAACCCTGGCCTATTCAACAACGGATAGCAGAA
CTTGTAGCAACTGAATTTTTTGATCAAGGAGACAGAGAGAGAAAAGAACTCAACATAGAA
CCCACTGATCTAATGAACAGGGAGAAGAAAAACAAAATCCCAAGTATGCAAGTTGGGTTC
ATAGATGCCATCTGCTTGCAACTGTATGAGGCCCTGACCCACGTGTCAGAGGACTGTTTC
CCTTTGCTAGATGGCTGCAGAAAGAACAGGCAGAAATGGCAGGCCCTTGCAGAACAGCAG
GAGAAGATGCTGATTAATGGGGAAAGCGGCCAGGCCAAGCGGAACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cardiac muscle hypertrophy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of oocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cGMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>relaxation of cardiac muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A14721</ref-id>
            <pubmed-id>8846619</pubmed-id>
            <citation>Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5.</citation>
          </article>
          <article>
            <ref-id>A415</ref-id>
            <pubmed-id>19515014</pubmed-id>
            <citation>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</citation>
          </article>
          <article>
            <ref-id>A14731</ref-id>
            <pubmed-id>9492382</pubmed-id>
            <citation>Hickman D, Wang JP, Wang Y, Unadkat JD: Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos. 1998 Mar;26(3):207-15.</citation>
          </article>
          <article>
            <ref-id>A38895</ref-id>
            <pubmed-id>14616429</pubmed-id>
            <citation>Hartter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K: Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003 Dec;56(6):679-82.</citation>
          </article>
          <article>
            <ref-id>A184400</ref-id>
            <pubmed-id>1302044</pubmed-id>
            <citation>Gu L, Gonzalez FJ, Kalow W, Tang BK: Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics. 1992 Apr;2(2):73-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
          <link>
            <ref-id>L9851</ref-id>
            <title>Caffeine citrate injection FDA label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20793s1lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
        <name>Cytochrome P450 1A2</name>
        <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
        <gene-name>CYP1A2</gene-name>
        <locus>15q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.43</theoretical-pi>
        <molecular-weight>58293.76</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2596</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP1A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z00036</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYPIA2</synonym>
          <synonym>Cytochrome P(3)450</synonym>
          <synonym>Cytochrome P450 4</synonym>
          <synonym>Cytochrome P450-P3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative deethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A184262</ref-id>
            <pubmed-id>17652830</pubmed-id>
            <citation>Kot M, Daniel WA: Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep. 2007 May-Jun;59(3):296-305.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="4">
      <id>BE0003533</id>
      <name>Cytochrome P450 2E1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A184394</ref-id>
            <pubmed-id>17222385</pubmed-id>
            <citation>Collom SL, Jamakhandi AP, Tackett AJ, Radominska-Pandya A, Miller GP: CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. Arch Biochem Biophys. 2007 Mar 1;459(1):59-69. doi: 10.1016/j.abb.2006.10.028. Epub 2006 Nov 2.</citation>
          </article>
          <article>
            <ref-id>A184397</ref-id>
            <pubmed-id>9156694</pubmed-id>
            <citation>Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH: Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics. 1996 Apr;6(2):159-76.</citation>
          </article>
          <article>
            <ref-id>A184400</ref-id>
            <pubmed-id>1302044</pubmed-id>
            <citation>Gu L, Gonzalez FJ, Kalow W, Tang BK: Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics. 1992 Apr;2(2):73-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P05181" source="Swiss-Prot">
        <name>Cytochrome P450 2E1</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.</specific-function>
        <gene-name>CYP2E1</gene-name>
        <locus>10q24.3-qter</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.22</theoretical-pi>
        <molecular-weight>56848.42</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2631</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J02625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181360</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1330</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05181</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2E1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.13.-</synonym>
          <synonym>4-nitrophenol 2-hydroxylase</synonym>
          <synonym>CYP2E</synonym>
          <synonym>CYPIIE1</synonym>
          <synonym>Cytochrome P450-J</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012460|Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012461|Cytochrome P450 2E1 (CYP2E1)
ATGTCTGCCCTCGGAGTCACCGTGGCCCTGCTGGTGTGGGCGGCCTTCCTCCTGCTGGTG
TCCATGTGGAGGCAGGTGCACAGCAGCTGGAATCTGCCCCCAGGCCCTTTCCCGCTTCCC
ATCATCGGGAACCTCTTCCAGTTGGAATTGAAGAATATTCCCAAGTCCTTCACCCGGTTG
GCCCAGCGCTTCGGGCCGGTGTTCACGCTGTACGTGGGCTCGCAGCGCATGGTGGTGATG
CACGGCTACAAGGCGGTGAAGGAAGCGCTGCTGGACTACAAGGACGAGTTCTCGGGCAGA
GGCGACCTCCCCGCGTTCCATGCGCACAGGGACAGGGGAATCATTTTTAATAATGGACCT
ACCTGGAAGGACATCCGGCGGTTTTCCCTGACCACCCTCCGGAACTATGGGATGGGGAAA
CAGGGCAATGAGAGCCGGATCCAGAGGGAGGCCCACTTCCTGCTGGAAGCACTCAGGAAG
ACCCAAGGCCAGCCTTTCGACCCCACCTTCCTCATCGGCTGCGCGCCCTGCAACGTCATA
GCCGACATCCTCTTCCGCAAGCATTTTGACTACAATGATGAGAAGTTTCTAAGGCTGATG
TATTTGTTTAATGAGAACTTCCACCTACTCAGCACTCCCTGGCTCCAGCTTTACAATAAT
TTTCCCAGCTTTCTACACTACTTGCCTGGAAGCCACAGAAAAGTCATAAAAAATGTGGCT
GAAGTAAAAGAGTATGTGTCTGAAAGGGTGAAGGAGCACCATCAATCTCTGGACCCCAAC
TGTCCCCGGGACCTCACCGACTGCCTGCTCGTGGAAATGGAGAAGGAAAAGCACAGTGCA
GAGCGCTTGTACACAATGGACGGTATCACCGTGACTGTGGCCGACCTGTTCTTTGCGGGG
ACAGAGACCACCAGCACAACTCTGAGATATGGGCTCCTGATTCTCATGAAATACCCTGAG
ATCGAAGAGAAGCTCCATGAAGAAATTGACAGGGTGATTGGGCCAAGCCGAATCCCTGCC
ATCAAGGATAGGCAAGAGATGCCCTACATGGATGCTGTGGTGCATGAGATTCAGCGGTTC
ATCACCCTCGTGCCCTCCAACCTGCCCCATGAAGCAACCCGAGACACCATTTTCAGAGGA
TACCTCATCCCCAAGGGCACAGTCGTAGTGCCAACTCTGGACTCTGTTTTGTATGACAAC
CAAGAATTTCCTGATCCAGAAAAGTTTAAGCCAGAACACTTCCTGAATGAAAATGGAAAG
TTCAAGTACAGTGACTATTTCAAGCCATTTTCCACAGGAAAACGAGTGTGTGCTGGAGAA
GGCCTGGCTCGCATGGAGTTGTTTCTTTTGTTGTGTGCCATTTTGCAGCATTTTAATTTG
AAGCCTCTCGTTGACCCAAAGGATATCGACCTCAGCCCTATACATATTGGGTTTGGCTGT
ATCCCACCACGTTACAAACTCTGTGTCATTCCCCGCTCATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organonitrogen compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ozone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>triglyceride metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="5">
      <id>BE0002887</id>
      <name>Cytochrome P450 2C8</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A36507</ref-id>
            <pubmed-id>22293536</pubmed-id>
            <citation>Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB: PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95. doi: 10.1097/FPC.0b013e3283505d5e.</citation>
          </article>
          <article>
            <ref-id>A19466</ref-id>
            <pubmed-id>18619574</pubmed-id>
            <citation>Kot M, Daniel WA: The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochem Pharmacol. 2008 Aug 15;76(4):543-51. doi: 10.1016/j.bcp.2008.05.025. Epub 2008 Jul 9.</citation>
          </article>
          <article>
            <ref-id>A19468</ref-id>
            <pubmed-id>19211970</pubmed-id>
            <citation>Kot M, Daniel WA: Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep. 2008 Nov-Dec;60(6):789-97.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10632" source="Swiss-Prot">
        <name>Cytochrome P450 2C8</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).</specific-function>
        <gene-name>CYP2C8</gene-name>
        <locus>10q23.33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.62</theoretical-pi>
        <molecular-weight>55824.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M17397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1325</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10632</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIC8</synonym>
          <synonym>Cytochrome P450 form 1</synonym>
          <synonym>Cytochrome P450 IIC2</synonym>
          <synonym>Cytochrome P450 MP-12</synonym>
          <synonym>Cytochrome P450 MP-20</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005650|Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8)
ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG
AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA
AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC
TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT
GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC
CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA
TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT
CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA
CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT
CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA
GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG
ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG
GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC
CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC
ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA
TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG
AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT
GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT
GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA
CCCTCATACCAGATCTGCTTCATCCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="6">
      <id>BE0002793</id>
      <name>Cytochrome P450 2C9</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A415</ref-id>
            <pubmed-id>19515014</pubmed-id>
            <citation>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</citation>
          </article>
          <article>
            <ref-id>A39427</ref-id>
            <pubmed-id>23679834</pubmed-id>
            <citation>Utoh M, Murayama N, Uno Y, Onose Y, Hosaka S, Fujino H, Shimizu M, Iwasaki K, Yamazaki H: Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica. 2013 Dec;43(12):1037-42. doi: 10.3109/00498254.2013.793874. Epub 2013 May 16.</citation>
          </article>
          <article>
            <ref-id>A19466</ref-id>
            <pubmed-id>18619574</pubmed-id>
            <citation>Kot M, Daniel WA: The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochem Pharmacol. 2008 Aug 15;76(4):543-51. doi: 10.1016/j.bcp.2008.05.025. Epub 2008 Jul 9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11712" source="Swiss-Prot">
        <name>Cytochrome P450 2C9</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.</specific-function>
        <gene-name>CYP2C9</gene-name>
        <locus>10q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.99</theoretical-pi>
        <molecular-weight>55627.365</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2623</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AY341248</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1326</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11712</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C9_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP2C10</synonym>
          <synonym>CYPIIC9</synonym>
          <synonym>Cytochrome P-450MP</synonym>
          <synonym>Cytochrome P450 MP-4</synonym>
          <synonym>Cytochrome P450 MP-8</synonym>
          <synonym>Cytochrome P450 PB-1</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005471|Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016893|Cytochrome P450 2C9 (CYP2C9)
ATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT
GAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG
TTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT
CCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG
AAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT
CAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT
GAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG
ACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA
GACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC
CTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC
ATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG
AAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG
GCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT
CTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG
CCCTTCTACCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular amide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urea metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="7">
      <id>BE0003543</id>
      <name>Cytochrome P450 1A1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A39039</ref-id>
            <pubmed-id>8474022</pubmed-id>
            <citation>Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO: Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther. 1993 Apr;265(1):401-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04798" source="Swiss-Prot">
        <name>Cytochrome P450 1A1</name>
        <general-function>Vitamin d 24-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
        <gene-name>CYP1A1</gene-name>
        <locus>15q24.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.47</theoretical-pi>
        <molecular-weight>58164.815</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2595</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>K03191</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181276</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04798</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIA1</synonym>
          <synonym>Cytochrome P450 form 6</synonym>
          <synonym>Cytochrome P450-C</synonym>
          <synonym>Cytochrome P450-P1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006827|Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012466|Cytochrome P450 1A1 (CYP1A1)
ATGCTTTTCCCAATCTCCATGTCGGCCACGGAGTTTCTTCTGGCCTCTGTCATCTTCTGT
CTGGTATTCTGGGTAATCAGGGCCTCAAGACCTCAGGTCCCCAAAGGCCTGAAGAATCCA
CCAGGGCCATGGGGCTGGCCTCTGATTGGGCACATGCTGACCCTGGGAAAGAACCCGCAC
CTGGCACTGTCAAGGATGAGCCAGCAGTATGGGGACGTGCTGCAGATCCGAATTGGCTCC
ACACCCGTGGTGGTGCTGAGCGGCCTGGACACCATCCGGCAGGCCCTGGTGCGGCAGGGC
GATGATTTCAAGGGCCGGCCCGACCTCTACACCTTCACCCTCATCAGTAATGGTCAGAGC
ATGTCCTTCAGCCCAGACTCTGGACCAGTGTGGGCTGCCCGCCGGCGCCTGGCCCAGAAT
GGCCTGAAAAGTTTCTCCATTGCCTCTGACCCAGCCTCCTCAACCTCCTGCTACCTGGAA
GAGCATGTGAGCAAGGAGGCTGAGGTCCTGATAAGCACGTTGCAGGAGCTGATGGCAGGG
CCTGGGCACTTTAACCCCTACAGGTATGTGGTGGTATCAGTGACCAATGTCATCTGTGCC
ATTTGCTTTGGCCGGCGCTATGACCACAACCACCAAGAACTGCTTAGCCTAGTCAACCTG
AATAATAATTTCGGGGAGGTGGTTGGCTCTGGAAACCCAGCTGACTTCATCCCTATTCTT
CGCTACCTACCCAACCCTTCCCTGAATGCCTTCAAGGACCTGAATGAGAAGTTCTACAGC
TTCATGCAGAAGATGGTCAAGGAGCACTACAAAACCTTTGAGAAGGGCCACATCCGGGAC
ATCACAGACAGCCTGATTGAGCACTGTCAGGAGAAGCAGCTGGATGAGAACGCCAATGTC
CAGCTGTCAGATGAGAAGATCATTAACATCGTCTTGGACCTCTTTGGAGCTGGGTTTGAC
ACAGTCACAACTGCTATCTCCTGGAGCCTCATGTATTTGGTGATGAACCCCAGGGTACAG
AGAAAGATCCAAGAGGAGCTAGACACAGTGATTGGCAGGTCACGGCGGCCCCGGCTCTCT
GACAGATCCCATCTGCCCTATATGGAGGCCTTCATCCTGGAGACCTTCCGACACTCTTCC
TTCGTCCCCTTCACCATCCCCCACAGCACAACAAGAGACACAAGTTTGAAAGGCTTTTAC
ATCCCCAAGGGGCGTTGTGTCTTTGTAAACCAGTGGCAGATCAACCATGACCAGAAGCTA
TGGGTCAACCCATCTGAGTTCCTACCTGAACGGTTTCTCACCCCTGATGGTGCTATCGAC
AAGGTGTTAAGTGAGAAGGTGATTATCTTTGGCATGGGCAAGCGGAAGTGTATCGGTGAG
ACCATTGCCCGCTGGGAGGTCTTTCTCTTCCTGGCTATCCTGCTGCAACGGGTGGAATTC
AGCGTGCCACTGGGCGTGAAGGTGGACATGACCCCCATCTATGGGCTAACCATGAAGCAT
GCCTGCTGTGAGCACTTCCAAATGCAGCTGCGCTCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>flavonoid 3'-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on diphenols and related substances as donors</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>9-cis-retinoic acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>amine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>camera-type eye development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestive tract development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo development ending in birth or egg hatching</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hepatocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insecticide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal process involved in parturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to arsenic-containing substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to food</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to herbicide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hyperoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to iron(III) ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nematode</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to wounding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="8">
      <id>BE0001111</id>
      <name>Cytochrome P450 1B1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A39067</ref-id>
            <pubmed-id>9152602</pubmed-id>
            <citation>Shimada T, Gillam EM, Sutter TR, Strickland PT, Guengerich FP, Yamazaki H: Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q16678" source="Swiss-Prot">
        <name>Cytochrome P450 1B1</name>
        <general-function>Oxygen binding</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compounds to their activated forms, including polycyclic aromatic hydrocarbons. Promotes angiogenesis by removing cellular oxygenation products, thereby decreasing oxidative stress, release of antiangiogenic factor THBS2, then allowing endothelial cells migration, cell adhesion and capillary morphogenesis. These changes are concommitant with the endothelial nitric oxide synthase activity and nitric oxide synthesis. Plays an important role in the regulation of perivascular cell proliferation, migration, and survival through modulation of the intracellular oxidative state and NF-kappa-B expression and/or activity, during angiogenesis. Contributes to oxidative homeostasis and ultrastructural organization and function of trabecular meshwork tissue through modulation of POSTN expression.</specific-function>
        <gene-name>CYP1B1</gene-name>
        <locus>2p21</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.23</theoretical-pi>
        <molecular-weight>60845.33</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2597</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP1B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U03688</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>501031</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1320</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q16678</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIB1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016314|Cytochrome P450 1B1
MGTSLSPNDPWPLNPLSIQQTTLLLLLSVLATVHVGQRLLRQRRRQLRSAPPGPFAWPLI
GNAAAVGQAAHLSFARLARRYGDVFQIRLGSCPIVVLNGERAIHQALVQQGSAFADRPAF
ASFRVVSGGRSMAFGHYSEHWKVQRRAAHSMMRNFFTRQPRSRQVLEGHVLSEARELVAL
LVRGSADGAFLDPRPLTVVAVANVMSAVCFGCRYSHDDPEFRELLSHNEEFGRTVGAGSL
VDVMPWLQYFPNPVRTVFREFEQLNRNFSNFILDKFLRHCESLRPGAAPRDMMDAFILSA
EKKAAGDSHGGGARLDLENVPATITDIFGASQDTLSTALQWLLLLFTRYPDVQTRVQAEL
DQVVGRDRLPCMGDQPNLPYVLAFLYEAMRFSSFVPVTIPHATTANTSVLGYHIPKDTVV
FVNQWSVNHDPLKWPNPENFDPARFLDKDGLINKDLTSRVMIFSVGKRRCIGEELSKMQL
FLFISILAHQCDFRANPNEPAKMNFSYGLTIKPKSFKVNVTLRESMELLDSAVQNLQAKE
TCQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016315|Cytochrome P450 1B1 (CYP1B1)
ATGGGCACCAGCCTCAGCCCGAACGACCCTTGGCCGCTAAACCCGCTGTCCATCCAGCAG
ACCACGCTCCTGCTACTCCTGTCGGTGCTGGCCACTGTGCATGTGGGCCAGCGGCTGCTG
AGGCAACGGAGGCGGCAGCTCCGGTCCGCGCCCCCGGGCCCGTTTGCGTGGCCACTGATC
GGAAACGCGGCGGCGGTGGGCCAGGCGGCTCACCTCTCGTTCGCTCGCCTGGCGCGGCGC
TACGGCGACGTTTTCCAGATCCGCCTGGGCAGCTGCCCCATAGTGGTGCTGAATGGCGAG
CGCGCCATCCACCAGGCCCTGGTGCAGCAGGGCTCGGCCTTCGCCGACCGGCCGGCCTTC
GCCTCCTTCCGTGTGGTGTCCGGCGGCCGCAGCATGGCTTTCGGCCACTACTCGGAGCAC
TGGAAGGTGCAGCGGCGCGCAGCCCACAGCATGATGCGCAACTTCTTCACGCGCCAGCCG
CGCAGCCGCCAAGTCCTCGAGGGCCACGTGCTGAGCGAGGCGCGCGAGCTGGTGGCGCTG
CTGGTGCGCGGCAGCGCGGACGGCGCCTTCCTCGACCCGAGGCCGCTGACCGTCGTGGCC
GTGGCCAACGTCATGAGTGCCGTGTGTTTCGGCTGCCGCTACAGCCACGACGACCCCGAG
TTCCGTGAGCTGCTCAGCCACAACGAAGAGTTCGGGCGCACGGTGGGCGCGGGCAGCCTG
GTGGACGTGATGCCCTGGCTGCAGTACTTCCCCAACCCGGTGCGCACCGTTTTCCGCGAA
TTCGAGCAGCTCAACCGCAACTTCAGCAACTTCATCCTGGACAAGTTCTTGAGGCACTGC
GAAAGCCTTCGGCCCGGGGCCGCCCCCCGCGACATGATGGACGCCTTTATCCTCTCTGCG
GAAAAGAAGGCGGCCGGGGACTCGCACGGTGGTGGCGCGCGGCTGGATTTGGAGAACGTA
CCGGCCACTATCACTGACATCTTCGGCGCCAGCCAGGACACCCTGTCCACCGCGCTGCAG
TGGCTGCTCCTCCTCTTCACCAGGTATCCTGATGTGCAGACTCGAGTGCAGGCAGAATTG
GATCAGGTCGTGGGGAGGGACCGTCTGCCTTGTATGGGTGACCAGCCCAACCTGCCCTAT
GTCCTGGCCTTCCTTTATGAAGCCATGCGCTTCTCCAGCTTTGTGCCTGTCACTATTCCT
CATGCCACCACTGCCAACACCTCTGTCTTGGGCTACCACATTCCCAAGGACACTGTGGTT
TTTGTCAACCAGTGGTCTGTGAATCATGACCCACTGAAGTGGCCTAACCCGGAGAACTTT
GATCCAGCTCGATTCTTGGACAAGGATGGCCTCATCAACAAGGACCTGACCAGCAGAGTG
ATGATTTTTTCAGTGGGCAAAAGGCGGTGCATTGGCGAAGAACTTTCTAAGATGCAGCTT
TTTCTCTTCATCTCCATCCTGGCTCACCAGTGCGATTTCAGGGCCAACCCAAATGAGCCT
GCGAAAATGAATTTCAGTTATGGTCTAACCATTAAACCCAAGTCATTTAAAGTCAATGTC
ACTCTCAGAGAGTCCATGGAGCTCCTTGATAGTGCTGTCCAAAATTTACAAGCCAAGGAA
ACTTGCCAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood vessel morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular aromatic compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>collagen fibril organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endothelial cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endothelial cell-cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrogen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intrinsic apoptotic signaling pathway in response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell adhesion mediated by integrin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of JAK-STAT cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of reactive oxygen species metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinal blood vessel morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinal metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>trabecular meshwork development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="9">
      <id>BE0002363</id>
      <name>Cytochrome P450 2D6</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A39309</ref-id>
            <pubmed-id>8857078</pubmed-id>
            <citation>Ha HR, Chen J, Krahenbuhl S, Follath F: Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol. 1996;49(4):309-15. doi: 10.1007/bf00226333.</citation>
          </article>
          <article>
            <ref-id>A39125</ref-id>
            <pubmed-id>9617978</pubmed-id>
            <citation>Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W: Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol. 1998 Jun;18(3):198-207.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10635" source="Swiss-Prot">
        <name>Cytochrome P450 2D6</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.</specific-function>
        <gene-name>CYP2D6</gene-name>
        <locus>22q13.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.26</theoretical-pi>
        <molecular-weight>55768.94</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2D6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M20403</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181350</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1329</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10635</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2D6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP2DL1</synonym>
          <synonym>CYPIID6</synonym>
          <synonym>Cytochrome P450-DB1</synonym>
          <synonym>Debrisoquine 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004641|Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6)
ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG
GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG
CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG
TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG
CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC
CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC
CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC
AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT
TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA
GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT
CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG
CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC
CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG
ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG
AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT
GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC
ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG
CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT
CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT
GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA
TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC
CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC
CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG
CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC
TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>isoquinoline alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular organofluorine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="20">
      <id>BE0001067</id>
      <name>ATP-binding cassette sub-family G member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187232</ref-id>
            <pubmed-id>22113078</pubmed-id>
            <citation>Ding R, Shi J, Pabon K, Scotto KW: Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance. Mol Pharmacol. 2012 Mar;81(3):328-37. doi: 10.1124/mol.111.075556. Epub 2011 Nov 23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UNQ0" source="Swiss-Prot">
        <name>ATP-binding cassette sub-family G member 2</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.</specific-function>
        <gene-name>ABCG2</gene-name>
        <locus>4q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>396-416
429-449
478-498
507-527
536-556
631-651</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.9</theoretical-pi>
        <molecular-weight>72313.47</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:74</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCG2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF103796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4185796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UNQ0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ABCP</synonym>
          <synonym>BCRP</synonym>
          <synonym>BCRP1</synonym>
          <synonym>Breast cancer resistance protein</synonym>
          <synonym>CDw338</synonym>
          <synonym>Mitoxantrone resistance-associated protein</synonym>
          <synonym>MXR</synonym>
          <synonym>Placenta-specific ATP-binding cassette transporter</synonym>
          <synonym>Urate exporter</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002125|ATP-binding cassette sub-family G member 2
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE
KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN
SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT
QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF
SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING
DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK
ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS
TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP
MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL
MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN
NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2)
ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC
CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT
AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG
AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA
CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT
GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT
TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA
CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG
ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT
CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT
ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA
GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC
TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC
TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT
GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA
GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG
CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC
TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG
ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT
TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT
GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT
ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC
AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC
AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC
ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG
CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC
AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC
ATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT
GGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA
ATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA
ACTATGCAACATGTACTGGCGAAGAATATTTGGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF01061</identifier>
            <name>ABC2_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heme transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>